Form (3)

P000068

THE REPUBLIC OF THE UNION OF MYANMAR

Myanmar Investment Commission

PERMIT

Permit No. 153/ 2019 Dated 8 April 2019

This Permit is issued by the Myanmar Investment Commission according to the section 25 (c) of the Myanmar Investment Law-

(1) Name of Investor U ZAW MOE KHINE

(2) Citizenship MYANMAR

(3) Residence Address NO. 126, 35th STREET, KYAUKTADA TOWNSHIP, YANGON

(4) Name and Address of Principle Organization -

(5) Place of Incorporation -

(6) Type of Business MANUFACTURING OF PHARMACEUTICAL AND RELATED PRODUCTS

(7) Place(s) at which investment is permitted PLOT NO. 209, 210, 211, ZONE (1), DAGON MYOTHIT SEIKKAN TOWNSHIP, YANGON REGION

(8) Amount of Foreign Capital -

(9) Period for Foreign Capital to be brought in -

(10) Total amount of capital (Kyat) 25,006.124 MILLION (INCLUDING US $ 10.380 MILLION)

(11) Construction Period -

(12) Validity of investment permit -

(13) Form of investment WHOLLY MYANMAR OWNED

(14) Name of Company incorporated in Myanmar PACIFIC MEDICAL INDUSTRIES LIMITED

(Remark: This Permit shall be effective from the issuance of Temporary Permit dated 27 December 2011)

Thaung Tun

(Thaung Tun)
Chairman

MIC
Myanmar Investment Commission

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
ခွင့်ပြုမိန့်

ခွင့်ပြုမိန့်အမှတ်၊ ၁၅၃/ ၂၀၁၉ ၂၀၁၉ ခုနှစ် ဧပြီလ ၈ ရက်

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သည် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှု ဥပဒေပုဒ်မ ၂၅ (ဂ) အရ ဤခွင့်ပြုမိန့်ကို ထုတ်ပေးလိုက်သည် -

(၁) ရင်းနှီးမြှုပ်နှံသူအမည် ဦးဇော်မိုးခိုင်

(၂) နိုင်ငံသား မြန်မာ

(၃) နေရပ်လိပ်စာ အမှတ် ၁၂၆၊ ၃၅လမ်း၊ ကျောက်တံတားမြို့နယ်၊ ရန်ကုန်မြို့

(၄) ပင်မအဖွဲ့အစည်းအမည်နှင့် လိပ်စာ -

(၅) ဖွဲ့စည်းရာအရပ် -

(၆) ရင်းနှီးမြှုပ်နှံသည့်လုပ်ငန်းအမျိုးအစား ဆေးဝါးထုတ်လုပ်ခြင်းနှင့်ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း

(၇) ရင်းနှီးမြှုပ်နှံသည့်အရပ်ဒေသ(များ) မြေကွက်အမှတ်- ၂၀၉၊ ၂၁၀၊၂၁၁၊ စက်မှုဇုန်-၁၊ ဒဂုံမြို့သစ်ဆိပ်ကမ်းမြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး

(၈) နိုင်ငံခြားမတည်ငွေရင်း ပမာဏ -

(၉) နိုင်ငံခြားမတည်ငွေရင်းယူဆောင်လာရမည့်ကာလ -

(၁၀) စုစုပေါင်းမတည်ငွေရင်းပမာဏ(ကျပ်) ၂၅,၀၀၆.၁၂၄ သန်း (အမေရိကန်ဒေါ်လာ ၁၀.၃၈၀ သန်း အပါအဝင် စုစုပေါင်းကျပ်သန်း နှစ်သောင်းငါးထောင့်ခြောက်နှင့် တစ်သိန်းနှစ်သောင်းလေးထောင်ခန့်)

(၁၁) တည်ဆောက်မှု/ ပြင်ဆင်မှုကာလ -

(၁၂) ရင်းနှီးမြှုပ်နှံမှုခွင့်ပြုသည့်သက်တမ်း -

(၁၃) ရင်းနှီးမြှုပ်နှံမှုပုံစံ ရာခိုင်နှုန်းပြည့် မြန်မာနိုင်ငံသားရင်းနှီးမြှုပ်နှံမှု

(၁၄) မြန်မာနိုင်ငံတွင်ဖွဲ့စည်းမည့်ကုမ္ပဏီအမည် ပစိဖိတ် ဆေးပစ္စည်းလုပ်ငန်း လီမိတက်

(မှတ်ချက်။ ဤအမိန့်သည် ၂၀၁၁ ခုနှစ် ဒီဇင်ဘာလ ၂၇ ရက်နေ့တွင် ယာယီ ခွင့်ပြုမိန့် ထုတ်ပေးသည့် နေ့မှစ၍ အကျိုးသက်ရောက်သည်။)

Thaung Tun

(သောင်းထွန်း)

ဥက္ကဋ္ဌ

ကန့်သတ်

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
အမှတ်(၁)၊ သစ္စာလမ်း၊ရန်ကင်းမြို့နယ်၊ ရန်ကုန်မြို့

(ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော် ★ စာအမှတ်-၀၄၀ ရက်စွဲ ၈-၄-၂၀၁၉ ★ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်)

☎ ၀၁-၆၅၈၁၂၈ | စာအမှတ်၊မရက- ၃/ခ-၀၃၇/၂၀၁၉ (၀၄၀)
🖶 ၀၁- ၆၅၈၁၄၁ | ရက်စွဲ ၊ ၂၀၁၉ ခုနှစ် ဧပြီလ ၈ ရက်

အကြောင်းအရာ။ **Pacific Medical Industries Limited (ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်)၏ ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း အဆိုပြုချက်အပေါ် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ ဆုံးဖြတ်ချက်**

ရည်ညွှန်းချက် ။ Pacific Medical Industries Limited (ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်) ၏ ၁၉-၃-၂၀၁၉ ရက်စွဲပါစာ

၁။ Pacific Medical Industries Limited (ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်) သည် ရန်ကုန်တိုင်းဒေသကြီး၊ ဒဂုံမြို့သစ်ဆိပ်ကမ်းမြို့နယ်၊ စက်မှုဇုန်-၁၊ မြေကွက်အမှတ် ၂၀၉၊ ၂၁၀နှင့် ၂၁၁ ရှိ မြေဧရိယာ ၅.၄၉၁ဧကတွင် ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်းအား မြန်မာနိုင်ငံသားများရင်းနှီးမြှုပ်နှံမှု ဥပဒေနှင့်အညီ ဆောင်ရွက်ခွင့်ပြုပါရန် အဆိုပြုချက်တင်ပြခြင်းအား ၂၀၁၁ ခုနှစ် နိုဝင်ဘာလ ၂၃ ရက်နေ့တွင် ကျင်းပပြုလုပ်သော မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ (၂၅/၂၀၁၁) ကြိမ်မြောက် အစည်းအဝေးသို့ တင်ပြခဲ့ရာ ခွင့်ပြုကြောင်း ဆုံးဖြတ်ခဲ့ပါသည်။

၂။ အဆိုပါ ဆုံးဖြတ်ချက်အရ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သည် ၂၀၁၁ ခုနှစ် ဒီဇင်ဘာလ ၂၇ ရက်နေ့တွင် ယာယီခွင့်ပြုမိန့်အမှတ်၊ မနသ-၀၀၁/၂၀၁၁(ယာယီ)ဖြင့် Pacific Medical Industries Limited (ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်)အား တည်ဆောက်ရေးလုပ်ငန်းများ ကြိုတင်ဆောင်ရွက်နိုင်ရန်အတွက် ယာယီခွင့်ပြုမိန့် ထုတ်ပေးခဲ့ပါသည်။ ကုမ္ပဏီမှ တည်ဆောက်ရေးလုပ်ငန်းများ ပြီးစီးကြောင်းနှင့် ဆေးဝါးထုတ်လုပ်ခွင့်လိုင်စင်၊ ဆေးတစ်မျိုးချင်းအတွက် ဆေးဝါးထုတ်လုပ်ခွင့်မှတ်ပုံတင်များ တင်ပြလာခြင်းအပေါ် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ ၂၀၁၉ ခုနှစ် ဧပြီလ ၅ရက်နေ့ တွင် ကျင်းပပြုလုပ်သည့် (၅/၂၀၁၉) ကြိမ်မြောက် အစည်းအဝေးမှ ခွင့်ပြုမိန့်(မူရင်း) ထုတ်ပေးရန် ဆုံးဖြတ်ခဲ့ပါသဖြင့် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုဥပဒေ၊ နည်းဥပဒေကို ကျင့်သုံးလျက် Pacific Medical Industries Limited (ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်)အား ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်

ကန့်သတ်

ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း ဆောင်ရွက်နိုင်ရန်အတွက် ခွင့်ပြုမိန့်အမှတ်၊ ၁၅၃/၂၀၁၉ ကို ထုတ်ပေး လိုက်သည်။ ဤအမိန့်သည် ၂၀၁၁ ခုနှစ် ဒီဇင်ဘာလ ၂၇ ရက်နေ့တွင် ယာယီခွင့်ပြုမိန့် ထုတ်ပေးသည့်နေ့မှစ၍ အကျိုးသက်ရောက်သည်။

၃။ Pacific Medical Industries Limited (ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်) အနေဖြင့် ဤခွင့်ပြုမိန့်အရ လုပ်ငန်းဆောင်ရွက်ရာတွင် အောက်ပါအချက်များကို လိုက်နာဆောင်ရွက်ရမည်-

(က) Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်း လုပ်ငန်းလီမိတက်) အနေဖြင့် ဤခွင့်ပြုမိန့်အရ ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း ဆောင်ရွက်ရာတွင် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုဥပဒေ ပုဒ်မ ၉၃ နှင့် နည်းဥပဒေ ၂၂၄ တွင် ဖော်ပြပါရှိသည့်အတိုင်း ယခင်ခွင့်ပြုမိန့်ပါ စည်းကမ်းချက်များနှင့်အညီ ထုတ်လုပ်မှုလုပ်ငန်း စီးပွားဖြစ်စတင်သောနှစ် အပါအဝင် တစ်ဆက်တည်း(၅)နှစ်အထိ ဝင်ငွေခွန်ကင်းလွတ်ခွင့်နှင့် ပထမ(၃)နှစ်အတွက် ကုန်ထုတ်လုပ်ရန် တင်သွင်းသည့် ကုန်ကြမ်းများအပေါ်တွင် အကောက်ခွန်နှင့် ပြည်တွင်းအခွန်အကောက်များ ကင်းလွတ်ခွင့် ရရှိပါသည်။

(ခ) Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်း လုပ်ငန်းလီမိတက်) သည် ဤခွင့်ပြုမိန့်အရ **ထုတ်လုပ်မှု ရည်မှန်းချက်များကို အနိမ့်ဆုံးရည်မှန်းချက်များ**အဖြစ် ထားရှိဆောင်ရွက် အကောင်အထည်ဖော်ရမည်။

(ဂ) Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်း လုပ်ငန်းလီမိတက်) အနေဖြင့် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုဥပဒေ ပုဒ်မ ၆၅ နှင့် နည်းဥပဒေ အခန်း (၂၀) တို့တွင် ပြဋ္ဌာန်းထားသည့် ရင်းနှီးမြှုပ်နှံသူ၏ တာဝန်ဝတ္တရားများနှင့်အညီ လိုက်နာဆောင်ရွက်ရမည်။

(ဃ) Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်း လုပ်ငန်းလီမိတက်)သည် အဆိုပြုလုပ်ငန်းဆောင်ရွက်ရာတွင် သယံဇာတနှင့် သဘာဝပတ်ဝန်းကျင် ထိန်းသိမ်းရေးဝန်ကြီးဌာနမှ ပြဋ္ဌာန်း ထုတ်ပြန်ထားပြီးဖြစ်သည့် ပတ်ဝန်းကျင်ထိန်းသိမ်းရေးဥပဒေ၊ နည်းဥပဒေ၊ ပတ်ဝန်းကျင်ထိခိုက်မှု ဆန်းစစ်ခြင်းဆိုင်ရာ လုပ်ထုံးလုပ်နည်း၊ အမျိုးသားပတ်ဝန်းကျင်ဆိုင်ရာ အရည်အသွေး (ထုတ်လွှတ်မှု) လမ်းညွှန်ချက်များတွင် ဖော်ပြပါရှိသည့် လိုက်နာဆောင်ရွက်ရမည့်

အချက်များ၊ လုပ်ထုံးလုပ်နည်းများ၊ လမ်းညွှန်ချက်များနှင့်အညီ လိုက်နာဆောင်ရွက်ရမည်။

(င) Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်း လုပ်ငန်း လီမိတက်) အဆိုပြုလုပ်ငန်းဆောင်ရွက်ရာတွင် မီးဘေးအန္တရာယ်မဖြစ်ပေါ်စေရန်အတွက် လိုအပ်သည့် မီးဘေးအန္တရာယ် ထိန်းသိမ်းကာကွယ်ရေးစနစ်များကို ဝန်ခံကတိပြုထားသည့်အတိုင်း စနစ်တကျထားရှိ ဆောင်ရွက်ရမည်ဖြစ်ပြီး မီးသတ်ဦးစီးဌာန၏ နည်းဥပဒေများ၊ လုပ်ထုံးလုပ်နည်းများ၊ ညွှန်ကြားချက်များနှင့် အမိန့်များကို တိကျလိုက်နာ ဆောင်ရွက်ရမည်။

(စ) Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်း လုပ်ငန်း လီမိတက်) သည် ရင်းနှီးမြှုပ်နှံမှုအား လုပ်ငန်းသက်တမ်း ကာလအတွင်း အခြားပုဂ္ဂိုလ်တစ်ဦးဦးသို့ တစ်ဆင့်ငှားရမ်းခြင်း၊ ပေါင်နှံခြင်း၊ အစုရှယ်ယာလွှဲပြောင်းခြင်းနှင့် လုပ်ငန်းလွှဲပြောင်းခြင်းတို့ကို မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုဥပဒေပုဒ်မ ၇၂ နှင့် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုနည်းဥပဒေ ၁၉၁ အရ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သို့ တင်ပြရမည်။

(ဆ) Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်း လုပ်ငန်း လီမိတက်) သည် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုနည်းဥပဒေ ၁၉၆ အရ နှစ်စဉ်ဘဏ္ဍာရေးနှစ် ကုန်ဆုံးပြီးနောက် သုံးလအတွင်း သတ်မှတ်ချက်ပါ အသေးစိတ်များပါရှိသည့် နှစ်စဉ်အစီရင်ခံစာအား သတ်မှတ်ပုံစံဖြင့် ကုမ္ပဏီ၏ ဝက်(ဘ်)ဆိုဒ်(သို့မဟုတ်) ကော်မရှင်ရုံး၏ ဝက်(ဘ်)ဆိုဒ်သို့ တင်ပြရမည်။

(ဇ) Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်းလုပ်ငန်း လီမိတက်) သည် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှု နည်းဥပဒေ ၁၉၇ အရ လုပ်ငန်းဆောင်ရွက်နေစဉ်အတွင်း လုပ်ငန်းအစီရင်ခံစာကို သုံးလလျှင်တစ်ကြိမ် ကော်မရှင်က သတ်မှတ်တောင်းခံသည့် ပုံစံဖြင့် တင်ပြရမည်။

၄။ Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်းလုပ်ငန်း လီမိတက်) သည် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုဥပဒေပုဒ်မ ၆၅ (ဃ) အရ သက်ဆိုင်သည့် ပြည်ထောင်စုဝန်ကြီးဌာနများ၊ အစိုးရဌာနနှင့် အဖွဲ့အစည်းများမှ လိုင်စင် သို့မဟုတ် ခွင့်ပြုမိန့်ရယူရန် လိုအပ်လျှင်ဖြစ်စေ၊ မှတ်ပုံတင်ရန် လိုအပ်လျှင်ဖြစ်စေ သက်ဆိုင်ရာဌာန၏ သတ်မှတ်ချက်နှင့်အညီ ဆောင်ရွက်ရမည်။

၅။ Pacific Medical Industries Limited (ပစိဖိတ် ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်)သည် လုပ်ငန်းဆောင်ရွက်ရာတွင် လုပ်ငန်းသဘာဝအရဖြစ်စေ၊ အခြားလိုအပ်ချက်အရဖြစ်စေ သက်ဆိုင်သည့် ပြည်ထောင်စုဝန်ကြီးဌာနများ၊ အစိုးရဌာနနှင့် အဖွဲ့အစည်းများမှ လိုင်စင်သို့မဟုတ် ခွင့်ပြုမိန့်ရယူရန် လိုအပ်လျှင်ဖြစ်စေ၊ သက်ဆိုင်ရာဌာနနှင့် မြေငှားရမ်းခြင်းစာချုပ် ချုပ်ဆိုသည်ဖြစ်စေ၊ မှတ်ပုံတင်ရန် လိုအပ်လျှင်ဖြစ်စေ သက်ဆိုင်ရာဌာန၏ သတ်မှတ်ချက်များနှင့်အညီ ဆောင်ရွက်ပြီး မိတ္တူ (၅)စုံစီအား ကော်မရှင်သို့ ပေးပို့ရမည်။

(သောင်းထွန်း)
ဥက္ကဋ္ဌ

Pacific Medical Industries Limited
(ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်)
ဖြန့်ဝေခြင်း
ပြည်ထဲရေးဝန်ကြီးဌာန
ပြည်ထောင်စု အစိုးရအဖွဲ့ရုံးဝန်ကြီးဌာန
သယံဇာတနှင့် သဘာဝပတ်ဝန်းကျင် ထိန်းသိမ်းရေးဝန်ကြီးဌာန
အလုပ်သမား၊ လူဝင်မှုကြီးကြပ်ရေးနှင့် ပြည်သူ့အင်အားဝန်ကြီးဌာန
စက်မှုဝန်ကြီးဌာန
ကျန်းမာရေးနှင့် အားကစားဝန်ကြီးဌာန
စီးပွားရေးနှင့် ကူးသန်းရောင်းဝယ်ရေးဝန်ကြီးဌာန
စီမံကိန်းနှင့် ဘဏ္ဍာရေးဝန်ကြီးဌာန
ရင်းနှီးမြှုပ်နှံမှုနှင့် နိုင်ငံခြားစီးပွားဆက်သွယ်ရေးဝန်ကြီးဌာန
ရန်ကုန်တိုင်းဒေသကြီးအစိုးရအဖွဲ့ရုံး
ရန်ကုန်တိုင်းဒေသကြီးရင်းနှီးမြှုပ်နှံမှုကော်မတီ
ညွှန်ကြားရေးမှူးချုပ်၊ ပတ်ဝန်းကျင်ထိန်းသိမ်းရေးဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ အလုပ်သမားညွှန်ကြားရေး ဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ လူဝင်မှုကြီးကြပ်ရေးဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ စက်မှုကြီးကြပ်ရေးနှင့် စစ်ဆေးရေးဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ အစားအသောက်နှင့် ဆေးဝါးကွပ်ကဲရေးဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ ကုန်သွယ်ရေးဦးစီးဌာန

ညွှန်ကြားရေးမှူးချုပ်၊ အကောက်ခွန်ဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ ပြည်တွင်းအခွန်များဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ အမျိုးသားမှတ်တမ်းများ မော်ကွန်းတိုက်ဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ ရင်းနှီးမြှုပ်နှံမှုနှင့် ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန
ဦးဆောင်ညွှန်ကြားရေးမှူး၊ မြန်မာ့ဆေးဝါးလုပ်ငန်း
ရန်ကုန်တိုင်းဒေသကြီးဦးစီးမှူးရုံး၊ ရင်းနှီးမြှုပ်နှံမှုနှင့် ကုမ္ပဏီများညွှန်ကြားမှုဦးစီးဌာန

ကန့်သတ်

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

စာအမှတ်၊မရက- ၃/ခ-၀၃၇/၂၀၁၉(၀၃၇)

ရက်စွဲ၊ ၂၀၁၉ ခုနှစ် ဧပြီလ ၁ ရက်

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်သို့

တင်ပြမည့် အမှာစာ

အကြောင်းအရာ။ **Pacific Medical Industries Ltd. မှ ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း ခွင့်ပြုမိန့် (မူရင်း) ထုတ်ယူခွင့်ပြုနိုင်ပါရန် တင်ပြလာခြင်းကိစ္စ**

၁။ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ ယာယီခွင့်ပြုမိန့်အမှတ် မနသ-၀၀၁/၂၀၁၁ (၂၇-၁၂-၂၀၁၁)ဖြင့် ဆောင်ရွက်လျက်ရှိသော Pacific Medical Industries Ltd. သည် ဆေးဝါး ထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း၏ ခွင့်ပြုမိန့်(မူရင်း) ထုတ်ယူခွင့်ပြုပါရန် တင်ပြလာပါသည်။

၂။ ကုမ္ပဏီမှ တင်ပြခဲ့သည့် လုပ်ငန်းအကျဉ်းချုပ် အချက်အလက်များမှာ အောက်ပါအတိုင်း ဖြစ်ပါသည်-

(က)	ကုမ္ပဏီအမည်	-	Pacific Medical Industries Ltd. (ရာခိုင်နှုန်းပြည့် မြန်မာနိုင်ငံသား ရင်းနှီးမြှုပ်နှံမှု)
(ခ)	လုပ်ငန်းအမျိုးအစား	-	ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း
(ဂ)	မြေအကျယ်အဝန်း	-	၅.၄၉၁ ဧက (၂၂,၂၂၁.၃၀၈စတုရန်းမီတာ)
(ဃ)	အဆောက်အဦ		အလျား ၃၀၀ ပေ x အနံ ၈၀ ပေ ရှိသော ၂ ထပ် အဆောက်အဦ ၂လုံး
(င)	တည်နေရာ	-	မြေကွက်အမှတ်- ၂၀၉၊ ၂၁၀၊ ၂၁၁၊ စက်မှုဇုန် - ၁၊ ဒဂုံဆိပ်ကမ်းမြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး
(စ)	စုစုပေါင်းမတည်ငွေရင်း	-	ကျပ်သန်း ၂၅,၀၀၆.၁၂၄ (အမေရိကန်ဒေါ်လာ ၁၀.၃၈၀ သန်း)
(ဆ)	ဝန်ထမ်းအင်အား	-	ပြည်တွင်း ၈၄ ဦး၊ ပြည်ပ ၈ ဦး
(ဇ)	ရောင်းချမည့်နည်းစနစ်	-	၁၀၀% ပြည်တွင်းရောင်း

၃။ စက်ရုံတည်ဆောက်ရေးကာလ ၂၄လ နှင့် ပဏာမ စမ်းသပ်လည်ပတ်မှုကာလ ၆လ တို့အား ခံစားခဲ့ပြီး၊ ပထမအကြိမ် ၁၂လ တိုးမြှင့်ခွင့်ကို ၂၅-၁၂-၂၀၁၄ မှ ၂၅-၁၂-၂၀၁၅ ထိလည်းကောင်း၊

ဒုတိယအကြိမ် ၆လ တိုးမြှင့်ခွင့်ကို ၂၆-၁၂-၂၀၁၅ မှ ၂၅-၆-၂၀၁၆ ထိ လည်းကောင်း တိုးမြှင့်ပေးခဲ့ပါသည်။ ယာယီခွင့်ပြုမိန့်ဖြင့် ဆောင်ရွက်ချိန်မှ ယနေ့အထိ ၇နှစ် ၃လ ကျော် ကြာမြင့်ခဲ့ပြီးဖြစ်ပါသည်။

စိစစ်တင်ပြချက်

၄။ အောက်ပါအတိုင်းစိစစ်တင်ပြအပ်ပါသည်-

(က) ကုမ္ပဏီမှ စက်ရုံတည်ဆောက်မှုလုပ်ငန်းများ ရာခိုင်နှုန်းပြည့် ပြီးစီးပါကြောင်းနှင့် စက်ပစ္စည်း တပ်ဆင်ပြီးစီးမှုများကို မှတ်တမ်းဓာတ်ပုံများနှင့်အတူ တင်ပြထားပါသည်။

(ခ) ထုတ်လုပ်မည့် **ဆေးပြားနှင့် ဆေးတောင့် ၅၈ မျိုးအနက် ၁၉ မျိုးမှာ မြန်မာအစားအသောက်နှင့် ဆေးဝါးအာဏာပိုင်အဖွဲ့မှ ဆေးဝါးထုတ်လုပ်ခွင့် မှတ်ပုံတင်ရရှိပြီး** ကျန်ဆေးဝါး ၃၉ မျိုးမှာ လျှောက်ထားဆဲဖြစ်ကြောင်း တင်ပြထားပါသည်။

(ဂ) ဆေးဝါးထုတ်လုပ်မှုအတွက် ကျန်းမာရေးနှင့် အားကစားဝန်ကြီးဌာန၊ မြန်မာအစားအသောက်နှင့် ဆေးဝါးအာဏာပိုင်အဖွဲ့မှ ခွင့်ပြုထားသည့် **ဆေးဝါးထုတ်လုပ်ခွင့်လိုင်စင်**နှင့် ထုတ်လုပ်ခွင့်ရရှိထားသည့် **ဆေးတစ်မျိုးချင်းအတွက် ဆေးဝါးထုတ်လုပ်ခွင့် မှတ်ပုံတင်နှင့် ထုတ်လုပ်မည့် ဆေးဝါးဓာတ်ပုံများ တင်ပြထား**ပါသည်။

(ဃ) စက်မှုကြီးကြပ်ရေးနှင့် စစ်ဆေးရေးဦးစီးဌာန၏ **ပုဂ္ဂလိကစက်မှုလုပ်ငန်းမှတ်ပုံတင်လက်မှတ်၊ ဘွိုင်လာ ယာယီ အသုံးပြုခွင့်လက်မှတ်နှင့် ရန်ကုန်မြို့တော် စည်ပင်သာယာရေးကော်မတီ၏ ကျန်းမာရေးဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ်တို့ တင်ပြ**ထားပါသည်။

(င) ကုမ္ပဏီမှ မူလအဆိုပြုစဉ်က ရင်းနှီးမြှုပ်နှံမှု ပမာဏ ကျပ်သန်း ၂၄,၈၀၆.၂၈၉ (အမေရိကန်ဒေါ်လာ ၉.၃၉၇သန်း) ဖြစ်ပါသည်။ နည်းပညာနှင့် ထုတ်လုပ်မည့်ဆေးဝါးပြောင်းလဲမှုများကြောင့် ရင်းနှီးမြှုပ်နှံမှု ပမာဏ ကျပ်သန်း ၂၅,၀၀၆.၁၂၄ (အမေရိကန်ဒေါ်လာ ၁၀.၃၈၀ သန်း) သို့ တိုးမြှင့်ခွင့်ပြုပါရန် တင်ပြထားပါသည်။

(စ) အဆိုပြုချက်ပါ စက်ပစ္စည်းတန်ဖိုး အမေရိကန်ဒေါ်လာ ၁၉.၇၆၅ သန်း အနက် အမေရိကန်ဒေါ်လာ ၅.၄၆၆ သန်း တန်ဖိုးတင်သွင်းခဲ့ပြီး အမေရိကန်ဒေါ်လာ ၁၄.၂၉၉ သန်းတန်ဖိုး တင်သွင်းရန်ကျန်ရှိကြောင်း တင်ပြထားပါသည်။

(ဆ) ထုတ်လုပ်ပြီး ဆေးဝါးများကို PACIFIC အမှတ်တံဆိပ်ဖြင့် ပြည်တွင်း၌ ၁၀၀% ထုတ်လုပ်ရောင်းချမည်ဖြစ်ပါသည်။

(ဇ) ကုမ္ပဏီသည် ကော်မရှင်ခွင့်ပြုမိန့်(မူရင်း) ရရှိပြီးပါက စီးပွားဖြစ်စတင်ဆောင်ရွက်ရမည်ဖြစ်ပြီး၊ တင်သွင်းရန်ကျန်ရှိသည့် အမေရိကန်ဒေါ်လာ ၁၄.၂၉၉ သန်းတန်ဖိုးရှိ ပစ္စည်းများကို ကျသင့်သည့်အခွန်အခများ ပေးဆောင်၍ တင်သွင်းရမည်ဖြစ်ပါသည်။

ဆုံးဖြတ်ရန်အချက်

၅။ Pacific Medical Industries Ltd. မှ ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း ဆောင်ရွက်ရန်အတွက် ခွင့်ပြုမိန့်(မူရင်း) ထုတ်ပေးရန် သဘောတူ-မတူ။

ဥက္ကဋ္ဌ(ကိုယ်စား)
(မြသူဇာ၊ တွဲဖက်အတွင်းရေးမှူး)

မိတ္တူကို
ရုံးလက်ခံ

မြန်မာနိုင်ငံသားများရင်းနှီးမြှုပ်နှံမှုဥပဒေအရ

ရင်းနှီးမြှုပ်နှံလိုသူ၏

အဆိုပြုချက်

မြန်မာနိုင်ငံသားများရင်းနှီးမြှုပ်နှံမှုဥပဒေအရ
ရင်းနှီးမြှုပ်နှံလိုသူ၏အဆိုပြုချက်

[ဥပဒေပုဒ်မ ၂ ပုဒ်မခွဲ (ဂ) နှင့် ပုဒ်မ ဂ]

သို့
ဥက္ကဋ္ဌ
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
နေပြည်တော်။

စာအမှတ် ၊
ရက်စွဲ ၊

ကျွန်တော်/ကျွန်မသည် မြန်မာနိုင်ငံသားများရင်းနှီးမြှုပ်နှံမှု ဥပဒေနှင့်အညီ ပြည်ထောင်စုမြန်မာ နိုင်ငံတော်အတွင်း ရင်းနှီးမြှုပ်နှံမှုပြုလုပ်လိုပါသဖြင့် ခွင့်ပြုမိန့်ထုတ်ပေးပါရန် အောက်ပါအချက်များကိုဖော်ပြ၍ လျှောက်ထားအပ်ပါသည်။

၁။ ရင်းနှီးမြှုပ်နှံလိုသူ၏ -

(က) အမည် ဦးဇော်မိုးခိုင်

(ခ) အဖအမည် ဦးမြတ်သင်းအောင်

(ဂ) နိုင်ငံသား/အမျိုးသားမှတ်ပုံတင်အမှတ် ၁၂/ကတတ(နိုင်) ဂ၂၈၇၄၄

(ဃ) နေရပ်လိပ်စာ အမှတ်(၁၂၆)၊ ၃၅ လမ်း ၊ ကျောက်တံတားမြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး။

(င) လူမျိုး၊ဘာသာ ဗမာ / ဗုဒ္ဓ

(စ) အဖွဲ့အစည်းအမည် ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်

(ဆ) လုပ်ငန်းအမျိုးအစား ဆေးဝါးထုတ်လုပ်ခြင်းနှင့်ဆက်စပ်လျှက်ရှိသောပစ္စည်းများထုတ်လုပ်ခြင်းလုပ်ငန်း

(ဇ) အဖွဲ့အစည်းတည်ရှိရာအရပ် အမှတ် ၄ဂ၈ ၊၄၁ဂ ၊ သတ္တမထပ် ၊ ဆမ်ဆောင်းပလာဇာ၊ မဟာဗန္ဓုလလမ်း၊ ကျောက်တံတားမြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး။

၂။ ဖက်စပ်ပြုလုပ်၍ ရင်းနှီးမြှုပ်နှံလိုပါက ဖက်စပ်ပြုလုပ်မည့်သူများ၏

(က) အမည် (၁) .... (၂) ....

(ခ) အဖအမည် (၁) .... (၂) ....

(ဂ) နိုင်ငံသား/ အမျိုးသားမှတ်ပုံတင်အမှတ်

(၁) .... (၂) ....

(ဃ) နေရပ်လိပ်စာ (၁) .... (၂) ....

....

....

(င) လူမျိုး၊ဘာသာ (၁) .... (၂) ....

....

....

(စ) အဖွဲ့အစည်းအမည် ....

(ဆ) လုပ်ငန်းအမျိုးအစား ....

(ဇ) အဖွဲ့အစည်းတည်ရှိရာအရပ် ....

....

....

(နှစ်ဦး သို့မဟုတ် အဖွဲ့အစည်း ၂ ထက်ပိုပါက သီခြားစာရွက်ဖြင့်ဖော်ပြပူးတွဲရန်)

၃။ ရင်းနှီးမြှုပ်နှံမှု ပြုလုပ်လိုသည့် လုပ်ငန်းအမျိုးအစား -

(က) ကုန်ထုတ်လုပ်မှုလုပ်ငန်း ဆေးဝါးထုတ်လုပ်ခြင်းနှင့်ဆက်စပ်လျက်ရှိသောပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း

(ခ) ဝန်ဆောင်မှုလုပ်ငန်း ....

(ကုန်ပစ္စည်းအမည် သို့မဟုတ် ဝန်ဆောင်မှု အမျိုးအစားကိုဖော်ပြရန်

၄။ လုပ်ကိုင်ရမည့် စီးပွားရေးပုံစံ -

(က) နိုင်ငံသား နှင့် နိုင်ငံသားတို့က ဖက်စပ်လုပ်ကိုင်ဆောင်ရွက်ခြင်း

ကုမ္ပဏီလီမိတက်

(ခ) အဖွဲ့အစည်း နှင့် နိုင်ငံသားတို့က ဖက်စပ်လုပ်ကိုင်ဆောင်ရွက်ခြင်း

မရှိပါ။

(ဂ) အဖွဲ့အစည်းနှင့် အခြားအဖွဲ့အစည်းတို့က ဖက်စပ်လုပ်ကိုင်ဆောင်ရွက်ခြင်း
မရှိပါ။

၅။ ဖွဲ့စည်းထားပြီးဖြစ်သည့် သို့မဟုတ် ဖွဲ့စည်းမည့် စီးပွားရေးအဖွဲ့အစည်း့ပုံသဏ္ဍာန် -

(က) တစ်ဦးတည်းပိုင် ....

(ခ) ဖက်စပ် / အစုစပ်လုပ်ငန်း ....

(ဂ) လီမိတက်ကုမ္ပဏီ အများနှင့် မသက်ဆိုင်သော ကုမ္ပဏီ

(ဃ) သမဂ္ဂါယမအသင်း ....

(အများနှင့်မသက်ဆိုင်သည့်ကုမ္ပဏီ/အများပိုင်ကုမ္ပဏီဟုဖော်ပြ၍ထည့်ဝင်မည့်မတည်ငွေရင်းအမျိုးအစား၊ စီမံခန့်ခွဲသူ/စီမံခန့်ခွဲမည့်သူများ၏ အမည်၊ နေရပ်လိပ်စာများနှင့် ရာထူးတို့ကို ပူးတွဲတင်ပြရန်)

၆။ ဖက်စပ်/အစုစပ်လုပ်ငန်းဖြစ်ပါက -

(က) အစုစပ်တို့က ထည့်ဝင်မည့် အစုငွေအချိုးအစားနှင့် ပမာဏ

....

(ခ) အကျိုးအမြတ်ခွဲဝေမည့် အချိုးအစား

....

(ဂ) အစုဝင်များ၏တာဝန်နှင့် လုပ်ပိုင်ခွင့်များ

....

(နေရာမလုံလောက်က သီးခြားစာရွက်ဖြင့် ဖော်ပြရန်)။

၇။ သမဂ္ဂါယမအသင်း/လီမိတက်ကုမ္ပဏီဖြစ်ပါက -

(က) ခွင့်ပြုမတည်ငွေရင်း ကျပ်သန်း ၁၀၀၀ (တစ်စုလျှင် ကျပ် ၁,၀၀၀ တန် အစုရှယ်ယာပေါင်း ၁,၀၀၀,၀၀၀ စု)

(ခ) အစုရှယ်ယာအမျိုးအစား သာမန်အစုရှယ်ယာ

(ဂ) အစုရှယ်ယာဝင်များက ကျပ် ၅၀၀,၀၀၀,၀၀၀
ထည့်ဝင်မည့်အစုရှယ်ယာ (ကျပ် ၁၀၀,၀၀၀ တန် အစုရှယ်ယာပေါင်း ၅,၀၀၀ စု)
ပမာဏ ....

၈။ ရင်းနှီးမြုပ်နှံမှုပြုလိုသည့် အဖွဲ့အစည်းနှင့် သက်ဆိုင်သော အချက်အလက်များ

(က) မတည်ငွေရင်းပမာဏ

		မတည်ငွေ (ကျပ်)	နိုင်ငံခြားငွေ (US$)	စုစုပေါင်း (ကျပ်)
(၁)	မတည်ငွေ (ကျပ်) (နိုင်ငံခြားမတည်ငွေ ပါဝင်ပါက သီးခြားဖော်ပြရန်)		၁,၂၁၇,၃၀၉	၁,၈၇၇,၀၈၉,၇၃၈
(၂)	စက်ပစ္စည်းကိရိယာတန်ဖိုးပမာဏ		၈,၃၉၃,၇၅၄	၁၂,၉၄၃,၁၆၈,၆၆၈
(၃)	မြေ	၃၀,၉၂၄,၀၀၀		၃၀,၉၂၄,၀၀၀
(၄)	အဆောက်အဦးများ	၈,၉၆၈,၇၀၄,၅၈၅		၈,၉၆၈,၇၀၄,၅၈၅
(၅)	စက်ရုံသုံးနှင့်အခြားလုပ်ငန်းသုံး ပစ္စည်းများတန်ဖိုးပမာဏ		၂၀၅,၂၉၄	၃၁၆,၅၆၃,၃၄၈
(၆)	လုပ်ငန်းသုံးယာဉ်ယန္တရား		၃၈၁,၆၆၉	၅၈၈,၅၃၃,၅၉၈
(၇)	ကုန်ကြမ်းပစ္စည်းများနှင့် အခြားအလားတူပစ္စည်းများ		၁၈၂,၃၂၂	၂၈၁,၁၄၀,၅၂၄
	စုစုပေါင်း	**၈,၉၉၉,၆၂၈,၅၈၅**	**၁၀,၃၈၀,၃၄၈**	**၂၅,၀၀၆,၁၂၄,၄၆၀**

(ခ) နိုင်ငံခြားမှ တင်သွင်း ခဲ့သည့်

	ကျပ်	အမေရိကန်ဒေါ်လာ
(၁) စက်ပစ္စည်းများ၊ စက်ကိရိယာများ စသည့်ပစ္စည်းတို့၏ တန်ဖိုးပမာဏ (အသေးစိတ်စာရင်း ပူးတွဲပါအတိုင်း)		၈,၃၉၃,၇၅၄
(၂) ကုန်ကြမ်းပစ္စည်းများနှင့်အခြား အလားတူပစ္စည်းများ၏ တန်ဖိုး		၁၈၂,၃၂၂
(၃) စက်ရုံသုံးနှင့်အခြားလုပ်ငန်းသုံးပစ္စည်း များတန်းဖိုးပမာဏ		၂၀၅,၂၉၄
(၄) လုပ်ငန်းသုံးယန္တရား		၃၈၁,၆၆၉
စုစုပေါင်း		၉,၁၆၃,၀၃၉

တင်သွင်းရန် လိုအပ်သည့် ပစ္စည်းစာရင်းများအား ပူးတွဲပါ နှစ်အလိုက်လိုအပ်ချက်ဇယားများ အတိုင်းတင်ပြအပ် ပါသည်

(ဂ) တည်ဆောက်မှု ကာလ　　　　　　　　　　(၂၄) လ

(ဃ) ပမာဏ စူးစမ်းလေ့လာမှုပြုလုပ်မည့်ကာလ　　　　(၆) လ

(င) တည်ဆောက်မှု စတင်မည့်အချိန်　　　　　　MIC ခွင့်ပြုချက်ရရှိသည့်အချိန်မှ စတင်ပါမည်။

၉။ ဆောင်ရွက်မည့် စီးပွားရေးလုပ်ငန်းနှင့် သက်ဆိုင်သော အချက်အလက်များ -

(က) လုပ်ငန်းအမျိုးအစား　　　　　　　　ကုန်ထုတ်လုပ်မှု

(ခ) ရင်းနှီးမြှုပ်နှံမှု ပြုလုပ်မည့်ဒေသများ - မြေကွက်အမှတ် (၂၀၉၊၂၁၀၊၂၁၁)၊ စက်မှုဇုန် (၁)၊ ဒဂုံမြို့သစ်ဆိပ်ကမ်းမြို့နယ်၊ ရန်ကုန်တိုင်းဒေသကြီး။

(ဂ) ဆောင်ရွက်ပုံနည်းစနစ်　　　　　　Myanmar GMP, WHO –GMP, Korea – GMP, နှင့် ISO စနစ်

(ဃ) နှစ်စဉ် စက်သုံးဆီ လိုအပ်ချက် -

	အမျိုးအစား	အရေအတွက်
၁။	ဒီဇယ်	၄၅,၀၀၀ ဂါလံ
၂။	ဓါတ်ဆီ	
၃။	စက်ဆီ၊ချောဆီ	

(င) နှစ်စဉ် လျှပ်စစ်အား လိုအပ်ချက် -

အားအသုံးပြုမှု	မြင်းကောင်ရေ
၁။ လျှပ်စစ်ဓါတ်အား	၉,၆၀၀ ကီလိုဝပ်
၂။ ဓါတ်ဆီ/ ဒီဇယ် အင်ဂျင်စက်အား	
၃။ ဘွိုင်လာအသုံးပြု အင်ဂျင်စက်အား	
၄။ သဘာဝဓါတ်ငွေ့သုံးစက်အား	
၅။ ပေးပို့သည့် အခြားအား (ရေအား/လေအား စသည်များ)	

(စ) နှစ်စဉ်ရေလိုအပ်ချက်　　　　　　၉,၀၀၀,၀၀၀

(နေ့စဉ် ရေလိုအပ်ချက်ရှိလျှင် ဖော်ပြရန်)

(ဆ) နှစ်စဉ် လုပ်ငန်းသုံးပစ္စည်း/ ကုန်ကြမ်း လိုအပ်ချက်

အမျိုးအမည်	ရေတွက်ပုံ	အရေအတွက်	တန်ဖိုး
၁။ အဓိက ကုန်ကြမ်း			
(၁) ပူးတွဲပါအတိုင်း	....	....	....
(၂)	....	....	....
၂။ အထောက်အကူ ကုန်ကြမ်း			
(၁) ပူးတွဲပါအတိုင်း	....	....	....
(၂)	....	....	....
၃။ စက်သုံးဆီ/ ဓါတ်ငွေ့များ -			
(၁) ဒီဇယ်	....	....	....
(၂)	....	....	....

(ဇ) အဆောက်အအုံလိုအပ်ချက်

(ဈ) မြေနေရာအမျိုးအစားနှင့် အကျယ်အဝန်း လိုအပ်ချက်

စုစုပေါင်းမြေ အကျယ်အဝန်း (၁.၇၁၈) ဧကခန့်ရှိသော မြေကွက်အမှတ် (၂၁၀)၊ (၁.၇၁၈) ဧကခန့် ရှိသောမြေကွက် အမှတ် (၂၁၁) နှင့် (၂.၀၅၅) ဧကခန့်ရှိသောမြေကွက် အမှတ်(၂၀၉)

(ည) ခန့်မှန်းထုတ်လုပ်မည့် ကုန်ပစ္စည်း/ ဆောင်ရွက်မည့် ဝန်ဆောင်မှု

အမျိုးအမည်	ရေတွက်ပုံ	အရေအတွက်	တန်ဖိုး

ပူးတွဲပါ အတိုင်း ဖော်ပြထားပြီး ဖြစ်ပါသည်။

(ဋ) ရောင်းချမည့် နည်းစနစ်

ပူးတွဲပါ အတိုင်း ဖော်ပြထားပြီး ဖြစ်ပါသည်။

၁၀။ နှစ်စဉ် ကုန်ထုတ်လုပ်မှု/ ဝန်ဆောင်မှု နှင့် စပ်လျဉ်းသော အချက်အလက်များ -

	ခန့်မှန်းခြေ	
	ကျပ်ငွေ	နိုင်ငံခြားငွေ
(က) လုပ်ငန်းလည်ပတ်ရန် လိုအပ်မည့် ကျပ်ငွေ	ပူးတွဲပါအတိုင်း	
(ခ) လိုအပ်မည့် နိုင်ငံခြားသုံးငွေ	ပူးတွဲပါအတိုင်း	
(ဂ) ရရှိမည့် နိုင်ငံခြားသုံးငွေ ပမာဏ	ပူးတွဲပါအတိုင်း	
(ဃ) ပြည်ပသို့ တင်ပို့ရောင်းချနိုင်မည့် ကုန်ပစ္စည်း/ ဝန်ဆောင်မှု တန်ဖိုးပမာဏ	ပူးတွဲပါအတိုင်း	
(င) နှစ်စဉ် ပြည်တွင်း၌ရောင်းချနိုင်မည့် ကုန်ပစ္စည်း/ ဝန်ဆောင်မှု တန်ဖိုးပမာဏ	ပူးတွဲပါအတိုင်း	

၁၁။ ဆောင်ရွက်မည့် စီးပွားရေးလုပ်ငန်းတွင် လိုအပ်မည့်အမှုထမ်းများစာရင်း -

(က) ပြည်တွင်းမှ လိုအပ်မည့်အမှုထမ်းများ - အမှုထမ်းအမျိုးအစား

ပူးတွဲပါအတိုင်း အသေးစိတ်ဖော်ပြထားပါသည်။

(ခ) နိုင်ငံခြားမှ လိုအပ်သည့် ကျွမ်းကျင်သူနှင့် အတတ်ပညာရှင်များ

ကျွမ်းကျင်မှုအမျိုးအစား	ဦးရေ	ခန့်ထားမည့်အချိန်ကာလ
ဆေးဝါးကျွမ်းကျင်ပညာရှင်	၃	၆ လ

၁၂။ စီးပွားရေးတွက်ခြေကိုက်မှုနှင့် စပ်လျဉ်းသော အချက်အလက်များ -

(က) နှစ်စဉ် ဝင်ငွေရရှိမှု	ပူးတွဲပါအတိုင်း
(ခ) နှစ်စဉ် လုပ်ငန်းကုန်ကျစရိတ်	ပူးတွဲပါအတိုင်း
(ဂ) နှစ်စဉ် အသားတင်အမြတ်	ပူးတွဲပါအတိုင်း
(ဃ) နှစ်အလိုက် ရင်းနှီးမြှုပ်နှံမှု	ပူးတွဲပါအတိုင်း
(င) အရင်းကျေကာလ	ပူးတွဲပါအတိုင်း

(စ) အခြား အကျိုးအမြတ်များ ပူးတွဲပါအတိုင်း

(ဆ) အလုပ်အကိုင်သစ်များ - အလုပ်အကိုင်အသစ်များပေါ် ပေါက်လာခြင်း

ပေါ် ပေါက်လာမည့် အခြေအနေ - နည်းပညာသစ်များရရှိခြင်း။

၁၃။ ဆောင်ရွက်ရန် အဆိုပြုချက်နှင့် စပ်လျဉ်းသည့် အထောက်အထားများ ၊ အဆိုပြု တင်ပြသည့် ရင်းနှီးမြှုပ်နှံမှု လုပ်ငန်းအတွက် အောက်ဖော်ပြပါ အထောက်အထားများကို ပူးတွဲတင်ပြအပ်ပါသည်။

(က) ပဋိညာဉ်စာချုပ်မူကြမ်း (လိုအပ်သည့် ကိစ္စတွင်)
(ခ) လုပ်ငန်းပိုင်နှင့် ငွေရေးကြေးရေးဆိုင်ရာ အထောက်အထားများ
(ဂ) လက်ရှိဖွဲ့စည်းဖြစ်ပါက သင်းဖွဲ့မှတ်တမ်းနှင့် သင်းဖွဲ့စည်းမျဉ်း/ ဖွဲ့စည်းခြင်းမရှိသေးပါက သင်းဖွဲ့မှတ်တမ်း မူကြမ်း သင်းဖွဲ့စည်းမျဉ်း မူကြမ်း
(ဃ) လက်ရှိဖွဲ့ကစည်းပြီး အဖွဲ့အစည်းဖြစ်ပါက လက်ရှိအခြေအနေနှင့် ပြင်ဆင်ဖွဲ့ကစည်းမည့် အခြေအနေ အထောက်အထားများ။

လက်မှတ် ၊

အမည် ၊ ဦးဇော်မိုးခိုင်

ရာထူး ၊ မန်နေဂျင်းဒါရိုက်တာ
ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက်

Pacific Medical Industries Ltd.
Head Office : No. 408/410,#07th floor, Samsung Plaza, Mahabandoola street, Kyauktada Tsp. Yangon, Myanmar. Tel: (95-1)391644~50,249592~3,Fax (95-1)249718
Factory : No. 209,210,211, Corner of Khun It Thar Minthar street and Kannar street, City of Industry, Dagon Seikkan Tsp.,Yangon, Myanmar. Tel: (95-1) 592223,592124.

သို့
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

နေ့စွဲ။ ။ ၂၀၁၉ ခုနှစ်၊ ဧပြီလ(၄)ရက်

အကြောင်းအရာ။ ။ ရင်းနှီးမြှုပ်နှံမှုပြုလုပ်မည့်လုပ်ငန်းအမျိုးအစား အသုံးအနှုန်း နှင့်ပါတ်သက်၍ ရှင်းလင်းတင်ပြခြင်း။

ပစိဖိတ်ဆေးပစ္စည်းလုပ်ငန်းလီမိတက် (Pacific Medical Industrial Ltd.,) နှင့် ပါတ်သက်၍ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင် မှ ခွင့်ပြုမိန်(ယာယီ)ဖြင့် ရင်းနှီးမြှုပ်နှံမှု ပြုလုပ်မည့် လုပ်ငန်းအမျိုးအစားအားဆေးဝါးထုတ်လုပ်ခြင်းနှင့်ဆက်စပ်လျှက်ရှိသောပစ္စည်းများထုတ်လုပ်ခြင်းလုပ်ငန်းအနေနှင့်ခွင့်ပြုခဲ့ပြီးဖြစ်ပါသည်။ယ္ခုအခါခွင့်ပြုမိန့် အတည်ပြုထုတ်ပေးရန်တင်ပြထားရာ ခွင့်ပြုမိန့်အတွက်အင်္ဂလိပ်ဘာသာပြန်ဆိုရာတွင် **"ဆက် စပ် လျှက်ရှိ သောပစ္စည်းများထုတ်လုပ်ခြင်း"** ဟူသော အသုံးအနှုန်းအားချန်လှပ်ထားကြောင်းသိရှိရပါသဖြင့် မိမိတို့ဆေးဝါးထုတ်လုပ်သည့်လုပ်ငန်းသည် ဆေးဝါးထုတ်လုပ်သည့်အချိန် နှင့် တပြေးညီ Quality Packaging Material များအား လုပ်ငန်းလိုအပ်ချက်အရလည်းကောင်း ၊ ဆေးဝါး Packaging အတုအပပြုလုပ်မှုကို ရှောင်ကျဉ်ရန်အတွက်သော်လည်းကောင်း၊ အရည်အသွေးအရလည်းကောင်း၊ Packaging Material များ ကို ပြည်တွင်းတွင်ဝယ်ယမရရှိနိုင်သည့်အခါ (သို့) ပြည်ပမှတင်သွင်းသည့် အခါ Packaging Material များ ၏ အခွန်အခ နှုန်းထား များသည် ထုပ်လုပ်ပြီး ကုန်ချောဆေးဝါး Finished Products Import တန်ဖိုး နှုန်းထားထက် ပိုမိုမြင့်မားသည့် အခါမျိုးတွင် သော်လည်းကောင်း မိမိတို့ကိုယ်တိုင်တင်သွင်းသည့် Raw Packaging Material များအား ပုံသွင်းခြင်း၊ တံဆိပ်ရိုက်ခြင်း စသဖြင့် ကိုယ်တိုင်ထုတ်လုပ်၍အသုံးပြုရမည်ဖြစ်ပါသည်။ သို့ဖြစ်ပါ၍ MIC မှ အတည်ပြု ထုတ်ပေးသည့် အချိန်တွင် ရင်းနှီးမြှုပ်နှံ မှုပြုလုပ်မည့် လုပ်ငန်း အမျိုး အစား အား **"ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျှက်ရှိသောပစ္စည်း များ ထုတ်လုပ်ခြင်းလုပ်ငန်း"** အနေနှင့် မဖြစ်မနေဆောင်ရွက်ရမည်ဖြစ်ပါသောကြောင့် MIC ခွင့်ပြုမိန်အတွက် အင်္ဂလိပ် ဘာသာပြန်ဆိုရာ တွင် (ဆက်စပ် လျှက်ရှိသော ပစ္စည်းများထုတ်လုပ်ခြင်း)ဆိုသည့် စကားရပ်အား ချန်လှပ်ထားပါက ရှေ့လျှောက် လုပ်ငန်းများဆက်လက် ဆောင်ရွက်ရာတွင် များစွာ အဆင်မပြေ ပါကြောင်းနှင့် တပါတည်း ဖြည့်စွက် ဘာသာပြန်ဆိုပေးနိုင်ပါရန် တင်ပြအပ်ပါသည်။

လေးစားစွာဖြင့်

ဦးဇော်မိုးခိုင်
Managing Director
Pacific Medical Industries Ltd.,

PACIFIC Pacific Medical Industries Ltd.

Head Office: No.408/410, #07th Floor, Mahabandoola Street, Kyauktada Township, Yangon, Myanmar.
Tel: (95-1) 391644-50, 249592-3 Fax: (95-1) 249718

Factory: No.209/210/211, Corner of Khun Act Minthar Street and Kannar Street, City of Industry, Dagon Seikkan Township, Yangon, Myanmar. Tel: (95-1) 592223, 592124

သို့

ဥက္ကဋ္ဌ
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

ရက်စွဲ။ ။ ၂၀၁၉ခုနှစ်၊ မတ်လ (၁၉) ရက်။

အကြောင်းအရာ။ ။ Pacific Medical Industries Ltd အတွက် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုခွင့်ပြုမိန့်အား အတည်ပြုထုတ်ပေးပါရန် လျှောက်ထားခြင်း။

Pacific Medical Industries Ltd သည် မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ ခွင့်ပြုမိန့်အမှတ် မနသ-၀၀၁/၂၀၁၁ (ယာယီ)အရ မြန်မာနိုင်ငံတွင် ပထမဦးဆုံး တည်ဆောက်သည့် အနောက်တိုင်း ဆေးဝါးထုတ်လုပ်သည့် စက်ရုံဖြစ်ပါသည်။ ကျန်းမာရေးနှင့်အားကစားဝန်ကြီးဌာန၊ အစားအသောက်နှင့်ဆေးဝါးကွပ်ကဲရေးဦးစီးဌာနမှ ဆေးဝါး ထုတ်လုပ်ခွင့်လိုင်စင်ကို ၂၀၁၇ခုနှစ်၊ နိုဝင်ဘာလ (၂၀) ရက်နေ့တွင်လည်းကောင်း၊ စက်မှုဝန်ကြီးဌာနမှ ပုဂ္ဂလိက စက်မှုလုပ်ငန်းမှတ်ပုံတင်လက်မှတ်ကို ၁၁-၁၂-၂၀၁၇ ရက်နေ့တွင်လည်းကောင်းရရှိခဲ့ပါသည်။ ထိုသို့အသီးသီး ရရှိခဲ့ပါသော်လည်း မြန်မာနိုင်ငံအစားအသောက်နှင့်ဆေးဝါးကွပ်ကဲရေးဦးစီးဌာန၏ တည်ဆဲဥပဒေ၊ အမျိုးသား ကျန်းမာရေးဥပဒေများနှင့်စပ်ဆက်လျှက်ရှိသော ညွှန်ကြားချက်များအရ စီးပွားဖြစ်ဆေးဝါးထုတ်လုပ်နိုင်ရန်အတွက် ဆေးဝါးတစ်ခုချင်းစီ၏ မှတ်ပုံတင် (Drug Registration Certificate) ဆေးဝါးမှတ်ပုံတင်ရရှိမှသာ ဆေးဝါးထုတ်လုပ်မှု စတင်နိုင်မည်ဖြစ်ပါသည်။ သို့ဖြစ်ပါ၍ ရင်းနှီးမြှုပ်နှံ မှုခွင့်ပြုမိန့် (MIC Permit) အား အတည်ပြုထုတ်ပေးနိုင်ပါရန် လျှောက်ထားတင်ပြအပ်ပါသည်။

ထို့အပြင် မြန်မာနိုင်ငံအစားအသောက်နှင့်ဆေးဝါးကွပ်ကဲရေးဦးစီးဌာနမှ ထုတ်ပေးသည့် Drug Registration Certificate တွင် ဖော်ပြထားသည့် DRC ထုတ်ပေးသည့် ရက်စွဲနှင့် မိမိတို့အမှန်တကယ် လက်ခံရရှိသည့် ရက်စွဲမှာလည်း ၂လခန့်ကွာသောကြောင့် စီးပွားဖြစ် Commercial ဆေးဝါးထုတ်လုပ်သည့်ရက်အား DRC လက်ခံရရှိသည့် နေ့စွဲ (၁၃.၀၉.၂၀၁၈) နောက်ပိုင်းမှသာစ၍ သတ်မှတ်ပေးပါရန်နှင့် မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှုကော်မရှင်၏ တရားဝင်အတည်ပြု လိုင်စင်ရရှိပြီးနောက် နောက်ဆက်တွဲ ခံစားခွင့်များထဲမှ တစ်ခုအပါအဝင်ဖြစ်သည့် အခွန်ကင်းလွတ်ခွင့် ကာလသတ်မှတ်ရာတွင်လည်း စီးပွားဖြစ် Commercial ဆေးဝါးထုတ်လုပ်နိုင်သည့် အချိန်မှစ၍ သတ်မှတ်ပေးပါရန် လေးစားစွာ တင်ပြအပ်ပါသည်။

လေးစားစွာဖြင့်

ဦးဇော်မိုးနိုင်
Managing Director
Pacific Medical Industries Ltd

INDEX

၁။ အဆောက်ဦးတည်ဆောက်ပြီးစီးမှုအခြေနေ

၂။ ကုန်ပစ္စည်းတင်သွင်းပြီးစီးမှုအခြေအနေ

၃။ ရင်းနှီးမြှုပ်နှံမှုစီမံချက် (Investment Plan)

၄။ FDA ဆေးဝါးထုတ်လုပ်ခွင့်လိုင်စင် နှင့် DRC ရရှိမှု အခြေအနေ

၅။ ဝန်ထမ်းခန့်ထားမှု အခြေပြဇယား

၆။ ပုဂ္ဂလိက စက်မှုလုပ်ငန်းမှတ်ပုံတင်လတ်မှတ်

၇။ ဘွိုင်လာ အသုံးပြုခွင့်လတ်မှတ်

၈။ YCDC - Certificate

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
ယာယီခွင့်ပြုမိန့်

ပုံစံ(မနသ-၂)

ခွင့်ပြုမိန့်အမှတ်၊ မနသ-၀၀၁/၂၀၁၁(ယာယီ)။ ၂၀၁၁ ခုနှစ်၊ ဒီဇင်ဘာလ ၂၆ ရက်။

မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှု ကော်မရှင်သည် မြန်မာနိုင်ငံသားများ ရင်းနှီးမြှုပ်နှံမှု ဥပဒေ ၁၀ အရ ဤ ခွင့်ပြုမိန့်ကို ယာယီ ထုတ်ပေးလိုက်သည်။

(က)	ရင်းနှီးမြှုပ်နှံသူအမည်	ဦးဇော်မိုးနိုင်
(ခ)	အဘအမည်	ဦးမြတ်သင်းအောင်
(ဂ)	နိုင်ငံသား/အမျိုးသားမှတ်ပုံတင်အမှတ်	၁၂/ကတတ(နိုင်)၀၂၈၃၄၄
(ဃ)	နေရပ်လိပ်စာ	အမှတ် (၁၂၆) ၊ ၃၅ လမ်း၊ ကျောက်တံတားမြို့နယ် ၊ ရန်ကုန်တိုင်းဒေသကြီး။
(င)	ဖွဲ့စည်းထားသည့်(သို့မဟုတ်) ဖွဲ့စည်းမည့်အဖွဲ့အမည်	ပစိဖိတ် ဆေးပစ္စည်း လုပ်ငန်း လီမိတက် (Pacific Medical Industries Ltd.)
(စ)	ရင်းနှီးမြှုပ်နှံမှုပြုလုပ်မည့်လုပ်ငန်း အမျိုးအစား	ဆေးဝါးထုတ်လုပ်ခြင်းနှင့်ဆက်စပ်လျက်ရှိသောပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်း
(ဆ)	ရင်းနှီးမြှုပ်နှံမှုပြုလုပ်သည့်အရပ် ဒေသ(များ)	မြေကွက် အမှတ် (၂၀၉၊ ၂၁၀၊ ၂၁၁)၊ စက်မှုဇုန်(၁)၊ ဒဂုံမြို့သစ်ဆိပ်ကမ်းမြို့နယ်၊ ရန်ကုန်တိုင်း ဒေသကြီး။

ဥက္ကဋ္ဌ
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

မှတ်ချက်

- ရင်းနှီးမြှုပ်နှံသူသည် ပူးတွဲပါ ကတိဝန်ခံချက် နှင့်အညီ လုပ်ငန်းများ ဆောင်ရွက်ရန်ဖြစ်ပြီး သတ်မှတ် စည်းမျဉ်း၊ စည်းကမ်းများနှင့်အညီ လိုက်နာဆောင်ရွက်ရန် ပျက်ကွက်လျှင် ဖြစ်စေ၊ သတ်မှတ်ကာလ အတွင်း ပြီးမြောက် အောင် အကောင်အထည်ဖော်နိုင်ခြင်း မရှိလျှင်ဖြစ်စေ ဤယာယီခွင့်ပြုမိန့်သည် အလိုအလျောက်ပျက်ပြယ်မည်။

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
ရုံးအမှတ်(၃၂)၊ နေပြည်တော်

ဖက်(စ်) ၉၅-၆၇-၄၀၆၁၀၆၀ | စာအမှတ်ရက-၆(က)/မ- ၁၁၈၄/၂၀၁၃(၂၉၅၅၉)
☎-၀၆၇-၄၀၆၁၃၃၄၊ ၄၀၆၃၆၂ | ရက်စွဲ၊ ၂၀၁၃ ခုနှစ် ဒီဇင်ဘာလ ၅ ရက်

သို့

မန်နေဂျင်းဒါရိုက်တာ
Pacific Medical Industries Ltd.

အကြောင်းအရာ။ Pacific Medical Industries Ltd. မှ ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းစက်ရုံ တည်ဆောက်ရေး ကာလ သက်တမ်း(၁)နှစ် တိုးမြှင့်ခွင့်ပြုပါရန် တင်ပြခြင်းကိစ္စ

ရည် ညွှန်း ချက် ။ Pacific Medical Industries Ltd. ၏ (၆-၁၁-၂၀၁၃) ရက်စွဲပါတင်ပြစာ

၁။ Pacific Medical Industries Ltd. မှ ဆေးဝါးစက်ရုံ တည်ဆောက်ရေး ကာလ သက်တမ်း(၁)နှစ်တိုးမြှင့်ခွင့်ပြုပါရန်ရည်ညွှန်းချက်ပါစာဖြင့်တင်ပြခြင်းကိုကော်မရှင်၏(၃၀/၂၀၁၃) (၆-၁၁-၂၀၁၃) အစည်းအဝေးသို့ တင်ပြခဲ့ရာ အောက်ပါအတိုင်း ဆုံးဖြတ်ခဲ့ပါသည်-

" PacificMedical Industries Ltd. မှ ဆေးဝါးထုတ်လုပ်ခြင်းနှင့်ဆက်စပ်လျက်ရှိသော ပစ္စည်းများ ထုတ်လုပ်ခြင်းစက်ရုံ. တည်ဆောက်ရေး ကာလအား [redacted] မှ [redacted] အထိ ပထမအကြိမ် ၁ နှစ် တည်ဆောက်ရေးကာလ တိုးမြှင့်ခွင့်ပြုရန်"

၂။ သို့ဖြစ်ပါ၍ အထက်ပါအစည်းအဝေး ဆုံးဖြတ်ချက်ကို သိရှိနိုင်ပါရန်နှင့် လိုအပ်သလို ဆက်လက် ဆောင်ရွက်နိုင်ပါရန် အကြောင်းကြားပါသည်။

ဥက္ကဋ္ဌ(ကိုယ်စား)
(အောင်နိုင်ဦး၊ ညွှန်ကြားရေးမှူးချုပ်)

မိတ္တူ

ရုံးလက်ခံ/ မျှောစာတွဲ

Myanmar Investment Commission

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်

မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

အမှတ်(၁)၊ သစ္စာလမ်း၊ ရန်ကင်းမြို့နယ်၊ ရန်ကုန်မြို့

တယ်လီဖုန်း-၀၁-၆၅၈၁၃၃ — စာအမှတ် ၊ ရကာ- ၉ / ၁ / ၂၀၁၅ (၀၀၅၉၀)

ဖက်(စ်)-၀၁-၆၅၇၈၂၄ — ရက်စွဲ ၂၀၁၅ ခုနှစ်၊ မတ်လ ၂၄ ရက်

အကြောင်းအရာ။ Pacific Medical Industries Ltd. ၏ ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသောပစ္စည်းများ ထုတ်လုပ်ခြင်းလုပ်ငန်းတွင် အသုံးပြုရန်အတွက် စက်ပစ္စည်းများနှင့်လုပ်ငန်းသုံးပစ္စည်းများအား ရင်းနှီးမြှုပ်နှံမှု တိုးမြှင့်၍ အခွန်အကောက် ကင်းလွတ်ခွင့်ဖြင့် တင်သွင်းခွင့်ပြုပါရန်နှင့် တည်ဆောက်ရေးကာလ တိုးမြှင့်ခွင့်ပြုပါရန် တင်ပြလာခြင်းကိစ္စ

ရည်ညွှန်းချက်။ Pacific Medical Industries Ltd. ၏ ၂၀၁၅ ခုနှစ်၊ ဇန်နဝါရီလ ၁၂ရက်နေ့ ရက်စွဲပါစာအမှတ်၊ 004/ PMIL / 2015

၁။ Pacific Medical Industries Ltd. ၏ ဆေးဝါးထုတ်လုပ်ခြင်းနှင့် ဆက်စပ်လျက်ရှိသောပစ္စည်းများထုတ်လုပ်ခြင်းလုပ်ငန်းတွင်အသုံးပြုရန်လိုအပ်သည့် စက်ပစ္စည်းနှင့်လုပ်ငန်းသုံးပစ္စည်းများ တန်ဖိုးအမေရိကန်ဒေါ်လာ ၁၄,၉၄၆,၀၆၉.၇၀ အား ရင်းနှီးမြှုပ်နှံမှုတိုးမြှင့်ပြီး ပြည်ပမှ အခွန်အကောက် ကင်းလွတ်ခွင့်ဖြင့် တင်သွင်းခွင့်ပြုပါရန် နှင့် တည်ဆောက်ရေးကာလအား မူလသက်တမ်းကုန်ဆုံးသည့်နေ့ ၂၀၁၄ ခုနှစ်၊ ဒီဇင်ဘာလ ၂၅ ရက်နေ့ မှ ၂၀၁၅ ခုနှစ်၊ ဒီဇင်ဘာလ ၂၅ ရက်နေ့ အထိ ၁၂ လ တိုးမြှင့်ခွင့်ပြုပါရန် ရည်ညွှန်းပါစာဖြင့် တင်ပြလာခြင်းအပေါ် ကော်မရှင်မှ အောက်ပါအတိုင်း ခွင့်ပြုကြောင်း အကြောင်းကြားပါသည်-

(က) တည်ဆောက်ရေးကာလအား မူလသက်တမ်း ကုန်ဆုံးသည့် ၂၀၁၄ ခုနှစ်၊ ဒီဇင်ဘာလ ၂၅ ရက်နေ့မှ ၂၀၁၅ ခုနှစ်၊ ဒီဇင်ဘာလ ၂၅ ရက်နေ့အထိ ၁၂ လ တိုးမြှင့်ခွင့်ပြုကြောင်း၊

(ခ) ဈေးနှုန်းမြင့် ကာကွယ်ခြင်းကြောင့် ကျော်လွန်တင်သွင်းခဲ့သည့် အမေရိကန်ဒေါ်လာ ၃.၀၈ သန်း နှင့် လုပ်ငန်းလိုအပ်ချက်အရ ထပ်မံတင်သွင်းမည့် စက်ပစ္စည်းနှင့် လုပ်ငန်းသုံးပစ္စည်း ၁၂၇၉ မျိုး တန်ဖိုး အမေရိကန်ဒေါ်လာ ၁၁.၈၇ သန်း အပါအဝင် စုစုပေါင်း အမေရိကန်ဒေါ်လာ ၁၄.၉၅ သန်း အား ရင်းနှီးမြှုပ်နှံမှု ပမာဏတွင်တိုးမြှင့်ခွင့်ပြုကြောင်း၊

၂။ သို့ဖြစ်ပါ၍ ကော်မရှင် ဆုံးဖြတ်ချက်အား သိရှိနိုင်ပါရန် နှင့် လိုအပ်သလိုဆက်လက် ဆောင်ရွက်နိုင်ပါရန် အကြောင်းကြားပါသည်။

ဥက္ကဋ္ဌ (ကိုယ်စား)
(မြသူဓာ၊ တွဲဖက်အတွင်းရေးမှူး)

မန်နေဂျင်းဒါရိုက်တာ
Pacific Medical Industries Ltd.

မိတ္တူကို
ရုံးလက်ခံ / မျှောစာတွဲ

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်
အမှတ်(၁)၊ သစ္စာလမ်း၊ ရန်ကင်းမြို့နယ်၊ ရန်ကုန်မြို့

[illegible]-၆၅၇၈၂၄
ဖက်(စ်)-၀၁-၆၅၇၈၂၄

စာအမှတ်၊ ရကာ - ၉ / ၁ / ၂၀၁၆ (၁၇၂၀)
ရက်စွဲ ၊ ၂၀၁၆ ခုနှစ်၊ မတ် လ ၁၇ ရက်

အကြောင်းအရာ။ Pacific Medical Industries Ltd.မှ တည်ဆောက်ရေးကာလ တိုးမြှင့်ခွင့် ပြုပါရန် တင်ပြလာခြင်းကိစ္စ

ရည်ညွှန်းချက်။ Pacific Medical Industries Ltd. ၏ ၂၀၁၆ ခုနှစ်၊ ဖေဖော်ဝါရီ လ ၄ ရက် နေ့ ရက်စွဲပါ စာအမှတ်၊ 016/ PMIL/ 2016

၁။ Pacific Medical Industries Ltd. မှ ရည်ညွှန်းပါစာဖြင့် တင်ပြလာသည့်ကိစ္စနှင့်စပ်လျဉ်း၍ မြန်မာနိုင်ငံရင်းနှီးမြှုပ်နှံမှုကော်မရှင်မှ ဆေးဝါးစက်ရုံ တည်ဆောက်ရေးကာလအား ၂၀၁၅ ခုနှစ် ဒီဇင်ဘာလ ၂၆ ရက်နေ့ မှ ၂၀၁၆ ခုနှစ် ဇွန် လ ၂၅ ရက်နေ့အထိ နောက်ထပ် (၆)လတာ ထပ်မံ တိုးမြှင့်ခွင့်ပြုပါသည်။

၂။ သို့ဖြစ်ပါ၍ ကော်မရှင် ဆုံးဖြတ်ချက်အား သိရှိနိုင်ပါရန်နှင့် လိုအပ်သလို ဆက်လက် ဆောင်ရွက်နိုင်ပါရန် အကြောင်းကြားပါသည်။

ဦး[illegible](ကိုယ်စား)
([illegible]တွဲဖက်အတွင်းရေးမှူး)

မန်နေဂျင်းဒါရိုက်တာ
Pacific Medical Industries Ltd.

မိတ္တူကို
ညွှန်ကြားရေးမှူးချုပ်၊ အကောက်ခွန်ဦးစီးဌာန
ညွှန်ကြားရေးမှူးချုပ်၊ ကုန်သွယ်ရေးဦးစီးဌာန
ရုံးလက်ခံ / မျှောစာတွဲ

၁။ အဆောက်ဦးတည်ဆောက်ပြီးစီးမှုအခြေနေ

Pacific Medical Industries Ltd.

Head Office : No. 408/410,#07th floor, Samsung Plaza, Mahabandoola street, Kyauktada Tsp.
Yangon, Myanmar. Tel: (95-1)391644~50,249592~3,Fax (95-1)249718
Factory : No. 209,210,211, Corner of Khun It Thar Minthar street and Kannar street, City of Industry, Dagon Seikkan Tsp.,Yangon, Myanmar. Tel: (95-1) 592223,592124.

သို့

အတွင်းရေးမှူး
မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

ရက်စွဲ။ ။၂၀၁၉ ခုနှစ်၊ မတ်လ(၁၉)ရက်

အကြောင်းအရာ။ ။ အဆောက်အဦးတည်ဆောက်ပြီးစီးမှု အခြေအနေ တင်ပြခြင်း။

Pacific Medical Industries Ltd ၏ MIC သို့ မူလ တင်ပြထားသည့် Proposal တွင် ဆေးဝါး ထုတ်လုပ်ခြင်း ဆိုင်ရာ လုပ်ငန်းများနှင့် ပါတ်သက်၍ လုပ်ဆောင်နိုင်ရန် ဒဂုံဆိပ်ကမ်း စက်မှုမြို့တော် အတွင်းရှိ ကမ်းနား လမ်းနှင့် ခွန်းအိပ်သား မင်းသားလမ်းထောင့် ရှိ မြေ (၅.၄၉၁) ဧက အကျယ်အဝန်းပေါ်တွင် ပေ၃၀၀ x ပေ ၈၀ နှစ်ထပ် အဆောက်အဦး နှစ်လုံး ပေ၁၅၀ x ပေ ၁၀၀ တစ်ထပ် အဆောက် အဦး တည်ဆောက်ရန် တင်ပြထားခဲ့ပါသည်။

ယခုအခါ ပထမအဆင့်အနေနှင့် ဆေးဝါးများ ထုပ်လုပ်နိုင်သည့် အဆောက်အဦးနှင့် အရည်အသွေး စစ်ဆေးမှုဆိုင်ရာနှင့် စီမံခန့်ခွဲမှုဆိုင်ရာလုပ်ငန်းများ ဆောင်ရွက်နိုင်မည့် ပေ ၃၀၀ x ပေ၈၀ နှစ်ထပ် အဆောက်အဦး (၂) လုံး ကို ၁၀၀% ဆောက်လုပ်ပြီးစီးပြီး ဆေးဝါးထုတ်ရန် လိုအပ်သည့် စက်ပစ္စည်းများ၊ ဓါတ်ခွဲခန်း သုံးပစ္စည်းများအား တပ်ဆင်ပြီးစီး၍ စမ်းသပ်လည်ပါတ်လျှက်ရှိပါကြောင်းနှင့် လက်ရှိအဆောက်အဦး နှစ်လုံးဖြင့် ဆေးဝါးထုတ်လုပ်မှုအတွက်လုံလောက်ခြင်း၊ သတ်မှတ်ထားသော budget မြန်မာကျပ်ငွေ (၂၄,၈၀၆,၂၈၉,၆၅၀) ထက်ကျော်လွန်နေပြီးဖြစ်သဖြင့် Proposal တွင်တင်ပြထားသော ပေ ၁၅၀ x ပေ ၁၀၀ တစ်ထပ် အဆောက်အဦးမှာ လက်ရှိအခြေအနေတွင် ထပ်မံတည်ဆောက်ရန်မလိုအပ်တော့ပါ။

သို့ဖြစ်ပါ၍ ကျန်အဆောက်အဦးနှစ်လုံးဖြင့် စက်ရုံတည်ဆောက်မှု ၁၀၀% ပြီးစီးပါကြောင်း တင်ပြအပ်ပါသည်။

တည်ဆောက်ပြီးစီးမှုအနေအထား အား ပူတွဲပါအတိုင်းတင်ပြအပ်ပါသည်။

လေးစားစွာဖြင့်

ဦးဇော်မိုးနိုင်

Managing Director
Pacific Medical Industries Ltd.,

(I) Photo of Building



Pacific Medical Industries Ltd.

(I) Photo of Building



Office Building (Right Side View)



Office Building (Back Side View)

(II) Photo of Work Place



Work Place (Quality Control Area)



Work Place (Quality Control Area)

(III) Photo of Machines (Quality Control)



HPLC (High Performance Liquid Chromatography)



Stability Chamber

(III) Photo of Machines (Research and Development)



HPLC (High Performance Liquid Chromatography)



Stability Chamber

(III) Photo of Machines (Research and Development)



Equipment (Density Apparatus , Sieve shaker,Disintegration Machine,Friability,Hardness tester,Moisture analyser,Weighing Balance)



Manual capsule filling machine, Induction cap sealer

(III) Photo of Machines (Research and Development)



Blister Packing Machine



Tablet Compression Machine

(IV) Photo of Building



Pacific Medical Industries Ltd.

(IV) Photo of Building



Manufacturing Building (Right Side View)



Manufacturing Building (Left Side View)

(VI) Photo of Machines (Manufacturing)



High Speed Mixer



Fluid Bed Dryer

(VI) Photo of Machines (Manufacturing)



IBC Blender
(Intermediate Bulk Container)



Capsule Filling Machine

(VI) Photo of Machines (Manufacturing)



Rotary Tablet Press Machine



Coating Machine

(VI) Photo of Machines (Manufacturing)



Blister Packaging Machine



Bottle Filling Machine

(VI) Photo of Machines (Manufacturing)



Sachet Packaging Machine




Strip Packaging Machine

(VI) Photo of Machines (Utility)



300kVA Generator Set 1



500kVA Generator Set 2

(VI) Photo of Machines (Utility)



Boiler System (1+2)



Oil Free Compress Air System

(VI) Photo of Machines (Utility)



Purified Water System



Air Handling Unit (AHU)

(VII) Photo of Raw Materials



Raw Materials

(V) Photo of Work Place



Work Place (Manufacturing Area)



Lighting Fixture Design of Work Place

၂။ ကုန်ပစ္စည်းတင်သွင်းပြီးစီးမှုအခြေအနေ

Pacific Medical Industries Ltd.

Head Office : No. 408/410,#07th floor, Samsung Plaza, Mahabandoola street, Kyauktada Tsp. Yangon, Myanmar. Tel: (95-1)391644~50,249592~3,Fax (95-1)249718

Factory : No. 209,210,211, Corner of Khun It Thar Minthar street and Kannar street, City of Industry, Dagon Seikkan Tsp.,Yangon, Myanmar. Tel: (95-1) 592223,592124.

သို့

အတွင်းရေးမှူး
မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

ရက်စွဲ၊ ၊ ၂၀၁၉ ခုနှစ်၊ မတ်လ(၁၉)ရက်

အကြောင်းအရာ၊ ၊ ကုန်ပစ္စည်းတင်သွင်းပြီးစီးမှု အခြေအနေ တင်ပြခြင်း။

Pacific Medical Industries Ltd ၏ MIC သို့ မှလာ တင်ပြထားသည့် Proposal Annex-4,5,6 အပေါ် အခြေခံ၍ MIC ခွင့်ပြုချက်ဖြင့် တင်သွင်းခွင့်ရရှိခဲ့သော အမေရိကန်ဒေါ်လာ (၁၉,၇၆၄,၆၉၄.၇၃) တန်ဖိုးအနက် အမေရိကန်ဒေါ်လာ (၅,၄၆၆,၁၀၂.၄၇) တန်ဖိုးရှိ ပစ္စည်းများအားတင်သွင်းခဲ့ပြီး အမေရိကန်ဒေါ်လာ (၁၄,၂၉၈,၅၉၂.၂၆) တန်ဖိုးရှိ ပစ္စည်းများတင်သွင်းရန်ကျန်ရှိနေပါသေးသည်။ (အသေးစိတ်စာရင်းအားပူးတွဲ ဖေါ်ပြထားပါသည်)။ သို့ဖြစ်ပါ၍ ရင်းနှီးမြှုပ်နှံမှုကော်မရှင်မှခွင့်ပြုပြီး တင်သွင်းရန်ကျန်ရှိသောပစ္စည်းများကို ဆက်လက်တင်သွင်းလိုပါကြောင်း တင်ပြအပ်ပါသည်။

လေးစားစွာဖြင့်

ဦးဇော်မိုးနိုင်
Managing Director
Pacific Medical Industries Ltd.,

စဉ်		ပစ္စည်းအမျိုးအစား	ရေတွက်ပုံ	Proposal မှ ခွင့်ပြုစာရင်း			တင်သွင်းပြီးစာရင်း				Proposal ခွင့်ပြု စာရင်းမှ တင်သွင်းရန်လက်ကျန်စာရင်း		Remark
				အရေအတွက်	ဈေးနှုန်း (USD)	တန်ဖိုး (US$)	Exp No	ID No./ Date	အရေအတွက်	တန်ဖိုး (US$)	အရေအတွက်	တန်ဖိုး (US$)	
1	0288	Air curtain	Pcs	10	687.60	6,876.00				-	10.00	6876.00	
2	0288	Air Handling Unit	Set	10	85,200.00	852,000.00	5406	151354(19.8.15)	7	596,400.00	3	255600.00	Returned to apply 01164
3	0288	Blister machine	Set	3	165,000.00	495,000.00	5580	184031(13.11.15)	1	165,000.00	2	330000.00	
4	0288	Boiler	Set	2	68,400.00	136,800.00	5326	122668(3.6.15)	1	68,400.00	1	68400.00	
5	0288	Bottle packaging M/C (Bottle wash,Desiccant inserter,Tablet counting &Capping Machine, etc)	Set	2	150,500.00	301,000.00	5465	151354(19.8.15)	1	150,500.00	1	150500.00	
6	0288	Bottle washing and Liquid filling & capping M/C	Set	1	147,000.00	147,000.00				-	1	147000.00	
7	0288	Capsule Filling and polishing Machine	Set	2	131,880.00	263,760.00	5122	196800(2.2.15)	1	131,880.00	1	131880.00	
8	0288	Capsule inspection machine (Manual)	Set	1	28,800.00	28,800.00				-	1	28800.00	
9	0288	Clean Booth	Pcs	1	5,184.00	5,184.00				-	1	5184.00	
10	0288	Coating Machine	Set	2	159,900.00	319,800.00	5122	196800(2.2.15)	1	159,900.00	1	159900.00	
11	0288	Coating preparation tank & stirrer	Set	1	7,800.00	7,800.00				-	1	7800.00	
12	0288	Door &Window	Set	250	510.96	127,740.00	5211 5212	101505(101496(3.4.15)	233	119,053.68	17	8686.32	
13	0288	Dry Cabinet for manufacturing tool	Pcs	1	2,208.00	2,208.00				-	1	2208.00	
14	0288	Dry Powder filling M/C	Set	1	42,000.00	42,000.00				-	1	42000.00	

15	0288	Dust collector	Set	5	43,320.00	216,600.00				-	5	216600.00	Returned to apply 01164
16	0288	Elevator	Set	2	46,000.00	92,000.00	5342	132782(29.7.15)	2	92,000.00	-	0.00	
17	0288	EPS panel (expanded poly stylene)m²	m²	8423	13.88	116,911.24	5211	101505(	8258.2	114,623.82	165	2287.42	
18	0288	Fluid Bed Dryer	Set	2	262,680.00	525,360.00	5122	196800(2.2.15)	1	262,680.00	1	262680.00	
19	0288	Hardness & thickness tester (with Printer)	Pcs	2	20,352.00	40,704.00				-	2	40704.00	
20	0288	High Speed Mixer	Set	2	146,340.00	292,680.00	5122	196800(2.2.15)	1	146,340.00	1	146340.00	
21	0288	IBC blend M/C	Set	1	70,752.00	70,752.00				-	1	70752.00	
22	0288	Inkjet Printer	Pcs	1	14,142.00	14,142.00				-	1	14142.00	
23	0288	Inter lock system	Set	30	1,056.00	31,680.00				-	30	31680.00	
24	0288	Liquid(Syrup) Preparation Tank	Set	1	85,800.00	85,800.00				-	1	85800.00	
25	0288	Metal detector	Set	6	17,280.00	103,680.00				-	6	103680.00	
26	0288	Oil free compressed air system	Set	1	324,000.00	324,000.00				-	1	324000.00	
27	0288	Ointment Filling Mahcine(AL.Tube)	Set	1	132,850.00	132,850.00				-	1	132850.00	
28	0288	Ointment Preparation Tank	Set	1	172,680.00	172,680.00				-	1	172680.00	
29	0288	PolyUrethane panel(m²)	m²	10493	19.55	205,138.15	5212	101496(3.4.15)	10150.8	198,448.14	342	6690.01	
30	0288	PolyUrethane Roof Panel	m²	12900	23.80	307,020.00				-	12,900	307020.00	
31	0288	Purified Water System	Set	1	458,040.00	458,040.00				-	1	458040.00	
32	0288	Roller compactor	Set	1	138,000.00	138,000.00				-	1	138000.00	
33	0288	Sechet Filing Machine	Set	2	175,900.00	351,800.00	5424	141075(	1	175,900.00	1	175900.00	
34	0288	Strip filling machine	Set	1	173,700.00	173,700.00	5424	141075(	1	173,700.00	-	0.00	
35	0288	Tablet Inspector by Manual	Set	1	31,200.00	31,200.00				-	1	31200.00	
36	0288	Tablet press 1-4	Set	4	205,200.00	820,800.00	5122	196800(2.2.15)	1	205,200.00	3	615600.00	
37	0288	Weighing Booth	Set	3	23,700.00	71,100.00			2	47,400.00	1	23700.00	
38	0288	Air sampler	Pcs	5	4,840.00	24,200.00	5443	153806(26.8.2015)	3	14,520.00	2	9680.00	
39	0288	Analytical Balance _ Printer	Set	3	4,560.00	13,680.00	5443	153806(26.8.2015)	1	4,560.00	2	9120.00	

40	0288	Atomic Absorption Spectrometer	Set	1	41,750.00	41,750.00	5443	153806(26.8.2015)	1	41,750.00	-	0.00	
41	0288	Autoclave (sliding)	Set	1	61,100.00	61,100.00	5443	153806(26.8.2015)	1	61,100.00	-	0.00	
42	0288	Autoclave for waste (Vertical)	Pcs	1	3,110.00	3,110.00	5443	153806(26.8.2015)	1	3,110.00	-	0.00	
43	0288	Centrifuge	Pcs	2	3,110.00	6,220.00	5443	153806(26.8.2015)	2	6,220.00	-	0.00	
44	0288	Clean Bench	Set	1	4,320.00	4,320.00	5443	153806(26.8.2015)	1	4,320.00	-	0.00	
45	0288	Density meter	Set	1	24,270.00	24,270.00	5443	153806(26.8.2015)	1	24,270.00	-	0.00	
46	0288	Desiccator	Pcs	1	2,720.00	2,720.00				-	1	2720.00	
47	0288	Disintegration Tester	Set	1	2,140.00	2,140.00	5443	153806(26.8.2015)	1	2,140.00	-	0.00	
48	0288	Dissolution tester	Set	1	8,250.00	8,250.00	5443	153806(26.8.2015)	1	8,250.00	-	0.00	
49	0288	Dry oven	Pcs	3	3,080.00	9,240.00	5443	153806(26.8.2015)	3	9,240.00	-	0.00	
50	0288	Dry Oven(Vaccum)	Pcs	1	8,510.00	8,510.00	5443	153806(26.8.2015)	1	8,510.00	-	0.00	
51	0288	Emergency Shower	Set	1	800.00	800.00	5443	153806(26.8.2015)	1	800.00	-	0.00	
52	0288	FT-IR spectrometer	Set	1	33,980.00	33,980.00	5443	153806(26.8.2015)	1	33,980.00	-	0.00	
53	0288	Fume hood	Set	1	5,667.00	5,667.00	5443	153806(26.8.2015)	1	5,667.00	-	0.00	
54	0288	Furnace	Pcs	1	2,400.00	2,400.00	5443	153806(26.8.2015)	1	2,400.00	-	0.00	
55	0288	Gas Chromatography	Set	1	29,130.00	29,130.00	5443	153806(26.8.2015)	1	29,130.00	-	0.00	
56	0288	Hardness tester	Set	1	16,960.00	16,960.00	5443	153806(26.8.2015)	1	16,960.00	-	0.00	
57	0288	HPLC with Autosampler	Set	2	50,480.00	100,960.00	5443	153806(26.8.2015)	1	50,480.00	1	50480.00	
58	0288	Incubator (20`25 degree)	Set	1	10,650.00	10,650.00	5443	153806(26.8.2015)	1	10,650.00	-	0.00	
59	0288	Incubator (35`37 degree)	Set	1	8,220.00	8,220.00	5443	153806(26.8.2015)	1	8,220.00	-	0.00	
60	0288	Karl-fisher titrator	Set	1	10,190.00	10,190.00	5443	153806(26.8.2015)	1	10,190.00	-	0.00	
61	0288	Laboratory water system	Set	2	6,020.00	12,040.00	5443	153806(26.8.2015)	2	12,040.00	-	0.00	
62	0288	Magnetic stirrer plate (+Hot)	Pcs	2	490.00	980.00	5443	153806(26.8.2015)	2	980.00	-	0.00	
63	0288	Melting Point Analyzer	Set	1	4,080.00	4,080.00	5443	153806(26.8.2015)	1	4,080.00	-	0.00	
64	0288	Microscope	Set	2	1,650.00	3,300.00	5443	153806(26.8.2015)	2	3,300.00	-	0.00	
65	0288	Moisture Analyzer _ Printer	Set	1	5,730.00	5,730.00	5443	153806(26.8.2015)	1	5,730.00	-	0.00	

66	0288	Particle analyzer for raw material	Set	1	13,560.00	13,560.00	5443	153806(26.8.2015)	1	13,560.00	-	0.00	
67	0288	pH/conductivity meter	Set	2	2,720.00	5,440.00	5443	153806(26.8.2015)	2	5,440.00	-	0.00	
68	0288	Pippet aid	Pcs	2	580.00	1,160.00	5443	153806(26.8.2015)	2	1,160.00	-	0.00	
69	0288	Pippet washer	Set	1	1,550.00	1,550.00	5443	153806(26.8.2015)	1	1,550.00	-	0.00	
70	0288	Polarimeter	Set	1	28,130.00	28,130.00	5443	153806(26.8.2015)	1	28,130.00	-	0.00	
71	0288	Potentiometric Auto titrator	Set	1	22,300.00	22,300.00	5443	153806(26.8.2015)	1	22,300.00	-	0.00	
72	0288	Refractometer	Set	1	20,360.00	20,360.00	5443	153806(26.8.2015)	1	20,360.00	-	0.00	
73	0288	Refrigerator & Freezer	Pcs	1	9,680.00	9,680.00	5443	153806(26.8.2015)	1	9,680.00	-	0.00	
74	0288	Refrigerator (+ Temperature Record)	Set	3	8,710.00	26,130.00	5443	153806(26.8.2015)	1	8,710.00	2	17420.00	
75	0288	Rotaray Evaporator _ (Aspirator)	Set	1	4,170.00	4,170.00	5443	153806(26.8.2015)	1	4,170.00	-	0.00	
76	0288	Separate funnel shaker	Pcs	1	3,690.00	3,690.00	5443	153806(26.8.2015)	1	3,690.00	-	0.00	
77	0288	Shaker	Pcs	1	1,940.00	1,940.00	5443	153806(26.8.2015)	1	1,940.00	-	0.00	
78	0288	Stability chamber (40C/75%RH)	Set	2	29,100.00	58,200.00	5443	153806(26.8.2015)	2	58,200.00	-	0.00	
79	0288	Stainless funnel for filter test	Set	1	2,520.00	2,520.00	5443	153806(26.8.2015)	1	2,520.00	-	0.00	
80	0288	Standard Material storagechanmber(1~30)	Set	1	6,770.00	6,770.00	5443	153806(26.8.2015)	1	6,770.00	-	0.00	
81	0288	TOC analyzer (Total Organic Carbon)	Set	1	45,770.00	45,770.00	5443	153806(26.8.2015)	1	45,770.00	-	0.00	
82	0288	Ultrasonic cleaner	Pcs	1	1,460.00	1,460.00	5443	153806(26.8.2015)	1	1,460.00	-	0.00	
83	0288	UV/Vis spectrophotometer	Set	1	14,560.00	14,560.00	5443	153806(26.8.2015)	1	14,560.00	-	0.00	
84	0288	Vaccum pump (for membrane filter test)	Set	1	390.00	390.00	5443	153806(26.8.2015)	1	390.00	-	0.00	
85	0288	Viscometer	Set	1	7,770.00	7,770.00	5443	153806(26.8.2015)	1	7,770.00	-	0.00	
86	0288	Voltex mixer	Pcs	2	580.00	1,160.00	5443	153806(26.8.2015)	2	1,160.00	-	0.00	
87	0288	Water bath	Pcs	3	630.00	1,890.00	5443	153806(26.8.2015)	3	1,890.00	-	0.00	
88	00147	HEPA FILTER BOX	SET	135	393.76	53,157.19	5407	149723 /14.8.15	135	53,157.19	-	0.00	
89	00147	HEPA FILTER BOX	SET	43	364.92	15,691.62	5407	149723 /14.8.15	43	15,691.62	-	0.00	

90	00147	HEPA FILTER BOX	SET	5	465.85	2,329.23	5407	149723 /14.8.15	5	2,329.23	-	0.00	
91	00147	CONDENSING UNIT-01	SET	1	3,788.22	3,788.22	5407	149723 /14.8.15	1	3,788.22	-	0.00	
92	00147	CONDENSING UNIT-02	SET	1	20,948.16	20,948.16	5407	149723 /14.8.15	1	20,948.16	-	0.00	
93	00147	CONDENSING UNIT-01	SET	1	12,563.88	12,563.88	5407	149723 /14.8.15	1	12,563.88	-	0.00	
94	00147	CONDENSING UNIT-01	SET	1	5,180.14	5,180.14	5407	149723 /14.8.15	1	5,180.14	-	0.00	
95	00147	CONDENSING UNIT-02	SET	1	54,242.94	54,242.94	5407	149723 /14.8.15	1	54,242.94	-	0.00	
96	00147	CONDENSING UNIT-01	SET	1	20,946.52	20,946.52	5407	149723 /14.8.15	1	20,946.52	-	0.00	
97	00147	CONDENSING UNIT-01	SET	1	36,229.83	36,229.83	5407	149723 /14.8.15	1	36,229.83	-	0.00	
98	00147	CONDENSING UNIT-01	SET	1	54,244.58	54,244.58	5407	149723 /14.8.15	1	54,244.58	-	0.00	
99	00147	CONDENSING UNIT-01	SET	1	25,200.89	25,200.89	5407	149723 /14.8.15	1	25,200.89	-	0.00	
100	00147	CONDENSING UNIT-01	SET	1	7,475.99	7,475.99	5407	149723 /14.8.15	1	7,475.99	-	0.00	
101	00147	CONDENSING UNIT-01	SET	1	25,200.89	25,200.89	5407	149723 /14.8.15	1	25,200.89	-	0.00	
102	00147	WATER TANK	SET	1	31,800.30	31,800.30				-	1	31800.30	
103	00147	WATER TANK	SET	1	14,467.10	14,467.10				-	1	14467.10	
104	00147	DIESEL TANK	SET	1	14,595.34	14,595.34				-	1	14595.34	
105	00147	CONDENSATE TANK	SET	1	4,167.50	4,167.50				-	1	4167.50	
106	00147	CONDENSATE TANK	SET	1	3,803.26	3,803.26				-	1	3803.26	
107	00147	BOOSTER PUMP	SET	1	25,686.40	25,686.40				-	1	25686.40	
108	00147	BOOSTER PUMP	SET	1	12,695.23	12,695.23				-	1	12695.23	
109	00147	HOT WATER CIRCULATION PUMP	SET	2	692.05	1,384.11				-	2	1384.11	
110	00147	CONDENSATE CIRCULATION PUMP	SET	4	749.72	2,998.90				-	4	2998.90	
111	00147	Insect Lamp	EA	2	15.18	30.35				-	2	30.35	
112	00147	Differential Pressure Gauge	EA	33	1,517.66	50,082.79				-	33	50082.79	
113	00147	Pass Box	EA	2	5,311.81	10,623.62				-	2	10623.62	
114	00147	PACKAGED AIR CONDITIONER (AIR COOLED)	SET	1	3,287.25	3,287.25				-	1	3287.25	
115	00147	CONSTANT TEMP. & HUMI. UNIT (AIR COOLED TYPE)	SET	2	1,643.63	3,287.25				-	2	3287.25	
116	00147	UNIT COOLER + CONDENSING UNIT	Set	2	4,249.45	8,498.90				-	2	8498.90	
117	00147	UNIT COOLER + CONDENSING UNIT	Set	1	4,249.45	4,249.45				-	1	4249.45	
118	00147	Pass Box	EA	1	5,311.81	5,311.81				-	1	5311.81	

119	00147	CONSTANT TEMP. & HUMI. UNIT (AIR COOLED TYPE)	SET	1	3,287.25	3,287.25				-	1	3287.25	
120	00147	CONSTANT TEMP. & HUMI. UNIT (AIR COOLED TYPE)	SET	1	3,287.25	3,287.25				-	1	3287.25	
121	00147	PACKAGED AIR CONDITIONER (AIR COOLED)	SET	8	410.91	3,287.25				-	8	3287.25	
122	00147	DOMESTIC HOT WATER GENERATOR	SET	1	17,248.21	17,248.21				-	1	17248.21	
123	00147	SIROCCO FAN #7 SS	Set	1	6,610.41	6,610.41				-	1	6610.41	
124	00147	FAN-IN LINE 380 HS	Set	1	1,566.91	1,566.91				-	1	1566.91	
125	00147	IN LINE FAN 1100×2	Set	1	7,736.63	7,736.63				-	1	7736.63	
126	00147	IN LINE FAN 830	Set	1	2,366.69	2,366.69				-	1	2366.69	
127	00147	SIROCCO FAN #7 SS	Set	1	6,610.41	6,610.41				-	1	6610.41	
128	00147	FAN-IN LINE 380 HS	Set	1	1,566.91	1,566.91				-	1	1566.91	
129	00147	IN LINE FAN 1100×2	Set	1	7,736.63	7,736.63				-	1	7736.63	
130	00147	IN LINE FAN 830	Set	1	2,366.69	2,366.69				-	1	2366.69	
131	00147	SIROCCO FAN #3 SS	Set	1	2,399.34	2,399.34				-	1	2399.34	
132	00147	WALL FAN Φ250 (STEEL)	Set	1	117.52	117.52				-	1	117.52	
133	00147	WALL FAN Φ250 (STEEL)	Set	1	117.52	117.52				-	1	117.52	
134	00147	FAN CEILING 200	Set	4	173.83	695.32				-	4	695.32	
135	00147	FAN IN LINE 300 GS	Set	1	914.03	914.03				-	1	914.03	
136	00147	GALV' STEEL DUCT SHEET	M2	2703	0.32	856.77	5,390	134112(1.7.2015)	2703	856.77	-	0.00	
137	00147	GALV' STEEL DUCT SHEET	M2	7533	1.89	14,235.56	5,390	134112(1.7.2015)	7533	14,235.56	-	0.00	
138	00147	GALV' STEEL DUCT SHEET	M2	5602	0.17	929.15	5,390	134112(1.7.2015)	5602	929.15	-	0.00	
139	00147	GALV' STEEL DUCT SHEET	M2	283	48.90	13,839.45	5,390	134112(1.7.2015)	283	13,839.45	-	0.00	
140	00147	GALV' STEEL DUCT SHEET	M2	22	55.50	1,221.10	5,390	134112(1.7.2015)	22	1,221.10	-	0.00	
141	00147	S.A CHAMBER	EA	9	1,454.85	13,093.69	5,389	135662/(6.7.2015)	9	13,093.69	-	0.00	

142	00147	S.A CHAMBER	EA	2	3,178.67	6,357.35	5,389	135662/(6.7.2015)	2	6,357.35	-	0.00	
143	00147	S.A CHAMBER	EA	15	2,644.82	39,672.28	5,389	135662/(6.7.2015)	15	39,672.28	-	0.00	
144	00147	DUCT INSULATION	M2	379	29.83	11,305.81				-	379	11305.81	
145	00147	LUVER	EA	2	61.13	122.26	5,389	135662/(6.7.2015)	2	122.26	-	0.00	
146	00147	LUVER	EA	3	61.13	183.38	5,389	135662/(6.7.2015)	3	183.38	-	0.00	
147	00147	LUVER	EA	1	61.13	61.13	5,389	135662/(6.7.2015)	1	61.13	-	0.00	
148	00147	ROUND PAN DIRRUSER	EA	12	4.89	58.68	5,389	135662/(6.7.2015)	12	58.68	-	0.00	
149	00147	SQUARE PAN DIRRUSER	EA	2	4.89	9.78	5,389	135662/(6.7.2015)	2	9.78	-	0.00	
150	00147	SQUARE PAN DIRRUSER	EA	4	4.89	19.56	5,389	135662/(6.7.2015)	4	19.56	-	0.00	
151	00147	GRILLE	EA	2	19.10	38.19	5,389	135662/(6.7.2015)	2	38.19	-	0.00	
152	00147	GRILLE	EA	10	19.10	190.96	5,389	135662/(6.7.2015)	10	190.96	-	0.00	
153	00147	GRILLE	EA	24	19.10	458.32	5,389	135662/(6.7.2015)	24	458.32	-	0.00	
154	00147	RA GRILLE(AL)	EA	2	19.10	38.19				-	2	38.19	
155	00147	RA GRILLE(AL)	EA	4	19.10	76.39				-	4	76.39	
156	00147	VOLUME DAMPER	EA	7	239.62	1,677.36	5,389	135662/(6.7.2015)	7	1,677.36	-	0.00	
157	00147	VOLUME DAMPER	EA	6	239.62	1,437.74	5,389	135662/(6.7.2015)	6	1,437.74	-	0.00	
158	00147	ROUND VOLUME DAMPER	EA	2	239.62	479.25	5,389	135662/(6.7.2015)	2	479.25	-	0.00	
159	00147	ROUND VOLUME DAMPER	EA	5	239.62	1,198.12	5,389	135662/(6.7.2015)	5	1,198.12	-	0.00	
160	00147	BACK DRAFT DAMPER	EA	1	464.58	464.58	5,389	135662/(6.7.2015)	1	464.58	-	0.00	
161	00147	BACK DRAFT DAMPER	EA	3	464.58	1,393.73	5,389	135662/(6.7.2015)	3	1,393.73	-	0.00	
162	00147	SOUND CHAMBER	EA	9	537.93	4,841.36				-	9	4841.36	
163	00147	DUCT FLEXIBLE HOSE(AL)	M	28	4.89	136.93	5,389	135662/(6.7.2015)	28	136.93	-	0.00	

164	00147	DUCT FLEXIBLE HOSE(AL)	M	8	4.89	39.12	5,389	135662/(6.7.2015)	8	39.12	-	0.00	
165	00147	DUCT FLEXIBLE HOSE(AL)	M	4	4.89	19.56	5,389	135662/(6.7.2015)	4	19.56	-	0.00	
166	00147	DUCT FLEXIBLE HOSE(AL)	M	4	4.89	19.56	5,389	135662/(6.7.2015)	4	19.56	-	0.00	
167	00147	SUS BAND	EA	28	3.67	102.70				-	28	102.70	
168	00147	SUS BAND	EA	12	3.67	44.01				-	12	44.01	
169	00147	SUS BAND	EA	4	3.67	14.67				-	4	14.67	
170	00147	SPIN IN	EA	14	10.07	141.04	5,389	135662/(6.7.2015)	14	141.04	-	0.00	
171	00147	SPIN IN	EA	6	10.07	60.44	5,389	135662/(6.7.2015)	6	60.44	-	0.00	
172	00147	SPIN IN	EA	2	10.07	20.15	5,389	135662/(6.7.2015)	2	20.15	-	0.00	
173	00147	CANVAS JOINT	M2	23	112.97	2,598.20	5,389	135662/(6.7.2015)	23	2,598.20	-	0.00	
174	00147	SPIRAL DUCT	m	13	30.81	400.51				-	13	400.51	
175	00147	ELBOW 90'	EA	5	36.68	183.38				-	5	183.38	
176	00147	DUCT INSULATION	M2	11510	29.83	343,350.46	5,389	135662/(6.7.2015)	11508	343,290.80	2	59.66	
		DUCT INSULATION	M2	2	29.83	59.66					-		
177	00147	DUCT INSULATION	M2	2302	12.96	29,832.09	5,389	135662/(6.7.2015)	2240	29,028.62	62	803.47	
			M2	62	12.96	803.52					-		
178	00147	CANVAS JOINT	M2	80	112.97	9,037.21	5,389	135662/(6.7.2015)	80	9,037.21	-	0.00	
179	00147	MIXING PAINTING	M2	1337	11.44	15,299.59	5,389	135662/(6.7.2015)	1337	15,299.59	-	0.00	
180	00147	PAINT	M2	1337	11.44	15,299.59	5,389	135662/(6.7.2015)	1337	15,299.59	-	0.00	
181	00147	ROUND PAN DIFFUSER	EA	16	239.62	3,833.97	5,389	135662/(6.7.2015)	12	2,875.48	4	958.49	
182	00147	ROUND PAN DIFFUSER	EA	6	4.89	29.34	5,389	135662/(6.7.2015)	6	29.34	-	0.00	
		ROUND PAN DIFFUSER		4	239.62	958.49				-	- 12	58.68	
183	00147	ROUND PAN DIFFUSER	EA	12	4.89	58.68				-	5	24.45	
184	00147	SQUARE PAN DIFFUSER	EA	5	4.89	24.45							

185	00147	SQUARE PAN DIFFUSER	EA	5	4.89	24.45	5,389	135662/(6.7.2015)	80	391.22	(75)	-366.77	
186	00147	SQUARE PAN DIFFUSER	EA	8	4.89	39.12				-	8	39.12	
187	00147	SQUARE PAN DIFFUSER	EA	43	4.89	210.28				-	43	210.28	
188	00147	NOZZLE	EA	26	4.89	127.15	5,389	135662/(6.7.2015)	26	127.15	-	0.00	
189	00147	LUVER	EA	6	183.38	1,100.31	5,389	135662/(6.7.2015)	6	1,100.31	-	0.00	
190	00147	LUVER	EA	7	183.38	1,283.69	5,389	135662/(6.7.2015)	7	1,283.69	-	0.00	
191	00147	REGISTER	EA	8	14.67	117.37	5,389	135662/(6.7.2015)	8	117.37	-	0.00	
192	00147	REGISTER	EA	26	14.67	381.44	5,389	135662/(6.7.2015)	26	381.44	-	0.00	
193	00147	REGISTER	EA	21	14.67	308.09	5,389	135662/(6.7.2015)	21	308.09	-	0.00	
194	00147	RA GRILLE (AL) D200	EA	242	14.67	3,550.33				-	242	3550.33	
195	00147	RA GRILLE (AL) D200	EA	71	14.67	1,041.63				-	71	1041.63	
196	00147	RA GRILLE (AL) D300	EA	19	14.67	278.75				-	19	278.75	
197	00147	RA GRILLE (AL) D350	EA	8	14.67	117.37				-	8	117.37	
198	00147	RA GRILLE (AL) D200	EA	5	14.67	73.35				-	5	73.35	
199	00147	RA GRILLE (AL) D300	EA	7	14.67	102.70				-	7	102.70	
200	00147	RA GRILLE (AL) D350	EA	4	14.67	58.68				-	4	58.68	
201	00147	RA GRILLE (AL)	EA	2	14.67	29.34				-	2	29.34	
202	00147	HOOD	EA	7	207.84	1,454.85				-	7	1454.85	
203	00147	INSPECTION DOOR	EA	25	88.02	2,200.62	5,389	135662/(6.7.2015)	25	2,200.62	-	0.00	
204	00147	FIRE VOLUME DAMPER	EA	2	239.62	479.25	5,389	135662/(6.7.2015)	2	479.25	-	0.00	
205	00147	FIRE VOLUME DAMPER	EA	4	239.62	958.49	5,389	135662/(6.7.2015)	4	958.49	-	0.00	
206	00147	FIRE VOLUME DAMPER	EA	2	239.62	479.25	5,389	135662/(6.7.2015)	2	479.25	-	0.00	
207	00147	FIRE VOLUME DAMPER	EA	2	239.62	479.25	5,389	135662/(6.7.2015)	2	479.25	-	0.00	
208	00147	FIRE VOLUME DAMPER	EA	3	239.62	718.87	5,389	135662/(6.7.2015)	3	718.87	-	0.00	

209	00147	FIRE VOLUME DAMPER	EA	2	239.62	479.25	5,389	135662/(6.7.2015)	2	479.25	-	0.00	
210	00147	FIRE VOLUME DAMPER	EA	2	239.62	479.25	5,389	135662/(6.7.2015)	2	479.25	-	0.00	
211	00147	FIRE VOLUME DAMPER	EA	2	239.62	479.25	5,389	135662/(6.7.2015)	2	479.25	-	0.00	
212	00147	FIRE VOLUME DAMPER	EA	2	239.62	479.25	5,389	135662/(6.7.2015)	2	479.25	-	0.00	
213	00147	FIRE VOLUME DAMPER	EA	1	239.62	239.62	5,389	135662/(6.7.2015)	1	239.62	-	0.00	
214	00147	FIRE VOLUME DAMPER	EA	3	239.62	718.87	5,389	135662/(6.7.2015)	3	718.87	-	0.00	
215	00147	FIRE VOLUME DAMPER	EA	1	239.62	239.62	5,389	135662/(6.7.2015)	1	239.62	-	0.00	
216	00147	VOLUME DAMPER	EA	13	39.12	508.59	5,389	135662/(6.7.2015)	13	508.59	-	0.00	
217	00147	VOLUME DAMPER	EA	4	45.85	183.38	5,389	135662/(6.7.2015)	4	183.38	-	0.00	
218	00147	VOLUME DAMPER	EA	1	611.28	611.28	5,389	135662/(6.7.2015)	1	611.28	-	0.00	
219	00147	VOLUME DAMPER	EA	3	146.71	440.12	5,389	135662/(6.7.2015)	3	440.12	-	0.00	
220	00147	VOLUME DAMPER	EA	1	440.12	440.12	5,389	135662/(6.7.2015)	1	440.12	-	0.00	
221	00147	VOLUME DAMPER	EA	1	44.01	44.01	5,389	135662/(6.7.2015)	1	44.01	-	0.00	
222	00147	VOLUME DAMPER	EA	1	41.57	41.57	5,389	135662/(6.7.2015)	1	41.57	-	0.00	
223	00147	VOLUME DAMPER	EA	1	46.46	46.46	5,389	135662/(6.7.2015)	1	46.46	-	0.00	
224	00147	BACK DRAFT DAMPER	EA	1	39.12	39.12	5,389	135662/(6.7.2015)	1	39.12	-	0.00	
225	00147	VOLUME DAMPER	EA	2	39.12	78.24	5,389	135662/(6.7.2015)	2	78.24	-	0.00	
226	00147	VOLUME DAMPER	EA	253	39.12	9,897.90	5,389	135662/(6.7.2015)	253	9,897.90	-	0.00	
227	00147	VOLUME DAMPER	EA	24	41.57	997.61	5,389	135662/(6.7.2015)	24	997.61	-	0.00	
228	00147	VOLUME DAMPER	EA	1	39.12	39.12	5,389	135662/(6.7.2015)	1	39.12	-	0.00	
229	00147	VOLUME DAMPER	EA	5	39.12	195.61	5,389	135662/(6.7.2015)	5	195.61	-	0.00	
230	00147	VOLUME DAMPER	EA	5	39.12	195.61	5,389	135662/(6.7.2015)	5	195.61	-	0.00	
231	00147	VOLUME DAMPER	EA	1	39.12	39.12	5,389	135662/(6.7.2015)	1	39.12	-	0.00	
232	00147	VOLUME DAMPER	EA	5	39.12	195.61	5,389	135662/(6.7.2015)	5	195.61	-	0.00	
233	00147	VOLUME DAMPER	EA	8	39.12	312.98	5,389	135662/(6.7.2015)	8	312.98	-	0.00	
234	00147	VOLUME DAMPER	EA	8	39.12	312.98	5,389	135662/(6.7.2015)	8	312.98	-	0.00	
235	00147	VOLUME DAMPER	EA	1	39.12	39.12	5,389	135662/(6.7.2015)	1	39.12	-	0.00	

236	00147	VOLUME DAMPER	EA	1	39.12	39.12	5,389	135662/(6.7.2015)	1	39.12	-	0.00	
237	00147	VOLUME DAMPER	EA	21	39.12	821.56	5,389	135662/(6.7.2015)	21	821.56	-	0.00	
238	00147	VOLUME DAMPER	EA	1	39.12	39.12	5,389	135662/(6.7.2015)	1	39.12	-	0.00	
239	00147	VOLUME DAMPER	EA	18	39.12	704.20	5,389	135662/(6.7.2015)	18	704.20	-	0.00	
240	00147	AIR CHAMBER	EA	1	770.22	770.22	5,389	135662/(6.7.2015)	1	770.22	-	0.00	
241	00147	AIR CHAMBER	EA	1	1,736.04	1,736.04	5,389	135662/(6.7.2015)	1	1,736.04	-	0.00	
242	00147	AIR CHAMBER	EA	1	1,289.81	1,289.81	5,389	135662/(6.7.2015)	1	1,289.81	-	0.00	
243	00147	AIR CHAMBER	EA	1	1,338.71	1,338.71	5,389	135662/(6.7.2015)	1	1,338.71	-	0.00	
244	00147	AIR CHAMBER	EA	1	1,289.81	1,289.81	5,389	135662/(6.7.2015)	1	1,289.81	-	0.00	
245	00147	AIR CHAMBER	EA	1	1,271.47	1,271.47	5,389	135662/(6.7.2015)	1	1,271.47	-	0.00	
246	00147	S.A SOUND CHAMBER	EA	1	305.64	305.64				-	1	305.64	
247	00147	SOUND CHAMBER	EA	1	305.64	305.64	5,389	135662/(6.7.2015)	1	305.64	-	0.00	
248	00147	SOUND CHAMBER	EA	1	305.64	305.64	5,389	135662/(6.7.2015)	1	305.64	-	0.00	
249	00147	SOUND CHAMBER	EA	1	305.64	305.64	5,389	135662/(6.7.2015)	1	305.64	-	0.00	
250	00147	SOUND CHAMBER	EA	1	305.64	305.64	5,389	135662/(6.7.2015)	1	305.64	-	0.00	
251	00147	SOUND CHAMBER	EA	1	305.64	305.64	5,389	135662/(6.7.2015)	1	305.64	-	0.00	
252	00147	SOUND CHAMBER	EA	1	305.64	305.64	5,389	135662/(6.7.2015)	1	305.64	-	0.00	
253	00147	SOUND CHAMBER	EA	1	305.64	305.64	5,389	135662/(6.7.2015)	1	305.64	-	0.00	
254	00147	SOUND CHAMBER	EA	1	305.64	305.64	5,389	135662/(6.7.2015)	1	305.64	-	0.00	
255	00147	DUCT FLEXIBLE HOSE(Taporin)	M	63	4.89	308.09	5407	149723 /14.8.15	63	308.09	-	0.00	
256	00147	DUCT FLEXIBLE HOSE(Taporin)	M	1227	4.89	6,000.36	5407	149723 /14.8.15	1227	6,000.36	-	0.00	
257	00147	DUCT FLEXIBLE HOSE (Taporin)	M	24	4.89	117.37	5407	149723 /14.8.15	24	117.37	-	0.00	
258	00147	DUCT FLEXIBLE HOSE (Taporin)	M	207	4.89	1,012.29	5407	149723 /14.8.15	207	1,012.29	-	0.00	
259	00147	DUCT FLEXIBLE HOSE (Taporin)	M	72	4.89	352.10	5407	149723 /14.8.15	72	352.10	-	0.00	
260	00147	DUCT FLEXIBLE HOSE(Taporin)	M	78	4.89	381.44	5407	149723 /14.8.15	78	381.44	-	0.00	
261	00147	DUCT FLEXIBLE HOSE(AL)	M	50	4.89	244.51				-	50	244.51	
262	00147	DUCT FLEXIBLE HOSE(AL)	M	164	4.89	802.00				-	164	802.00	
263	00147	DUCT FLEXIBLE HOSE(AL)	M	390	4.89	1,907.20				-	390	1907.20	
264	00147	DUCT FLEXIBLE HOSE(AL)	M	8	4.89	39.12				-	8	39.12	
265	00147	DUCT FLEXIBLE HOSE(AL)	M	44	4.89	215.17				-	44	215.17	
266	00147	SUS BAND	EA	42	3.20	134.48				-	42	134.48	

267	00147	SUS BAND	EA	818	3.36	2,750.77				-	818	2750.77
268	00147	SUS BAND	EA	16	3.50	55.99				-	16	55.99
269	00147	SUS BAND	EA	138	3.67	506.14				-	138	506.14
270	00147	SUS BAND	EA	48	3.67	176.05				-	48	176.05
271	00147	SUS BAND	EA	52	4.61	239.62				-	52	239.62
272	00147	SUS BAND	EA	50	3.37	168.71				-	50	168.71
273	00147	SUS BAND	EA	164	3.50	574.61				-	164	574.61
274	00147	SUS BAND	EA	390	3.67	1,430.40				-	390	1430.40
275	00147	SUS BAND	EA	8	3.67	29.34				-	8	29.34
276	00147	SUS BAND	EA	44	4.17	183.38				-	44	183.38
277	00147	SPIN	EA	42	7.82	328.63	5,389	135662/(6.7.2015)	34	266.03	8	62.60
		SPIN	EA	8	7.82	62.60					-	
278	00147	SPIN	EA	818	9.78	8,000.48	5,389	135662/(6.7.2015)	650	6,357.35	168	1643.13
		SPIN	EA	168	9.78	1,643.13					-	
279	00147	SPIN	EA	16	9.78	156.49	5,389	135662/(6.7.2015)	16	156.49	-	0.00
280	00147	SPIN	EA	138	11.00	1,518.43	5,389	135662/(6.7.2015)	138	1,518.43	-	0.00
281	00147	SPIN	EA	48	12.23	586.83	5,389	135662/(6.7.2015)	10	122.26	38	464.58
		SPIN	EA	38	12.23	464.58					-	
282	00147	SPIN	EA	52	17.12	890.03	5,389	135662/(6.7.2015)	52	890.03	-	0.00
283	00147	SPIRAL DUCT	m	60	25.92	1,555.10	5,389	135662/(6.7.2015)	60	1,555.10	-	0.00
284	00147	SPIRAL DUCT	m	17	28.36	482.18	5,389	135662/(6.7.2015)	17	482.18	-	0.00
285	00147	SPIRAL DUCT	m	132	30.81	4,066.75	5,389	135662/(6.7.2015)	132	4,066.75	-	0.00
286	00147	SPIRAL DUCT	m	29	34.72	1,006.91	5,389	135662/(6.7.2015)	29	1,006.91	-	0.00
287	00147	SPIRAL DUCT	m	201	36.92	7,421.22	5,389	135662/(6.7.2015)	201	7,421.22	-	0.00
288	00147	SPIRAL DUCT	m	61	40.59	2,475.94	5,389	135662/(6.7.2015)	61	2,475.94	-	0.00
289	00147	SPIRAL DUCT	m	75	51.59	3,869.42	5,389	135662/(6.7.2015)	75	3,869.42	-	0.00
290	00147	SPIRAL DUCT	m	38	57.71	2,192.80	5,389	135662/(6.7.2015)	38	2,192.80	-	0.00
291	00147	SPIRAL DUCT	m	65	66.26	4,307.10	5,389	135662/(6.7.2015)	65	4,307.10	-	0.00
292	00147	SPIRAL DUCT	m	8	72.38	579.01	5,389	135662/(6.7.2015)	8	579.01	-	0.00
293	00147	ELBOW 90'	EA	13	17.12	222.51	5,389	135662/(6.7.2015)	13	222.51	-	0.00

294	00147	ELBOW 90'	EA	7	18.34	128.37	5,389	135662/(6.7.2015)	7	128.37	-	0.00	
295	00147	ELBOW 90'	EA	3	23.23	69.69	5,389	135662/(6.7.2015)	3	69.69	-	0.00	
296	00147	ELBOW 90'	EA	16	29.34	469.47	5,389	135662/(6.7.2015)	16	469.47	-	0.00	
297	00147	ELBOW 90'	EA	6	35.45	212.73	5,389	135662/(6.7.2015)	6	212.73	-	0.00	
298	00147	ELBOW 90'	EA	5	42.79	213.95	5,389	135662/(6.7.2015)	5	213.95	-	0.00	
299	00147	ELBOW 90'	EA	11	48.90	537.93	5,389	135662/(6.7.2015)	11	537.93	-	0.00	
300	00147	ELBOW 90'	EA	8	63.57	508.59	5,389	135662/(6.7.2015)	8	508.59	-	0.00	
301	00147	ELBOW 90'	EA	3	75.80	227.40	5,389	135662/(6.7.2015)	3	227.40	-	0.00	
302	00147	TEE	Ea	2	17.12	34.23	5,389	135662/(6.7.2015)	2	34.23	-	0.00	
303	00147	TEE	Ea	2	20.78	41.57	5,389	135662/(6.7.2015)	2	41.57	-	0.00	
304	00147	TEE	Ea	5	23.23	116.14	5,389	135662/(6.7.2015)	5	116.14	-	0.00	
305	00147	TEE	Ea	1	23.23	23.23	5,389	135662/(6.7.2015)	1	23.23	-	0.00	
306	00147	TEE	Ea	2	23.23	46.46	5,389	135662/(6.7.2015)	2	46.46	-	0.00	
307	00147	TEE	Ea	5	29.34	146.71	5,389	135662/(6.7.2015)	5	146.71	-	0.00	
308	00147	TEE	Ea	2	30.08	60.15	5,389	135662/(6.7.2015)	2	60.15	-	0.00	
309	00147	TEE	Ea	3	29.34	88.02	5,389	135662/(6.7.2015)	3	88.02	-	0.00	
310	00147	TEE	Ea	4	34.23	136.93	5,389	135662/(6.7.2015)	4	136.93	-	0.00	
311	00147	TEE	Ea	1	30.08	30.08	5,389	135662/(6.7.2015)	1	30.08	-	0.00	
312	00147	TEE	Ea	1	39.12	39.12	5,389	135662/(6.7.2015)	1	39.12	-	0.00	
313	00147	TEE	Ea	4	30.08	120.30	5,389	135662/(6.7.2015)	4	120.30	-	0.00	
314	00147	TEE	Ea	4	34.23	136.93	5,389	135662/(6.7.2015)	4	136.93	-	0.00	
315	00147	TEE	Ea	2	39.12	78.24	5,389	135662/(6.7.2015)	2	78.24	-	0.00	
316	00147	TEE	Ea	2	44.01	88.02	5,389	135662/(6.7.2015)	2	88.02	-	0.00	
317	00147	CAP	Ea	2	12.23	24.45	5,389	135662/(6.7.2015)	2	24.45	-	0.00	
318	00147	CAP	Ea	1	12.23	12.23	5,389	135662/(6.7.2015)	1	12.23	-	0.00	
319	00147	CAP	Ea	3	12.23	36.68	5,389	135662/(6.7.2015)	3	36.68	-	0.00	
320	00147	CAP	Ea	1	13.45	13.45	5,389	135662/(6.7.2015)	1	13.45	-	0.00	
321	00147	CAP	Ea	4	13.45	53.79	5,389	135662/(6.7.2015)	4	53.79	-	0.00	
322	00147	CAP	Ea	2	14.67	29.34	5,389	135662/(6.7.2015)	2	29.34	-	0.00	
323	00147	CAP	Ea	3	14.67	44.01	5,389	135662/(6.7.2015)	3	44.01	-	0.00	

324	00147	CAP	Ea	2	17.12	34.23	5,389	135662/(6.7.2015)	2	34.23	-	0.00	
325	00147	REDUCER	Ea	1	17.12	17.12	5,389	135662/(6.7.2015)	1	17.12	-	0.00	
326	00147	REDUCER	Ea	1	18.34	18.34	5,389	135662/(6.7.2015)	1	18.34	-	0.00	
327	00147	REDUCER	Ea	1	22.01	22.01	5,389	135662/(6.7.2015)	1	22.01	-	0.00	
328	00147	FIRE ROUND VOLUME DAMPER	EA	5	58.68	293.42	5,389	135662/(6.7.2015)	5	293.42	-	0.00	
329	00147	FIRE ROUND VOLUME DAMPER	EA	4	58.68	234.73	5,389	135662/(6.7.2015)	4	234.73	-	0.00	
330	00147	FIRE ROUND VOLUME DAMPER	EA	4	58.68	234.73	5,389	135662/(6.7.2015)	4	234.73	-	0.00	
331	00147	FIRE ROUND VOLUME DAMPER	EA	2	58.68	117.37	5,389	135662/(6.7.2015)	2	117.37	-	0.00	
332	00147	ROUND VOLUME DAMPER	Ea	13	46.46	603.95	5,389	135662/(6.7.2015)	13	603.95	-	0.00	
333	00147	ROUND VOLUME DAMPER	Ea	7	46.46	325.20	5,389	135662/(6.7.2015)	7	325.20	-	0.00	
334	00147	ROUND VOLUME DAMPER	Ea	1	46.46	46.46	5,389	135662/(6.7.2015)	1	46.46	-	0.00	
335	00147	ROUND VOLUME DAMPER	Ea	7	46.46	325.20	5,389	135662/(6.7.2015)	7	325.20	-	0.00	
336	00147	ROUND VOLUME DAMPER	Ea	1	46.46	46.46	5,389	135662/(6.7.2015)	1	46.46	-	0.00	
337	00147	ROUND VOLUME DAMPER	Ea	4	46.46	185.83	5,389	135662/(6.7.2015)	4	185.83	-	0.00	
338	00147	ROUND VOLUME DAMPER	Ea	2	46.46	92.92	5,389	135662/(6.7.2015)	2	92.92	-	0.00	
339	00147	TRANSITION	EA	1	61.13	61.13	5,389	135662/(6.7.2015)	1	61.13	-	0.00	
340	00147	TRANSITION	EA	2	78.24	156.49	5,389	135662/(6.7.2015)	2	156.49	-	0.00	
341	00147	TRANSITION	EA	2	112.48	224.95	5,389	135662/(6.7.2015)	2	224.95	-	0.00	
342	00147	TRANSITION	EA	1	158.93	158.93	5,389	135662/(6.7.2015)	1	158.93	-	0.00	

343	00147	HANGER	EA	40	7.34	293.42	5,389	135662/(6.7.2015)	40	293.42	-	0.00	
344	00147	HANGER	EA	11	7.34	83.13	5,389	135662/(6.7.2015)	11	83.13	-	0.00	
345	00147	HANGER	EA	88	7.34	645.52	5,389	135662/(6.7.2015)	88	645.52	-	0.00	
346	00147	HANGER	EA	19	8.56	165.45	5,389	135662/(6.7.2015)	19	165.45	-	0.00	
347	00147	HANGER	EA	134	8.56	1,146.77	5,389	135662/(6.7.2015)	134	1,146.77	-	0.00	
348	00147	HANGER	EA	40.667	9.78	397.74	5,389	135662/(6.7.2015)	40.667	397.74	-	0.00	
349	00147	HANGER	EA	50	9.78	489.03	5,389	135662/(6.7.2015)	50	489.03	-	0.00	
350	00147	HANGER	EA	25	11.00	278.75	5,389	135662/(6.7.2015)	25	278.75	-	0.00	
351	00147	HANGER	EA	43	14.67	635.73	5,389	135662/(6.7.2015)	43	635.73	-	0.00	
352	00147	HANGER	EA	5	14.67	78.24	5,389	135662/(6.7.2015)	5	78.24	-	0.00	
353	00147	STS MESH	M2	51	36.68	1,870.53	5,389	135662/(6.7.2015)	51	1,870.53	-	0.00	
354	00147	CEILING & WALL PANEL	M2	8797	25.80	226,964.59				-	8,797	226964.59	Return to apply 01164
355	00147	CEILING & WALL PANEL	M2	9090	18.21	165,546.39				-	9,090	165546.39	Return to apply 01164
356	00147	PANEL PART	M2	22992	10.05	230,998.59				-	22,992	230998.59	Return to apply 01164
357	00147	CAULKING	M	75665	0.30	22,966.69				-	75,665	22966.69	Return to apply 01164
358	00147	PANEL DOOR	SET	110	984.86	108,334.80				-	110	108334.80	Return to apply 01164
359	00147	PANEL DOOR	SET	3	542.10	1,626.30				-	3	1626.30	Return to apply 01164
360	00147	PANEL DOOR	SET	35	699.86	24,495.11				-	35	24495.11	Return to apply 01164
361	00147	PANEL DOOR	SET	19	283.93	5,394.68				-	19	5394.68	Return to apply 01164
362	00147	AL FIX WINDOW	SET	36	283.93	10,221.49				-	36	10221.49	Return to apply 01164
363	00147	AL FIX WINDOW	SET	29	283.93	8,233.98				-	29	8233.98	Return to apply 01164
364	00147	ACCESS DOOR	SET	40	499.07	19,962.96				-	40	19962.96	Return to apply 01164
365	00147	PIPE(WELL KSD3507)	M	108	6.95	750.16	5615	189889 (02/12/2015)	108	750.16	-	0.00	
366	00147	PIPE(WELL KSD3507)	M	42	6.05	253.99	5615	189889 (02/12/2015)	42	253.99	-	0.00	
367	00147	PIPE(WELL KSD3507)	M	96	3.07	294.72	5615	189889 (02/12/2015)	96	294.72	-	0.00	

368	00147	ELBOW(WELL)	EA	25	2.28	56.90	5615	189889 (02/12/2015)	25	56.90	-	0.00	
369	00147	ELBOW(WELL)	EA	10	1.82	18.21	5615	189889 (02/12/2015)	10	18.21	-	0.00	
370	00147	ELBOW(WELL)	EA	1	17.70	17.70	5615	189889 (02/12/2015)	1	17.70	-	0.00	
371	00147	ELBOW(WELL)	EA	1	4.25	4.25	5615	189889 (02/12/2015)	1	4.25	-	0.00	
372	00147	ELBOW(WELL)	EA	3	2.35	7.06	5615	189889 (02/12/2015)	3	7.06	-	0.00	
373	00147	REDUCER(WELL)	EA	2	4.50	9.00	5615	189889 (02/12/2015)	2	9.00	-	0.00	
374	00147	REDUCER(WELL)	EA	2	2.58	5.16	5615	189889 (02/12/2015)	2	5.16	-	0.00	
375	00147	FLANGE (KS/JIS 10K)	EA	10	7.03	70.25	5615	189889 (02/12/2015)	10	70.25	-	0.00	
376	00147	FLANGE (KS/JIS 10K)	EA	2	6.71	13.43	5615	189889 (02/12/2015)	2	13.43	-	0.00	
377	00147	METAL GASKET	EA	10	5.39	53.95	5615	189889 (02/12/2015)	10	53.95	-	0.00	
378	00147	METAL GASKET	EA	2	5.06	10.12	5649	195178 (15/12/2015)	2	10.12	-	0.00	
379	00147	BUCKET STEAM TRAP	EA	3	387.76	1,163.27				-	3	1163.27	
380	00147	BUCKET TRAP(BOLT)	EA	3	165.08	495.25	5649	195178 (15/12/2015)	3	495.25	-	0.00	
381	00147	FORGEING GLOVE VALVE	EA	2	182.20	364.41	5615	189889 (02/12/2015)	2	364.41	-	0.00	
382	00147	PRESSURE GUAGE& CYPHONE VALVE	EA	2	42.15	84.30	5615	189889 (02/12/2015)	2	84.30	-	0.00	
383	00147	AUTO AIR VENT (10K)	EA	2	80.92	161.85	5615	189889 (02/12/2015)	2.00	161.85	-	0.00	
384	00147	GS VALVE	EA	2	59.01	118.01				-	2	118.01	
385	00147	PIPE INSILATION	M	108	7.59	819.35				-	108	819.35	
386	00147	PIPE INSILATION	M	42	5.90	247.83				-	42	247.83	
387	00147	PIPE INSILATION	M	96	5.90	566.46	5649	195178 (15/12/2015)	96	566.46	-	0.00	
388	00147	ㄷ-PIPE	ton	1	1,517.31	1,517.31				-	1	1517.31	
389	00147	GENERAL PLATE	ton	1	5,010.74	5,010.74	5649	195178 (15/12/2015)	1	5,010.74	-	0.00	
390	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
391	00147	PAINT	m2	83	2.02	168.46				-	83	168.46	
392	00147	ANTI-RUST PAINTING	m2	83	2.28	190.38				-	83	190.38	
393	00147	PIPE SUE	EA	100	14.33	1,433.02				-	100	1433.02	
394	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	108	9.78	1,056.78	5615	189889 (02/12/2015)	108	1,056.78	-	0.00	

395	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	60	6.95	416.76	5615	189889 (02/12/2015)	60	416.76		0.00	
396	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	90	6.05	544.26	5615	189889 (02/12/2015)	90	544.26	-	0.00	
397	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	78	4.71	367.15	5615	189889 (02/12/2015)	78	367.15	-	0.00	
398	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	36	3.07	110.52	5615	189889 (02/12/2015)	36	110.52	-	0.00	
399	00147	BLACK ELBOW (WELDING)	EA	12	3.74	44.91	5615	189889 (02/12/2015)	12.00	44.91	-	0.00	
400	00147	BLACK ELBOW (WELDING)	EA	16	2.28	36.42				-	16	36.42	
401	00147	BLACK ELBOW (WELDING)	EA	16	1.82	29.13	5615	189889 (02/12/2015)	16.00	29.13	-	0.00	
402	00147	BLACK ELBOW (WELDING)	EA	20	1.21	24.28	5615	189889 (02/12/2015)	20.00	24.28	-	0.00	
403	00147	BLACK TEE (WELDING)	EA	2	5.56	11.13				-	2	11.13	
404	00147	BLACK TEE (WELDING)	EA	2	4.25	8.50	5615	189889 (02/12/2015)	2	8.50	-	0.00	
405	00147	BLACK TEE (WELDING)	EA	4	3.59	14.36	5615	189889 (02/12/2015)	4	14.36	-	0.00	
406	00147	BLACK TEE (WELDING)	EA	1	2.35	2.35	5615	189889 (02/12/2015)	1	2.35	-	0.00	
407	00147	BLACK REDUCER (WELDING)	EA	1	3.12	3.12	5649	195178 (15/12/2015)	1	3.12	-	0.00	
408	00147	BLACK REDUCER (WELDING)	EA	2	2.58	5.16	5649	195178 (15/12/2015)	2	5.16	-	0.00	
409	00147	BLACK REDUCER (WELDING)	EA	1	3.12	3.12	5649	195178 (15/12/2015)	1	3.12	-	0.00	
410	00147	BLACK REDUCER (WELDING)	EA	1	1.92	1.92	5649	195178 (15/12/2015)	1	1.92	-	0.00	
411	00147	WELDING FLANGE (KS/JIS 10K)	EA	4	8.43	33.72	5615	189889 (02/12/2015)	4	33.72	-	0.00	
412	00147	WELDING FLANGE (KS/JIS 10K)	EA	8	7.03	56.20	5615	189889 (02/12/2015)	8	56.20	-	0.00	
413	00147	WELDING FLANGE (KS/JIS 10K)	EA	10	6.71	67.15	5615	189889 (02/12/2015)	10	67.15	-	0.00	

414	00147	WELDING FLANGE (KS/JIS 10K)	EA	2	7.78	15.57	5615	189889 (02/12/2015)	2	15.57	-	0.00	
415	00147	EXP.JOINT(STEEL, DOUBLE)	EA	3	196.91	590.74	5615	189889 (02/12/2015)	3	590.74	-	0.00	
416	00147	EXP.JOINT(STEEL, DOUBLE)	EA	3	167.24	501.72	5615	189889 (02/12/2015)	3	501.72	-	0.00	
417	00147	EXP.JOINT(STEEL, DOUBLE)	EA	2	134.87	269.74	5615	189889 (02/12/2015)	2	269.74	-	0.00	
418	00147	EXP.JOINT(STEEL, DOUBLE)	EA	1	134.87	134.87	5615	189889 (02/12/2015)	1	134.87	-	0.00	
419	00147	BUCKET STEAM TRAP	EA	5	387.76	1,938.79				-	5	1938.79	
420	00147	BUCKET TRAP(BOLT)	EA	5	165.08	825.42	5649	195178 (15/12/2015)	5	825.42	-	0.00	
421	00147	PRESSURE GUAGE& CYPHONE VALVE	EA	2	42.15	84.30	5649	195178 (15/12/2015)	2	84.30	-	0.00	
422	00147	AUTO AIR VENT (10K)㉥	EA	2	80.92	161.85				-	2	161.85	
423	00147	GS VALVE	EA	2	59.01	118.01				-	2	118.01	
424	00147	PIPE INSILATION	M	108	9.27	1,001.43	5649	195178 (15/12/2015)	108	1,001.43	-	0.00	
425	00147	PIPE INSILATION	M	60	7.59	455.19	5649	195178 (15/12/2015)	60	455.19	-	0.00	
426	00147	PIPE INSILATION	M	90	5.90	531.06	5649	195178 (15/12/2015)	90	531.06	-	0.00	
427	00147	PIPE INSILATION	M	78	6.41	499.70	5649	195178 (15/12/2015)	78	499.70	-	0.00	
428	00147	PIPE INSILATION	M	36	5.90	212.42	5649	195178 (15/12/2015)	36	212.42	-	0.00	
429	00147	ㄷ-PIPE	ton	1	1,517.31	1,517.31				-	1	1517.31	
430	00147	GENERAL PLATE	ton	1	5,010.74	2,505.37				-	1	2505.37	
431	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
432	00147	PAINT	m2	42	2.02	84.23				-	42	84.23	
433	00147	ANTI-RUST PAINTING	m2	83	2.28	190.38				-	83	190.38	
434	00147	PIPE SUE	EA	200	14.33	2,866.04				-	200	2866.04	

435	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	96	23.30	2,236.56	5615	189889 (02/12/2015)	96	2,236.56	-	0.00	
436	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	42	9.78	410.97	5615	189889 (02/12/2015)	42	410.97	-	0.00	
437	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	21	6.95	145.86	5615	189889 (02/12/2015)	21	145.86	-	0.00	
438	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	96	6.05	580.54	5615	189889 (02/12/2015)	96	580.54	-	0.00	
439	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	120	4.71	564.85	5615	189889 (02/12/2015)	120	564.85	-	0.00	
440	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	120	3.07	368.40	5615	189889 (02/12/2015)	120	368.40	-	0.00	
441	00147	BLACK ELBOW (WELDING)	EA	8	12.14	97.11	5615	189889 (02/12/2015)	8	97.11	-	0.00	
442	00147	BLACK ELBOW (WELDING)	EA	20	6.78	135.55	5615	189889 (02/12/2015)	20	135.55	-	0.00	
443	00147	BLACK ELBOW (WELDING)	EA	12	3.74	44.91	5615	189889 (02/12/2015)	12	44.91	-	0.00	
444	00147	BLACK ELBOW (WELDING)	EA	20	2.28	45.52	5615	189889 (02/12/2015)	20	45.52	-	0.00	
445	00147	BLACK ELBOW (WELDING)	EA	40	1.82	72.83	5615	189889 (02/12/2015)	40	72.83	-	0.00	
446	00147	BLACK ELBOW (WELDING)	EA	45	1.37	61.45	5615	189889 (02/12/2015)	45	61.45	-	0.00	
447	00147	BLACK ELBOW (WELDING)	EA	45	1.21	54.62	5615	189889 (02/12/2015)	45	54.62	-	0.00	
448	00147	BLACK TEE (WELDING)	EA	5	9.61	48.05				-	5	48.05	
449	00147	BLACK TEE (WELDING)	EA	1	9.61	9.61	5615	189889 (02/12/2015)	1	9.61	-	0.00	
450	00147	BLACK TEE (WELDING)	EA	4	5.56	22.25	5615	189889 (02/12/2015)	4	22.25	-	0.00	
451	00147	BLACK TEE (WELDING)	EA	3	4.25	12.75	5615	189889 (02/12/2015)	3	12.75	-	0.00	

452	00147	BLACK TEE (WELDING)	EA	2	3.59	7.18	5615	189889 (02/12/2015)	2	7.18	-	0.00	
453	00147	BLACK TEE (WELDING)	EA	2	3.59	7.18	5615	189889 (02/12/2015)	2	7.18	-	0.00	
454	00147	BLACK TEE (WELDING)	EA	2	2.91	5.82	5615	189889 (02/12/2015)	2	5.82	-	0.00	
455	00147	BLACK TEE (WELDING)	EA	5	2.35	11.76	5615	189889 (02/12/2015)	5	11.76	-	0.00	
456	00147	BLACK REDUCER (WELDING)	EA	1	4.50	4.50	5649	195178 (15/12/2015)	1	4.50	-	0.00	
457	00147	BLACK REDUCER (WELDING)	EA	4	2.58	10.32	5615	189889 (02/12/2015)	4	10.32	-	0.00	
458	00147	BLACK REDUCER (WELDING)	EA	1	3.55	3.55	5615	189889 (02/12/2015)	1	3.55	-	0.00	
459	00147	BLACK REDUCER (WELDING)	EA	1	4.50	4.50	5615	189889 (02/12/2015)	1	4.50	-	0.00	
460	00147	BLACK REDUCER (WELDING)	EA	1	3.12	3.12	5615	189889 (02/12/2015)	1	3.12	-	0.00	
461	00147	BLACK REDUCER (WELDING)	EA	18	1.63	29.41	5615	189889 (02/12/2015)	18	29.41	-	0.00	
462	00147	WELDING FLANGE (KS/JIS 10K)	EA	2	11.49	22.99	5615	189889 (02/12/2015)	2	22.99	-	0.00	
463	00147	WELDING FLANGE (KS/JIS 10K)	EA	12	7.03	84.30	5615	189889 (02/12/2015)	12	84.30	-	0.00	
464	00147	WELDING FLANGE (KS/JIS 10K)	EA	13	6.71	87.29	5615	189889 (02/12/2015)	13	87.29	-	0.00	
465	00147	WELDING FLANGE (KS/JIS 10K)	EA	42	5.09	213.63	5615	189889 (02/12/2015)	42	213.63	-	0.00	
466	00147	WELDING FLANGE (KS/JIS 10K)	EA	66	3.29	216.98	5615	189889 (02/12/2015)	66.00	216.98	-	0.00	
467	00147	WELDING FLANGE (KS/JIS 10K)/WITHOUT BOLT	EA	2	15.17	30.35	5615	189889 (02/12/2015)	2	30.35	-	0.00	
468	00147	WELDING FLANGE (KS/JIS 10K)/WITHOUT BOLT	EA	1	7.78	7.78	5615	189889 (02/12/2015)	1	7.78	-	0.00	
469	00147	METAL GASKET	EA	1	6.74	6.74	5649	195178 (15/12/2015)	1	6.74	-	0.00	
470	00147	METAL GASKET	EA	12	5.39	64.74	5615	189889 (02/12/2015)	12	64.74	-	0.00	

471	00147	METAL GASKET	EA	13	5.06	65.75	5615	189889 (02/12/2015)	13	65.75	-	0.00	
472	00147	METAL GASKET	EA	42	5.06	212.42	5615	189889 (02/12/2015)	42	212.42	-	0.00	
473	00147	METAL GASKET	EA	66	4.21	278.17	5615	189889 (02/12/2015)	66	278.17	-	0.00	
474	00147	CAST STEEL GLOVE VALVE	EA	1	939.77	939.77	5615	189889 (02/12/2015)	1	939.77	-	0.00	
475	00147	CAST STEEL GLOVE VALVE	EA	2	652.17	1,304.33	5615	189889 (02/12/2015)	2	1,304.33	-	0.00	
476	00147	CAST STEEL GLOVE VALVE	EA	1	482.21	482.21	5615	189889 (02/12/2015)	1	482.21	-	0.00	
477	00147	CAST STEEL GLOVE VALVE	EA	2	417.29	834.59	5615	189889 (02/12/2015)	2	834.59	-	0.00	
478	00147	FORGEING GLOVE VALVE	EA	2	182.20	364.41	5615	189889 (02/12/2015)	2	364.41	-	0.00	
479	00147	FORGEING GLOVE VALVE	EA	2	182.20	364.41	5615	189889 (02/12/2015)	2	364.41	-	0.00	
480	00147	FORGEING GLOVE VALVE	EA	7	108.11	756.76	5615	189889 (02/12/2015)	7	756.76	-	0.00	
481	00147	FORGEING GLOVE VALVE	EA	9	76.12	685.07	5615	189889 (02/12/2015)	9	685.07	-	0.00	
482	00147	FORGEING GATE VALVE	EA	4	187.77	751.07	5615	189889 (02/12/2015)	4	751.07	-	0.00	
483	00147	FORGEING GATE VALVE	EA	4	187.77	751.07	5615	189889 (02/12/2015)	4	751.07	-	0.00	
484	00147	FORGEING GATE VALVE	EA	14	113.42	1,587.87	5615	189889 (02/12/2015)	14	1,587.87	-	0.00	
485	00147	FORGEING GATE VALVE	EA	18	79.41	1,429.31	5615	189889 (02/12/2015)	18	1,429.31	-	0.00	
486	00147	EXP.JOINT(STEEL TUBE. DOUBLE)	EA	2	342.58	685.15	5615	189889 (02/12/2015)	2	685.15	-	0.00	
487	00147	EXP.JOINT(STEEL TUBE. DOUBLE)	EA	2	167.24	334.48	5615	189889 (02/12/2015)	2	334.48	-	0.00	
488	00147	EXP.JOINT(STEEL TUBE. DOUBLE)	EA	2	134.87	269.74	5615	189889 (02/12/2015)	2	269.74	-	0.00	
489	00147	REDUCING VALVE INSTALLTION	EA	1	3,118.92	3,118.92	5649	195178 (15/12/2015)	1	3,118.92	-	0.00	
490	00147	TWO WAY VALVE (BLACK STEEL)	EA	1	1,264.43	1,264.43				-	1	1264.43	
491	00147	BUCKET STEAM TRAP INSTALLTION	EA	2	758.66	1,517.31				-	2	1517.31	

492	00147	BUCKET STEAM TRAP INSTALLTION	EA	4	387.76	1,551.03				-	4	1551.03	
493	00147	BUCKET TRAP(BOLT)	EA	2	190.17	380.34	5649	195178 (15/12/2015)	2	380.34	-	0.00	
494	00147	BUCKET TRAP(BOLT)	EA	2	165.08	330.17	5649	195178 (15/12/2015)	2	330.17		0.00	
495	00147	STEAM REDUCING PRESSURE VALVE	EA	1	5,132.57	5,132.57	5615	189889 (02/12/2015)	1	5,132.57	-	0.00	
496	00147	2WAY VALVE(TEMP.)	EA	1	3,032.29	3,032.29	5615	189889 (02/12/2015)	1	3,032.29	-	0.00	
497	00147	PRESSURE GUAGE& CYPHONE VALVE	EA	10	42.15	421.48	5649	195178 (15/12/2015)	10	421.48	-	0.00	
498	00147	AUTO AIR VENT (10K)®	EA	30	80.92	2,427.70	5649	195178 (15/12/2015)	20	1,618.47	10	809.23	
499	00147	GS VALVE	EA	30	59.01	1,770.20	5649	195178 (15/12/2015)	20	1,180.13	10	590.07	
500	00147	PIPE INSULATION	M	96	11.80	1,132.93	5649	195178 (15/12/2015)	96	1,132.93		0.00	
501	00147	PIPE INSULATION	M	42	9.27	389.44	5649	195178 (15/12/2015)	42	389.44	-	0.00	
502	00147	PIPE INSULATION	M	21	7.59	159.32	5649	195178 (15/12/2015)	21	159.32	-	0.00	
503	00147	PIPE INSULATION	M	96	5.90	566.46	5649	195178 (15/12/2015)	96	566.46	-	0.00	
504	00147	PIPE INSULATION	M	120	6.41	768.77	5649	195178 (15/12/2015)	120	768.77	-	0.00	
505	00147	PIPE INSULATION	M	120	5.90	708.08	5649	(15/12/2015)	120	708.08	-	0.00	
506	00147	⊏-PIPE	ton	2	1,517.31	3,034.63				-	2	3034.63	
507	00147	GENERAL PLATE	ton	1	5,010.74	5,010.74				-	1	5010.74	
508	00147	INSERT PLATE	EA	50	7.42	370.81					50	370.81	
509	00147	PAINT	m2	83	2.02	168.46				-	83	168.46	
510	00147	ANTI-RUST PAINTING	m2	167	2.28	380.76				-	167	380.76	
511	00147	PIPE SUE	EA	250	14.33	3,582.55				-	250	3582.55	
512	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	30	12.51	375.18	5615	189889 (02/12/2015)	30	375.18	-	0.00	

513	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	42	9.78	410.97	5615	189889 (02/12/2015)	42	410.97	-	0.00	
514	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	24	6.95	166.70	5615	189889 (02/12/2015)	24	166.70	-	0.00	
515	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	66	6.05	399.12	5615	189889 (02/12/2015)	66	399.12	-	0.00	
516	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	108	4.71	508.36	5615	189889 (02/12/2015)	108	508.36	-	0.00	
517	00147	BLACK PIPE(WELDING TYPE KSD3507)	M	132	3.07	405.24	5615	189889 (02/12/2015)	132	405.24	-	0.00	
518	00147	BLACK ELBOW (WELDING)	EA	6	5.21	31.26	5615	189889 (02/12/2015)	6	31.26	-	0.00	
519	00147	BLACK ELBOW (WELDING)	EA	5	3.74	18.71	5615	189889 (02/12/2015)	5	18.71	-	0.00	
520	00147	BLACK ELBOW (WELDING)	EA	5	2.28	11.38	5615	189889 (02/12/2015)	5	11.38	-	0.00	
521	00147	BLACK ELBOW (WELDING)	EA	20	1.82	36.42	5615	189889 (02/12/2015)	20	36.42	-	0.00	
522	00147	BLACK ELBOW (WELDING)	EA	60	1.37	81.93	5615	189889 (02/12/2015)	60	81.93	-	0.00	
523	00147	BLACK ELBOW (WELDING)	EA	74	1.21	89.82	5615	189889 (02/12/2015)	74	89.82	-	0.00	
524	00147	BLACK TEE (WELDING)	EA	1	9.61	9.61	5615	189889 (02/12/2015)	1	9.61	-	0.00	
525	00147	BLACK TEE (WELDING)	EA	6	5.56	33.38	5615	189889 (02/12/2015)	6	33.38	-	0.00	
526	00147	BLACK TEE (WELDING)	EA	1	4.25	4.25	5615	189889 (02/12/2015)	1	4.25	-	0.00	
527	00147	BLACK TEE (WELDING)	EA	1	4.25	4.25	5615	189889 (02/12/2015)	1	4.25	-	0.00	
528	00147	BLACK TEE (WELDING)	EA	4	3.59	14.36	5615	189889 (02/12/2015)	4	14.36	-	0.00	
529	00147	BLACK TEE (WELDING)	EA	2	3.59	7.18	5615	189889 (02/12/2015)	2	7.18	-	0.00	
530	00147	BLACK TEE (WELDING)	EA	14	2.91	40.71	5615	189889 (02/12/2015)	14	40.71	-	0.00	
531	00147	BLACK TEE (WELDING)	EA	2	2.91	5.82	5615	189889 (02/12/2015)	2		-	0.00	
532	00147	BLACK TEE (WELDING)	EA	16	2.35	37.63	5615	189889 (02/12/2015)	16	37.63	-	0.00	

533	00147	BLACK REDUCER (WELDING)	EA	1	4.50	4.50	5615	189889 (02/12/2015)	1	4.50	-	0.00	
534	00147	BLACK REDUCER (WELDING)	EA	1	4.50	4.50	5615	189889 (02/12/2015)	1	4.50	-	0.00	
535	00147	BLACK REDUCER (WELDING)	EA	2	2.58	5.16	5615	189889 (02/12/2015)	2	5.16	-	0.00	
536	00147	BLACK REDUCER (WELDING)	EA	1	4.50	4.50	5615	189889 (02/12/2015)	1	4.50	-	0.00	
537	00147	BLACK REDUCER (WELDING)	EA	1	3.12	3.12	5615	189889 (02/12/2015)	1	3.12	-	0.00	
538	00147	BLACK REDUCER (WELDING)	EA	18	1.63	29.41	5615	189889 (02/12/2015)	18	29.41	-	0.00	
539	00147	WELDING FLANGE (KS/JIS 10K)	EA	2	11.49	22.99	5615	189889 (02/12/2015)	2	22.99	-	0.00	
540	00147	WELDING FLANGE (KS/JIS 10K)	EA	12	7.03	84.30	5615	189889 (02/12/2015)	12	84.30	-	0.00	
541	00147	WELDING FLANGE (KS/JIS 10K)	EA	13	6.71	87.29	5615	189889 (02/12/2015)	13	87.29	-	0.00	
542	00147	WELDING FLANGE (KS/JIS 10K)	EA	42	5.09	213.63	5615	189889 (02/12/2015)	42	213.63	-	0.00	
543	00147	WELDING FLANGE (KS/JIS 10K)	EA	66	3.29	216.98	5615	189889 (02/12/2015)	66	216.98	-	0.00	
544	00147	WELDING FLANGE (KS/JIS 10K)/WITHOUT BOLT	EA	2	15.17	30.35	5615	189889 (02/12/2015)	2	30.35	-	0.00	
545	00147	WELDING FLANGE (KS/JIS 10K)/WITHOUT BOLT	EA	1	7.78	7.78	5615	189889 (02/12/2015)	1	7.78	-	0.00	
546	00147	METAL GASKET	EA	1	6.74	6.74	5649	195178 (15/12/2015)	1	6.74	-	0.00	
547	00147	METAL GASKET	EA	12	5.39	64.74	5615	189889 (02/12/2015)	12	64.74	-	0.00	
548	00147	METAL GASKET	EA	13	5.06	65.75	5615	189889 (02/12/2015)	13	65.75	-	0.00	
549	00147	METAL GASKET	EA	42	5.06	212.42	5615	189889 (02/12/2015)	42	212.42	-	0.00	
550	00147	METAL GASKET	EA	66	4.21	278.17	5615	189889 (02/12/2015)	66	278.17	-	0.00	
551	00147	CAST STEEL GLOVE VALVE	EA	2	182.20	364.41	5615	189889 (02/12/2015)	2	364.41	-	0.00	
552	00147	CAST STEEL GLOVE VALVE	EA	2	182.20	364.41	5615	189889 (02/12/2015)	2	364.41	-	0.00	
553	00147	CAST STEEL GLOVE VALVE	EA	7	108.11	756.76	5615	189889 (02/12/2015)	7	756.76	-	0.00	

554	00147	CAST STEEL GLOVE VALVE	EA	9	76.12	685.07	5615	189889 (02/12/2015)	9	685.07	-	0.00	
555	00147	CAST STEEL GLOVE VALVE	EA	4	187.77	751.07	5615	189889 (02/12/2015)	4	751.07	-	0.00	
556	00147	CAST STEEL GLOVE VALVE	EA	4	187.77	751.07	5615	189889 (02/12/2015)	4	751.07	-	0.00	
557	00147	CAST STEEL GLOVE VALVE	EA	14	113.42	1,587.87	5615	189889 (02/12/2015)	14	1,587.87	-	0.00	
558	00147	CAST STEEL GLOVE VALVE	EA	18	79.41	1,429.31	5615	189889 (02/12/2015)	18	1,429.31	-	0.00	
559	00147	EXP.JOINT(STEEL TUBE, DOUBLE)	EA	1	196.91	196.91	5615	189889 (02/12/2015)	1	196.91	-	0.00	
560	00147	EXP.JOINT(STEEL TUBE, DOUBLE)	EA	1	178.03	178.03	5615	189889 (02/12/2015)	1	178.03	-	0.00	
561	00147	EXP.JOINT(STEEL TUBE, DOUBLE)	EA	1	167.24	167.24	5615	189889 (02/12/2015)	1	167.24	-	0.00	
562	00147	EXP.JOINT(STEEL TUBE, DOUBLE)	EA	1	134.87	134.87	5615	189889 (02/12/2015)	1	134.87	-	0.00	
563	00147	TWO WAY VALVE INSTALLATION	EA	2	893.53	1,787.06				-	2	1787.06	
564	00147	TWO WAY VALVE INSTALLATION	EA	7	674.36	4,720.53				-	7	4720.53	
565	00147	FLOAT STEAM TRAP INSTALLATION	EA	9	421.48	3,793.28	5649	195178 (15/12/2015)	9	3,793.28	-	0.00	
566	00147	BUCKET STEAM TRAP INSTALLATION	EA	2	387.76	775.52				-	2	775.52	
567	00147	FLOAT TRAP(BOLT)	EA	7	233.85	1,636.96	5615	189889 (02/12/2015)	7	1,636.96	-	0.00	
568	00147	BUCKET TRAP(BOLT)	EA	2	165.08	330.17	5649	195178 (15/12/2015)	2	330.17	-	0.00	
569	00147	PLATE CHECK VALVE	EA	9	64.06	576.58	5615	189889 (02/12/2015)	9	576.58	-	0.00	
570	00147	2WAY VALVE(TEMP.)	EA	2	2,261.92	4,523.84	5615	189889 (02/12/2015)	2	4,523.84	-	0.00	
571	00147	2WAY VALVE(TEMP.)	EA	7	1,425.99	9,981.96	5649	195178 (15/12/2015)	7	9,981.96	-	0.00	
572	00147	PRESSURE GUAGE& CYPHONE VALVE	EA	9	42.15	379.33	5649	195178 (15/12/2015)	9	379.33	-	0.00	
573	00147	STEAM HEADER	EA	1	81,543.89	81,543.89	5649	195178 (15/12/2015)	1	81,543.89	-	0.00	
574	00147	AUTO AIR VENT (10K)®	EA	12	80.92	971.08				-	12	971.08	

575	00147	GS VALVE	EA	12	59.01	708.08	5649	195178 (15/12/2015)	12	708.08	-	0.00	
576	00147	PIPE INSULATION	M	30	10.96	328.75	5649	195178 (15/12/2015)	30	328.75	-	0.00	
577	00147	PIPE INSULATION	M	42	9.27	389.44	5649	195178 (15/12/2015)	42	389.44	-	0.00	
578	00147	PIPE INSULATION	M	24	7.59	182.08	5649	195178 (15/12/2015)	24	182.08	-	0.00	
579	00147	PIPE INSULATION	M	66	5.90	389.44	5649	195178 (15/12/2015)	66	389.44	-	0.00	
580	00147	PIPE INSULATION	M	108	6.41	691.89	5649	195178 (15/12/2015)	108	691.89	-	0.00	
581	00147	PIPE INSULATION	M	132	5.90	778.89	5649	195178 (15/12/2015)	132	778.89	-	0.00	
582	00147	ㄷ-PIPE	ton	2	1,517.31	3,034.63				-	2	3034.63	
583	00147	GENERAL PLATE	ton	1	5,010.74	5,010.74				-	1	5010.74	
584	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
585	00147	PAINT	m2	83	2.02	168.46				-	83	168.46	
586	00147	ANTI-RUST PAINTING	m2	167	2.28	380.76				-	167	380.76	
587	00147	PIPE SUE	EA	300	14.33	4,299.05				-	300	4299.05	
588	00147	STS PIPE (WELDING KSD3576)	M	72	38.78	2,792.34	5590	181978 (13/11/15)	72.00	2,792.34	-	0.00	
589	00147	STS PIPE (WELDING KSD3576)	M	264	31.34	8,273.12	5590	181978 (13/11/15)	264.00	8,273.12	-	0.00	
590	00147	STS PIPE (WELDING KSD3576)	M	12	24.88	298.61	5590	181978 (13/11/15)	12.00	298.61	-	0.00	
591	00147	STS PIPE (WELDING KSD3576)	M	54	21.67	1,170.03	5590	181978 (13/11/15)	54.00	1,170.03	-	0.00	
592	00147	STS PIPE (WELDING KSD3576)	M	138	16.95	2,339.58	5590	181978 (13/11/15)	138.00	2,339.58	-	0.00	
593	00147	STS PIPE (WELDING KSD3576)	M	48	11.17	536.04	5590	181978 (13/11/15)	48.00	536.04	-	0.00	
594	00147	STS PIPE (WELDING KSD3576)	M	600	8.72	5,231.70	5590	181978 (13/11/15)	600.00	5,231.70	-	0.00	
595	00147	STS ELBOW (W)	EA	6	14.76	88.57	5615	189889 (02/12/2015)	6	88.57	-	0.00	

596	00147	STS ELBOW (W)	EA	20	9.66	193.24	5615	189889 (02/12/2015)	20	193.24	-	0.00	
597	00147	STS ELBOW (W)	EA	2	6.59	13.19	5615	189889 (02/12/2015)	2	13.19	-	0.00	
598	00147	STS ELBOW (W)	EA	12	3.74	44.85	5615	189889 (02/12/2015)	12	44.85	-	0.00	
599	00147	STS ELBOW (W)	EA	16	2.69	43.02	5615	189889 (02/12/2015)	16	43.02	-	0.00	
600	00147	STS ELBOW (W)	EA	186	2.15	400.13				-	186	400.13	
601	00147	STS TEE (W)	EA	1	26.66	26.66				-	1	26.66	
602	00147	STS TEE (W)	EA	6	17.41	104.43				-	6	104.43	
603	00147	STS TEE (W)	EA	1	17.41	17.41				-	1	17.41	
604	00147	STS TEE (W)	EA	1	17.41	17.41				-	1	17.41	
605	00147	STS TEE (W)	EA	1	17.41	17.41				-	1	17.41	
606	00147	STS TEE (W)	EA	1	17.41	17.41				-	1	17.41	
607	00147	STS TEE (W)	EA	7	17.41	121.84				-	7	121.84	
608	00147	STS TEE (W)	EA	4	13.57	54.27				-	4	54.27	
609	00147	STS TEE (W)	EA	1	10.37	10.37				-	1	10.37	
610	00147	STS TEE (W)	FA	8	10.37	82.93				-	8	82.93	
611	00147	STS TEE (W)	EA	8	7.25	58.01				-	8	58.01	
612	00147	STS TEE (W)	EA	2	7.25	14.50	5615	189889 (02/12/2015)	2	14.50	-	0.00	
613	00147	STS TEE (W)	EA	4	7.25	29.00	5615	189889 (02/12/2015)	4	29.00	-	0.00	
614	00147	STS TEE (W)	EA	4	4.69	18.77	5615	189889 (02/12/2015)	4	18.77	-	0.00	
615	00147	STS REDUCER (W)	EA	1	10.65	10.65				-	1	10.65	
616	00147	STS REDUCER (W)	EA	1	15.99	15.99				-	1	15.99	
617	00147	STS REDUCER (W)	EA	1	7.35	7.35				-	1	7.35	
618	00147	STS FLANGE(KSB 1506)	EA	9	25.67	231.06	5615	189889 (02/12/2015)	9	231.06	-	0.00	
619	00147	STS FLANGE(KSB 1506)	EA	1	19.80	19.80	5615	189889 (02/12/2015)	1	19.80	-	0.00	
620	00147	STS FLANGE(KSB 1506)	EA	4	18.30	73.20	5615	189889 (02/12/2015)	4	73.20	-	0.00	
621	00147	STS FLANGE(KSB 1506)	EA	3	16.52	49.57	5615	189889 (02/12/2015)	3	49.57	-	0.00	
622	00147	STS FLANGE(KSB 1506)/WITHOUT BOLT	EA	1	32.50	32.50	5649	195178 (15/12/2015)	1	32.50	-	0.00	
623	00147	STS FLANGE(KSB 1506)/WITHOUT BOLT	EA	1	25.54	25.54	5649	195178 (15/12/2015)	1	25.54	-	0.00	

624	00147	STS FLANGE(KSB 1506)/WITHOUT BOLT	EA	3	21.30	63.91	5615	189889 (02/12/2015)	3	63.91	-	0.00	
625	00147	STS FLANGE(KSB 1506)/WITHOUT BOLT	EA	2	19.66	39.33	5615	189889 (02/12/2015)	2	39.33	-	0.00	
626	00147	STS NIPPLE	EA	4	3.37	13.49	5649	195178 (15/12/2015)	4	13.49	-	0.00	
627	00147	STS NIPPLE	EA	62	2.53	156.79	5615	189889 (02/12/2015)	62	156.79	-	0.00	
628	00147	STS BALL VALVE (FLG'D)	EA	4	246.82	987.27	5615	189889 (02/12/2015)	4	987.27	-	0.00	
629	00147	STS BALL VALVE (SCR'D)	EA	2	21.24	42.48	5615	189889 (02/12/2015)	2	42.48	-	0.00	
630	00147	STS BALL VALVE (SCR'D)	EA	31	16.52	512.18	5615	189889 (02/12/2015)	31	512.18	-	0.00	
631	00147	STS FLANGE(KSB 1506)	EA	8	25.67	205.38	5615	189889 (02/12/2015)	8	205.38	-	0.00	
632	00147	GASKET	EA	8	5.06	40.46	5615	189889 (02/12/2015)	8	40.46	-	0.00	
633	00147	INSULATION	M	72	7.08	509.82				-	72	509.82	
634	00147	INSULATION	M	264	5.25	1,386.86	5649	195178 (15/12/2015)	264	1,386.86	-	0.00	
635	00147	INSULATION	M	12	5.90	70.81	5649	195178 (15/12/2015)	12	70.81	-	0.00	
636	00147	INSULATION	M	54	5.39	291.32	5649	195178 (15/12/2015)	54	291.32	-	0.00	
637	00147	INSULATION	M	138	5.06	697.96	5649	195178 (15/12/2015)	138	697.96	-	0.00	
638	00147	INSULATION	M	48	4.21	202.31	5649	195178 (15/12/2015)	48	202.31	-	0.00	
639	00147	INSULATION	M	600	4.21	2,528.86	5649	195178 (15/12/2015)	600	2,528.86	-	0.00	
640	00147	ㄷ-PIPE	ton	1	1,517.31	1,517.31				-	1	1517.31	
641	00147	GENERAL PLATE	ton	1	5,010.74	2,505.37				-	1	2505.37	
642	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
643	00147	PAINT	m2	42	2.02	84.23				-	42	84.23	
644	00147	ANTI-RUST PAINTING	m2	83	2.28	190.38				-	83	190.38	
645	00147	STS PIPE (WELDING KSD3576)	M	36	47.85	1,722.45	5590	181978 (13/11/15)	36.00	1,722.45	-	0.00	
646	00147	STS PIPE (WELDING KSD3576)	M	12	38.78	465.39	5590	181978 (13/11/15)	12.00	465.39	-	0.00	
647	00147	STS PIPE (WELDING KSD3576)	M	138	31.34	4,324.59	5590	181978 (13/11/15)	138.00	4,324.59	-	0.00	

648	00147	STS PIPE (WELDING KSD3576)	M	120	21.67	2,600.07	5590	181978 (13/11/15)	120.00	2,600.07	-	0.00	
649	00147	STS PIPE (WELDING KSD3576)	M	42	11.17	469.03	5590	181978 (13/11/15)	42.00	469.03	-	0.00	
650	00147	STS PIPE (WELDING KSD3576)	M	204	8.72	1,778.78	5590	181978 (13/11/15)	204.00	1,778.78	-	0.00	
651	00147	STS ELBOW (W)	EA	6	20.14	120.84	5615	189889 (02/12/2015)	6	120.84	-	0.00	
652	00147	STS ELBOW (W)	EA	6	14.76	88.57	5615	189889 (02/12/2015)	6	88.57	-	0.00	
653	00147	STS ELBOW (W)	EA	12	9.66	115.94	5615	189889 (02/12/2015)	12	115.94	-	0.00	
654	00147	STS ELBOW (W)	EA	6	5.14	30.82	5615	189889 (02/12/2015)	6	30.82	-	0.00	
655	00147	STS ELBOW (W)	EA	3	2.69	8.07	5615	189889 (02/12/2015)	3	8.07	-	0.00	
656	00147	STS ELBOW (W)	EA	66	2.15	141.98	5615	189889 (02/12/2015)	66	141.98	-	0.00	
657	00147	STS TEE (W)	EA	1	31.36	31.36				-	1	31.36	
658	00147	STS TEE (W)	EA	2	17.41	34.81	5615	189889 (02/12/2015)	2	34.81	-	0.00	
659	00147	STS TEE (W)	EA	2	10.37	20.73	5615	189889 (02/12/2015)	2	20.73	-	0.00	
660	00147	STS TEE (W)	EA	7	10.37	72.57	5615	189889 (02/12/2015)	7	72.57	-	0.00	
661	00147	STS TEE (W)	EA	1	4.69	4.69	5615	189889 (02/12/2015)	1	4.69	-	0.00	
662	00147	STS TEE (W)	EA	3	4.69	14.08	5615	189889 (02/12/2015)	3	14.08	-	0.00	
663	00147	STS REDUCER (W)	EA	1	6.14	6.14	5615	189889 (02/12/2015)	1	6.14	-	0.00	
664	00147	STS BALL VALVE (FLG'D)	EA	1	360.11	360.11	5615	189889 (02/12/2015)	1	360.11	-	0.00	
665	00147	STS BALL VALVE (FLG'D)	EA	3	246.82	740.45	5615	189889 (02/12/2015)	3	740.45	-	0.00	
666	00147	STS BALL VALVE (FLG'D)	EA	1	164.54	164.54	5615	189889 (02/12/2015)	1	164.54	-	0.00	
667	00147	STS BALL VALVE (SCR'D)	EA	2	21.24	42.48	5615	189889 (02/12/2015)	2	42.48	-	0.00	
668	00147	STS BALL VALVE (SCR'D)	EA	11	16.52	181.74	5615	189889 (02/12/2015)	11	181.74	-	0.00	
669	00147	STS FLANGE(KSB 1506)	EA	3	34.82	104.47	5615	189889 (02/12/2015)	3	104.47	-	0.00	
670	00147	STS FLANGE(KSB 1506)	EA	6	25.67	154.04	5649	195178 (15/12/2015)	6	154.04	-	0.00	

671	00147	STS FLANGE(KSB 1506)	EA	1	19.80	19.80	5615	189889 (02/12/2015)	1	19.80	-	0.00	
672	00147	STS FLANGE(KSB 1506)	EA	2	16.52	33.05	5615	189889 (02/12/2015)	2	33.05	-	0.00	
673	00147	STS FLANGE(KSB 1506)/WITHOUT BOLT	EA	1	32.50	32.50	5615	189889 (02/12/2015)	1	32.50	-	0.00	
674	00147	STS FLANGE(KSB 1506)/WITHOUT BOLT	EA	1	25.54	25.54	5615	189889 (02/12/2015)	1	25.54	-	0.00	
675	00147	STS FLANGE(KSB 1506)/WITHOUT BOLT	EA	2	19.66	39.33	5615	189889 (02/12/2015)	2	39.33	-	0.00	
676	00147	GASKET	EA	6	5.06	30.35	5615	189889 (02/12/2015)	6	30.35	-	0.00	
677	00147	GASKET	EA	2	4.21	8.43	5615	189889 (02/12/2015)	2	8.43	-	0.00	
678	00147	GASKET	EA	4	3.37	13.49	5615	189889 (02/12/2015)	4	13.49	-	0.00	
679	00147	INSULATION	M	36	7.59	273.12	5649	195178 (15/12/2015)	36	273.12	-	0.00	
680	00147	INSULATION	M	12	7.08	84.97	5649	195178 (15/12/2015)	12	84.97	-	0.00	
681	00147	INSULATION	M	138	5.25	724.95	5649	195178 (15/12/2015)	138	724.95	-	0.00	
682	00147	INSULATION	M	120	5.39	647.39				-	120	647.39	
683	00147	INSULATION	M	42	4.21	177.02				-	42	177.02	
684	00147	INSULATION	M	204	4.21	859.81				-	204	859.81	
685	00147	ㄷ-PIPE	ton	1	1,517.31	1,517.31				-	1	1517.31	
686	00147	GENERAL PLATE	ton	1	5,010.74	2,505.37				-	1	2505.37	
687	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
688	00147	PAINT	m2	42	2.02	84.23				-	42	84.23	
689	00147	ANTI-RUST PAINTING	m2	83	2.28	190.38				-	83	190.38	
690	00147	STS PIPE (WELDING KSD3576)	M	24	47.85	1,148.30	5590	181978 (13/11/15)	24.00	1,148.30	-	0.00	
691	00147	STS PIPE (WELDING KSD3576)	M	18	38.78	698.09	5615	189889 (02/12/2015)	18	698.09	-	0.00	
692	00147	STS ELBOW (W)	EA	6	20.14	120.84	5615	189889 (02/12/2015)	6	120.84	-	0.00	

693	00147	STS ELBOW (W)	EA	6	14.76	88.57	5615	...9889 (02/12/2015)	6	88.57	-	0.00	
694	00147	STS TEE (W)	EA	2	26.66	53.32	5615	189889 (02/12/2015)	2	53.32	-	0.00	
695	00147	STS FLANGE(KSB 1506)	EA	6	37.42	224.50	5615	189889 (02/12/2015)	6	224.50	-	0.00	
696	00147	STS FLANGE(KSB 1506)	EA	6	34.82	208.93	5615	189889 (02/12/2015)	6	208.93	-	0.00	
697	00147	STS FLANGE(KSB 1506)	EA	12	25.67	308.08	5615	189889 (02/12/2015)	12	308.08	-	0.00	
698	00147	STS BUTTERFLY VALVE(G/W)	EA	1	249.51	249.51	5615	189889 (02/12/2015)	1	249.51	-	0.00	
699	00147	STS BUTTERFLY VALVE(G/W)	EA	1	210.74	210.74	5615	189889 (02/12/2015)	1	210.74	-	0.00	
700	00147	STS STRAINER(FLG'D)	EA	1	391.13	391.13	5615	189889 (02/12/2015)	1	391.13	-	0.00	
701	00147	STS CHECK VALVE	EA	1	340.55	340.55	5615	189889 (02/12/2015)	1	340.55	-	0.00	
702	00147	STS FLEXIBLE JOINT	EA	1	198.94	198.94	5615	189889 (02/12/2015)	1	198.94	-	0.00	
703	00147	STS FLEXIBLE JOINT	EA	1	178.71	178.71	5615	189889 (02/12/2015)	1	178.71	-	0.00	
704	00147	GASKET	EA	8	7.59	60.69	5615	189889 (02/12/2015)	8	60.69	-	0.00	
705	00147	GASKET	EA	24	5.06	121.39	5615	189889 (02/12/2015)	24	121.39	-	0.00	
706	00147	INSULATION	M	24	7.59	182.08				-	24	182.08	
707	00147	INSULATION	M	18	7.08	127.45				-	18	127.45	
708	00147	ㄷ-PIPE	ton	1	1,517.31	1,517.31				-	1	1517.31	
709	00147	GENERAL PLATE	ton	1	5,010.74	2,505.37				-	1	2505.37	
710	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
711	00147	PAINT	m2	42	2.02	84.23				-	42	84.23	
712	00147	ANTI-RUST PAINTING	m2	83	2.28	190.38				-	83	190.38	
713	00147	STS PIPE (WELDING KSD3576)	M	72	24.88	1,791.64	5590	181978 (13/11/15)	72.00	1,791.64	-	0.00	
714	00147	STS PIPE (WELDING KSD3576)	M	96	21.67	2,080.05	5590	181978 (13/11/15)	96.00	2,080.05	-	0.00	
715	00147	STS PIPE (WELDING KSD3576)	M	204	16.95	3,458.50	5590	181978 (13/11/15)	204.00	3,458.50	-	0.00	
716	00147	STS PIPE (WELDING KSD3576)	M	324	11.17	3,618.25	5590	181978 (13/11/15)	324.00	3,618.25	-	0.00	
717	00147	STS PIPE (WELDING KSD3576)	M	234	8.72	2,040.36	5590	181978 (13/11/15)	234.00	2,040.36	-	0.00	
718	00147	STS ELBOW (W)	EA	6	6.59	39.56	5615	189889 (02/12/2015)	6	39.56	-	0.00	

719	00147	STS ELBOW (W)	EA	10	5.14	51.37				-	10	51.37	
720	00147	STS ELBOW (W)	EA	12	3.74	44.85	5615	189889 (02/12/2015)	12	44.85	-	0.00	
721	00147	STS ELBOW (W)	EA	30	2.69	80.67	5615	189889 (02/12/2015)	30	80.67	-	0.00	
722	00147	STS ELBOW (W)	EA	80	2.15	172.10				-	80	172.10	
723	00147	STS TEE (W)	EA	1	13.57	13.57	5615	189889 (02/12/2015)	1	13.57	-	0.00	
724	00147	STS TEE (W)	EA	2	10.37	20.73	5615	189889 (02/12/2015)	2	20.73	-	0.00	
725	00147	STS TEE (W)	EA	2	10.37	20.73	5615	189889 (02/12/2015)	2	20.73	-	0.00	
726	00147	STS TEE (W)	EA	3	7.25	21.75	5615	189889 (02/12/2015)	3	21.75	-	0.00	
727	00147	STS TEE (W)	EA	2	7.25	14.50	5615	189889 (02/12/2015)	2	14.50	-	0.00	
728	00147	STS TEE (W)	EA	7	4.69	32.84	5615	189889 (02/12/2015)	7	32.84	-	0.00	
729	00147	STS TEE (W)	EA	3	10.37	31.10	5615	189889 (02/12/2015)	3	31.10	-	0.00	
730	00147	STS TEE (W)	EA	1	7.25	7.25	5615	189889 (02/12/2015)	1	7.25	-	0.00	
731	00147	STS TEE (W)	EA	15	4.69	70.38	5615	189889 (02/12/2015)	15	70.38	-	0.00	
732	00147	STS TEE (W)	EA	5	4.07	20.36	5615	189889 (02/12/2015)	5	20.36	-	0.00	
733	00147	STS REDUCER (W)	EA	1	7.35	7.35	5615	189889 (02/12/2015)	1	7.35	-	0.00	
734	00147	STS REDUCER (W)	EA	2	4.54	9.08	5615	189889 (02/12/2015)	2	9.08	-	0.00	
735	00147	STS REDUCER (W)	EA	1	6.14	6.14	5615	189889 (02/12/2015)	1	6.14	-	0.00	
736	00147	STS REDUCER (W)	EA	3	3.88	11.65	5615	189889 (02/12/2015)	3	11.65	-	0.00	
737	00147	STS BALL VALVE (FLG'D)	EA	1	164.54	164.54	5615	189889 (02/12/2015)	1	164.54	-	0.00	
738	00147	STS BALL VALVE (FLG'D)	EA	4	142.96	571.86	5615	189889 (02/12/2015)	4	571.86	-	0.00	
739	00147	STS BALL VALVE (SCR'D)	EA	6	21.24	127.45	5615	189889 (02/12/2015)	6	127.45	-	0.00	
740	00147	STS BALL VALVE (SCR'D)	EA	13	16.52	214.78	5615	189889 (02/12/2015)	13	214.78	-	0.00	
741	00147	STS FLANGE(KSB 1506)	EA	2	19.80	39.60	5615	189889 (02/12/2015)	2	39.60	-	0.00	
742	00147	STS FLANGE(KSB 1506)	EA	8	19.80	158.41	5615	189889 (02/12/2015)	8	158.41	-	0.00	
743	00147	STS FLANGE(KSB 1506)	EA	12	19.80	237.61	5615	189889 (02/12/2015)	12	237.61	-	0.00	
744	00147	GASKET	EA	2	5.06	10.12	5615	189889 (02/12/2015)	2	10.12	-	0.00	
745	00147	GASKET	EA	8	4.21	33.72	5615	189889 (02/12/2015)	8	33.72	-	0.00	
746	00147	GASKET	EA	12	3.37	40.46	5615	189889 (02/12/2015)	12	40.46	-	0.00	

747	00147	INSULATION	M	72	5.90	424.85				-	72	424.85	
748	00147	INSULATION	M	96	5.39	517.91				-	96	517.91	
749	00147	INSULATION	M	204	5.06	1,031.77				-	204	1031.77	
750	00147	INSULATION	M	324	4.21	1,365.58				-	324	1365.58	
751	00147	INSULATION	M	234	4.21	986.25				-	234	986.25	
752	00147	⊏-PIPE	ton	1	1,517.31	1,517.31				-	1	1517.31	
753	00147	GENERAL PLATE	ton	1	5,010.74	2,505.37				-	1	2505.37	
754	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
755	00147	PAINT	m2	42	2.02	84.23				-	42	84.23	
756	00147	ANTI-RUST PAINTING	m2	83	2.28	190.38				-	83	190.38	
757	00147	STS PIPE (WELDING KSD3576)	M	24	28.73	689.43				-	24	689.43	
758	00147	STS PIPE (WELDING KSD3576)	M	30	24.88	746.52	5590	181978 (13/11/15)	30.00	746.52	-	0.00	
759	00147	STS PIPE (WELDING KSD3576)	M	324	16.95	5,492.92	5590	181978 (13/11/15)	324.00	5,492.92	-	0.00	
760	00147	STS PIPE (WELDING KSD3576)	M	210	11.17	2,345.16	5590	181978 (13/11/15)	210.00	2,345.16	-	0.00	
761	00147	STS PIPE (WELDING KSD3576)	M	108	8.72	941.71	5590	181978 (13/11/15)	108.00	941.71	-	0.00	
762	00147	STS ELBOW (W)	EA	12	9.66	115.94	5615	189889 (02/12/2015)	12	115.94	-	0.00	
763	00147	STS ELBOW (W)	EA	6	6.59	39.56	5615	189889 (02/12/2015)	6	39.56	-	0.00	
764	00147	STS ELBOW (W)	EA	20	3.74	74.75	5615	189889 (02/12/2015)	20	74.75	-	0.00	
765	00147	STS ELBOW (W)	EA	25	2.69	67.23	5615	189889 (02/12/2015)	25	67.23	-	0.00	
766	00147	STS ELBOW (W)	EA	36	2.15	77.44	5615	189889 (02/12/2015)	36	77.44	-	0.00	
767	00147	STS TEE (W)	EA	1	17.41	17.41	5615	189889 (02/12/2015)	1	17.41	-	0.00	
768	00147	STS TEE (W)	EA	1	17.41	17.41	5615	189889 (02/12/2015)	1	17.41	-	0.00	
769	00147	STS TEE (W)	EA	2	17.41	34.81	5615	189889 (02/12/2015)	2	34.81	-	0.00	

770	00147	STS TEE (W)	EA	1	17.41	17.41	5615	9889 (02/12/2015)	1	17.41	-	0.00	
771	00147	STS TEE (W)	EA	6	7.25	43.51	5615	189889 (02/12/2015)	6	43.51	-	0.00	
772	00147	STS TEE (W)	EA	2	7.25	14.50	5615	189889 (02/12/2015)	2	14.50	-	0.00	
773	00147	STS TEE (W)	EA	4	4.69	18.77	5615	189889 (02/12/2015)	4	18.77	-	0.00	
774	00147	STS TEE (W)	EA	6	4.69	28.15	5615	189889 (02/12/2015)	6	28.15	-	0.00	
775	00147	STS REDUCER (W)	EA	2	3.88	7.77	5615	189889 (02/12/2015)	2	7.77	-	0.00	
776	00147	STS FLANGE(KSB 1506)	EA	16	25.67	410.77	5615	189889 (02/12/2015)	16	410.77	-	0.00	
777	00147	STS FLANGE(KSB 1506)	EA	2	21.03	42.06	5615	189889 (02/12/2015)	2	42.06	-	0.00	
778	00147	STS FLANGE(KSB 1506)	EA	1	18.30	18.30	5615	189889 (02/12/2015)	1	18.30	-	0.00	
779	00147	STS FLANGE(KSB 1506)/WITHOUT BOLT	EA	1	26.77	26.77	5615	189889 (02/12/2015)	1	26.77	-	0.00	
780	00147	STS FLANGE(KSB 1506)/WITHOUT BOLT	EA	1	21.30	21.30	5615	189889 (02/12/2015)	1	21.30	-	0.00	
781	00147	GASKET	EA	20	5.06	101.15	5615	189889 (02/12/2015)	20	101.15	-	0.00	
782	00147	GASKET	EA	1	4.21	4.21				-	1	4.21	
783	00147	GASKET	EA	1	2.53	2.53				-	1	2.53	
784	00147	STS BALL VALVE (FLG'D)	EA	4	142.96	571.86	5615	189889 (02/12/2015)	4	571.86	-	0.00	
785	00147	STS BALL VALVE (FLG'D)	EA	2	142.96	285.93	5615	189889 (02/12/2015)	2	285.93	-	0.00	
786	00147	STS BALL VALVE (SCR'D)	EA	2	21.24	42.48	5615	189889 (02/12/2015)	2	42.48	-	0.00	
787	00147	STS BALL VALVE (SCR'D)	EA	6	16.52	99.13	5615	189889 (02/12/2015)	6	99.13	-	0.00	
788	00147	STS STRAINER(FLG'D)	EA	2	261.32	522.63	5615	189889 (02/12/2015)	2	522.63	-	0.00	
789	00147	STS CHECK VALVE	EA	2	266.37	532.75	5615	189889 (02/12/2015)	2	532.75	-	0.00	
790	00147	INSULATION	M	24	5.25	126.08					24	126.08	
791	00147	INSULATION	M	30	5.90	177.02				-	30	177.02	
792	00147	INSULATION	M	324	5.06	1,638.70				-	324	1638.70	

793	00147	INSULATION	M	210	4.21	885.10				-	210	885.10	
794	00147	INSULATION	M	108	4.21	455.19				-	108	455.19	
795	00147	⊏-PIPE	ton	1	1,517.31	1,517.31				-	1	1517.31	
796	00147	GENERAL PLATE	ton	1	5,010.74	2,505.37				-	1	2505.37	
797	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
798	00147	PAINT	m2	42	2.02	84.23				-	42	84.23	
799	00147	ANTI-RUST PAINTING	m2	83	2.28	190.38				-	83	190.38	
800	00147	STS PIPE (WELDING KSD3576)	M	42	61.85	2,597.52	5615	189889 (02/12/2015)	42.00	2,597.52	-	0.00	
801	00147	STS PIPE (WELDING KSD3576)	M	48	47.85	2,296.61	5590	181978 (13/11/15)	48.00	2,296.61	-	0.00	
802	00147	STS PIPE (WELDING KSD3576)	M	30	31.34	940.13	5590	181978 (13/11/15)	30.00	940.13	-	0.00	
803	00147	STS PIPE (WELDING KSD3576)	M	36	8.72	313.90	5590	181978 (13/11/15)	36.00	313.90	-	0.00	
804	00147	STS ELBOW (W)	EA	10	33.49	334.92	5615	189889 (02/12/2015)	10	334.92	-	0.00	
805	00147	STS ELBOW (W)	EA	10	20.14	201.40	5615	189889 (02/12/2015)	10	201.40	-	0.00	
806	00147	STS ELBOW (W)	EA	6	14.76	88.57	5615	189889 (02/12/2015)	6	88.57	-	0.00	
807	00147	STS ELBOW (W)	EA	12	9.66	115.94	5615	189889 (02/12/2015)	12	115.94	-	0.00	
808	00147	STS ELBOW (W)	EA	30	2.15	64.54	5615	189889 (02/12/2015)	30	64.54	-	0.00	
809	00147	STS TEE (W)	EA	14	31.36	439.03	5615	189889 (02/12/2015)	14	439.03	-	0.00	
810	00147	STS TEE (W)	EA	3	31.36	94.08	5615	189889 (02/12/2015)	3	94.08	-	0.00	
811	00147	STS TEE (W)	EA	3	26.66	79.98	5615	189889 (02/12/2015)	3	79.98	-	0.00	
812	00147	STS TEE (W)	EA	6	17.41	104.43	5615	189889 (02/12/2015)	6	104.43	-	0.00	
813	00147	STS TEE (W)	EA	6	4.07	24.43	5615	189889 (02/12/2015)	6	24.43	-	0.00	
814	00147	STS REDUCER (W)	EA	1	18.69	18.69	5615	189889 (02/12/2015)	1	18.69	-	0.00	
815	00147	STS REDUCER (W)	EA	2	12.76	25.51	5615	189889 (02/12/2015)	2	25.51	-	0.00	
816	00147	STS REDUCER (W)	EA	3	4.67	14.02	5615	189889 (02/12/2015)	3	14.02	-	0.00	

817	00147	STS REDUCER (W)	EA	6	2.49	14.93	5615	89889 (02/12/2015)	6	14.93	-	0.00	
818	00147	STS BALL VALVE (FLG'D)	EA	21	496.33	10,422.93	5615	189889 (02/12/2015)	21	10,422.93	-	0.00	
819	00147	STS BALL VALVE (FLG'D)	EA	3	360.11	1,080.33				-	3	1080.33	
820	00147	STS BALL VALVE (SCR'D)	EA	27	16.52	446.09	5649	195178 (15/12/2015)	27	446.09	-	0.00	
821	00147	STS UNION	EA	16	6.95	111.22	5615	189889 (02/12/2015)	16	111.22	-	0.00	
822	00147	STS NIPPLE	EA	10	3.37	33.72	5649	195178 (15/12/2015)	10	33.72	-	0.00	
823	00147	STS NIPPLE	EA	64	2.53	161.85	5615	189889 (02/12/2015)	64	161.85	-	0.00	
824	00147	STS FLANGE(KSB 1506)	EA	44	37.42	1,646.35	5615	189889 (02/12/2015)	44	1,646.35	-	0.00	
825	00147	STS FLANGE(KSB 1506)	EA	6	34.82	208.93	5615	189889 (02/12/2015)	6	208.93	-	0.00	
826	00147	GASKET	EA	50	10.96	547.92	5615	189889 (02/12/2015)	50	547.92	-	0.00	
827	00147	GASKET	EA	5	8.43	42.15	5615	189889 (02/12/2015)	5	42.15	-	0.00	
828	00147	ㄷ-PIPE	ton	2	1,517.31	3,034.63				-	2	3034.63	
829	00147	GENERAL PLATE	ton	1	5,010.74	5,010.74				-	1	5010.74	
830	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
831	00147	PAINT	m2	83	2.02	168.46				-	83	168.46	
832	00147	ANTI-RUST PAINTING	m2	167	2.28	380.76				-	167	380.76	
833	00147	STS PIPE (WELDING KSD3576)	M	30	61.85	1,855.37	5590	181978 (13/11/15)	30.00	1,855.37	-	0.00	
834	00147	STS PIPE (WELDING KSD3576)	M	278	47.85	13,301.17	5590	181978 (13/11/15)	278.00	13,301.17	-	0.00	
835	00147	STS PIPE (WELDING KSD3576)	M	90	31.34	2,820.38	5590	181978 (13/11/15)	90.00	2,820.38	-	0.00	
836	00147	STS PIPE (WELDING KSD3576)	M	36	11.17	402.03	5590	181978 (13/11/15)	36.00	402.03	-	0.00	
837	00147	STS PIPE (WELDING KSD3576)	M	1044	8.72	9,103.15	5590	181978 (13/11/15)	1044	9,103.15	-	0.00	
838	00147	STS ELBOW (W)	EA	10	33.49	334.92	5615	189889 (02/12/2015)	10	334.92	-	0.00	
839	00147	STS ELBOW (W)	EA	30	20.14	604.19	5615	189889 (02/12/2015)	30	604.19	-	0.00	

840	00147	STS ELBOW (W)	EA	12	2.69	32.27	5615	189889 (02/12/2015)	12	32.27	-	0.00	
841	00147	STS ELBOW (W)	EA	348	2.15	748.62	5615	189889 (02/12/2015)	348	748.62	-	0.00	
842	00147	STS TEE (W)	EA	1	47.57	47.57	5615	189889 (02/12/2015)	1	47.57	-	0.00	
843	00147	STS TEE (W)	EA	1	47.57	47.57	5615	189889 (02/12/2015)	1	47.57	-	0.00	
844	00147	STS TEE (W)	EA	1	31.36	31.36	5615	189889 (02/12/2015)	1	31.36	-	0.00	
845	00147	STS TEE (W)	EA	2	31.36	62.72	5615	189889 (02/12/2015)	2	62.72	-	0.00	
846	00147	STS TEE (W)	EA	52	31.36	1,630.69	5615	189889 (02/12/2015)	52	1,630.69	-	0.00	
847	00147	STS TEE (W)	EA	1	17.41	17.41	5615	189889 (02/12/2015)	1	17.41	-	0.00	
848	00147	STS TEE (W)	EA	7	17.41	121.84	5615	189889 (02/12/2015)	7	121.84	-	0.00	
849	00147	STS REDUCER (W)	EA	1	34.10	34.10	5615	189889 (02/12/2015)	1	34.10	-	0.00	
850	00147	STS REDUCER (W)	EA	1	3.88	3.88	5615	189889 (02/12/2015)	1	3.88	-	0.00	
851	00147	STS REDUCER (W)	EA	52	5.89	306.13	5615	189889 (02/12/2015)	52	306.13	-	0.00	
852	00147	STS BALL VALVE (SCR'D)	EA	2	21.24	42.48				-	2	42.48	
853	00147	STS BALL VALVE (SCR'D)	EA	58	16.52	958.27	5615	189889 (02/12/2015)	58	958.27	-	0.00	
854	00147	STS NIPPLE	EA	4	3.37	13.49	5649	195178 (15/12/2015)	4	13.49	-	0.00	
855	00147	STS NIPPLE	EA	116	2.53	293.35	5615	189889 (02/12/2015)	116	293.35	-	0.00	
856	00147	⊏-PIPE	ton	2	1,517.31	3,034.63				-	2	3034.63	
857	00147	GENERAL PLATE	ton	1	5,010.74	5,010.74				-	1	5010.74	
858	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
859	00147	PAINT	m2	83	2.02	168.46				-	83	168.46	
860	00147	ANTI-RUST PAINTING	m2	167	2.28	380.76				-	167	380.76	
861	00147	STS PIPE (WELDING KSD3576)	M	192	31.34	6,016.82	5615	189889 (02/12/2015)	192.00	6,016.82	-	0.00	
862	00147	STS PIPE (WELDING KSD3576)	M	272	8.72	2,371.70	5590	181978 (13/11/15)	272.00	2,371.70	-	0.00	
863	00147	STS ELBOW (W)	EA	30	9.66	289.86	5615	189889 (02/12/2015)	30	289.86	-	0.00	
864	00147	STS ELBOW (W)	EA	102	2.15	219.42	5615	189889 (02/12/2015)	102	219.42	-	0.00	
865	00147	STS TEE (W)	EA	1	17.41	17.41	5615	189889 (02/12/2015)	1	17.41	-	0.00	

866	00147	STS TEE (W)	EA	17	17.41	295.89	5615	189889 (02/12/2015)	17	295.89	-	0.00	
867	00147	STS BALL VALVE (SCR'D)	EA	17	16.52	280.87	5615	189889 (02/12/2015)	17	280.87	-	0.00	
868	00147	STS NIPPLE	EA	34	2.53	85.98	5615	189889 (02/12/2015)	34	85.98	-	0.00	
869	00147	⊏-PIPE	ton	1	1,517.31	1,517.31				-	1	1517.31	
870	00147	GENERAL PLATE	ton	1	5,010.74	2,505.37				-	1	2505.37	
871	00147	INSERT PLATE	EA	50	7.42	370.81				-	50	370.81	
872	00147	PAINT	m2	42	2.02	84.23				-	42	84.23	
873	00147	ANTI-RUST PAINTING	m2	83	2.28	190.38				-	83	190.38	
874	00147	LP-A-GA	LOT	1	6,631.88	6,631.88	5634	192837(09/12/15)	1	6,631.88	-	0.00	
875	00147	LP-A-GB	LOT	1	7,018.35	7,018.35	5634	192837(09/12/15)	1	7,018.35	-	0.00	
876	00147	LP-A-GBa	LOT	1	6,631.88	6,631.88	5634	192837(09/12/15)	1	6,631.88	-	0.00	
877	00147	LP-A-GC	LOT	1	6,794.23	6,794.23	5634	192837(09/12/15)	1	6,794.23	-	0.00	
878	00147	LP-A-GCa	LOT	1	6,153.63	6,153.63	5634	192837(09/12/15)	1	6,153.63	-	0.00	
879	00147	LP-A-1A	LOT	1	3,277.11	3,277.11				-	1	3277.11	
880	00147	LP-A-1B	LOT	1	4,662.43	4,662.43	5634	192837(09/12/15)	1	4,662.43	-	0.00	
881	00147	LP-A-1C	LOT	1	6,153.63	6,153.63				-	1	6153.63	
882	00147	PP-A-GA	LOT	1	7,024.53	7,024.53	5634	192837(09/12/15)	1	7,024.53	-	0.00	
883	00147	PP-A-GB	LOT	1	6,153.63	6,153.63	5634	192837(09/12/15)	1	6,153.63	-	0.00	
884	00147	PP-A-GC	LOT	1	6,444.81	6,444.81	5634	192837(09/12/15)	1	6,444.81	-	0.00	
885	00147	PP-A-1	LOT	1	3,088.29	3,088.29				-	1	3088.29	
886	00147	PP-A-AC	LOT	1	2,872.99	2,872.99	5634	192837(09/12/15)	1	2,872.99	-	0.00	
887	00147	PE-A-GB	LOT	1	3,965.36	3,965.36	5634	192837(09/12/15)	1	3,965.36	-	0.00	
888	00147	PE-A-1	LOT	1	1,530.03	1,530.03				-	1	1530.03	
889	00147	PP-A-EV1	LOT	1	2,011.80	2,011.80	5634	192837(09/12/15)	1	2,011.80	-	0.00	
890	00147	PP-A-EV2	LOT	1	2,011.80	2,011.80	5634	192837(09/12/15)	1	2,011.80	-	0.00	
891	00147	Cable Tray(Ladder Type)	M	188	34.74	6,530.38	5590	181978 (13/11/15)	188.00	6,530.38	-	0.00	
892	00147	Cable Tray(Ladder Type)	M	8	31.30	250.42	5590	181978 (13/11/15)	8.00	250.42	-	0.00	

893	00147	Cable Tray(Ladder Type)	M	57	29.62	1,688.11	5634	192837(09/12/15)	57	1,688.11	-	0.00	
894	00147	Cable Tray(Ladder Type)	M	48	27.91	1,339.65	5634	192837(09/12/15)	48	1,339.65	-	0.00	
895	00147	Cable Tray(Ladder Type)	M	22	26.22	576.90				-	22	576.90	
896	00147	Cable Tray(Ladder Type)	M	97	24.52	2,378.05	5634	192837(09/12/15)	97	2,378.05	-	0.00	
897	00147	Cable Tray(Ladder Type)	M	217	22.81	4,949.63	5614	189064 (01/12/2015)	217	4,949.63	-	0.00	
898	00147	Cable Tray(Ladder Type)	M	314	21.12	6,632.54	5614	189064 (01/12/2015)	314	6,632.54	-	0.00	
899	00147	Cable Tray(Ladder Type)	M	569	19.42	11,047.73	5590	181978 (13/11/15)	569.00	11,047.73	-	0.00	
900	00147	Cable Tray(Ladder Type)	M	137	17.71	2,426.18	5614	189064 (01/12/2015)	137	2,426.18	-	0.00	
901	00147	HOR-CROSS	EA	2	124.99	249.98	5590	181978 (13/11/15)	2.00	249.98	-	0.00	
902	00147	HOR-CROSS	EA	1	106.48	106.48	5590	181978 (13/11/15)	1.00	106.48	-	0.00	
903	00147	HOR-TEE	EA	6	111.12	666.69	5590	181978 (13/11/15)	6.00	666.69	-	0.00	
904	00147	HOR-TEE	EA	2	68.17	136.33	5634	192837(09/12/15)	2	136.33	-	0.00	
905	00147	HOR-TEE	EA	5	61.28	306.40	5634	192837(09/12/15)	5	306.40	-	0.00	
906	00147	HOR-TEE	EA	4	40.76	163.04	5590	181978 (13/11/15)	4.00	163.04	-	0.00	
907	00147	HOR-TEE	EA	1	35.42	35.42	5634	192837(09/12/15)	1	35.42	-	0.00	
908	00147	HOR-ELBOW	EA	1	68.11	68.11				-	1	68.11	
909	00147	HOR-ELBOW	EA	3	61.42	184.26	5634	192837(09/12/15)	3	184.26	-	0.00	
910	00147	HOR-ELBOW	EA	5	46.56	232.81	5590	181978 (13/11/15)	5.00	232.81	-	0.00	
911	00147	HOR-ELBOW	EA	3	41.06	123.18	5634	192837(09/12/15)	3	123.18	-	0.00	
912	00147	HOR-ELBOW	EA	5	33.77	168.86	5590	181978 (13/11/15)	5.00	168.86	-	0.00	
913	00147	HOR-ELBOW	EA	6	29.09	174.56	5590	181978 (13/11/15)	6.00	174.56	-	0.00	
914	00147	HOR-ELBOW	EA	3	26.56	79.69				-	3	79.69	
915	00147	VER-BLBOW	EA	6	59.01	354.07	5590	181978 (13/11/15)	6.00	354.07	-	0.00	
916	00147	VER-BLBOW	EA	3	53.21	159.63	5590	181978 (13/11/15)	3.00	159.63	-	0.00	
917	00147	VER-BLBOW	EA	4	47.47	189.86	5590	181978 (13/11/15)	4.00	189.86	-	0.00	
918	00147	VER-BLBOW	EA	6	41.68	250.10	5590	181978 (13/11/15)	6.00	250.10	-	0.00	
919	00147	VER-BLBOW	EA	4	38.75	155.01	5634	192837(09/12/15)	4	155.01	-	0.00	

920	00147	VER-BLBOW	EA	8	35.88	287.04	5634	192837(09/12/15)	8	287.04	-	0.00	
921	00147	VER-BLBOW	EA	3	33.01	99.03	5590	181978 (13/11/15)	3.00	99.03	-	0.00	
922	00147	VER-BLBOW	EA	6	30.10	180.59	5634	192837(09/12/15)	6	180.59	-	0.00	
923	00147	Cable Tray Accessories	EA	1279	1.43	1,823.32	5634	192837(09/12/15)	1279	1,823.32	-	0.00	
924	00147	Cable Tray Accessories	EA	17278	0.10	1,734.59	5590	181978 (13/11/15)	17278	1,734.59	-	0.00	
925	00147	Cable Tray Accessories	EA	1279	2.23	2,850.55	5634	192837(09/12/15)	1279	2,850.55	-	0.00	
926	00147	Cable Tray Accessories	EA	2244	0.40	901.13	5634	192837(09/12/15)	2244	901.13	-	0.00	
927	00147	Cable Tray Accessories	M	671	8.09	5,429.53	5634	192837(09/12/15)	671	5,429.53	-	0.00	
928	00147	Cable Tray Accessories	M	4488	1.10	4,956.21	5634	192837(09/12/15)	4488	4,956.21	-	0.00	
929	00147	Gal. Steel Conduit (Exposed)	M	13	6.28	81.70	5615	189889 (02/12/2015)	13	81.70	-	0.00	
930	00147	Gal. Steel Conduit (Exposed)	M	30	7.21	216.25				-	30	216.25	
931	00147	Gal. Steel Conduit (Exposed)	M	52	10.14	527.27	5649	195178 (15/12/2015)	52	527.27	-	0.00	
932	00147	Gal. Steel Conduit (Exposed)	M	45	12.91	580.98	5615	189889 (02/12/2015)	45	580.98	-	0.00	
933	00147	Pipe Hanger	Lot	8	2.53	20.24				-	8	20.24	
934	00147	Pipe Hanger	Lot	19	2.79	53.03				-	19	53.03	
935	00147	Pipe Hanger	Lot	32	2.99	95.73	5615	189889 (02/12/2015)	32	95.73	-	0.00	
936	00147	Pipe Hanger	Lot	27	3.39	91.62				-	27	91.62	
937	00147	0.6/1KV CU/XLPE/PVC Cable	M	754	45.02	33,942.31	5634	192837(09/12/15)	754	33,942.31	-	0.00	
938	00147	0.6/1KV CU/XLPE/PVC Cable	M	1646	36.06	59,356.82	5634	192837(09/12/15)	1646	59,356.82	-	0.00	
939	00147	0.6/1KV CU/XLPE/PVC Cable	M	827	27.55	22,782.12	5634	192837(09/12/15)	827	22,782.12	-	0.00	

940	00147	0.6/1KV CU/XLPE/PVC Cable	M	235	22.33	5,246.95	5634	192837(09/12/15)	235	5,246.95	-	0.00	
941	00147	0.6/1KV CU/XLPE/PVC Cable	M	252	18.69	4,710.69	5634	192837(09/12/15)	252	4,710.69	-	0.00	
942	00147	0.6/1KV CU/XLPE/PVC Cable	M	248	14.98	3,714.71	5634	192837(09/12/15)	248	3,714.71	-	0.00	
943	00147	0.6/1KV CU/XLPE/PVC Cable	M	2379	11.04	26,271.91	5614	189064 (01/12/2015)	2379	26,271.91	-	0.00	
944	00147	0.6/1KV CU/XLPE/PVC Cable	M	172	7.91	1,360.69	5634	192837(09/12/15)	172	1,360.69	-	0.00	
945	00147	0.6/1KV CU/XLPE/PVC Cable	M	847	23.27	19,710.67	5634	192837(09/12/15)	847	19,710.67	-	0.00	
946	00147	0.6/1KV CU/XLPE/PVC Cable	M	291	16.85	4,902.18	5634	192837(09/12/15)	291	4,902.18	-	0.00	
947	00147	0.6/1KV CU/XLPE/PVC Cable	M	121	10.84	1,311.94	5634	192837(09/12/15)	121	1,311.94	-	0.00	
948	00147	0.6/1KV CU/XLPE/PVC Cable	M	122	7.53	918.60	5634	192837(09/12/15)	122	918.60	-	0.00	
949	00147	0.6/1KV CU/XLPE/PVC Cable	M	29	4.26	123.44	5634	192837(09/12/15)	29	123.44	-	0.00	
950	00147	0.6/1KV CU/PVC Cable	M	167	36.86	6,156.35				-	167	6156.35	
951	00147	0.6/1KV CU/PVC Cable	M	168	22.83	3,835.34	5590	181978 (13/11/15)	168	3,835.34	-	0.00	
952	00147	0.6/1KV CU/PVC Cable	M	125	15.78	1,972.73	5614	189064 (01/12/2015)	125	1,972.73	-	0.00	
953	00147	0.6/1KV CU/PVC Cable	M	6	11.73	70.36				-	6	70.36	
954	00147	0.6/1KV CU/PVC Cable	M	6	8.33	50.00				-	6	50.00	
955	00147	0.6/1KV CU/PVC Cable	M	890	6.14	5,468.22				-	890	5468.22	
956	00147	0.6/1KV CU/PVC Cable	M	6	4.34	26.02				-	6	26.02	
957	00147	0.6/1KV CU/PVC Cable	M	578	2.83	1,636.37	5662	198275 (22/12/2015)	578	1,636.37	-	0.00	
958	00147	0.6/1KV CU/PVC Cable	M	38	2.05	77.82	5590	181978 (13/11/15)	38	77.82	-	0.00	
959	00147	PRESS TERMINAL	EA	22	0.18	3.98	5590	181978 (13/11/15)	22	3.98	-	0.00	
960	00147	PRESS TERMINAL	EA	60	0.32	19.28	5590	181978 (13/11/15)	60	19.28	-	0.00	

961	00147	PRESS TERMINAL	EA	34	0.42	14.34	5590	181978 (13/11/15)	34	14.34	-	0.00	
962	00147	PRESS TERMINAL	EA	102	0.46	47.10	5590	181978 (13/11/15)	102	47.10	-	0.00	
963	00147	PRESS TERMINAL	EA	10	1.00	10.04	5590	181978 (13/11/15)	10	10.04	-	0.00	
964	00147	PRESS TERMINAL	EA	58	1.39	80.35	5590	181978 (13/11/15)	58	80.35	-	0.00	
965	00147	PRESS TERMINAL	EA	10	1.57	15.66	5590	181978 (13/11/15)	10	15.66	-	0.00	
966	00147	PRESS TERMINAL	EA	8	1.75	13.97	5590	181978 (13/11/15)	8	13.97	-	0.00	
967	00147	PRESS TERMINAL	EA	10	1.95	19.48	5590	181978 (13/11/15)	10	19.48	-	0.00	
968	00147	PRESS TERMINAL	EA	18	3.57	64.33	5590	181978 (13/11/15)	18	64.33	-	0.00	
969	00147	PRESS TERMINAL	EA	36	3.81	137.34	5590	181978 (13/11/15)	36	137.34	-	0.00	
970	00147	PRESS TERMINAL	EA	8	6.02	48.19	5590	181978 (13/11/15)	8	48.19	-	0.00	
971	00147	MCC	Lot	5	18,548.84	92,744.22	5634	192837(09/12/15)	5	92,744.22	-	0.00	
972	00147	Gal. Steel Conduit(Exposed)	M	1212	3.03	3,674.63	5615	189889 (02/12/2015)	1212	3,674.63	-	0.00	
973	00147	Gal. Steel Conduit(Exposed)	M	124	5.12	634.89	5615	189889 (02/12/2015)	124	634.89	-	0.00	
974	00147	Gal. Steel Conduit(Exposed)	M	31	6.57	203.54	5615	189889 (02/12/2015)	31	203.54	-	0.00	
975	00147	Gal. Steel Conduit(Exposed)	M	118	7.53	888.48	5615	189889 (02/12/2015)	118	888.48	-	0.00	
976	00147	Gal. Steel Conduit(Exposed)	M	107	10.58	1,132.21	5615	189889 (02/12/2015)	107	1,132.21	-	0.00	
977	00147	Gal. Steel Conduit(Exposed)	M	112	13.47	1,508.95	5615	189889 (02/12/2015)	112	1,508.95	-	0.00	
978	00147	Gal. Steel Conduit(Exposed)	M	24	15.48	371.54	5615	189889 (02/12/2015)	24	371.54	-	0.00	
979	00147	Gal. Steel Conduit(Exposed)	M	32	24.96	798.65	5615	189889 (02/12/2015)	32	798.65	-	0.00	
980	00147	HI PVC Conduit(Exposed)	M	220	0.48	106.02				-	220	106.02	
981	00147	Flexible Conduit	M	59	0.72	42.65				-	59	42.65	
982	00147	Flexible Conduit	M	31	1.55	47.93				-	31	47.93	
983	00147	Flexible Conduit	M	7	2.33	16.30				-	7	16.30	
984	00147	Flexible Conduit	M	23	3.13	72.04				-	23	72.04	
985	00147	Flexible Conduit	M	22	4.42	97.18				-	22	97.18	
986	00147	Flexible Conduit	M	3	7.97	23.91				-	3	23.91	
987	00147	Flexible Conduit(Connector)	M	216	0.98	212.51				-	216	212.51	

988	00147	Flexible Conduit(Connector)	M	56	1.77	98.95				-	56	98.95	
989	00147	Flexible Conduit(Connector)	M	8	2.53	20.24				-	8	20.24	
990	00147	Flexible Conduit(Connector)	M	28	3.29	92.20				-	28	92.20	
991	00147	Flexible Conduit(Connector)	M	32	4.66	149.06				-	32	149.06	
992	00147	Flexible Conduit(Connector)	M	4	13.47	53.89				-	4	53.89	
993	00147	Pipe Hanger	Lot	735	2.33	1,711.91	5590	181978 (13/11/15)	735	1,711.91	-	0.00	
994	00147	Pipe Hanger	Lot	77	2.91	224.18	5590	181978 (13/11/15)	77	224.18	-	0.00	
995	00147	Pipe Hanger	Lot	18	2.65	47.71	5590	181978 (13/11/15)	18	47.71	-	0.00	
996	00147	Pipe Hanger	Lot	57	2.91	165.95	5590	181978 (13/11/15)	57	165.95	-	0.00	
997	00147	Pipe Hanger	Lot	61	3.13	191.07				-	61	191.07	
998	00147	Pipe Hanger	Lot	63	3.53	222.63				-	63	222.63	
999	00147	Pipe Hanger	Lot	14	4.12	57.63				-	14	57.63	
1000	00147	Pipe Hanger	Lot	18	4.88	87.82				-	18	87.82	
1001	00147	0.6/1KV CU/XLPE/PVC Cable	M	2039	8.25	16,826.49	5614	189064 (01/12/2015)	2039	16,826.49	-	0.00	
1002	00147	0.6/1KV CU/XLPE/PVC Cable	M	1495	11.53	17,230.09	5634	192837(09/12/15)	1495	17,230.09	-	0.00	
1003	00147	0.6/1KV CU/XLPE/PVC Cable	M	498	15.64	7,789.35	5634	192837(09/12/15)	498	7,789.35	-	0.00	
1004	00147	0.6/1KV CU/XLPE/PVC Cable	M	361	23.31	8,415.38	5634	192837(09/12/15)	361	8,415.38	-	0.00	
1005	00147	0.6/1KV CU/XLPE/PVC Cable	M	166	28.75	4,772.94	5634	192837(09/12/15)	166	4,772.94	-	0.00	
1006	00147	0.6/1KV CU/XLPE/PVC Cable	M	231	37.65	8,696.56	5634	192837(09/12/15)	231	8,696.56	-	0.00	
1007	00147	0.6/1KV CU/XLPE/PVC Cable	M	99	47.00	4,653.41	5634	192837(09/12/15)	99	4,653.41	-	0.00	

1008	00147	0.6/1KV CU/XLPE/PVC Cable	M	343	24.30	8,333.24	5634	192837(09/12/15)	343	8,333.24	-	0.00	
1009	00147	0.6/1KV CU/XLPE/PVC Cable	M	436	17.59	7,668.76	5662	198275 (22/12/2015)	436	7,668.76	-	0.00	
1010	00147	0.6/1KV CU/XLPE/PVC Cable	M	1071	11.32	12,128.39	5614	189064 (01/12/2015)	1071	12,128.39	-	0.00	
1011	00147	0.6/1KV CU/XLPE/PVC Cable	M	193	7.87	1,519.07				-	193	1519.07	
1012	00147	0.6/1KV CU/XLPE/PVC Cable	M	100	4.84	483.90	5662	198275 (22/12/2015)	100	483.90	-	0.00	
1013	00147	0.6/1KV CU/XLPE/PVC Cable	M	542	4.08	2,209.17	5662	198275 (22/12/2015)	542	2,209.17	-	0.00	
1014	00147	0.6/1KV CU/XLPE/PVC Cable	M	785	3.13	2,458.83	5662	198275 (22/12/2015)	785	2,458.83	-	0.00	
1015	00147	0.6/1KV CU/XLPE/PVC Cable	M	785	2.07	1,623.46	5662	198275 (22/12/2015)	785	1,623.46	-	0.00	
1016	00147	PRESS TERMINAL	EA	50	0.18	9.04	5590	181978 (13/11/15)	50	9.04	-	0.00	
1017	00147	PRESS TERMINAL	EA	176	0.34	60.08				-	176	60.08	
1018	00147	PRESS TERMINAL	EA	92	0.44	40.64				-	92	40.64	
1019	00147	PRESS TERMINAL	EA	86	0.48	41.44	5590	181978 (13/11/15)	86	41.44	-	0.00	
1020	00147	PRESS TERMINAL	EA	86	1.04	89.79	5590	181978 (13/11/15)	86	89.79	-	0.00	
1021	00147	PRESS TERMINAL	EA	56	1.45	80.96	5590	181978 (13/11/15)	56	80.96	-	0.00	
1022	00147	PRESS TERMINAL	EA	30	1.63	48.79	5590	181978 (13/11/15)	30	48.79	-	0.00	
1023	00147	PRESS TERMINAL	EA	2	1.83	3.65				-	2	3.65	
1024	00147	PRESS TERMINAL	EA	16	2.03	32.45				-	16	32.45	
1025	00147	PRESS TERMINAL	EA	8	3.73	29.88				-	8	29.88	
1026	00147	PRESS TERMINAL	EA	8	3.98	31.80				-	8	31.80	
1027	00147	CD Conduit(PVC)	M	300	0.36	108.42				-	300	108.42	

1028	00147	CD Conduit(PVC)	M	200	0.56	112.44				-	200	112.44	
1029	00147	HI PVC Conduit(Exposed)	M	7485	0.48	3,606.93				-	7,485	3606.93	
1030	00147	HI PVC Conduit(Exposed)	M	360	0.64	231.31	5590	181978 (13/11/15)	360	231.31	-	0.00	
1031	00147	HI PVC Conduit(Exposed)	M	550	1.16	640.51	5590	181978 (13/11/15)	550	640.51	-	0.00	
1032	00147	Flexible Conduit	M	4690	0.68	3,201.74	5590	181978 (13/11/15)	4690	3,201.74	-	0.00	
1033	00147	Flexible Conduit	M	100	1.14	114.45				-	100	114.45	
1034	00147	Flexible Conduit (Connector)	EA	4790	0.48	2,308.24	5590	181978 (13/11/15)	4790	2,308.24	-	0.00	
1035	00147	Flexible Conduit (Connector)	EA	300	0.68	204.80				-	300	204.80	
1036	00147	Outlet Box	EA	1701	1.69	2,868.92	5590	181978 (13/11/15)	1701	2,868.92	-	0.00	
1037	00147	Outlet Box	EA	662	1.43	943.74	5590	181978 (13/11/15)	662	943.74	-	0.00	
1038	00147	Switch Box	EA	285	0.42	120.17				-	285	120.17	
1039	00147	Outlet Box Cover	EA	1701	0.58	990.46	5590	181978 (13/11/15)	1701	990.46	-	0.00	
1040	00147	Outlet Box Cover	EA	662	0.58	385.47	5590	181978 (13/11/15)	662	385.47	-	0.00	
1041	00147	Outlet Box Cover	EA	133	0.86	114.83	5590	181978 (13/11/15)	133	114.83	-	0.00	
1042	00147	Junction Box	EA	65	3.59	233.62				-	65	233.62	
1043	00147	450/750V CU/PVC Cable	M	87000	0.56	48,911.58				-	87,000	48911.58	
1044	00147	Switch	EA	48	5.78	277.57	5590	181978 (13/11/15)	48	277.57	-	0.00	
1045	00147	Switch	EA	65	8.61	559.89	5590	181978 (13/11/15)	65	559.89	-	0.00	
1046	00147	Switch	EA	28	11.48	321.58				-	28	321.58	
1047	00147	Switch	EA	38	17.25	655.41				-	38	655.41	
1048	00147	Switch	EA	85	6.45	547.85				-	85	547.85	
1049	00147	Switch	EA	20	9.66	193.16	5590	181978 (13/11/15)	20	193.16	-	0.00	
1050	00147	Receptacle	EA	10	3.86	38.55				-	10	38.55	
1051	00147	Pipe Hanger	Lot	7485	2.35	17,583.77				-	7,485	17583.77	
1052	00147	Pipe Hanger	Lot	290	2.47	716.21	5615	189889 (02/12/2015)	290	716.21	-	0.00	
1053	00147	Pipe Hanger	Lot	497	2.51	1,247.39	5590	181978 (13/11/15)	497	1,247.39	-	0.00	
1054	00147	Rece Way	M	2238	6.26	14,020.04	5590	181978 (13/11/15)	2238	14,020.04	-	0.00	
1055	00147	Rece Way	M	2238	2.35	5,257.51				-	2,238	5257.51	
1056	00147	Rece Way	EA	650	0.46	300.18				-	650	300.18	

1057	00147	Rece Way	EA	430	2.53	1,087.86					-	430	1087.86	
1058	00147	Rece Way	EA	30	1.35	40.36					-	30	40.36	
1059	00147	Rece Way	EA	35	4.86	170.07					-	35	170.07	
1060	00147	Rece Way	EA	650	1.45	939.68					-	650	939.68	
1061	00147	Rece Way	EA	550	0.52	287.12					-	550	287.12	
1062	00147	Rece Way	EA	40	8.33	333.31					-	40	333.31	
1063	00147	Rece Way	EA	25	9.22	230.40					-	25	230.40	
1064	00147	Lighting Fixture ("FA" Type)	EA	553	59.17	32,721.99	5614	189064 (01/12/2015)	553	32,721.99	-	-	0.00	
1065	00147	Lighting Fixture ("FB" Type)	EA	288	76.08	21,910.46	5662	198275 (22/12/2015)	288	21,910.46	-	-	0.00	
1066	00147	Lighting Fixture ("GA" Type)	EA	31	306.46	9,500.27					-	31	9500.27	
1067	00147	Lighting Fixture ("GB" Type)	EA	438	358.91	157,200.74					-	438	157200.74	
1068	00147	Lighting Fixture ("FE" Type)	EA	22	78.21	1,720.54					-	22	1720.54	
1069	00147	Lighting Fixture ("FF" Type)	EA	154	88.77	13,670.23	5614	189064 (01/12/2015)	154	13,670.23	-	-	0.00	
1070	00147	Lighting Fixture ("FC" Type)	EA	159	59.17	9,408.31					-	159	9408.31	
1071	00147	Lighting Fixture ("FD" Type)	EA	334	52.83	17,644.19	5634	192837(09/12/15)	334	17,644.19	-	-	0.00	
1072	00147	Lighting Fixture ("FG" Type)	EA	18	570.66	10,271.79					-	18	10271.79	
1073	00147	Lighting Fixture("EA" Type)	EA	150	52.83	7,924.04					-	150	7924.04	
1074	00147	Lighting Fixture("EB" Type)	EA	13	29.58	384.49	5634	192837(09/12/15)	13	384.49	-	-	0.00	
1075	00147	Lighting Fixture("FI" Type)	EA	6	84.55	507.31					-	6	507.31	
1076	00147	Lighting Fixture("EC" Type)	EA	10	19.01	190.14	5634	192837(09/12/15)	10	190.14	-	-	0.00	
1077	00147	HI PVC Conduit(Exposed)	M	2033	0.48	979.68					-	2,033	979.68	
1078	00147	HI PVC Conduit(Exposed)	M	2044	0.64	1,313.30					-	2,044	1313.30	

1079	00147	Switch Box	EA	720	1.69	1,214.36				-	720	1214.36	
1080	00147	Outlet Box Cover	EA	113	0.86	97.56				-	113	97.56	
1081	00147	Junction Box	EA	67	5.50	368.60				-	67	368.60	
1082	00147	Outlet Box	EA	149	1.69	251.30				-	149	251.30	
1083	00147	Outlet Box	EA	567	1.43	808.31	5590	181978 (13/11/15)	567	808.31	-	0.00	
1084	00147	Outlet Box Cover	EA	149	0.58	86.76	5590	181978 (13/11/15)	149	86.76	-	0.00	
1085	00147	Outlet Box Cover	EA	567	0.58	330.15				-	567	330.15	
1086	00147	Receptacle	EA	10	3.47	34.74				-	10	34.74	
1087	00147	Receptacle	EA	552	4.16	2,294.27	5590	181978 (13/11/15)	552	2,294.27	-	0.00	
1088	00147	Receptacle	EA	142	8.21	1,166.13				-	142	1166.13	
1089	00147	450/750V CU/PVC Cable	M	25100	0.56	14,111.27				-	25,100	14111.27	
1090	00147	450/750V CU/PVC Cable	M	78400	0.88	69,263.30				-	78,400	69263.30	
1091	00147	0.6/1KV CU/XLPE/PVC Cable	M	1000	3.13	3,132.27	5662	198275 (22/12/2015)	1000	3,132.27	-	0.00	
1092	00147	Pipe Hanger	Lot	10165	2.35	23,879.63				-	10,165	23879.63	
1093	00147	Pipe Hanger	Lot	10165	2.47	25,104.23				-	10,165	25104.23	
1094	00147	CABLE DUCT	M	59	57.69	3,403.47				-	59	3403.47	
1095	00147	CABLE DUCT	M	64	46.98	3,006.98				-	64	3006.98	
1096	00147	CABLE DUCT	M	568	36.32	20,631.05				-	568	20631.05	
1097	00147	HOR-BLBOW	EA	3	107.22	321.66	5634	192837(09/12/15)	3	321.66	-	0.00	
1098	00147	HOR BLBOW	EA	3	59.15	177.46	5634	192837(09/12/15)	3	177.46	-	0.00	
1099	00147	CROSS-TEE	EA	2	152.32	304.63				-	2	304.63	
1100	00147	HOR-TEE	EA	2	133.70	267.41				-	2	267.41	
1101	00147	HOR-TEE	EA	3	104.41	313.23				-	3	313.23	
1102	00147	HOR-TEE	EA	3	77.32	231.97				-	3	231.97	
1103	00147	VER-ELBOW	EA	3	98.02	294.07				-	3	294.07	
1104	00147	VER-ELBOW	EA	6	61.72	370.33				-	6	370.33	
1105	00147	Tray Hanger	EA	290	2.53	733.67				-	290	733.67	
1106	00147	Tray Hanger	EA	42	3.39	142.52				-	42	142.52	
1107	00147	Tray Hanger	EA	39	4.24	165.23				-	39	165.23	
1108	00147	Cable Tray Accessories	EA	371	6.34	2,353.94	5634	192837(09/12/15)	371	2,353.94	-	0.00	

1109	00147	Cable Tray Accessories	EA	1855	0.10	186.23	5634	192837(09/12/15)	1855	186.23	-	0.00	
1110	00147	Cable Tray Accessories	EA	371	2.33	864.10	5634	192837(09/12/15)	371	864.10	-	0.00	
1111	00147	Flexible Conduit	M	500	0.68	341.34				-	500	341.34	
1112	00147	Flexible Conduit(Connector)	EA	1000	0.48	481.89	5614	189064 (01/12/2015)	1000	481.89	-	0.00	
1113	00147	Gal. Steel Conduit(Exposed)	M	2448	3.03	7,422.03	5614	189064 (01/12/2015)	2448	7,422.03	-	0.00	
1114	00147	Gal. Steel Conduit(Exposed)	M	940	3.94	3,699.29				-	940	3699.29	
1115	00147	HI PVC Conduit(Exposed)	M	264	0.48	127.22				-	264	127.22	
1116	00147	HI PVC Conduit(Exposed)	M	356	0.64	228.74				-	356	228.74	
1117	00147	HI PVC Conduit(Exposed)	M	96	1.69	161.91				-	96	161.91	
1118	00147	Pipe Hanger	Lot	1483	2.33	3,454.09	5590	181978 (13/11/15)	1483	3,454.09	-	0.00	
1119	00147	Pipe Hanger	Lot	548	2.47	1,353.38	5590	181978 (13/11/15)	548	1,353.38	-	0.00	
1120	00147	Outlet Box	EA	53	1.69	89.39				-	53	89.39	
1121	00147	Outlet Box Cover	EA	53	0.58	30.86				-	53	30.86	
1122	00147	Outlet Box	EA	305	1.43	434.80				-	305	434.80	
1123	00147	Outlet Box Cover	EA	305	0.58	177.60				-	305	177.60	
1124	00147	Junction Box	EA	10	18.25	182.51				-	10	182.51	
1125	00147	450/750V CU/PVC Cable	M	25400	0.36	9,179.96				-	25,400	9179.96	
1126	00147	Interphone	EA	22	76.08	1,673.72				-	22	1673.72	
1127	00147	Speaker	EA	212	23.25	4,929.23				-	212	4929.23	
1128	00147	Speaker	EA	38	48.61	1,847.20				-	38	1847.20	
1129	00147	Speaker Terminal Box	SET	2	65.54	131.07				-	2	131.07	
1130	00147	RacK Amp	SET	1	11,218.68	11,218.68				-	1	11218.68	
1131	00147	Modular Jack	EA	41	11.83	484.88				-	41	484.88	
1132	00147	Modular Jack	EA	90	21.14	1,902.85				-	90	1902.85	
1133	00147	UTP Cable	M	25800	0.50	12,950.73				-	25,800	12950.73	
1134	00147	UTP Cable	M	244	16.75	4,085.92				-	244	4085.92	
1135	00147	UTP Cable	M	133	12.63	1,679.72				-	133	1679.72	
1136	00147	UTP Cable	M	154	8.55	1,317.24				-	154	1317.24	
1137	00147	UTP Cable	M	16	6.77	108.26				-	16	108.26	
1138	00147	CPEV	M	985	2.63	2,590.85				-	985	2590.85	

1139	00147	F-GV	M	150	1.29	192.76				-	150	192.76	
1140	00147	Optic Fiber Cable(indoor)	M	303	2.53	766.56				-	303	766.56	
1141	00147	IDF-A-G (DATA)	Side	1	4,199.61	4,199.61				-	1	4199.61	
1142	00147	IDF-A-1 (DATA)	Side	1	3,248.50	3,248.50				-	1	3248.50	
1143	00147	CABLE F-GV	M	5	9.08	45.38				-	5	45.38	
1144	00147	CABLE F-GV	M	15	3.07	46.08				-	15	46.08	
1145	00147	HARD-DRAWN COPPER STANDARD WIRE	M	110	10.64	1,170.59	5614	189064 (01/12/2015)	110	1,170.59	-	0.00	
1146	00147	WATER STOP PIPE	EA	4	40.16	160.63	5590	181978 (13/11/15)	4	160.63	-	0.00	
1147	00147	EARTH TERMINAL BOX(STAINLESS DOOR)	EA	1	501.97	501.97	5634	192837(09/12/15)	1	501.97	-	0.00	
1148	00147	EARTH TERMINAL BOX(STAINLESS DOOR)	EA	1	803.15	803.15	5634	192837(09/12/15)	1	803.15	-	0.00	
1149	00147	SLEEVE	EA	1	50.20	50.20	5634	192837(09/12/15)	1	50.20	-	0.00	
1150	00147	EXTENSION JOINT	EA	1	64.25	64.25	5634	192837(09/12/15)	1	64.25	-	0.00	
1151	00147	CONTINUITY BOX FOR STRUCTURE	EA	1	194.76	194.76	5634	192837(09/12/15)	1	194.76	-	0.00	
1152	00147	BONDING BLOCK	SET	1	401.57	401.57	5634	192837(09/12/15)	1	401.57	-	0.00	
1153	00147	CONNECTION WITH STRUCTURE (BONDING WIRE)	M	20	9.08	181.51	5614	189064 (01/12/2015)	20	181.51	-	0.00	
1154	00147	G-ROD CARBON RESISTENANCE LIGHTINING CONNECTOR	EA	10	15.66	156.61	5634	192837(09/12/15)	10	156.61	-	0.00	
1155	00147	OPTIMA LIGHTINING CONNECTOR(SUS)	EA	1	602.36	602.36	5634	192837(09/12/15)	1	602.36	-	0.00	
1156	00147	LP-B-GA	LOT	1	5,153.21	5,153.21				-	1	5153.21	
1157	00147	LP-B-GB	LOT	1	3,136.40	3,136.40				-	1	3136.40	
1158	00147	LP-B-1A	LOT	1	4,919.15	4,919.15				-	1	4919.15	
1159	00147	LP-B-1B	LOT	1	4,568.06	4,568.06				-	1	4568.06	

1160	00147	LP-B-1Ba	LOT	1	3,553.81	3,553.81					-	1	3553.81	
1161	00147	PP-B-1	LOT	1	4,919.15	4,919.15					-	1	4919.15	
1162	00147	PE-B-G	LOT	1	1,691.08	1,691.08					-	1	1691.08	
1163	00147	PE-B-1	LOT	1	2,508.34	2,508.34					-	1	2508.34	
1164	00147	STEEL PIPE	M	14	17.36	243.03					-	14	243.03	
1165	00147	STEEL PIPE	M	24	22.43	538.34					-	24	538.34	
1166	00147	STEEL PIPE	M	147	29.26	4,300.85					-	147	4300.85	
1167	00147	STEEL PIPE	M	11	37.06	407.65					-	11	407.65	
1168	00147	STEEL PIPE	M	27	42.91	1,158.60	5649	195178 (15/12/2015)	27	1,158.60	-		0.00	
1169	00147	STEEL PIPE FITTING	LOT	1	1,329.69	1,329.69	5590	181978 (13/11/15)	1	1,329.69	-		0.00	
1170	00147	PIPE 고정대	LOT	1	501.28	501.28					-	1	501.28	
1171	00147	CLAMP	LOT	1	741.19	741.19					-	1	741.19	
1172	00147	PULL BOX	EA	72	19.90	1,432.45	5590	181978 (13/11/15)	72	1,432.45	-		0.00	
1173	00147	CABLE 600V F-CV	M	1520	3.43	5,213.03					-	1,520	5213.03	
1174	00147	CABLE TEE	EA	24	29.26	702.18					-	24	702.18	
1175	00147	STEEL PIPE	M	24	42.91	1,029.86					-	24	1029.86	
1176	00147	STEEL PIPE	M	18	37.06	667.07					-	18	667.07	
1177	00147	STEEL PIPE	M	24	29.26	702.18					-	24	702.18	
1178	00147	STEEL PIPE	M	34	22.43	762.64					-	34	762.64	
1179	00147	STEEL PIPE	M	147	17.36	2,551.84					-	147	2551.84	
1180	00147	PIPE FITTING	LOT	1	1,142.72	1,142.72	5590	181978 (13/11/15)	1	1,142.72	-		0.00	
1181	00147	GUID LIGHT	EA	41	46.81	1,919.29					-	41	1919.29	
1182	00147	FIRE SENSOR	EA	99	6.63	656.54					-	99	656.54	
1183	00147	SMOKE SENSOR	EA	4	36.08	144.34					-	4	144.34	
1184	00147	OUTLET BOX	R/L	103	120.39	12,400.63					-	103	12400.63	
1185	00147	OUTLET BOX	EA	144	1.30	187.25					-	144	187.25	
1186	00147	BOX COVER	EA	48	1.41	67.88					-	48	67.88	
1187	00147	BOX COVER	EA	144	0.57	81.92					-	144	81.92	
1188	00147	WIRE 600V	EA	48	0.57	27.31	5614	189064 (01/12/2015)	48	27.31	-		0.00	
1189	00147	TRANSMITTER	SET	9	48.76	438.86					-	9	438.86	

1190	00147	PULL BOX	EA	28	16.58	464.22					-	28	464.22	
1191	00593	Bottle Inspection Machine	Set	1	25,000	25,000.00					-	1	25000.00	
1192	00593	Drum Mixer	Pcs	3	45,000	135,000.00					-	3	135000.00	
1193	00593	Homo Mixer System(AGI)	Set	1	180,000	180,000.00					-	1	180000.00	
1194	00593	Line Homo Mixer	Set	2	40,000	80,000.00					-	2	80000.00	
1195	00593	Separator	Set	2	30,000	60,000.00					-	2	60000.00	
1196	00593	Storage Tank System	Set	1	60,000	60,000.00					-	1	60000.00	
1197	00593	Tube UV Sterilizer	Set	1	15,000	15,000.00					-	1	15000.00	
1198	00593	Ultra Heat Temperature System	Set	1	80,000	80,000.00					-	1	80000.00	
1199	00593	Weight Checker	Set	5	10,000	50,000					-	5	50000.00	Returned to apply 01164
1200	00593	Compressed gas Air Sampler	Set	1	16,800	16,800.00					-	1	16800.00	
1201	00593	Disintegration Tester	Set	1	35,000	35,000.00					-	1	35000.00	
1202	00593	Electronic balance(4EA)	Set	4	1,400	5,600.00	5443	153806(26.8.2015)	4	5,600.00		-	0.00	
1203	00593	Endotoxin tester	Set	1	7,000	7,000.00					-	1	7000.00	
1204	00593	Halogen Moisture determination balance	Set	1	3,500	3,500.00					-	1	3500.00	
1205	00593	Heating block	Set	1	1,400	1,400.00					-	1	1400.00	Returned to apply 01164
1206	00593	Isolator	Set	1	126,600	126,600.00					-	1	126600.00	
1207	00593	Liquid Particle Counter	Set	1	21,000	21,000.00					-	1	21000.00	Returned to apply 01164
1208	00593	Air conditioned Box Truck (Less than 3 ton)	Set	3	10,000	30,000.00					-	3	30000.00	Value Increased USD 45000/Unit . see in 5156
1209	00593	CCTV camera and monitoring system	Set	2	20,000	40,000.00					-	2	40000.00	

1210	00593	Central Air-con System	Set	2	3,000	6,000.00				-	2	6000.00	
1211	00593	Cold room compressor	Set	2	3,000	6,000.00				-	2	6000.00	
1212	00593	Diesel Generator(100KVA)	Set	4	15,000	60,000.00				-	4	60000.00	
1213	00593	Dock Leveler	PCS	8	3,000	24,000.00				-	8	24000.00	
1214	00593	Electric car for driving within factory compound	PCS	3	2,500	7,500.00				-	3	7500.00	
1215	00593	Fire Prevention System in clean room	Set	2	10,000	20,000.00				-	2	20000.00	
1216	00593	Industrial exhaust fan	Set	20	200	4,000.00				-	20	4000.00	
1217	00593	Light Truck (Less than 3 ton)	PCS	2	9,000	18,000.00				-	2	18000.00	Value Increased 28000/ Unit. see in 5156
1218	00593	Micro/Mini Bus (12 seater or less)	PCS	2	9,000	18,000.00				-	2	18000.00	Changed item as Alphard. Value increased to USD 97000.00. See in 0773.
1219	00593	Plastic pallet	PCS	3800	39	148,200.00	5387	136726(8.7.15)	2340	91,260.00	1,460	56940.00	
1220	00593	Salon car for Chief Technical Officer	PCS	1	60,000	60,000.00	6166	172891	1	60,000.00	-	0.00	Changed item as Cadillac Model: 2016
1221	00593	Shelves and Racks	Set	4	52,000	208,000.00	5270 5363	112172(8.5.15) 131115(24.6.15)	2	104,000.00	2	104000.00	
1222	00593	Split Type Air-Con System	Set	30	200	6,000.00				-	30	6000.00	
1223	00593	Station wagon	PCS	2	16,000	32,000.00				-	2	32000.00	
							6044		1	26,367.00	1		price change
1224	00593	Waste water treatment system	Set	1	50,000	50,000.00				-	1	50000.00	

1225	00593	Airborne particle generator,dilutor & count & scan system for checking particles in cleanroom	Pcs	1	50,000.00	50,000.00				-	1	50000.00	
1226	00593	Air curtain for GMP area	Pcs	1	688	688.00				-	1	688.00	
1227	00593	Air fog Generator for checking air direction in cleanroom	Set	1	4,000	4,000.00				-	1	4000.00	
1228	00593	Aluminium composit panel for external wall	m²	74500	9	670,500.00				-	74,500	670500.00	Returnd to apply 0266
1229	00593	Aluminium pallet for using in cleanroom area	Pcs	20	154	3,080.00				-	20	3080.00	
1230	00593	Automatic control work for AHU	Set	1	160,000	160,000.00	5407	149723(	1	160,000.00	-	0.00	
1231	00593	Beam Projector and screen for GMP training 'Resolution-1920x1080	set	1	1,089	1,089.00				-	1	1089.00	
1232	00593	Big and small weighing Balance for manufacturing	Set	18	3,000	54,000.00	5443	153806(26.8.2015)	8	24,000.00	10	30000.00	
1233	00593	Carton Printing Machine in packing area	Set	1	10,000	10,000.00				-	1	10000.00	
1234	00593	Checkweigher for Blister packaging	Set	2	2,000	4,000				-	2	4000.00	
1235	00593	Checkweigher for Sachet	Set	2	2,000	4,000				-	2	4000.00	
1236	00593	Checkweigher for strip	Set	1	2,000	2,000.00				-	1	2000.00	
1237	00593	Checkweigher for Bottle packaging	Set	1	2,000	2,000.00				-	1	2000.00	
1238	00593	Chemical balance for tablet weight check	Set	4	4,700	18,800.00				-	4	18800.00	
1239	00593	Compressed air gun fordrying in washing room	Pcs	7	800	5,600				-	7	5600.00	
1240	00593	Computer for office	Set	29	1,200	34,800				-	29	34800.00	
1241	00593	Conveyer belt for manual packaging	Set	10	1,500	15,000.00				-	10	15000.00	
1242	00593	Conmill for granule	Set	2	20,000	40,000.00				-	2	40000.00	
1243	00593	Copy machine for GMP documents	Set	2	1,680	3,360				-	2	3360.00	

1244	00593	Deblister machine for tablet and capsule	Set	3	10,000	30,000.00				-	3	30000.00	
1245	00593	Dry Cabinet for manufacturing tool (~250°C)	Pcs	1	2,208	2,208				-	1	2208.00	
1246	00593	Drying Machine for cleanroom garments	Set	1	5,000	5,000				-	1	5000.00	
1247	00593	Differential pressure gauge for clean room	Pcs	32	3,000	96,000.00				-	32	96000.00	
1248	00593	Duct System for Clean Room	Set	1	420,000	420,000.00				-	1	420000.00	Returnd to apply 0266
1249	00593	Fingerprint or ID card system	Set	1	1,500	1,500				-	1	1500.00	
1250	00593	Hand dryer for GMP area	Set	17	200	3,400				-	17	3400.00	
1251	00593	Hand pallet truck for logistics	Set	10	1,000	10,000.00				-	10	10000.00	
1252	00593	High voltage insect eliminator for GMP area	Pcs	9	400	3,600				-	9	3600.00	
1253	00593	Humidity calibrator for cleanroom	Pcs	1	18,000	18,000				-	1	18000.00	
1254	00593	Hygrothermograph in cleanroom area	Pcs	60	300	18,000				-	60	18000.00	
1255	00593	Labelling machine for solid and liquid	set	3	40,000	120,000				-	3	120000.00	
1256	00593	Leaflet Folding Machine for packaging	set	1	3,000	3,000.00				-	1	3000.00	
1257	00593	Leak tester for blister	Set	1	5,000	5,000.00				-	1	5000.00	
1258	00593	Light (Lux) meter for cleanroom	Pcs	1	2,000	2,000				-	1	2000.00	
1259	00593	Metal cabinet for server room	Pcs	5	200	1,000				-	5	1000.00	
1260	00593	Narrow aisle truck or Folk lift for manufacturing	Pcs	2	100,000	200,000.00	5469	154685(20.8.15)	1	100,000.00	1	100000.00	
1261	00593	Pipe Insulation for plumbing system	m²	23450	8	187,600				-	23,450	187600.00	Returned to apply 5156.
1262	00593	Punch & die storage cabinet(polishing Machine) for tablet	Set	1	20,000	20,000.00				-	1	20000.00	
1263	00593	Passing machine (Osilator) for granule	Set	1	10,000	10,000.00				-	1	10000.00	
1264	00593	Pre-filter for air handling unit	Set	50	76	3,800				-	50	3800.00	
1265	00593	Pressure calibrator for cleanroom	Pcs	1	8,550	8,550				-	1	8550.00	
1266	00593	Pressure gauge calibrator for machine	Pcs	1	16,200	16,200				-	1	16200.00	

1267	00593	Printer for GMP documents	Pcs	6	150	900				-	6	900.00	
1268	00593	Revolution meter for machine	Pcs	1	1,200	1,200				-	1	1200.00	
1269	00593	Shoe Capboard /Sitting bench in GMP area	Pcs	254	150	38,100				-	254	38100.00	
1270	00593	Sound meter for machine	Pcs	1	7,000	7000				-	1	7000.00	
1271	00593	Stainless steel Cart for GMP area	Pcs	5	150	750				-	5	750.00	
1272	00593	Stainless steel half cabinet for tools in clean room	Pcs	230	100	23,000				-	230	23000.00	
1273	00593	Stainless steel hanger and shelves for gowning area	Set	31	400	12,400				-	31	12400.00	
1274	00593	Stainless steel Sink table in cleanroom area	Set	4	270	1,080				-	4	1080.00	
1275	00593	Steel Cabinet for GMP document storage	Pcs	307	130	39,910				-	307	39910.00	
1276	00593	Steel rack for material storage	Pcs	48	180	8,640				-	48	8640.00	
1277	00593	Steel Shutter	Set	4	2,400	9,600				-	4	9600.00	
1278	00593	Temperature calibrator for machine	pcs	1	17,089.50	17,090				-	1	17089.50	
1279	00593	Temp.& Humidity monitoring sensor & recorder (Data logger) for storage area	Set	4	10,000	40,000.00				-	4	40000.00	
1280	00593	Thermocouple calibrater (dry block system) for temperature sensor	pcs	1	50,340	50,340				-	1	50340.00	

1281	00593	Thermal balance for granule	Set	1	5,000	5,000.00				-	1	5000.00	
1282	00593	Toque tester for liquid bottle	Set	3	3,000	9,000.00				-	3	9000.00	
1283	00593	Ultrasonic mouse repellent for GMP area	Pcs	5	20	100				-	5	100.00	
1284	00593	UPS for sensitive QC equipment	Pcs	2	120,000	240,000				-	2	240000.00	
1285	00593	UV chamber for weighing tool and container ,etc	Pcs	1	7,000	7,000				-	1	7000.00	
1286	00593	Vacuum cleaner with HEPA filter in clean room	Set	19	5,000	95,000.00				-	19	95000.00	
1287	00593	Vibration meter for machine	Pcs	1	4,000	4,000				-	1	4000.00	
1288	00593	Washing Machine for cleanroom garments	Set	1	10,000	10,000				-	1	10000.00	
1289	00593	Colony counter	Pcs	1	1,000	1,000.00	5443	153806(26.8.2015)	1	1,000.00	-	0.00	
1290	00593	Cool chamber (8 - 15 ·C)	Set	1	7,540	7,540.00	5443	153806(26.8.2015)	1	7,540.00	-	0.00	
1291	00593	Desiccator (Daihan/DH.DeLH)	Pcs	2	2,720	5,440.00	5443	153806(26.8.2015)	2	5,440.00	-	0.00	
1292	00593	Disintegration Tester(KJE/KDIT-200)	Set	1	2,140	2,140.00	5443	153806(26.8.2015)	1	2,140.00	-	0.00	
1293	00593	Fume hood9Hanmi /HM-1500)	Set	1	5,667	5,667.00	5443	153806(26.8.2015)	1	5,667.00	-	0.00	
1294	00593	Friablity tester for tablet	Set	1	3,500	3,500.00	5443	153806(26.8.2015)	1	3,500.00	-	0.00	
1295	00593	Hardness tester(Charls Ischi AG/HC 6.2)	Set	1	16,960	16,960.00	5443	153806(26.8.2015)	1	16,960.00	-	0.00	
1296	00593	Laboratory Furniture	Pcs	159	1,146	182,214.00				-	159	182214.00	

1297	00593	Laboratory glassware	Set	1	67,221	67,221.00	5443	153806(26.8.2015)	1	67,221.00	-	0.00	
1298	00593	Particle counter for air sample	Set	1	20,000	20,000.00				-	1	20000.00	
1299	00593	Stability chamber (30·C)	Set	2	29,100	58,200.00				-	2	58200.00	
1300	00593	TLC Image analyzer	Set	1	33,000	33,000.00	5443	153806(26.8.2015)	1	33,000.00	-	0.00	
1301	00593	Ultra water generator for HPLC	Set	1	11,000	11,000.00	5443	153806(26.8.2015)	1	11,000.00	-	0.00	
1302	00593	Ultrasonic cleaner(HWASHIN/ POWERSONIC420)	Pcs	1	1,460	1,460.00	5443	153806(26.8.2015)	1	1,460.00	-	0.00	
1303	00593	UV chamber for media storage	Set	1	3,000	3,000.00	5443	153806(26.8.2015)	1	3,000.00	-	0.00	
1304	00593	Constant temperature & humidity unit (Air cooled)	Set	2	2,760	5,520.00				-	2	5520.00	
1305	00593	Electric heat pump (EHP) system	Set	50	8,902	445,100.00				-	50	445100.00	
1306	00593	Emergency Light and exit sign in clean room	Set	151	80	12,080.00				-	151	12080.00	
1307	00593	Fire Alarm System in clean room	Set	1	27,115	27,115.00				-	1	27115.00	
1308	00593	Emergency Generator	Set	1	66,950	66,950.00				-	1	66950.00	
1309	00593	HEPA filter - H13 for clean room	Set	183	152	27,816.00				-	183	27816.00	
1310	00593	High voltage Switchboard C/W Equipment for manufacturing	Set	5	32,656	163,280.00				-	5	163280.00	
1311	00593	Low Voltage feeders for clean room	Set	8	43,218	345,744.00				-	8	345744.00	

1312	00593	Low Voltage Panel Board for clean room	Set	7	19,489	136,423.00				-	7	136423.00	
	00593	Oil free compressed air system for clean room	Set	1	324,000	324,000.00				-	1	324000.00	
	00593	Public Adress system (PA system)	Set	1	20,000	20,000.00				-	1	20000.00	
	00593	Transformer with enclosure	Set	4	46,150	184,600.00				-	4	184600.00	Returnd to apply 0266
	00593	Vinyl flooring Rolls	m²	3073	18	55,314.00				-	3,073	55314.00	
131	00593	Private Automatic Branch Exchange system (PABE System)	Set	1	31,115	31,115.00				-	1	31115.00	Returnd to apply 0266
1318	00593	Epoxy 3T lining for clean room	m²	15150	33	499,950.00				-	15,150	499950.00	Returnd to apply 0266
1319	00593	1 Way Ceiling Casette(Indoor Unit)	NMB	2	667.72	1,335.45	5275 5276	110589(6.5.15) 110588(6.5.15)	2	1,335.45	-	0.00	
1320	00593	2 Way Ceiling Casette(Indoor Unit)	NMB	13	973.50	12,655.55	5276	110588(6.5.15)	13	12,655.55	-	0.00	
1321	00593	2 Way Ceiling Casette(Indoor Unit)	NMB	21	1,010.95	21,229.86	5275	110589(6.5.15)	21	21,229.86	-	0.00	
1322	00593	4 Way Ceiling Casette(Indoor Unit)	NMB	9	942.30	8,480.71	5276	110588(6.5.15)	9	8,480.71	-	0.00	
1323	00593	4 Way Ceiling Casette(Indoor Unit)	NMB	8	973.50	7,788.03	5276	110588(6.5.15)	8	7,788.03	-	0.00	
1324	00593	4 Way Ceiling Casette(Indoor Unit)	NMB	10	1,054.63	10,546.29	5276	110588(6.5.15)	10	10,546.29	-	0.00	
1325	00593	4 Way Ceiling Casette(Indoor Unit)	NMB	3	1,110.79	3,332.38	5276	110588(6.5.15)	3	3,332.38	-	0.00	
1326	00593	4 Way Ceiling Casette(Indoor Unit)	NMB	39	1,160.72	45,267.91	5276	110588(6.5.15)	39	45,267.91	-	0.00	
1327	00593	4 Way Ceiling Casette(Indoor Unit)	NMB	10	1,266.80	12,668.03	5276	110588(6.5.15)	10	12,668.03	-	0.00	
1328	00593	4 Way Ceiling Casette(Indoor Unit)	NMB	4	1,354.17	5,416.67	5276	110588(6.5.15)	4	5,416.67	-	0.00	
1329	00593	Multi V Outdoor Unit	NMB	2	6,783.32	13,566.64	5276	110588(6.5.15)	2	13,566.64	-	0.00	
1330	00593	Multi V Outdoor Unit	NMB	2	10,689.82	21,379.63	5276	110588(6.5.15)	2	21,379.63	-	0.00	
1331	00593	Multi V Outdoor Unit	NMB	2	11,432.43	22,864.85	5276	110588(6.5.15)	2	22,864.85	-	0.00	
1332	00593	Multi V Outdoor Unit	NMB	2	12,536.98	25,073.96	5276	110588(6.5.15)	2	25,073.96	-	0.00	
1333	00593	Multi V Outdoor Unit	NMB	2	17,473.14	34,946.28	5276	110588(6.5.15)	2	34,946.28	-	0.00	

1334	00593	Multi V Outdoor Unit	NMB	2	18,084.70	36,169.40	5276	1105[illegible](6.5.15)	2	36,169.40	-	0.00	
1335	00593	Multi V Outdoor Unit	NMB	2	21,991.19	43,982.39	5276	110588(6.5.15)	2	43,982.39	-	0.00	
1336	00593	Multi V Outdoor Unit	NMB	3	23,838.35	71,515.06	5276	110588(6.5.15)	3	71,515.06	-	0.00	
1337	00593	Multi V Outdoor Unit	NMB	3	27,888.38	83,665.14	5276	110588(6.5.15)	3	83,665.14	-	0.00	
1338	00593	Multi V Outdoor Unit	NMB	3	28,450.02	85,350.05	5276	110588(6.5.15)	3	85,350.05	-	0.00	
1339	00593	AC Smart Premium	NMB	2	2,053.09	4,106.19	5275	110589(6.5.15)	2	4,106.19	-	0.00	
1340	00593	Standard Wire Remote	NMB	52	87.37	4,543.02	5276	110588(6.5.15)	52	4,543.02	-	0.00	
1341	00593	PI 485 Card for Central Control	NMB	4	117.32	469.28	5275	110589(6.5.15)	4	469.28	-	0.00	
1342	00593	Panel for 1 Way Ceiling Cassette	NMB	2	99.85	199.69	5276	110588(6.5.15)	2	199.69	-	0.00	
1343	00593	Panel for 2 Way Ceiling Cassette	NMB	34	137.29	4,667.82	5275 5276	110589(6.5.15) 110588(6.5.15)	34	4,667.82	-	0.00	
1344	00593	Panel for 4 Way Ceiling Cassette(S)	NMB	17	121.06	2,058.09	5276	110588(6.5.15)	17	2,058.09	-	0.00	
1345	00593	Panel for 4 Way Ceiling Cassette(L)	NMB	67	143.53	9,616.47	5276	110588(6.5.15)	67	9,616.47	-	0.00	
1346	00593	Y Branch for Indoor	NMB	37	89.86	3,324.89	5276	110588(6.5.15)	37	3,324.89	-	0.00	
1347	00593	Y Branch for Indoor	NMB	38	112.33	4,268.44	5276	110588(6.5.15)	38	4,268.44	-	0.00	
1348	00593	Y Branch for Indoor	NMB	17	174.73	2,970.43	5276	110588(6.5.15)	17	2,970.43	-	0.00	
1349	00593	Y Branch for Indoor	NMB	14	230.90	3,232.53	5276	110588(6.5.15)	14	3,232.53	-	0.00	
1350	00593	Y Branch for Outdoor	NMB	7	180.97	1,266.80	5276	110588(6.5.15)	7	1,266.80	-	0.00	
1351	00593	Y Branch for Outdoor	NMB	3	180.97	542.92	5276	110588(6.5.15)	3	542.92	-	0.00	
1352	00593	4 Way Ceiling Casette(Single CAC)	NMB	2	2,383.84	4,767.67				-	2	4767.67	
1353	00593	Floor Standing Type (Single CAC)	NMB	4	2,508.64	10,034.57	5275	110588(6.5.15)	4	10,034.57	-	0.00	
1354	00593	Floor Standing Type (Single CAC)	NMB	4	5,104.65	20,418.61	5275	110588(6.5.15)	4	20,418.61	-	0.00	
1355	00593	Wall Mounted (Single RAC)	NMB	2	471.77	943.55				-	2	943.55	
1356	00593	Basic Blister Machine	Set	1	93705.61	93705.61				-	1	93705.61	
1357	00593	Interior Chiller	Set	1	2461.91	2461.91				-	1	2461.91	

1358	00593	Cold forming(Alu/Alu blister) System	Set	1	6147.50	6147.50				-	1	6147.50	
1359	00593	Proudct hopper with vibratory chute	Set	1	6213.05	6213.05				-	1	6213.05	
1360	00593	Central exhaust housing connection	Set	1	670.11	670.11				-	1	670.11	
1361	00593	Emboss Coding Station	Set	1	2658.57	2658.57				-	1	2658.57	
1362	00593	150 pieces of digit codes(letter & numbers 0-9)	Set	1	1179.97	1179.97				-	1	1179.97	
1363	00593	Format Part for "Name of Product" packed in PVC/ Alu Consistings of A pair of pre-heating plate Blowing head plate(forming top)/PVC Forming Mold plate(forming bottom)/PVC Sealing top plate Digit Ledge Sealing Bottom plate Cooling plate Die punching set Guide rail set	Set	1	10503.19	10503.19				-	1	10503.19	
1364	00593	Size parts for Track feeder	Set	1	3000.91	3000.91				-	1	3000.91	
1365	00593	Format Part for "Name of Product" packed in Alu/Alu Consisting Of Cold forming plug set Cold Froming Female plate Sealing top plate Digit ledge Sealing Bottom plate Cooling Plate Die punching set Guide rail set	Set	1	11508.35	11508.35				-	1	11508.35	
1366	00593	Size parts for shutter gate feeder	Set	1	5950.83	5950.83				-	1	5950.83	

1367	01164	Hepa Filter Box	SET	56	209.00	11,704.00	5407	149723(1[illegible]08/2015)	12	2,508.00	44	9196.00	
1368	01164	PIPING & CABLING	LOT	7	13,762.49	96,337.43	5407	149723(14/08/2015)	1	13,762.49	6	82574.94	
1369	01164	Condensing unit	SET	9	26,110.00	234,990.00	5407	149723(14/08/2015)	7	182,770.00	2	52220.00	
1370	01164	Clean Booth	EA	1	5,184.00	5,184.00				-	1	5184.00	
1371	01164	Weighing Booth	EA	1	23,700.00	23,700.00				-	1	23700.00	
1372	01164	GALV' STEEL DUCT SHEET	M2	3,231	21.36	69,014.16	5407	149723(14/08/2015)	2069	44,193.84	1,162	24820.32	
1373	01164	GALV' STEEL SHEET	M2	1,814	20.00	36,280.00	5406 5407	149724(14.8.15) 149723(	1510	30,200.00	304	6080.00	
1374	01164	DUCT INSULATION	M2	3,218	29.83	95,992.94	5407	149723(	2702	80,600.66	516	15392.28	
1375	01164	AIR CHAMBER	EA	6	1,282.68	7,696.08	5407	149723(14/08/2015)		-	6	7696.08	
1376	01164	S.A CHAMBER	EA	6	305.64	1,833.84	5407	149723(14/08/2015)		-	6	1833.84	
1377	01164	SOUND CHAMBER	EA	10	305.64	3,056.40	5407	149723(14/08/2015)	1	305.64	9	2750.76	
1378	01164	SPIN IN	EA	6	10.07	60.42				-	6	60.42	
1379	01164	SPIN	EA	392	11.29	4,425.68	5407	149723(14/08/2015)	355	4,007.95	37	417.73	
1380	01164	Silicone	BOX	360	25.00	9,000.00	5407	149723(14/08/2015)	102	2,550.00	258	6450.00	
1381	01164	C-CLIP	SET	1	1,250.00	1,250.00				-	1	1250.00	
1382	01164	Bolt & Nut	SET	1	3,000.00	3,000.00				-	1	3000.00	
1383	01164	CANVAS JOINT	M2	21	112.97	2,372.37	5407	149723(14/08/2015)	11	1,242.67	10	1129.70	
1384	01164	MIXING PAINTING	M2	268	11.44	3,065.92	5407	149723(14/08/2015)	180	2,059.20	88	1006.72	
1385	01164	PAINT	M2	268	11.44	3,065.92	5407	149723(14/08/2015)	180	2,059.20	88	1006.72	
1386	01164	SPIRAL DUCT	M	156	44.53	6,946.68	5407	149723(14/08/2015)	13	578.89	143	6367.79	
1387	01164	ELBOW 90'	EA	25	39.40	985.00	5407	149723(14/08/2015)	5	197.00	20	788.00	
1388	01164	TEE	EA	15	29.81	447.15				-	15	447.15	
1389	01164	CAP	EA	8	13.75	110.00				-	8	110.00	
1390	01164	REDUCER	EA	3	19.15	57.45				-	3	57.45	
1391	01164	TRANSITION	EA	4	102.69	410.76				-	4	410.76	
1392	01164	HANGER	EA	96	9.90	950.40	5407	149723(14/08/2015)	6	59.40	90	891.00	
1393	01164	LUVER	EA	9	183.38	1,650.42	5407	149723(14/08/2015)	2	366.76	7	1283.66	
1394	01164	RA LUVER (AL)	EA	401	24.04	9,640.04	5407	149723(14/08/2015)	332	7,981.28	69	1658.76	
1395	01164	REGISTER	EA	13	14.67	190.71				-	13	190.71	
1396	01164	GRILLE	EA	8	19.10	152.80				-	8	152.80	

1397	01164	ROUND VOLUME DAMPER	EA	13	46.46	603.98				-	13	603.98	
1398	01164	BACK DRAFT DAMPER	EA	3	322.76	968.28				-	3	968.28	
1399	01164	DUCT FLEXIBLE HOSE(AL)	M	1,314	4.89	6,425.46	5407	149723(14/08/2015)	706	3,452.34	608	2973.12	
1400	01164	STS/SUS Band	EA	1,760	3.67	6,459.20	5407	149723(14/08/2015)	1557	5,714.19	203	745.01	
1401	01164	ROUND PAN DIFFUSER	EA	10	4.89	48.90	5407	149723(14/08/2015)	4	19.56	6	29.34	
1402	01164	SQUARE PAN DIRRUSER	EA	80	4.89	391.20	5407	149723(14/08/2015)	67	327.63	13	63.57	
1403	01164	NOZZLE	EA	20	4.89	97.80	5407	149723(14/08/2015)	14	68.46	6	29.34	
1404	01164	INSPECTION DOOR	EA	7	88.02	616.14	5407	149723(14/08/2015)	1	88.02	6	528.12	
1405	01164	VOLUME DAMPER	EA	123	39.12	4,811.76				-	123	4811.76	
1406	01164	FIRE ROUND VOLUME DAMPER	EA	4	58.68	234.72				-	4	234.72	
1407	01164	FIRE VOLUME DAMPER	EA	12	239.62	2,875.44				-	12	2875.44	
1408	01164	STS MESH	M2	45	56.68	2,550.60	5407	149723(14/08/2015)	36	2,040.48	9	510.12	
1409	01164	EPS Panel	M2	567.30	13.88	7,874.12	5407	149723(14/08/2015)	488	6,773.44	79.3	1100.68	
1410	01164	Air Curtain for GMP area	EA	7	687.60	4,813.20				-	7	4813.20	
1411	01164	Tablet Printer	SET	1	60,000.00	60,000.00				-	1	60000.00	
1412	01164	Fitz Mill	SET	1	45,000.00	45,000.00				-	1	45000.00	
1413	01164	Inkjet Printer for Carton	PCS	1	14,142.00	14,142.00				-	1	14142.00	
1414	01164	Burner	SET	1	900.00	900.00	5443	153806(26.8.2015)	1	900.00	-	0.00	
1415	01164	Balance with printer	SET	7	1,600.00	11,200.00	5443	153806(26.8.2015)	7	11,200.00	-	0.00	
1416	01164	Chemical Balance with printer	SET	1	5,000.00	5,000.00	5443	153806(26.8.2015)	1	5,000.00	-	0.00	
1417	01164	Clean Bench	SET	1	4,320.00	4,320.00	5443	153806(26.8.2015)	1	4,320.00	-	0.00	
1418	01164	Conductivity meter	SET	1	2,720.00	2,720.00	5443	153806(26.8.2015)	1	2,720.00	-	0.00	
1419	01164	Fume hood	SET	2	5,667.00	11,334.00	5443	153806(26.8.2015)	2	11,334.00	-	0.00	
1420	01164	Gelometer	SET	1	13,110.00	13,110.00	5443	153806(26.8.2015)	1	13,110.00	-	0.00	
1421	01164	Magnetic stirrer plate (+Hot)	PCS	1	490.00	490.00	5443	153806(26.8.2015)	1	490.00	-	0.00	
1422	01164	Pass box	SET	1	5,312.00	5,312.00	5443	153806(26.8.2015)	1	5,312.00	-	0.00	

1423	01164	Pipette	SET	2	580.00	1,160.00	5443	153806(26.8.2015)	2	1,160.00	-	0.00	
1424	01164	Voltex mixer	PCS	1	580.00	580.00	5443	153806(26.8.2015)	1	580.00	-	0.00	
1425	01164	Chemical and Reference Standards	SET	1	170,000.00	170,000.00				-	1	170000.00	
1426	01164	Water Pretreatment System for Feed Water	SET	1	78,000.00	78,000.00	5973	131166(14/06/2016)		-	1	78000.00	
1427	0266	Multi VS_Outdoor Unit(ARUN100LSS0)	Set	20	4,476.00	89,520.00	6555	100021722360(21.0 3.2017)	11	49,236.00	9	40284.00	
1428	0266	Multi VS_Outdoor Unit(ARUN120LSS0)	Set	2	5,025.00	10,050.00	6555	100021722360(21.0 3.2017)	2	10,050.00	-	0.00	
1429	0266	Multi VS_Outdoor Unit(ARUN080LSS0)	Set	1	4,035.00	4,035.00	6555	100021722360(21.0 3.2017)	1	4,035.00	-	0.00	
1430	0266	Multi VS_Outdoor Unit(ARUN120LSS0)	Set	1	5,265.00	5,265.00	6555	100021722360(21.0 3.2017)	1	5,265.00	-	0.00	
1431	0266	Multi VIV_Outdoor Unit (ARUV520LTS4)	Set	1	23,550.00	23,550.00					1	23550.00	
1432	0266	Indoor Unit_4 Way Ceiling Cassette Arnu18Gtqa2	Set	3	780.00	2,340.00					3	2340.00	
1433	0266	Indoor Unit_4 Way Ceiling Cassette Arnu42Gtma2	Set	10	1,015.00	10,150.00					10	10150.00	
1434	0266	Indoor Unit_4 Way Ceiling Cassette Arnu48Gtma2	Set	21	1,085.00	22,785.00				-	21	22785.00	
1435	0266	Indoor Unit_1 Way Ceiling Cassette Arnu09Gtua2	Set	9	535.00	4,815.00	6555	100021722360(21.0 3.2017)	9	4,815.00	-	0.00	
1436	0266	Indoor Unit_1 Way Ceiling Cassette Arnu12Gtua2	Set	15	560.00	8,400.00	6555	100021722360(21.0 3.2017)	15	8,400.00	-	0.00	
1437	0266	Indoor Unit_1 Way Ceiling Cassette Arnu24Gtta2	Set	2	665.00	1,330.00	6555	100021722360(21.0 3.2017)	1	665.00	1	665.00	
1438	0266	Indoor Unit_2 Way Ceiling Cassette Arnu24Gtla2	Set	11	810.00	8,910.00					11	8910.00	

1439	0266	Indoor Unit_4 Way Ceiling Cassette Arnu28Gtpa2	Set	5	890.00	4,450.00					5	4450.00	
1440	0266	Indoor Unit_4 Way Ceiling Cassette Arnu36Gtma2	Set	13	930.00	12,090.00					13	12090.00	
1441	0266	Indoor Unit_4 Way Ceiling Cassette Arnu18Gtma2	Set	8	780.00	6,240.00					8	6240.00	
1442	0266	Panel for Model 0-18 Pt-uqc	Set	3	97.00	291.00					3	291.00	
1443	0266	Panel for Model 24-48 Pt-umc1	Set	49	115.00	5,635.00					49	5635.00	
1444	0266	Panel for Model 07-12 Pt-uuc	Set	24	80.00	1,920.00					24	1920.00	
1445	0266	Panel for Model 18-24 Pt-utc	Set	2	95.00	190.00					2	190.00	
1446	0266	Panel for Model 18-24 Pt-hlc	Set	19	110.00	2,090.00					19	2090.00	
1447	0266	Standard Wired (White Color) Pqrcvsloqw	Set	97	70.00	6,790.00					97	6790.00	
1448	0266	Y-branch_Indoor Arbln03321	Set	36	90.00	3,240.00					36	3240.00	
1449	0266	Y-branch_Indoor Arbln01621	Set	30	72.00	2,160.00					30	2160.00	
1450	0266	Y-branch_Indoor Arbln07121	Set	4	140.00	560.00					4	560.00	
1451	0266	Y-branch_Indoor Arbln014521	Set	5	185.00	925.00					5	925.00	
1452	0266	Y-branch_Outdoor Unit _2 Odu Arcnn21	Set	2	145.00	290.00					2	290.00	
1453	0266	Y-branch_Outdoor Unit _3 Odu Arcnn22	Set	1	145.00	145.00					1	145.00	
1454	0266	Brand New Generator, Brand:Aksa, 440/400 kva, Engine: Cummins Apd44oc	Set	1	48,900.00	48,900.00					1	48900.00	
1455	0266	Plastics Pallet (1200x1000x160) En4 1210	Nmb	7967	28.50	227,059.50		184686	7967	227,059.50	-	0.00	
1456	0266	Plastics Pallet (1200x1000x160) Wen4 1210	Nmb	2340	28.50	66,690.00					2,340	66690.00	
1457	0266	Punch and Die Tools For Tableting	Set	3200	50.00	160,000.00	6465	100025295160	250	12,500.00	-		
							6876	100025295160	300	15,000.00	2,650	132500.00	

1458	0266	Blister Mould and Accessories for Blister Packaging (HM V6 plus change part)	Set	100	11,000.00	1,100,000.00	7038	100050111560	6	66,000.00	-		
							7224		22.00	242,000.00	72	792,000.00	
1459	0375	Homo Mixer	SET	1	40,000.00	40,000.00					-	0.00	
1460	0375	Bottle Inspection Machine	SET	1	25,000.00	25,000.00					-	0.00	
1461	0375	Homo Mixer	SET	1	40,000.00	40,000.00					-	0.00	
1462	0375	Dry syrup Filling Machine	SET	1	80,000.00	80,000.00					-	0.00	
1463	0375	Softgel Encapsulator	SET	1	200,000 .00	200,000.00					-	2000000.00	
1464	0375	Softgel Preparation system	SET	1	180,000.00	180,000.00					-	0.00	
1465	0375	Other accessaries equi:pment	Lot	1	30,000.00	30,000.00					-	0.00	
1466	0375	Freezer	SET	1	1,750.00	1,750.00					-	0.00	
1467	0375	Termo-hygr ostat chamber(3 EA)	SET	3	17500.00	52,500.00					-	0.00	
1468	0375	KF Moisture Analyzer	Pcs	1	21,000 .00	21,000.00					-	210000.00	
				Total		**23,724,205.32**				**7,851,596.27**		**17434728.26**	
				Total Returned Items		**3,959,510.59**				**2,385,483.80**		**3136146.00**	
				Balance Total		**19,764,694.73**				**5,466,112.47**		**14298582.26**	

၃။ ရင်းနှီးမြှုပ်နှံမှုစီမံချက်

(Investment Plan)

Pacific Medical Industries Ltd.
Head Office : No. 408/410,#07th floor, Samsung Plaza, Mahabandoola street, Kyauktada Tsp. Yangon, Myanmar. Tel: (95-1)391644~50,249592~3,Fax (95-1)249718
Factory : No. 209,210,211, Corner of Khun It Thar Minthar street and Kannar street, City of Industry, Dagon Seikkan Tsp.,Yangon, Myanmar. Tel: (95-1) 592223,592124.

သို့

အတွင်းရေးမှူး
မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

ရက်စွဲ၊ ။၂၀၁၉ ခုနှစ်၊ မတ်လ(၁၉)ရက်

အကြောင်းအရာ။ ။ ရင်းနှီးမြှုပ်နှံမှုစီမံချက် တင်ပြခြင်း။

Pacific Medical Industries Ltd ၏ MIC သို့ မူလ တင်ပြထားသည့် Proposal တွင် အမေရိကန်ဒေါ်လာ (၉,၃၉၇,၀၇၅) နှင့် မြန်မာကျပ် (၁၀,၃၁၆,၀၀၀,၀၀၀) ဟုဖော်ပြထားသော်လည်း လက်ရှိအခြေအနေတွင် အမေရိကန်ဒေါ်လာ (၁၀,၃၈၀,၃၄၈) နှင့် မြန်မာကျပ် (၈၉၉,၆၂၈,၅၈၅) ရင်းနှီးမြှုပ်နှံပြီး ဖြစ်ပါသည်။ သို့သော် မြန်မာနိုင်ငံသားပိုင်ရင်းနှီးမြှုပ်နှံမှုဖြစ်သောကြောင့် ရင်းနှီးမြှုပ်နှံမှုစုစုပေါင်းပမာဏအားမြန်မာကျပ်ငွေဖြင့် ဖော်ပြရလျှင် မြန်မာနိုင်ငံတော် ဗဟိုဘဏ် ၏ ၁၉.၀၃.၂၀၁၉ ရက် နေ့သတ်မှတ်ထားသော ငွေလဲလှယ်နှုန်းထား (အမေရိကန်တစ်ဒေါ်လာလျှင် ၁၅၄၂ ကျပ်နှုန်း) ဖြင့်သင့်၍ တွက်ပေးလျှင် မူလ အဆိုပြုချက် အရ ရင်းနှီးမြန်မာကျပ်ငွေ (၂၄,၈၈၆,၂၈၉,၆၅၀) ဖြစ်ပြီး လက်ရှိတွင် မြန်မာကျပ်ငွေ (၂၅,၀၀၆,၁၂၄,၄၆၁) ရင်းနှီးသုံးစွဲထား ပြီး ဖြစ်ပါသည်။

သို့ဖြစ်ပါ၍ မြန်မာကျပ်ငွေ (၁၉၉,၈၃၄,၈၁၁) အား လုပ်ငန်းလိုအပ်ချက်အရ အဆိုပြုပမာဏ ၁၀၀% ပြည့်မီသည့်အပြင်ပမာဏကို၍မြှုပ်နှံထားပြီးဖြစ်သောကြောင့်ရင်းနှီးမြှုပ်နှံမှုကော်မရှင်အနေနှင့် လက်ရှိမြှုပ်နှံထားသော မြန်မာကျပ်ငွေ (၂၅,၀၀၆,၁၂၄,၄၆၁) အား အတည်ပြုပေးနိုင်ပါရန် တင်ပြအပ်ပါသည်။ နှစ်အလိုက် ရင်းနှီးမြှုပ်နှံလိုသော ပမာဏ ကိုလည်း ခွင့်ပြုပေးနိုင်ပါရန် မူးတွဲပါ အတိုင်း တင်ပြအပ်ပါသည်။

လေးစားစွာဖြင့်

ဦးဇော်မိုးနိုင်
Managing Director
Pacific Medical Industries Ltd.,

PACIFIC MEDICAL INDUSTRIES LIMITED

Investment Plan Base On Actutal Data

Sr. No.	Particular	PROPOSAL		CURRENT(31/12/2018)		Different (Amount)	
		US$	Kyats	US$	Kyats	US$	Kyats
1	Working Capital	20,000	8,100,000,000	1,217,309		1,197,309	(8,100,000,000)
2	Value of Machineries and Equipment	4,348,160	-	8,393,754		4,045,594	-
3	Value of Factory Accessories	661,700	-	205,294		(456,406)	-
4	Value of Automobile	158,000	-	381,669		223,669	-
5	Value of Land	-	356,000,000		30,924,000	-	(325,076,000)
6	Value of Building	-	1,860,000,000		8,968,704,585	-	7,108,704,585
7	Raw material (Including Raw /API / Semi Finished Bulks,QC & R&D Equipment, Consumables, Manufacturing Accessories, etc)	4,209,215	-	182,322		(4,026,893)	-
	Total	**9,397,075**	**10,316,000,000**	**10,380,348**	**8,999,628,585**	**983,273**	**(1,316,371,415)**

Pacific Medical Industries Limited

5-Year Projection

	Year 1	Year 2	Year 3	Year 4	Year 5
	US$	US$	US$	US$	US$
Raw Material	63,277,985	75,933,582	91,120,298	104,788,343	115,267,177
Packaging Material	46,141,962	55,370,355	66,444,426	76,411,090	84,052,199
QC Laboratory consumable/accessories	859,975	396,990	476,388	547,846	602,631
QC Reference Standard	94,735	113,682	136,418	156,881	172,569
QC Chemical	1,926,339	2,311,607	2,773,928	3,190,017	3,509,019
QC HPLC/GC	133,717	160,460	192,552	221,435	243,578
Microbial Lab consumables	32,750	39,300	47,160	54,234	59,657
R&D/Manufacturing/Utility Accessories and R&D Chemicals	2,317,201	239,281	287,137	344,565	413,478
R&D Reference Standard	224,149	268,978	322,774	387,329	464,794
R&D HPLC/GC Columns	121,975	146,370	175,644	210,772	252,927
	115,130,787	134,980,604	161,976,725	186,312,512	205,038,030

Pacific Medical Industries Limited

Raw Material

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
1	Raw/Semi finished goods for Acetaminophen	12,900.00	4.00	51,600	61,920	74,304	85,450	93,995
2	Raw/Semi finished goods for Acyclovir	15.00	58.00	870	1,044	1,253	1,441	1,585
3	Raw/Semi finished goods for Ammonium Chloride	2,100.00	2.00	4,200	5,040	6,048	6,955	7,651
4	Raw/Semi finished goods for Amoxicillin	14,962.50	24.00	359,100	430,920	517,104	594,670	654,137
5	Raw/Semi finished goods for Amoxicillin Trihydrate USP	3,000.00	24.00	72,000	86,400	103,680	119,232	131,155
6	Raw/Semi finished goods for Ampicillin	4,507.50	29.00	130,718	156,861	188,233	216,468	238,115
7	Raw/Semi finished goods for Ascorbic Acid (Vitamin C)	14,517.00	6.00	87,102	104,522	125,427	144,241	158,665
8	Raw/Semi finished goods for Acetylcysteine	1,560.00	64.00	99,840	119,808	143,770	165,335	181,869
9	Raw/Semi finished goods for Acid aminocaproic	5.00	50.00	250	300	360	414	455
10	Raw/Semi finished goods for Albendazole	24.00	19.00	456	547	657	755	831
11	Raw/Semi finished goods for Alendronic Acid	100.00	28.00	2,800	3,360	4,032	4,637	5,100
12	Raw/Semi finished goods for Allopurinol	600.00	35.00	21,000	25,200	30,240	34,776	38,254
13	Raw/Semi finished goods for Aluminium Hydroxide	3,468.00	13.25	45,951	55,141	66,169	76,095	83,704
14	Raw/Semi finished goods for Amlodipine	135.00	53.00	7,155	8,586	10,303	11,849	13,034
15	Raw/Semi finished goods for Ampicillin Sodium	600.00	63.00	37,800	45,360	54,432	62,597	68,856
16	Raw/Semi finished goods for Amylase	60,000.00	100.00	6,000,000	7,200,000	8,640,000	9,936,000	10,929,600
17	Raw/Semi finished goods for Anhydrous Glucose	60,000.00	8.50	510,000	612,000	734,400	844,560	929,016
18	Raw/Semi finished goods for Anhydrous sodium lactate	93.00	8.50	791	949	1,138	1,309	1,440
19	Raw/Semi finished goods for Anise essential oil	5.00	1.00	5	6	7	8	9
20	Raw/Semi finished goods for Arginine	360.00	8.00	2,880	3,456	4,147	4,769	5,246
21	Raw/Semi finished goods for Artemether	36.00	193.00	6,948	8,338	10,005	11,506	12,656
22	Raw/Semi finished goods for Aspartame	5.00	11.00	55	66	79	91	100
23	Raw/Semi finished goods for Atenolol	300.00	6.00	1,800	2,160	2,592	2,981	3,279
24	Raw/Semi finished goods for Atorvastatin	200.00	195.00	39,000	46,800	56,160	64,584	71,042
25	Raw/Semi finished goods for Atorvastatin Calcium	48.00	194.00	9,312	11,174	13,409	15,421	16,963
26	Raw/Semi finished goods for Betamethasone	10.00	823.00	8,230	9,876	11,851	13,629	14,992
27	Raw/Semi finished goods for Bromelain	720.00	44.00	31,680	38,016	45,619	52,462	57,708

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
28	Raw/Semi finished goods for Bromhexine	48.48	26.00	1,260	1,513	1,815	2,087	2,296
29	Raw/Semi finished goods for BacillusSubtilis	6,600.00	4.50	29,700	35,640	42,768	49,183	54,102
30	Raw/Semi finished goods for Beclometasone	20.00	2,187.00	43,740	52,488	62,986	72,433	79,677
31	Raw/Semi finished goods for Benzyl Alcohol	27.00	1.00	27	32	39	45	49
32	Raw/Semi finished goods for Biotin	63.00	10.00	630	756	907	1,043	1,148
33	Raw/Semi finished goods for Biphenyl Dimethyl Dicarboxylate	350.00	3.00	1,050	1,260	1,512	1,739	1,913
34	Raw/Semi finished goods for Budesonide BP	518.40	393.00	203,731	244,477	293,373	337,379	371,117
35	Raw/Semi finished goods for Calcium Pantothenate	1,863.00	56.46	105,185	126,222	151,466	174,186	191,605
36	Raw/Semi finished goods for Chlopheniramine meleate	89.11	30.57	2,724	3,269	3,923	4,511	4,962
37	Raw/Semi finished goods for Clotrimazole	423.00	19.00	8,037	9,644	11,573	13,309	14,640
38	Raw/Semi finished goods for Cloxacillin	7,500.00	29.00	217,500	261,000	313,200	360,180	396,198
39	Raw/Semi finished goods for Cyanocobalamin	117.00	27.00	3,159	3,791	4,549	5,231	5,754
40	Raw/Semi finished goods for Calcitriol	10.00	788.00	7,880	9,456	11,347	13,049	14,354
41	Raw/Semi finished goods for Calcium	6,004,200.00	2.00	12,008,400	14,410,080	17,292,096	19,885,910	21,874,501
42	Raw/Semi finished goods for Calcium chloride	1,950.00	3.00	5,850	7,020	8,424	9,688	10,656
43	Raw/Semi finished goods for Caramel colouring agent	5.00	700.00	3,500	4,200	5,040	5,796	6,376
44	Raw/Semi finished goods for Carvedilol	131.25	108.00	14,175	17,010	20,412	23,474	25,821
45	Raw/Semi finished goods for Cefepime	100.00	191.00	19,100	22,920	27,504	31,630	34,793
46	Raw/Semi finished goods for Cefixime	960.00	125.00	120,000	144,000	172,800	198,720	218,592
47	Raw/Semi finished goods for Cefoperazone Sodium	90.00	141.00	12,690	15,228	18,274	21,015	23,116
48	Raw/Semi finished goods for Cefotaxime	120.00	57.00	6,840	8,208	9,850	11,327	12,460
49	Raw/Semi finished goods for Cefpodoxime Proxetil	360.00	62.00	22,320	26,784	32,141	36,962	40,658
50	Raw/Semi finished goods for Ceftazidine	5.00	718.00	3,590	4,308	5,170	5,945	6,540
51	Raw/Semi finished goods for Various Pharmaceutical Bulk Tablet/Cap	500,000.00	6.00	3,000,000	3,600,000	4,320,000	4,968,000	5,464,800
52	Raw/Semi finished goods for Ceftriaxone	120.00	63.00	7,560	9,072	10,886	12,519	13,771
53	Raw/Semi finished goods for Cefuroxime	90.00	101.00	9,090	10,908	13,090	15,053	16,558
54	Raw/Semi finished goods for Celecoxib	1,800.00	150.00	270,000	324,000	388,800	447,120	491,832
55	Raw/Semi finished goods for Cephalexin	9,000.00	40.00	360,000	432,000	518,400	596,160	655,776
56	Raw/Semi finished goods for Cetirizine Dihydrochloride	60.00	32.00	1,920	2,304	2,765	3,180	3,497

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
57	Raw/Semi finished goods for Chloramphenicol	0.30	53.00	16	19	23	26	29
58	Raw/Semi finished goods for Cholic acid	150.00	31.00	4,650	5,580	6,696	7,700	8,470
59	Raw/Semi finished goods for Chromium	5.00	40.00	200	240	288	331	364
60	Raw/Semi finished goods for Cimetidine	1,200.00	22.00	26,400	31,680	38,016	43,718	48,090
61	Raw/Semi finished goods for Ciprofloxacin	9,012.00	18.00	162,216	194,659	233,591	268,630	295,493
62	Raw/Semi finished goods for Citicoline	2,100.00	72.00	151,200	181,440	217,728	250,387	275,426
63	Raw/Semi finished goods for Citicoline Sodium	3,000.00	72.00	216,000	259,200	311,040	357,696	393,466
64	Raw/Semi finished goods for Citronella	5.00	20.00	100	120	144	166	182
65	Raw/Semi finished goods for Clacium pantothenate	156.00	38.00	5,928	7,114	8,536	9,817	10,798
66	Raw/Semi finished goods for Clarithromycin	210.00	26.00	5,460	6,552	7,862	9,042	9,946
67	Raw/Semi finished goods for Clavulanic acid	312.00	36.00	11,232	13,478	16,174	18,600	20,460
68	Raw/Semi finished goods for Clominphene Citrate	30.00	36.00	1,080	1,296	1,555	1,788	1,967
69	Raw/Semi finished goods for Clopidogrel	270.00	157.00	42,390	50,868	61,042	70,198	77,218
70	Raw/Semi finished goods for Copper	6,606.60	6.00	39,640	47,568	57,081	65,643	72,207
71	Raw/Semi finished goods for Cotrimoxazole	11,520.00	22.29	256,781	308,137	369,764	425,229	467,752
72	Raw/Semi finished goods for Dextromethorphan	92.10	108.00	9,947	11,936	14,323	16,472	18,119
73	Raw/Semi finished goods for Diphenhydramine HCL	5.00	13.00	65	78	94	108	118
74	Raw/Semi finished goods for Desloratadine	30.00	13.00	390	468	562	646	710
75	Raw/Semi finished goods for Desoxycholic acid	180.00	280.00	50,400	60,480	72,576	83,462	91,809
76	Raw/Semi finished goods for Dexamethasone	20.00	804.00	16,080	19,296	23,155	26,628	29,291
77	Raw/Semi finished goods for Dexchlorpheniramine Maleate	12.00	172.00	2,064	2,477	2,972	3,418	3,760
78	Raw/Semi finished goods for Dextran	5.00	32.00	160	192	230	265	291
79	Raw/Semi finished goods for Dextrose	100,500.00	5.00	502,500	603,000	723,600	832,140	915,354
80	Raw/Semi finished goods for Dibasic calcium phosphate	2,580.00	0.60	1,548	1,858	2,229	2,563	2,820
81	Raw/Semi finished goods for Diclofenac	22.50	63.34	1,425	1,710	2,052	2,360	2,596
82	Raw/Semi finished goods for Dicloxacillin	750.00	35.00	26,250	31,500	37,800	43,470	47,817
83	Raw/Semi finished goods for Dicyclomine HCL	5.00	39.00	195	234	281	323	355
84	Raw/Semi finished goods for Diluted Potassium Clavulanate BP	975.00	82.00	79,950	95,940	115,128	132,397	145,637
85	Raw/Semi finished goods for Dimethylpolysiloxane	60.00	4.00	240	288	346	397	437

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
86	Raw/Semi finished goods for Dimeticone	150.00	8.00	1,200	1,440	1,728	1,987	2,186
87	Raw/Semi finished goods for Dipropionate	5.00	10.00	50	60	72	83	91
88	Raw/Semi finished goods for Dispersible Cefixime	180.00	200.00	36,000	43,200	51,840	59,616	65,578
89	Raw/Semi finished goods for DL-α-Tocopherol	30.00	180.00	5,400	6,480	7,776	8,942	9,837
90	Raw/Semi finished goods for Docetaxel	10.00	38,695	386,950	464,340	557,208	640,789	704,868
91	Raw/Semi finished goods for Docosahexanoic acid	5.00	54.00	270	324	389	447	492
92	Raw/Semi finished goods for Econazole	10.00	75.00	750	900	1,080	1,242	1,366
93	Raw/Semi finished goods for Eicosapentanoic acid	10.00	1,301	13,010	15,612	18,734	21,545	23,699
94	Raw/Semi finished goods for Enalapril Maleate	60.00	535.00	32,100	38,520	46,224	53,158	58,473
95	Raw/Semi finished goods for Erythromycin	4,504.80	117.34	528,593	634,312	761,174	875,350	962,885
96	Raw/Semi finished goods for Essential Amino acids	5.00	43.00	215	258	310	356	392
97	Raw/Semi finished goods for Ethanol	5.00	2.00	10	12	14	17	18
98	Raw/Semi finished goods for Etofylline	2,070.00	2.00	4,140	4,968	5,962	6,856	7,541
99	Raw/Semi finished goods for Etoricoxib	900.00	20.00	18,000	21,600	25,920	29,808	32,789
100	Raw/Semi finished goods for Fenofibrate	1,200.00	533.50	640,200	768,240	921,888	1,060,171	1,166,188
101	Raw/Semi finished goods for Ferrous Fumarate	291.60	135.18	39,418	47,302	56,763	65,277	71,805
102	Raw/Semi finished goods for Multiviitamins + Minerals Soft gel	200,000.00	8.00	1,600,000	1,920,000	2,304,000	2,649,600	2,914,560
103	Raw/Semi finished goods for Ferrous sulphate	180.00	2.00	360	432	518	596	656
104	Raw/Semi finished goods for Ferup Fumarate	1,094.40	27.00	29,549	35,459	42,550	48,933	53,826
105	Raw/Semi finished goods for Flavoured Syrupy Base q.s	600.00	20.00	12,000	14,400	17,280	19,872	21,859
106	Raw/Semi finished goods for Fluocinonide	6,000.00	19.20	115,200	138,240	165,888	190,771	209,848
107	Raw/Semi finished goods for Fluocinoline Acetonide	450.00	64.00	28,800	34,560	41,472	47,693	52,462
108	Raw/Semi finished goods for Fluorometholone	10.00	11,047	110,470	132,564	159,077	182,938	201,232
109	Raw/Semi finished goods for Fluticasone	75.00	1,910.00	143,250	171,900	206,280	237,222	260,944
110	Raw/Semi finished goods for Folic acid	612.45	20.00	12,249	14,699	17,639	20,284	22,313
111	Raw/Semi finished goods for Fresh Garlic	1,438.78	55.56	79,938	95,926	115,111	132,378	145,616
112	Raw/Semi finished goods for Furosemide	12.00	137.60	1,651	1,981	2,378	2,734	3,008
113	Raw/Semi finished goods for Gentamicin sulfate	5.00	41.25	206	248	297	342	376
114	Raw/Semi finished goods for Glyceryl guaiacolate	5.00	9.00	45	54	65	75	82

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
115	Raw/Semi finished goods for Guaiphenesin	1,680.00	8.00	13,440	16,128	19,354	22,257	24,482
116	Raw/Semi finished goods for Ginkgo Biloba	109.30	55.56	6,072	7,287	8,744	10,056	11,062
117	Raw/Semi finished goods for Ginseng	300.00	47.00	14,100	16,920	20,304	23,350	25,685
118	Raw/Semi finished goods for Gliclazide	480.00	200.00	96,000	115,200	138,240	158,976	174,874
119	Raw/Semi finished goods for Glimepiride	12.00	383.00	4,596	5,515	6,618	7,611	8,372
120	Raw/Semi finished goods for Glipizide	30.00	183.00	5,490	6,588	7,906	9,091	10,001
121	Raw/Semi finished goods for Glucose	76,500.00	5.00	382,500	459,000	550,800	633,420	696,762
122	Raw/Semi finished goods for Glutamic Acid	180,000.00	1.00	180,000	216,000	259,200	298,080	327,888
123	Raw/Semi finished goods for Griseofulvin	750.00	125.60	94,200	113,040	135,648	155,995	171,595
124	Raw/Semi finished goods for Hemicellulase	300.00	4.00	1,200	1,440	1,728	1,987	2,186
125	Raw/Semi finished goods for Hydrochlorothiazide USP	804.00	3.00	2,412	2,894	3,473	3,994	4,394
126	Raw/Semi finished goods for Hydrocortisone	6.00	387.00	2,322	2,786	3,344	3,845	4,230
127	Raw/Semi finished goods for Hydromellose	5.00	4.00	20	24	29	33	36
128	Raw/Semi finished goods for Hydroxychloroquine Sulfate USP	1,200.00	132.00	158,400	190,080	228,096	262,310	288,541
129	Raw/Semi finished goods for Ibesartan	900.00	161.60	145,440	174,528	209,434	240,849	264,934
130	Raw/Semi finished goods for Ibuprofen	9,600.00	36.00	345,600	414,720	497,664	572,314	629,545
131	Raw/Semi finished goods for Iodine	1,500.60	8.00	12,005	14,406	17,287	19,880	21,868
132	Raw/Semi finished goods for Iron	360.00	145.00	52,200	62,640	75,168	86,443	95,088
133	Raw/Semi finished goods for Isorsorbide-mono Nitrate	144.00	92.00	13,248	15,898	19,077	21,939	24,133
134	Raw/Semi finished goods for Ketoconazole	200.00	70.00	14,000	16,800	20,160	23,184	25,502
135	Raw/Semi finished goods for Ketoprofen	25.20	52.00	1,310	1,572	1,887	2,170	2,387
136	Raw/Semi finished goods for Ketotifen fumarate	50.00	1,003.00	50,150	60,180	72,216	83,048	91,353
137	Raw/Semi finished goods for Korean Ginseng	6.00	47.00	282	338	406	467	514
138	Raw/Semi finished goods for Lysine	68.40	178.69	12,222	14,667	17,600	20,240	22,264
139	Raw/Semi finished goods for Lansoprazole	54.00	30.00	1,620	1,944	2,333	2,683	2,951
140	Raw/Semi finished goods for Levocetirizine Dihydrochloride	60.00	650.00	39,000	46,800	56,160	64,584	71,042
141	Raw/Semi finished goods for Levofloxacin	2,700.30	29.00	78,309	93,970	112,765	129,679	142,647
142	Raw/Semi finished goods for Levofloxacin hemihydrate	4,500.00	62.00	279,000	334,800	401,760	462,024	508,226
143	Raw/Semi finished goods for Levomenthol B.P 0.	5.00	2.00	10	12	14	17	18

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
144	Raw/Semi finished goods for Levonorgestrel	1,000.00	800.00	800,000	960,000	1,152,000	1,324,800	1,457,280
145	Raw/Semi finished goods for Lincomycin	3,600.00	100.41	361,476	433,771	520,525	598,604	658,465
146	Raw/Semi finished goods for Lipase	1,440.00	277.00	398,880	478,656	574,387	660,545	726,600
147	Raw/Semi finished goods for Loperamide Hydrochloride	50.00	192.00	9,600	11,520	13,824	15,898	17,487
148	Raw/Semi finished goods for Loratidine	60.00	590.00	35,400	42,480	50,976	58,622	64,485
149	Raw/Semi finished goods for Losartan Potassium	1,215.00	288.00	349,920	419,904	503,885	579,468	637,414
150	Raw/Semi finished goods for Lumefantrine	129.60	29.00	3,758	4,510	5,412	6,224	6,846
151	Raw/Semi finished goods for Menthol crystal	14.40	11.00	158	190	228	262	289
152	Raw/Semi finished goods for Magnesium	588.00	3.00	1,764	2,117	2,540	2,921	3,213
153	Raw/Semi finished goods for Ginseng containing supplement Soft gel	250,000.00	13.00	3,250,000	3,900,000	4,680,000	5,382,000	5,920,200
154	Raw/Semi finished goods for Magnesium Hydroxide	3,798.00	13.25	50,324	60,388	72,466	83,336	91,669
155	Raw/Semi finished goods for Manganese	3,906.00	4.00	15,624	18,749	22,499	25,873	28,461
156	Raw/Semi finished goods for Mebendazole	30.00	157.60	4,728	5,674	6,808	7,830	8,613
157	Raw/Semi finished goods for Mefenamic acid	6,000.00	22.80	136,800	164,160	196,992	226,541	249,195
158	Raw/Semi finished goods for Metformin	6,000.00	3.00	18,000	21,600	25,920	29,808	32,789
159	Raw/Semi finished goods for Metformin Hydrochloride USP	4,500.00	12.60	56,700	68,040	81,648	93,895	103,285
160	Raw/Semi finished goods for Methyl salicylate	1,200.00	1.00	1,200	1,440	1,728	1,987	2,186
161	Raw/Semi finished goods for Metronidazole	30.00	21.28	638	766	919	1,057	1,163
162	Raw/Semi finished goods for Molybdenum	270.00	20.00	5,400	6,480	7,776	8,942	9,837
163	Raw/Semi finished goods for Montelukast	18.00	225.00	4,050	4,860	5,832	6,707	7,377
164	Raw/Semi finished goods for Montelukast Sodium	16.20	239.00	3,872	4,646	5,575	6,412	7,053
165	Raw/Semi finished goods for Multi-Vitamin	294.00	32.60	9,584	11,501	13,802	15,872	17,459
166	Raw/Semi finished goods for Nicotinamide	1,410.00	7.00	9,870	11,844	14,213	16,345	17,979
167	Raw/Semi finished goods for Na fluoride	6.00	12.00	72	86	104	119	131
168	Raw/Semi finished goods for Naphazoline HCL	5.00	309.00	1,545	1,854	2,225	2,559	2,814
169	Raw/Semi finished goods for Natural Fish Oil	3,000.00	3.00	9,000	10,800	12,960	14,904	16,394
170	Raw/Semi finished goods for Natural Ginseng	410.18	47.00	19,279	23,134	27,761	31,925	35,118
171	Raw/Semi finished goods for Natural micronised progesterone	1,704.00	233.00	397,032	476,438	571,726	657,485	723,233
172	Raw/Semi finished goods for Neomycin	100.00	45.00	4,500	5,400	6,480	7,452	8,197

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
173	Raw/Semi finished goods for Neostigmine Methylsufate	10.00	3,966.00	39,660	47,592	57,110	65,677	72,245
174	Raw/Semi finished goods for Nifedipine Slow Release	120.00	380.50	45,660	54,792	65,750	75,613	83,174
175	Raw/Semi finished goods for Norfloxacin	7,200.00	43.15	310,680	372,816	447,379	514,486	565,935
176	Raw/Semi finished goods for Nystatin	7,200.00	199.00	1,432,800	1,719,360	2,063,232	2,372,717	2,609,988
177	Raw/Semi finished goods for Oflaxin	1,200.00	36.00	43,200	51,840	62,208	71,539	78,693
178	Raw/Semi finished goods for Omega-3	810.00	7.00	5,670	6,804	8,165	9,390	10,328
179	Raw/Semi finished goods for Omeprazole	122.40	10.00	1,224	1,469	1,763	2,027	2,230
180	Raw/Semi finished goods for Orlistat	604.80	290.00	175,392	210,470	252,564	290,449	319,494
181	Raw/Semi finished goods for Oxytocin	10.00	309.00	3,090	3,708	4,450	5,117	5,629
182	Raw/Semi finished goods for Paracetamol	141,914.70	9.40	1,333,998	1,600,798	1,920,957	2,209,101	2,430,011
183	Raw/Semi finished goods for Phenylephrine Hydrochloride	246.00	30.57	7,520	9,024	10,829	12,453	13,699
184	Raw/Semi finished goods for Phenylpropanolamine Hydrochloride	150.36	134.00	20,148	24,178	29,013	33,365	36,702
185	Raw/Semi finished goods for Piracetam	9,240.00	37.50	346,500	415,800	498,960	573,804	631,184
186	Raw/Semi finished goods for Potassium Chloride B.P	9,009.00	44.16	397,837	477,405	572,886	658,819	724,701
187	Raw/Semi finished goods for Pyridoxine HCl (Vitamin B6)	39.00	16.00	624	749	899	1,033	1,137
188	Raw/Semi finished goods for Pancreatin	1,050.00	23.00	24,150	28,980	34,776	39,992	43,992
189	Raw/Semi finished goods for Penicillin	16,500.00	12.00	198,000	237,600	285,120	327,888	360,677
190	Raw/Semi finished goods for Peppermint essential oil	5.00	9.00	45	54	65	75	82
191	Raw/Semi finished goods for Peppermint verona	5.00	9.00	45	54	65	75	82
192	Raw/Semi finished goods for Phenylpropanolamine	300.00	63.00	18,900	22,680	27,216	31,298	34,428
193	Raw/Semi finished goods for Phosphorus	300.00	8.00	2,400	2,880	3,456	3,974	4,372
194	Raw/Semi finished goods for Phytonadione	10.00	5,006.00	50,060	60,072	72,086	82,899	91,189
195	Raw/Semi finished goods for Polymyxin B Sulfate	500.00	800.00	400,000	480,000	576,000	662,400	728,640
196	Raw/Semi finished goods for Polyvinyl Pyrrolidone	2,400.00	6.00	14,400	17,280	20,736	23,846	26,231
197	Raw/Semi finished goods for Potassium	15.00	8.00	120	144	173	199	219
198	Raw/Semi finished goods for Potassium Iodide	5.00	20.00	100	120	144	166	182
199	Raw/Semi finished goods for Povidone	5.00	6.00	30	36	43	50	55
200	Raw/Semi finished goods for Propofol	60.00	171.00	10,260	12,312	14,774	16,991	18,690
201	Raw/Semi finished goods for Protase	540.00	487.80	263,412	316,094	379,313	436,210	479,831

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
202	Raw/Semi finished goods for Pseudoephedrine HCL	36.00	49.00	1,764	2,117	2,540	2,921	3,213
203	Raw/Semi finished goods for Pyridoxine Hydrochloride (Vit B 6)	39.00	33.00	1,287	1,544	1,853	2,131	2,344
204	Raw/Semi finished goods for Suppliment Softgel	500,000.00	11.00	5,500,000	6,600,000	7,920,000	9,108,000	10,018,800
205	Raw/Semi finished goods for Riboflavin	228.00	42.00	9,576	11,491	13,789	15,858	17,444
206	Raw/Semi finished goods for Rabeprazole	120.00	85.00	10,200	12,240	14,688	16,891	18,580
207	Raw/Semi finished goods for Raloxifene	252.00	983.00	247,716	297,259	356,711	410,218	451,239
208	Raw/Semi finished goods for Ranitidine	907.50	72.00	65,340	78,408	94,090	108,203	119,023
209	Raw/Semi finished goods for Ranitidine Hydrochloride BP	900.00	72.00	64,800	77,760	93,312	107,309	118,040
210	Raw/Semi finished goods for Refined Fish Oil	72.00	7.00	504	605	726	835	918
211	Raw/Semi finished goods for Rosuvastatin	200.00	1,164.00	232,800	279,360	335,232	385,517	424,068
212	Raw/Semi finished goods for Roxithromycin	960.00	142.00	136,320	163,584	196,301	225,746	248,321
213	Raw/Semi finished goods for Royal jelly	75.00	2,729.00	204,675	245,610	294,732	338,942	372,836
214	Raw/Semi finished goods for Sodium Citrate	26,100.00	1.20	31,320	37,584	45,101	51,866	57,053
215	Raw/Semi finished goods for Salmeterol	480.00	307.00	147,360	176,832	212,198	244,028	268,431
216	Raw/Semi finished goods for Selenium in dried yeast	277.80	12.00	3,334	4,000	4,800	5,520	6,072
217	Raw/Semi finished goods for Serratiopeptidase	100.00	383.00	38,300	45,960	55,152	63,425	69,767
218	Raw/Semi finished goods for Sildenafil Citrate	720.00	33.00	23,760	28,512	34,214	39,347	43,281
219	Raw/Semi finished goods for Silicon Dioxide	150.00	8.00	1,200	1,440	1,728	1,987	2,186
220	Raw/Semi finished goods for Sodium Alendronate (EP)	11.75	57.00	670	804	965	1,109	1,220
221	Raw/Semi finished goods for Sodium Chloride	29,250.00	2.00	58,500	70,200	84,240	96,876	106,564
222	Raw/Semi finished goods for Sodium dichloroisocyanurate (NaDCC) (ACL60)	247.20	3.00	742	890	1,068	1,228	1,351
223	Raw/Semi finished goods for Sodium Fusidate	12.00	240.00	2,880	3,456	4,147	4,769	5,246
224	Raw/Semi finished goods for Sodium Hyaluronate	5.00	1.00	5	6	7	8	9
225	Raw/Semi finished goods for Sodium Iodide	5.00	225.00	1,125	1,350	1,620	1,863	2,049
226	Raw/Semi finished goods for Streptococcus	194.31	15.00	2,915	3,498	4,197	4,827	5,309
227	Raw/Semi finished goods for Sugar	900.00	1.00	900	1,080	1,296	1,490	1,639
228	Raw/Semi finished goods for Sulbactam Sodium	30.00	385.00	11,550	13,860	16,632	19,127	21,039
229	Raw/Semi finished goods for Sulphamethoxazole	7,212.00	10.00	72,120	86,544	103,853	119,431	131,374
230	Raw/Semi finished goods for Telmisartan BP	888.00	583.00	517,704	621,245	745,494	857,318	943,050

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
231	Raw/Semi finished goods for Tenofovir Disoproxil Fumarate	1,800.00	108.00	194,400	233,280	279,936	321,926	354,119
232	Raw/Semi finished goods for Terbinafine Hydrochloride	1,800.00	50.00	90,000	108,000	129,600	149,040	163,944
233	Raw/Semi finished goods for Terpin Hydrate U.S.P	24.00	8.00	192	230	276	318	350
234	Raw/Semi finished goods for Tetracain hydrochloride	5.00	143.00	715	858	1,030	1,184	1,302
235	Raw/Semi finished goods for Tetracycline	3,000.00	65.00	195,000	234,000	280,800	322,920	355,212
236	Raw/Semi finished goods for Theophylline	1,044.00	13.00	13,572	16,286	19,544	22,475	24,723
237	Raw/Semi finished goods for Thiamine Mononitrate	180.00	38.00	6,840	8,208	9,850	11,327	12,460
238	Raw/Semi finished goods for Thiamine nitrate	390.00	19.00	7,410	8,892	10,670	12,271	13,498
239	Raw/Semi finished goods for Tinidazole	3,000.00	12.00	36,000	43,200	51,840	59,616	65,578
240	Raw/Semi finished goods for Tobromycin	100.00	464.00	46,400	55,680	66,816	76,838	84,522
241	Raw/Semi finished goods for Tolu Balsam U.S.P	5.00	30.00	150	180	216	248	273
242	Raw/Semi finished goods for Tramadol Hydrochloride BP	330.00	43.00	14,190	17,028	20,434	23,499	25,849
243	Raw/Semi finished goods for Tranexamic Acid	1,500.00	281.92	422,880	507,456	608,947	700,289	770,318
244	Raw/Semi finished goods for Trans-Anethol	5.00	9.00	45	54	65	75	82
245	Raw/Semi finished goods for Tretinoin	5.00	385.00	1,925	2,310	2,772	3,188	3,507
246	Raw/Semi finished goods for Triamcinolone acetonide	100.00	1,511.00	151,100	181,320	217,584	250,222	275,244
247	Raw/Semi finished goods for Trimethoprim	1,680.00	21.00	35,280	42,336	50,803	58,424	64,266
248	Raw/Semi finished goods for Trypsin	18.00	487.80	8,780	10,536	12,644	14,540	15,994
249	Raw/Semi finished goods for Tyrothricin	5.00	50.00	250	300	360	414	455
250	Raw/Semi finished goods for Vitamin A	90,000.00	4.00	360,000	432,000	518,400	596,160	655,776
251	Raw/Semi finished goods for Vitamin B1	2,355.00	201.00	473,355	568,026	681,631	783,876	862,263
252	Raw/Semi finished goods for Vitamin B12	7,434.00	32.00	237,888	285,466	342,559	393,943	433,337
253	Raw/Semi finished goods for Vitamin B2	132.00	43.00	5,676	6,811	8,173	9,399	10,339
254	Raw/Semi finished goods for Vitamin B6	2,988.00	20.00	59,760	71,712	86,054	98,963	108,859
255	Raw/Semi finished goods for Vitamin C	2,766.00	6.00	16,596	19,915	23,898	27,483	30,231
256	Raw/Semi finished goods for Vitamin D	4,320.00	31.00	133,920	160,704	192,845	221,772	243,949
257	Raw/Semi finished goods for Vitamin E (D-α-Tocopherol)	2,370.00	16.00	37,920	45,504	54,605	62,796	69,075
258	Raw/Semi finished goods for Valaciclovir Hydrochloride Monohydrat	3,504.00	197.00	690,288	828,346	994,015	1,143,117	1,257,429
259	Raw/Semi finished goods for Vit B3 as niacinamide	120.00	6.00	720	864	1,037	1,192	1,312

Sr No.	Description3	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
260	Raw/Semi finished goods for Vit B5 as calcium pantothenate	45.00	24.00	1,080	1,296	1,555	1,788	1,967
261	Raw/Semi finished goods for Vitamin D3	5,400.00	44.00	237,600	285,120	342,144	393,466	432,812
262	Raw/Semi finished goods for Wintergreen Oil & Flavor	864.00	3.00	2,592	3,110	3,732	4,292	4,722
263	Raw/Semi finished goods for Zinc	3,090.00	1.00	3,090	3,708	4,450	5,117	5,629
264	Raw/Semi finished goods for Zinc Sulphate	108.00	6.00	648	778	933	1,073	1,180
265	Raw/Semi finished goods for β- carotene	45.00	115.00	5,175	6,210	7,452	8,570	9,427
266	Raw/Semi finished goods for β Estradiol	9,600.00	1,022.00	9,811,200	11,773,440	14,128,128	16,247,347	17,872,082
				63,277,985	**75,933,582**	**91,120,298**	**104,788,343**	**115,267,177**

Pacific Medical Industries Limited

Packaging Material

Sr No.	Description	UOM	Kg / Year	Cost in USD per Kg	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
1	PVC film	Kg	1.50	517,532	776,298	931,557	1,117,868	1,285,549	1,414,104
2	PVDC film	Kg	1.70	517,532	879,804	1,055,765	1,266,918	1,456,955	1,602,651
3	PE Bottle	No.	0.50	41,647,200	20,823,600	24,988,320	29,985,984	34,483,882	37,932,270
4	HDPE Bottle	No.	0.50	41,647,200	20,823,600	24,988,320	29,985,984	34,483,882	37,932,270
5	Alu Foil	Kg	6.05	133,258	806,208	967,450	1,160,940	1,335,081	1,468,589
6	Alu Alu Foil/ cold foil	Kg	6.05	133,258	806,208	967,450	1,160,940	1,335,081	1,468,589
7	Alu Foil For Strip Packing	Kg	5.25	185,795	975,421	1,170,506	1,404,607	1,615,298	1,776,828
8	Sachet Foil	Kg	5.25	47,776	250,823	300,987	361,185	415,362	456,899
					46,141,962	**55,370,355**	**66,444,426**	**76,411,090**	**84,052,199**

Pacific Medical Industries Limited

QC Laboratory consumable/accessories

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
1	150 Cannon Fenske Glass U Tube Reverce Viscometer	Set	1,000	1.00	1,000				
2	Absorbent (Cellulose MN 300 plate)	Pcs	100	250	25,000	30,000	36,000	41,400	45,540
3	Acrosol Photometer /Dop Tester	Unit	2000	1	2,000	2,400	2,880	3,312	3,643
4	Auto Titrator	Unit	6,000	1.00	6,000				
5	Capillary tube viscometer	Set	1,000	1.00	1,000				
6	Class A Glasswares of various types for QC testing	Pcs	3	1,000.00	3,000	3,600	4,320	4,968	5,465
7	Deep Freezer (-20)	Unit	1,000	1.00	1,000				
8	Deep Freezer (-80)	Unit	1,000	1.00	1,000				
9	Dissolution Apparatus (Autosampler)	Set	12,000	1.00	12,000				
10	Dissolution Apparatus (Manual)	Set	5,000	1.00	5,000				
11	Energy Dispersive X-Ray Fluorescence Spectrometer	Unit	40,000	1.00	40,000				
12	Filter Paper (12.5 cm) (100pcs/box)	Box	4	2,500.00	10,000	12,000	14,400	16,560	18,216
13	Filter paper (Ashless) (100pcs/ box)	Box	12	2,500.00	30,000	36,000	43,200	49,680	54,648
14	Fluorometer	Set	5,000	1.00	5,000				
15	FT-NIR	Set	20,000	1.00	20,000				
16	GC with Auto sampler	Set	50,000	1.00	50,000				
17	Glassware washer	Unit	7,500	1.00	7,500				
18	Heating Block or Dry Block	Unit	3,000	1.00	3,000				
19	HPLC with Autosampler	Set	25,000	2.00	50,000				
20	ICP-MS spectrometry	Set	120,000	1.00	120,000				
21	Incubator	Unit	3,500	1.00	3,500				
22	Inductivity coupled plasma spectrometer	Set	10,000	1.00	10,000				
23	Karl Fisher Titrator	Unit	6,000	1.00	6,000				
24	Light Intensity Measuring Instrument	Unit	20,000	1.00	20,000				
25	Microcentrifuge II(GMC 361 Robo Spin ē timer)	Unit	500	1.00	500				
26	pH meter with printer	Unit	800	1.00	800				
27	Pipette 100µl, 1ml, 5ml (C-100, C-1000, C-5000) Calibrated	Unit	200	1.00	200	240	288	331	364
28	Platinum wire (0.5m)	Pcs	100	1.00	100	120	144	166	182
29	Powder Diffractometers	Set	5,000	1.00	5,000				
30	Raman IR Spectrometer	Unit	40,000	1.00	40,000				

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
31	Raman Spectrophotometer	Set	30,000	1.00	30,000				
32	Scientific Refrigerator for standard material storage	Unit	350	1.00	350				
33	Single Channel Pipette (adjustable pipette)	Unit	100	3.00	300				
34	Sterility Test System	Set	28,000	1.00	28,000				
35	Syringe filter for HPLC 0.25um (100pcs/ box)	Box	50	2,500.00	125,000	150,000	180,000	207,000	227,700
36	Syringe filter for HPLC 0.45um (100pcs/ box)	Box	50	2,500.00	125,000	150,000	180,000	207,000	227,700
37	Ubbelohole type capillary viscometer	Set	3,000	1.00	3,000				
38	Ultra HPLC with Autosampler	Set	50,000	1.00	50,000				
39	UV quatz cell (10cm pathlength)	Pcs	400	2.00	800	960	1,152	1,325	1,457
40	UV quatz cell (1cm pathlength)	Pcs	500	2.00	1,000	1,200	1,440	1,656	1,822
41	Various type of glassware (not class A)	Pcs	2	200.00	400	480	576	662	729
42	Voltexer	Unit	600	1.00	600				
43	Volumeter (Capicicty 25.0 ± 0.06ml)	Set	1,000	1.00	1,000				
44	Vortexer	Unit	100	1.00	100				
45	Walk in Stability Chambers	Pcs	5,000	1.00	5,000				
46	Water bath	Unit	2,500	1.00	2,500				
47	Weighing paper (10" x 13") (100pcs/ pack)	Pack	3	2,500.00	8,325	9,990	11,988	13,786	15,165
					859,975	**396,990**	**476,388**	**547,846**	**602,631**

Pacific Medical Industries Limited

QC Reference Standard

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
1	1-Cyanoguanidine RS (Metformin related compound A) RS	24,333,333	0.000030	Kg	730	876	1,051	1,209	1,330
2	1,3 Thiazolidine 2,4-dicarboxylic acid RS	331,800	0.000250	Kg	83	100	119	137	151
3	10-hydroxydecanoic acid RS	12,380	0.005000	Kg	62	74	89	103	113
4	10-Hydroxydecanoic acid RS	270,900	0.001000	Kg	271	325	390	449	493
5	1-Vinyl-2-Pyrrolidinone RS	1,821,750	0.000200	Kg	364	437	525	603	664
6	2- Methyl-5-nitroimidazole -1-ethanol RS	25,872	0.025000	Kg	647	776	931	1,071	1,178
7	2,3-Dimethylaniline RS	14,600,000	0.000050	Kg	730	876	1,051	1,209	1,330
8	2-amino-n-cyclohexyl-n-methyl benzylamine (Bromhexine Impurity C) RS	6,880	0.005000	Kg	34	41	50	57	63
9	2-Pyrrolidinone RS	2,142	0.050000	Kg	107	129	154	177	195
10	3-Ketofuside Acid RS	80,000,000	0.000005	Kg	400	480	576	662	729
11	4- Chloro 5-Sulfamoylanthranilic (Furosemide Related Compound B) RS	20,517	0.100000	Kg	2,052	2,462	2,954	3,398	3,737
12	4-Aminophenol RS	2,220,000	0.000100	Kg	222	266	320	368	404
13	4-Aminophenol RS	403,200	0.000100	Kg	40	48	58	67	73
14	4-Epianhydrotetracycline Hydrochloride RS	29,106,000	0.000025	Kg	728	873	1,048	1,205	1,325
15	9,10-Diphenylanthracene RS	495,600	0.000250	Kg	124	149	178	205	226
16	Acetal RS	2,000	0.020000	Kg	40	48	58	66	73
						-	-	-	-

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
18	Acetaminophen Related Compound B RS	23,066,667	0.000030	Kg	692	830	996	1,146	1,261
19	Acetaminophen Related Compound C RS	13,840,000	0.000050	Kg	692	830	996	1,146	1,261
20	Acetaminophen Related Compound C RS	5,397,000	0.000050	Kg	270	324	389	447	492
21	Acetaminophen Related Compound D RS	13,840,000	0.000050	Kg	692	830	996	1,146	1,261
22	Acetaminophen Related Compound J RS	13,840,000	0.000050	Kg	692	830	996	1,146	1,261
23	Acetaminophen RS	278,250	0.000400	Kg	111	134	160	184	203
24	Acetaminophen RS	555,000	0.000400	Kg	222	266	320	368	404
25	Acetylcysteine EP CRS	3,360,000	0.000050	Kg	168	202	242	278	306
26	Acetylcysteine impurity C RS	16,800,000	0.000010	Kg	168	202	242	278	306
27	Acetylcysteine impurity D RS	17,600,000	0.000010	Kg	176	211	253	291	321
28	Acyclovir RS	966,667	0.000300	Kg	290	348	418	480	528
29	Adipic Acid RS	2,550,000	0.000100	Kg	255	306	367	422	465
30	Albendazole RS	1,150,000	0.000200	Kg	230	276	331	381	419
31	Allopurinol Related Compound A RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
32	Allopurinol Related Compound B RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
33	Allopurinol Related Compound C RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
34	Allopurinol Related Compound D RS	20,857,143	0.000035	Kg	730	876	1,051	1,209	1,330
35	Allopurinol Related Compound E RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
36	Allopurinol Related Compound F RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
37	Allopurinol RS	920,000	0.000250	Kg	230	276	331	381	419
38	Aloin RS	8,000,000	0.000025	Kg	200	240	288	331	364
39	Alpha Tocopherol Acetate RS	920,000	0.000250	Kg	230	276	331	381	419
40	Aluminium Standard solution	19,068	0.100000	L	1,907	2,288	2,746	3,158	3,473

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
41	Amlodipine Besylate RS	657,143	0.000350	Kg	230	276	331	381	419
42	Amlodipine Related Compound A RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
43	Amlodipine Related Compound C RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
44	Amlodipine Related Compound D RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
45	Amodiaquin Dihydrochloride Dihydrate RS	5,540	0.005000	Kg	28	33	40	46	50
46	Anethole in hexane RS	510,000	0.000500	L	255	306	367	422	465
47	Arginine Hydrochloride RS	1,720,000	0.000125	Kg	215	258	310	356	392
48	Arsenic Tricholride RS	333	0.500000	L	167	200	240	276	304
49	Artemether RS	2,300,000	0.000100	Kg	230	276	331	381	419
50	Artesunate RS	1,150,000	0.000200	Kg	230	276	331	381	419
51	Ascorbic Acid RS	230,000	0.001000	Kg	230	276	331	381	419
52	Atenolol RS	258,000	0.000500	Kg	129	155	186	214	235
53	Atorvastatin Calcium RS	2,300,000	0.000100	Kg	230	276	331	381	419
54	Atorvastatin Related Compound A RS	36,500,000	0.000020	Kg	730	876	1,051	1,209	1,330
55	Atorvastatin Related Compound B RS	36,500,000	0.000020	Kg	730	876	1,051	1,209	1,330
56	Atorvastatin Related Compound C RS	36,500,000	0.000020	Kg	730	876	1,051	1,209	1,330
57	Atorvastatin Related Compound D RS	36,500,000	0.000020	Kg	730	876	1,051	1,209	1,330
58	Atorvastatin Related Compound E RS	36,500,000	0.000020	Kg	730	876	1,051	1,209	1,330
59	Atorvastatin Related Compound H RS	36,500,000	0.000020	Kg	730	876	1,051	1,209	1,330
60	Atorvastatin Related Compound I RS	36,500,000	0.000020	Kg	730	876	1,051	1,209	1,330
61	Beclomethasone Dipropionate RS	1,150,000	0.000200	Kg	230	276	331	381	419
62	Benzoic Acid RS	168,000	0.001000	Kg	168	202	242	278	306

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
63	Benzyl Alcohol RS	497,700	0.000500	Kg	249	299	358	412	453
64	Beta-Carotene RS	2,250,000	0.000100	Kg	225	270	324	373	410
65	Betamethasone 21-Valerate CRS	11,200,000	0.000015	Kg	168	202	242	278	306
66	Betamethasone Dipropionate RS	69,000	0.001000	Kg	69	83	99	114	126
67	Betamethasone Valerate RS	186,000	0.001000	Kg	186	223	268	308	339
68	B-Nicotinamide Adenine Dinucleotide Tetrahydrate RS	60,000	0.001000	Kg	60	72	86	99	109
69	Bromhexine HCL CRS	1,910,000	0.000100	Kg	191	229	275	316	348
70	Bromilain from pineapple RS	2,204,000	0.000250	Kg	551	661	793	912	1,004
71	Caffeine Std solution	2,919	0.050000	L	146	175	210	242	266
72	Caffine RS powder	1,150,000	0.000200	Kg	230	276	331	381	419
73	Calcitriol RS	12,500,000	0.000010	Kg	125	150	180	207	228
74	Calcium carbonate (Chelometric STD) RS	1,218	0.100000	Kg	122	146	175	202	222
75	Calcium Carbonate RS	230,000	0.001000	Kg	230	276	331	381	419
76	Calcium Pantothanate RS	1,150,000	0.000200	Kg	230	276	331	381	419
77	Calcium Standard Solution RS	573	0.100000	L	57	69	83	95	104
78	Ceterizine Hydrochloride RS	920,000	0.000250	Kg	230	276	331	381	419
79	Ceterizine Related Compound A RS	40,250,000	0.000020	Kg	805	966	1,159	1,333	1,466
80	Ceterizine Related Compound B RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
81	Ceterizine Related Compound C RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
82	Chlomiphene Citrate RS	460,000	0.000500	Kg	230	276	331	381	419
83	Chlormipene Related compound A RS	8,050,000	0.000100	Kg	805	966	1,159	1,333	1,466
84	Chlorpheniramine Maleate RS	785,440	0.000125	Kg	98	118	141	163	179
85	Cholecalciferol RS	7,833,333	0.000030	Kg	235	282	338	389	428
86	Cimetidine RS	1,150,000	0.000200	Kg	230	276	331	381	419

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
87	Ciprofloxacin ethylenediamine analog RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
88	Ciprofloxacin Hydrochloride RS	1,212,500	0.000400	Kg	485	582	698	803	883
89	Clarithromycin RS	2,300,000	0.000100	Kg	230	276	331	381	419
90	Clarithromycin Related Compound A RS	14,600,000	0.000050	Kg	730	876	1,051	1,209	1,330
91	Clopidogrel Bisulfate RS	8,200,000	0.000125	Kg	1,025	1,230	1,476	1,697	1,867
92	Clopidogrel related compound A RS	44,250,000	0.000020	Kg	885	1,062	1,274	1,466	1,612
93	Clopidogrel related compound B RS	44,250,000	0.000020	Kg	885	1,062	1,274	1,466	1,612
94	Clopidogrel related compound C RS	44,250,000	0.000020	Kg	885	1,062	1,274	1,466	1,612
95	Clotrimazole Related compound A RS	32,200,000	0.000025	Kg	805	966	1,159	1,333	1,466
96	Clotrimazole RS	58,700	0.001000	Kg	59	70	85	97	107
97	Copper Standard Solution RS	2,400	0.100000	L	240	288	346	397	437
98	Cyanocobalamin RS	1,533,333	0.000150	Kg	230	276	331	381	419
99	D- Panthenol RS	2,615	0.100000	L	261	314	376	433	476
100	Decosahexaenoic Acid ethyl ester(DHA) RS	106,000	0.001000	Kg	106	127	153	176	193
101	Dexamethasone Acetate RS	1,200,000	0.000200	Kg	240	288	346	397	437
102	Dexamethoasone RS	1,480,000	0.000125	Kg	185	222	266	306	337
103	Dextran RS	1,140	0.100000	Kg	114	137	164	189	208
104	Dextromethophan hydrobromide RS	460,000	0.000500	Kg	230	276	331	381	419
105	Dextrose RS	460,000	0.000500	Kg	230	276	331	381	419
106	Diaveridine Crystalline RS	327,600	0.000250	Kg	82	98	118	136	149
107	Diaveridine RS	9,400,000	0.000025	Kg	235	282	338	389	428
108	Diclofenac Potassium RS	750,000	0.000200	Kg	150	180	216	248	273
109	Diclofenac Related Compound A RS	29,200,000	0.000025	Kg	730	876	1,051	1,209	1,330
110	Diclofenac Sodium RS	1,150,000	0.000200	Kg	230	276	331	381	419

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
111	Diethanolamine Fusidate RS	3,750,000	0.000200	Kg	750	900	1,080	1,242	1,366
112	Diethylene Glycol RS	1,150,000	0.000200	L	230	276	331	381	419
113	Dihydroartemisinin RS	512,400	0.001000	Kg	512	615	738	849	933
114	Dimethyl 4,4' - Biphenyldicarboxylate RS	5,103	0.050000	Kg	255	306	367	423	465
115	Dimethyl 7,7' dimethoxy-4,4'bibenzol[d][1,3]dioxole 55'dicarboxylate RS	4,998,000	0.000025	Kg	125	150	180	207	228
116	Dimethyl Sulfoxide RS	101,667	0.003000	Kg	305	366	439	505	556
117	Dithizone RS	7,260	0.010000	Kg	73	87	105	120	132
118	D-L alpha Tocopherol Acetate RS	224,000	0.000100	Kg	22	27	32	37	41
119	Dry Aluminium Hydroxide Gel RS	1,150,000	0.000200	Kg	230	276	331	381	419
120	Econazole Nitrate RS	920,000	0.000250	Kg	230	276	331	381	419
121	Eicosapentaenoic acid ethyl ester (EPA) RS	159,000	0.001000	Kg	159	191	229	263	290
122	Enalapril Maleate RS	1,150,000	0.000200	Kg	230	276	331	381	419
123	Enalaprilate RS	616,667	0.000300	Kg	185	222	266	306	337
124	Ergocalciferol RS	8,333,333	0.000030	Kg	250	300	360	414	455
125	Erythromycin B RS	2,709,000	0.000100	Kg	271	325	390	449	493
126	Erythromycin C Reference Standard	10,836,000	0.000025	Kg	271	325	390	449	493
127	Erythromycin Related Compound N(N-demethylerythromycinA) RS	41,034,000	0.000050	Kg	2,052	2,462	2,954	3,398	3,737
128	Erythromycin RS	920,000	0.000250	Kg	230	276	331	381	419
129	Erythromycin Stearate RS	1,150,000	0.000200	Kg	230	276	331	381	419
130	Ethyl Paraben RS	1,150,000	0.000200	Kg	230	276	331	381	419
131	Ethylene Glycol RS	117,400	0.000500	L	59	70	85	97	107
132	Ethylene oxide RS	91,875	0.001200	L	110	132	159	183	201
133	Ethylene oxide Stock Sol RS	147,875	0.001200	L	177	213	256	294	323

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
134	Fluocinolone Acetonide RS	1,150,000	0.000200	kg	230	276	331	381	419
135	Fluocinonide RS	1,150,000	0.000200	kg	230	276	331	381	419
136	Folic Acid Related Compound A RS	4,700,000	0.000050	kg	235	282	338	389	428
137	Folic Acid RS	460,000	0.000500	kg	230	276	331	381	419
138	Formic Acid RS	191,667	0.001200	L	230	276	331	381	419
139	Fructose RS	1,560,000	0.000125	kg	195	234	281	323	355
140	Furosemide RS	22,050	0.005000	kg	110	132	159	183	201
141	Garlic Oil RS	2,000	0.020000	Kg	40	48	58	66	73
142	Gentamicin Sulfate RS	60,400	0.001000	kg	60	72	87	100	110
143	Ginsenoside Rb1 RS	51,200,000	0.000010	kg	512	614	737	848	933
144	Ginsenoside RG1 RS	10,000,000	0.000020	kg	200	240	288	331	364
145	Gliclazide CRS	8,400,000	0.000020	kg	168	202	242	278	306
146	Gliclazide Impurity B CRS	5,418,000	0.000050	Kg	271	325	390	449	493
147	Gliclazide Impurity F CRS	5,418,000	0.000050	Kg	271	325	390	449	493
148	Griseofulvin RS	1,150,000	0.000200	kg	230	276	331	381	419
149	Guanine RS	2,350,000	0.000100	kg	235	282	338	389	428
150	Hydrochlorothiazide RS	323,000	0.000200	kg	65	78	93	107	118
151	Hydrocortisone RS	174,300	0.000500	kg	87	105	125	144	159
152	Hydrocortisone 21-hemisuccinate Sodium Salt RS	761,300	0.000100	kg	76	91	110	126	139
153	Ibuprofen impurity B RS	36,500,000	0.000020	Kg	730	876	1,051	1,209	1,330
154	Ibuprofen RS	306,667	0.000750	kg	230	276	331	381	419
155	Imidazole RS	3,650,000	0.000200	kg	730	876	1,051	1,209	1,330
156	Irbesartan Related compound (A) RS	29,200,000	0.000025	kg	730	876	1,051	1,209	1,330
157	Irbesartan RS	1,150,000	0.000200	kg	230	276	331	381	419
158	Iron (Fe) Standard Solution	7,627	0.250000	L	1,907	2,288	2,746	3,158	3,474
159	Ketoconazole RS	1,150,000	0.000200	kg	230	276	331	381	419
160	L- Arginine RS	105,000	0.001000	kg	105	126	151	174	191

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
161	Lactose Anhydrous RS	57,600	0.001000	kg	58	69	83	95	105
162	Lactose Monohydrate RS	480,000	0.000500	kg	240	288	346	397	437
163	Lansoprazole RS	1,533,333	0.000150	kg	230	276	331	381	419
164	L-Cysteine RS	1,155,000	0.000100	kg	116	139	166	191	210
165	L-Cystine RS	420,000	0.000500	kg	210	252	302	348	383
166	Lead Standard for ICP RS	2,825	0.100000	L	282	339	407	468	515
167	Lead Standard Solution RS	19,068	0.100000	L	1,907	2,288	2,746	3,158	3,473
168	Levocetrizine dihydrochloride RS	1,150,000	0.000200	kg	230	276	331	381	419
169	Levofloxacin Hemihydrate RS	103,000	0.001000	kg	103	124	148	171	188
170	Lincomycin Hydrochloride RS	1,150,000	0.000200	kg	230	276	331	381	419
171	L-Lysine Hydrochloride RS	1,325,000	0.000200	kg	265	318	382	439	483
172	Loperamide Hydrochloride RS	1,150,000	0.000200	kg	230	276	331	381	419
173	Loratadine RS	1,925,000	0.000200	kg	385	462	554	638	701
174	Losartan Potassium RS	1,533,333	0.000150	kg	230	276	331	381	419
175	L-Tyrosine RS	3,465,000	0.000050	kg	173	208	249	287	316
176	Lysozyme Chloride RS	65,100	0.001000	kg	65	78	94	108	119
177	L-α-Lecithin, Egg yolk RS	244,000	0.000250	kg	61	73	88	101	111
178	Magnesium Hydroxide RS	230,000	0.001000	kg	230	276	331	381	419
179	Mebendazole RS	1,150,000	0.000200	kg	230	276	331	381	419
180	Mefenamic Acid RS	1,150,000	0.000200	kg	230	276	331	381	419
181	Mefloquine HCL RS	2,300,000	0.000100	kg	230	276	331	381	419
182	Menthol RS	920,000	0.000250	kg	230	276	331	381	419
183	Metformin Hydrochloride RS	1,350,000	0.000200	kg	270	324	389	447	492
184	Methyiprednisolone hydrogen Succinate RS	1,200,000	0.000250	kg	300	360	432	497	546
185	Methyl Paraben RS	1,480,000	0.000125	kg	185	222	266	306	337
186	Methyltestosterone RS	750,000	0.000100	kg	75	90	108	124	137
187	Metronidazole Benzoate RS	500,000	0.000100	Kg	50	60	72	83	91

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
188	Metronidazole Impurity A RS	2,000,000	0.000050	kg	100	120	144	166	182
189	n-Dodecane, n-Tetradecane,n-Hexadecane (FID STD RS)	375,000	0.002000	L	750	900	1,080	1,242	1,366
190	Neomycin Sulfate RS	1,150,000	0.000200	kg	230	276	331	381	419
191	Nervonic acid RS	510,000	0.000100	Kg	51	61	73	84	93
192	Niacinamide RS	460,000	0.000500	kg	230	276	331	381	419
193	Norethindrone RS	1,150,000	0.000200	kg	230	276	331	381	419
194	Norfloxacin RS	1,150,000	0.000200	kg	230	276	331	381	419
195	Nystatin RS	1,150,000	0.000200	kg	230	276	331	381	419
196	Ofloxacin RS	1,150,000	0.000200	kg	230	276	331	381	419
197	O-toluene sulfonamide RS	1,825,000	0.000200	kg	365	438	526	604	665
198	Palmitate Acid RS	1,500,000	0.000500	kg	750	900	1,080	1,242	1,366
199	Palmitic acid RS	444,000	0.000500	kg	222	266	320	368	404
200	Parbendazole (Internal STD) RS	1,150,000	0.000200	kg	230	276	331	381	419
201	Phenylephrine HCl RS	1,150,000	0.000200	kg	230	276	331	381	419
202	Phytonadione RS	98,180	0.001000	kg	98	118	141	163	179
203	Piracetam CRS See Leaflet RS	1,120,000	0.000150	kg	168	202	242	278	306
204	Polymycin (poymycin B sulphate) RS	1,150,000	0.000200	kg	230	276	331	381	419
205	Ponceau 4R RS	11,130,000	0.000025	kg	278	334	401	461	507
206	Potassium Chloride RS	1,350	0.081000	kg	109	131	157	181	199
207	Potassium Standard Solution RS	19,068	0.100000	L	1,907	2,288	2,746	3,158	3,473
208	Povidone RS	2,300,000	0.000100	kg	230	276	331	381	419
209	Powder Asian Ginseng Extract RS	446,667	0.001500	kg	670	804	965	1,110	1,220
210	Progesterone RS	997,500	0.000200	kg	200	239	287	330	363
211	Propylene Glycol RS	230,000	0.001000	L	230	276	331	381	419
212	Propylparaben RS	1,150,000	0.000200	kg	230	276	331	381	419
213	P-toluene sulfonamide RS	1,825,000	0.000200	kg	365	438	526	604	665
214	Pyridoxine Hydrochloride RS	1,150,000	0.000200	kg	230	276	331	381	419

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
215	Quercetin RS	400,000	0.000500	kg	200	240	288	331	364
216	Quetiapine Fumarate RS	2,750,000	0.000020	kg	55	66	79	91	100
217	Ranitidine HCL RS	1,150,000	0.000200	kg	230	276	331	381	419
218	Ranitidine Related Compound A RS	14,600,000	0.000050	kg	730	876	1,051	1,209	1,330
219	Ranitidine Related Compound B RS	14,600,000	0.000050	kg	730	876	1,051	1,209	1,330
220	Residual Solvent Class-1 RS	191,667	0.001200	L	230	276	331	381	419
221	Residual Solvent Class-2-1,4Dioxane RS	191,667	0.001200	L	230	276	331	381	419
222	Residual Solvent Class-2-Methylcyclohexane RS	191,667	0.001200	L	230	276	331	381	419
223	Residual Solvent Class-2-Mixture A RS	191,667	0.001200	L	230	276	331	381	419
224	Residual Solvent Class-2-Mixture B RS	191,667	0.001200	L	230	276	331	381	419
225	Retinol Acetate (Vitamin A) CRS	336,000	0.000500	Kg	168	202	242	278	306
226	Retinol palmitate RS	603,800	0.000100	Kg	60	72	87	100	110
227	Retinyl Acetate RS	460,000	0.000500	Kg	230	276	331	381	419
228	Retinyl Palmitate RS	4,600,000	0.000050	Kg	230	276	331	381	419
229	Riboflavin RS	460,000	0.000500	Kg	230	276	331	381	419
230	Rosuvastatin Calcium RS	586,667	0.000300	Kg	176	211	253	291	321
231	Roxithromycin RS	735,040	0.000125	Kg	92	110	132	152	167
232	Saccharim Sodium RS	2,300,000	0.000100	Kg	230	276	331	381	419
233	Sildenafil Citrate RS	4,850,000	0.000100	Kg	485	582	698	803	883
234	Sildenafil Related compound A RS	80,500,000	0.000010	Kg	805	966	1,159	1,333	1,466
235	Sodium L-Lactate RS	138,600	0.001000	Kg	139	166	200	230	252
236	Sodium Starch Glycolate Type A RS	575,000	0.000400	Kg	230	276	331	381	419
237	Sodium Starch Glycolate Type B RS	575,000	0.000400	Kg	230	276	331	381	419
238	Sodium Sulfate Anhydrous RS	230,000	0.001000	Kg	230	276	331	381	419

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
239	Sodium Sulfite RS	47,100	0.001000	Kg	47	57	68	78	86
240	Stearic Acid RS	210,000	0.000500	Kg	105	126	151	174	191
241	Stearic Acid RS	444,000	0.000500	Kg	222	266	320	368	404
242	Sucrose RS	2,300,000	0.000100	Kg	230	276	331	381	419
243	Sulfamethoxazole RS	1,150,000	0.000200	Kg	230	276	331	381	419
244	Sulfanilamide RS	46,000	0.005000	Kg	230	276	331	381	419
245	Telmisartan Related Compound A RS	36,500,000	0.000020	Kg	730	876	1,051	1,209	1,330
246	Telmisartan Related Compound B RS	48,666,667	0.000015	Kg	730	876	1,051	1,209	1,330
247	Telmisartan RS	1,150,000	0.000200	Kg	230	276	331	381	419
248	Terbinafine Hydrochloride RS	1,150,000	0.000200	Kg	230	276	331	381	419
249	Testosterone Propionate RS	375,000	0.000200	Kg	75	90	108	124	137
250	Tetracycline HCL RS	1,150,000	0.000200	Kg	230	276	331	381	419
251	Thallium STD for ICP RS	1,445	0.100000	L	145	173	208	239	263
252	Thiamine Hydrochloride RS	1,150,000	0.000200	Kg	230	276	331	381	419
253	Thiamine Nitrate CRS	11,200,000	0.000015	Kg	168	202	242	278	306
254	Tretinoin RS	7,666,667	0.000030	Kg	230	276	331	381	419
255	Triamcinolone Acetonide STD RS	460,000	0.000500	Kg	230	276	331	381	419
256	Trimethoprim RS	766,667	0.000300	Kg	230	276	331	381	419
257	Trypsin RS	1,680,000	0.000100	Kg	168	202	242	278	306
258	Vanillin RS	1,275,000	0.000200	Kg	255	306	367	422	465
259	Vitamin D Assay System suitability RS	156,667	0.001500	Kg	235	282	338	389	428
260	Zinc Standard Solution / Zinc Standard (For AAS)	93	1.000000	L	93	112	134	155	170
261	Various Reference standard for Laboratory testing	2,500	0.005000	Kg	13	15	18	21	23
262	Various Impurity standard for Laboratory testing	24,333	0.005000	Kg	122	146	175	201	222

Sr no.	Description	Price per KG or Ltr	Qty	UOM	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
263	Refrence Pharmacopoeia USP/BP/EP/IP/KP	5	950.000000	Set	4,750	5,700	6,840	7,866	8,653
17	Aldehyde dehydrogenase RS	2,664	0.500000	kg	1,332	1,598	1,918	2,206	2,426
					94,735	**113,682**	**136,418**	**156,881**	**172,569**

Pacific Medical Industries Limited

QC Chemical

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
1	1,4 Dioxane	26	10	Ltr	260	312.0	374.4	430.6	473.6
2	1 naphthol	532	3	kg	1,596	1915.2	2298.2	2643.0	2907.3
3	1(naphthyl)ethylenediamine dihydrochloride(98%)	480	0.25	kg	120	144.0	172.8	198.7	218.6
4	1-Hexane sulfonate Sodium Salt Monohydrate	6,952	1.25	kg	8,690	10428.0	12513.6	14390.6	15829.7
5	1-naphtholbenzene	10,093	0.5	kg	5,047	6056.0	7267.2	8357.3	9193.0
6	2 Butanol (1L)	26	100	Ltr	2,600	3120.0	3744.0	4305.6	4736.2
7	2- methyl 2-propanol (Tert -Butanol)	43	25	ltr	1,067	1280.0	1536.0	1766.4	1943.0
8	2 naphthol bottle	333	0.75	kg	250	300.0	360.0	414.0	455.4
9	2- phenoxyethanol (ethylene glycol monopenyl ether)	61	25	ltr	1,533	1840.0	2208.0	2539.2	2793.1
10	2,2,4-trimethylpentane	218	50	Ltr	10,920	13104.0	15724.8	18083.5	19891.9
11	2,2´Bipyridine 99%(α-α´-dipyridyl)	1,440	3	kg	4,320	5184.0	6220.8	7153.9	7869.3
12	2,2'Thiodiethanol	315	3	kg	945	1134.0	1360.8	1564.9	1721.4
13	2,6 dichloroindophenol sodium salt	47,000	0.5	kg	23,500	28200.0	33840.0	38916.0	42807.6
14	2,6-Dichloroquinone-4-chloromide	6,560	1.25	kg	8,200	9840.0	11808.0	13579.2	14937.1
15	2,7 dihydronaphthalene	368	15	kg	5,520	6624.0	7948.8	9141.1	10055.2
16	2-Iodopropane	328	15	kg	4,920	5904.0	7084.8	8147.5	8962.3
17	3-(2-pyridy)-5,6-di(2-fury)-1,2,4-triazine-5,disulfonic acid, disodium salt	99,230	0.03	kg	2,977	3572.3	4286.7	4929.7	5422.7
18	3-Mercaptopropionic Acid	253	25	kg	6,333	7600.0	9120.0	10488.0	11536.8
19	3-Mercaptopropionic Acid(99%)	154	25	ltr	3,843	4611.6	5533.9	6364.0	7000.4
20	4 Chloracetanilide	2,400	2.5	kg	6,000	7200.0	8640.0	9936.0	10929.6
21	4 Methyl 2 Pentanone (Methyl Isobutyl Ketone)	123	25	ltr	3,067	3680.0	4416.0	5078.4	5586.2

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
22	4-Bromoniline 98%	560	2.5	kg	1,400	1680.0	2016.0	2318.4	2550.2
23	4-Methyl-2-Pentanol	14	125	Ltr	1,792	2149.8	2579.8	2966.7	3263.4
24	9-Fluorenyl Methyl Formate	13,140	3	kg	39,420	47304.0	56764.8	65279.5	71807.5
25	Acetaldehyde	107	25	Ltr	2,667	3200.0	3840.0	4416.0	4857.6
26	Acetic Acid	15	100	ltr	1,493	1792.0	2150.4	2473.0	2720.3
27	Acetonitrile	14	1500	Ltr	20,800	24960.0	29952.0	34444.8	37889.3
28	Activated Charcoal	7	75	Ltr	520	624.0	748.8	861.1	947.2
29	Adipic Acid	960	1.5	kg	1,440	1728.0	2073.6	2384.6	2623.1
30	Aldehyde Dehydrogenase (-20 Degree)	2,664	1.25	kg	3,330	3996.0	4795.2	5514.5	6065.9
31	Alkaline Beta Naphthol	80	5	Ltr	400	480.0	576.0	662.4	728.6
32	Alpha lactose monohydrate	64	15	kg	960	1152.0	1382.4	1589.8	1748.7
33	Aluminium chloride	35	25	kg	867	1040.0	1248.0	1435.2	1578.7
34	Aluminium Hydroxide	37	25	kg	933	1120.0	1344.0	1545.6	1700.2
35	Aluminium Oxide	139	15	kg	2,079	2494.8	2993.8	3442.8	3787.1
36	Aluminium Powder	240	5	kg	1,200	1440.0	1728.0	1987.2	2185.9
37	Ammonia Solution	10	750	Ltr	7,600	9120.0	10944.0	12585.6	13844.2
38	Ammonium Acetate	43	50	kg	2,133	2560.0	3072.0	3532.8	3886.1
39	Ammonium carbonate	35	25	kg	867	1040.0	1248.0	1435.2	1578.7
40	Ammonium ceric nitrate	110	50	kg	5,500	6600.0	7920.0	9108.0	10018.8
41	Ammonium cerium 4 sulfate	587	1.25	kg	733	880.0	1056.0	1214.4	1335.8
42	Ammonium Chloride	35	15	kg	520	624.0	748.8	861.1	947.2
43	Ammonium Citrate	93	5	kg	467	560.0	672.0	772.8	850.1
44	Ammonium Cyanide Solution	120	5	Ltr	600	720.0	864.0	993.6	1093.0
45	Ammonium dihydrogen Orthophosphate	43	100	kg	4,267	5120.0	6144.0	7065.6	7772.2
46	Ammonium dihydrogen Orthophosphate (or) monoammonium phosphate	43	50	kg	2,133	2560.0	3072.0	3532.8	3886.1
47	Ammonium ferric (II) Sulfate hexahydrade	51	25	kg	1,267	1520.0	1824.0	2097.6	2307.4
48	Ammonium Ferric Sulphate	37	25	kg	933	1120.0	1344.0	1545.6	1700.2

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
49	Ammonium Formate	9	12.5	kg	109	130.2	156.2	179.7	197.6
50	Ammonium Hydroxide	7	50	Ltr	373	448.0	537.6	618.2	680.1
51	Ammonium Molybdate	107	30	kg	3,200	3840.0	4608.0	5299.2	5829.1
52	Ammonium Persulphate	48	25	kg	1,200	1440.0	1728.0	1987.2	2185.9
53	Ammonium Sulfamate	213	10	kg	2,133	2560.0	3072.0	3532.8	3886.1
54	Ammonium Sulfate	16	25	kg	400	480.0	576.0	662.4	728.6
55	Ammonium Sulfate	16	25	kg	400	480.0	576.0	662.4	728.6
56	Ammonium Thiocyanate	51	50	kg	2,533	3040.0	3648.0	4195.2	4614.7
57	Anhydrous Tetramethyl ammonium hydroxide	66	25	kg	1,646	1975.2	2370.2	2725.8	2998.4
58	Arsenic Trioxide	40	25	kg	1,000	1200.0	1440.0	1656.0	1821.6
59	Ascorbic Acid	25	30	kg	760	912.0	1094.4	1258.6	1384.4
60	Barium Chloride	24	25	kg	600	720.0	864.0	993.6	1093.0
61	Barium Sulphate	43	25	kg	1,067	1280.0	1536.0	1766.4	1943.0
62	Benzoic Acid 99%	63	12.5	kg	783	939.0	1126.8	1295.8	1425.4
63	Benzyldehyde	48	25	ltr	1,200	1440.0	1728.0	1987.2	2185.9
64	Beta-D-Lactose	128	12.5	kg	1,600	1920.0	2304.0	2649.6	2914.6
65	Bismuth Subnitrate	100	5	kg	500	600.0	720.0	828.0	910.8
66	Blue Tetrazolium	41,685	0.3	kg	12,506	15006.6	18007.9	20709.1	22780.0
67	Boric Acid	43	25	kg	1,067	1280.0	1536.0	1766.4	1943.0
68	Boron Trifluoride Diethyl Ether	480	12.5	ltr	6,000	7200.0	8640.0	9936.0	10929.6
69	Boron Trifluoride Methanol	370	100	ltr	36,960	44352.0	53222.4	61205.8	67326.3
70	Brij L23	50	30	kg	1,500	1800.0	2160.0	2484.0	2732.4
71	Bromocersol Green	1,867	0.3	kg	560	672.0	806.4	927.4	1020.1
72	Bromophenol Blue	693	1.25	kg	867	1040.0	1248.0	1435.2	1578.7
73	Bromothymol Blue	693	0.75	kg	520	624.0	748.8	861.1	947.2
74	Butane - 1- Sulphonic Acid Sodium Salt	20,000	1	kg	20,000	24000.0	28800.0	33120.0	36432.0
75	Butyl alcohol (HPLC Grade)	29	50	ltr	1,428	1713.6	2056.3	2364.8	2601.2
76	Butylated Hydroxy Toluene	15	50	kg	750	900.0	1080.0	1242.0	1366.2

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
77	Cadmium Chloride	653	5	kg	3,267	3920.0	4704.0	5409.6	5950.6
78	Calcium carbonate	25	15	kg	380	456.0	547.2	629.3	692.2
79	Calcium Chloride	121	15	kg	1,815	2178.0	2613.6	3005.6	3306.2
80	Calcium Chloride dihydrate	43	15	kg	640	768.0	921.6	1059.8	1165.8
81	Calcium Hydroxide	29	25	kg	733	880.0	1056.0	1214.4	1335.8
82	Calcon indicator	640	0.75	kg	480	576.0	691.2	794.9	874.4
83	Calconcarboxylic acid sodium indicator	587	0.75	kg	440	528.0	633.6	728.6	801.5
84	Carbon disulfide	80	25	Ltr	2,000	2400.0	2880.0	3312.0	3643.2
85	Carbon Tetrachloride	25	50	Ltr	1,267	1520.0	1824.0	2097.6	2307.4
86	Casein	51	50	kg	2,533	3040.0	3648.0	4195.2	4614.7
87	Castor Oil	80	3	Ltr	240	288.0	345.6	397.4	437.2
88	Ceric sulfate	220	30	kg	6,600	7920.0	9504.0	10929.6	12022.6
89	Cerium (IV) Sulfate VS	32	25	Ltr	800	960.0	1152.0	1324.8	1457.3
90	Cesium Chloride	3,733	1.25	kg	4,667	5600.0	6720.0	7728.0	8500.8
91	Chlolic Acid	595	50	kg	29,750	35700.0	42840.0	49266.0	54192.6
92	Chloral Hydrate	129	12.5	kg	1,617	1940.0	2328.0	2677.2	2944.9
93	Chloramine T	160	5	kg	800	960.0	1152.0	1324.8	1457.3
94	Chlorobutanol	72	50	kg	3,600	4320.0	5184.0	5961.6	6557.8
95	Chloroform (AR)	52	200	Ltr	10,400	12480.0	14976.0	17222.4	18944.6
96	Chloroform (HPLC Grade)	121	50	Ltr	6,027	7232.4	8678.9	9980.7	10978.8
97	Chloroplatinic Acid	14,667	0.05	kg	733	880.0	1056.0	1214.4	1335.8
98	Chlorotrimethylsilane	80	15	Ltr	1,200	1440.0	1728.0	1987.2	2185.9
99	Chromotropic acid	12,193	0.25	kg	3,048	3658.0	4389.6	5048.0	5552.8
100	Chromotropic acid sodium salt dihydrate	2,439	0.75	kg	1,829	2194.8	2633.8	3028.8	3331.7
101	Citric Acid	29	25	kg	733	880.0	1056.0	1214.4	1335.8
102	Cobalt nitrate (or)Cobalt II nitrate	253	3	kg	760	912.0	1094.4	1258.6	1384.4
103	Cobaltous Chloride	61	15	kg	920	1104.0	1324.8	1523.5	1675.9
104	Copper II Sulfate (Pentahydrate)	56	15	kg	840	1008.0	1209.6	1391.0	1530.1
105	Crystal Violet	480	0.75	kg	360	432.0	518.4	596.2	655.8

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
106	Cupric (Copper Tartrate)	5,805	0.75	kg	4,354	5224.7	6269.6	7210.1	7931.1
107	Cupric Sulfate (copper sulfate anhydrous)	61	15	kg	920	1104.0	1324.8	1523.5	1675.9
108	Cupriethylenediamine solution	51	50	ltr	2,550	3060.0	3672.0	4222.8	4645.1
109	Cyclohexane (HPLC) Grade	80	30	ltr	2,400	2880.0	3456.0	3974.4	4371.8
110	Diammonium hydrogen phosphate	37	20	kg	747	896.0	1075.2	1236.5	1360.1
111	Diammonium Oxalate Monohydrate	37	15	kg	560	672.0	806.4	927.4	1020.1
112	Dibasic Ammonium phosphate (anhydrous)	37	50	kg	1,867	2240.0	2688.0	3091.2	3400.3
113	Dibasic calcium phosphate or Calcium Hydrogen Phosphate Anhydrous	43	20	kg	853	1024.0	1228.8	1413.1	1554.4
114	Dibutylamine	11	25	ltr	275	330.0	396.0	455.4	500.9
115	Dichloromethane (methylene Chloride)	40	1000	ltr	40,000	48000.0	57600.0	66240.0	72864.0
116	Dicyclohexamine 99%	288	3	kg	864	1036.8	1244.2	1430.8	1573.9
117	Diethylamine	40	50	ltr	2,000	2400.0	2880.0	3312.0	3643.2
118	Diethylene glycol	31	20	ltr	613	736.0	883.2	1015.7	1117.2
119	Diisopropyl Ether	17	75	Ltr	1,300	1560.0	1872.0	2152.8	2368.1
120	Dimethyl Acetamide	498	20	kg	9,954	11944.8	14333.8	16483.8	18132.2
121	Dimethyl Formamide	52	20	Ltr	1,040	1248.0	1497.6	1722.2	1894.5
122	Dimethyl Sulfoxide	109	20	Ltr	2,187	2624.0	3148.8	3621.1	3983.2
123	Diphosphorous Pentoxide (to drying)	61	25	kg	1,533	1840.0	2208.0	2539.2	2793.1
124	Dipotassium Hydrogen phosphate	75	20	kg	1,493	1792.0	2150.4	2473.0	2720.3
125	Disodium Hydrogen Orthophosphate (Sodium phosphate Anhydrous)	35	300	kg	10,400	12480.0	14976.0	17222.4	18944.6
126	Disodium Hydrogen Phosphate Dodecahydrate	35	25	kg	867	1040.0	1248.0	1435.2	1578.7
127	Di-Sodium tetraborate 10-hydrate cryst	51	25	kg	1,283	1540.0	1848.0	2125.2	2337.7
128	Di-Sodium tetraborate anhydrous	51	50	kg	2,567	3080.0	3696.0	4250.4	4675.4
129	Disodium Tetraborate Decahydrate	43	25	kg	1,067	1280.0	1536.0	1766.4	1943.0

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
130	Dithizone Extraction Solution	64	50	Ltr	3,200	3840.0	4608.0	5299.2	5829.1
131	Dithizone powder	413	25	kg	10,333	12400.0	14880.0	17112.0	18823.2
132	Dotriacontane	5,000	1.25	kg	6,250	7500.0	9000.0	10350.0	11385.0
133	Dragendorff Reagent	1,180	5	Ltr	5,900	7080.0	8496.0	9770.4	10747.4
134	Edatate Disodium	56	50	kg	2,800	3360.0	4032.0	4636.8	5100.5
135	Eosin Y Stain	960	0.75	kg	720	864.0	1036.8	1192.3	1311.6
136	Eriochrome Black T	520	0.75	kg	390	468.0	561.6	645.8	710.4
137	Ethanol (AR)	17	200	Ltr	3,467	4160.0	4992.0	5740.8	6314.9
138	Ethanol (HPLC) Grade	32	100	Ltr	3,200	3840.0	4608.0	5299.2	5829.1
139	Ethyl Acetate	25	20	Ltr	507	608.0	729.6	839.0	922.9
140	Ethylene Diamine Tetra Acetic Acid	51	15	Ltr	760	912.0	1094.4	1258.6	1384.4
141	Ethylene Glycol	33	30	Ltr	980	1176.0	1411.2	1622.9	1785.2
142	Ferric Chloride Anhydrous	21	20	kg	427	512.0	614.4	706.6	777.2
143	Ferric chloride hexahydrate	69	20	kg	1,387	1664.0	1996.8	2296.3	2526.0
144	Ferrion Solution	213	3	Ltr	640	768.0	921.6	1059.8	1165.8
145	folin Reagent (Qualigens)	227	3	Ltr	680	816.0	979.2	1126.1	1238.7
146	Formic Acid	11	50	Ltr	533	640.0	768.0	883.2	971.5
147	Glycerol	6	10	Ltr	64	76.8	92.2	106.0	116.6
148	Glycine	6	10	Ltr	64	76.8	92.2	106.0	116.6
149	Glycolic acid	840	1.25	kg	1,050	1260.0	1512.0	1738.8	1912.7
150	Heptane -1 sulfonic acid sodium salt	36,432	0.75	kg	27,324	32788.8	39346.6	45248.5	49773.4
151	Hexamethylenetetraamine	51	15	kg	760	912.0	1094.4	1258.6	1384.4
152	Hydrazine Sulfate	307	5	kg	1,533	1840.0	2208.0	2539.2	2793.1
153	Hydriodic Acid	128	25	ltr	3,200	3840.0	4608.0	5299.2	5829.1
154	Hydrofluoric Acid	15	75	ltr	1,160	1392.0	1670.4	1921.0	2113.1
155	Hydrogen Peroxide	9	75	ltr	700	840.0	1008.0	1159.2	1275.1
156	Hydroxy -napthol Blue	781	3	kg	2,344	2812.8	3375.4	3881.7	4269.8
157	Hydroxyl Ammonium Chloride	1,467	3	kg	4,400	5280.0	6336.0	7286.4	8015.0
158	Hypoxanthene	3,080	0.75	kg	2,310	2772.0	3326.4	3825.4	4207.9

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
159	Imidazole (99.5%)	9,462	3	kg	28,386	34063.2	40875.8	47007.2	51707.9
160	Iodine	115	25	kg	2,867	3440.0	4128.0	4747.2	5221.9
161	Iodine Momobromide	891	3	kg	2,673	3207.6	3849.1	4426.5	4869.1
162	Iodine VS	48	15	ltr	720	864.0	1036.8	1192.3	1311.6
163	Iron Powder	93	15	kg	1,395	1674.0	2008.8	2310.1	2541.1
164	Iso octane (2,2,4, trimethyl pentane)	40	50	ltr	2,000	2400.0	2880.0	3312.0	3643.2
165	Isopropyl Alcohol	17	200	ltr	3,467	4160.0	4992.0	5740.8	6314.9
166	Karlfischer Reagent	64	120	ltr	7,680	9216.0	11059.2	12718.1	13989.9
167	Lanthanum (III) Chloride	900	75	kg	67,500	81000.0	97200.0	111780.0	122958.0
168	Lanthanum (III) Oxide	533	10	kg	5,333	6400.0	7680.0	8832.0	9715.2
169	Lanthanum chloride heptahydrate	480	150	kg	72,000	86400.0	103680.0	119232.0	131155.2
170	L-Cysteine Hydrochloride	1,067	1.25	kg	1,333	1600.0	1920.0	2208.0	2428.8
171	Lead acetate (or)Lead II acetate	43	25	kg	1,067	1280.0	1536.0	1766.4	1943.0
172	Lead nitric (Or) Lead nitrate	51	25	kg	1,267	1520.0	1824.0	2097.6	2307.4
173	Liquid Parafin	7	10	Ltr	67	80.0	96.0	110.4	121.4
174	Locust Bean Gum	184	15	kg	2,760	3312.0	3974.4	4570.6	5027.6
175	Magnesium Acetate	61	50	kg	3,067	3680.0	4416.0	5078.4	5586.2
176	Magnesium Chloride hexahydrate	32	15	kg	480	576.0	691.2	794.9	874.4
177	Magnesium Hydroxide	26	15	kg	390	468.0	561.6	645.8	710.4
178	Magnesium Ribbon (Coil)	320	0.75	kg	240	288.0	345.6	397.4	437.2
179	Magnesium sulfate heptahydrate	69	15	kg	1,040	1248.0	1497.6	1722.2	1894.5
180	Manganese (II)Chloride tetrahydrate	43	15	kg	640	768.0	921.6	1059.8	1165.8
181	Mercaptoacetic Acid (Thioglycolic Acid)	51	10	Ltr	507	608.0	729.6	839.0	922.9
182	Mercuric acetate (99%)	820	5	kg	4,100	4920.0	5904.0	6789.6	7468.6
183	Mercuric chloride	453	5	kg	2,267	2720.0	3264.0	3753.6	4129.0
184	Mercuric Iodide(Red)	800	3	kg	2,400	2880.0	3456.0	3974.4	4371.8
185	Metallic selenium	800	5	kg	4,000	4800.0	5760.0	6624.0	7286.4
186	Metaphosphoric acid	64	150	kg	9,600	11520.0	13824.0	15897.6	17487.4
187	Methanesulphonic acid	15	75	Ltr	1,100	1320.1	1584.1	1821.8	2003.9

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
188	Methanol HPLC Grade	17	1000	Ltr	17,333	20800.0	24960.0	28704.0	31574.4
189	Methanol(AR)	9	200	Ltr	1,867	2240.0	2688.0	3091.2	3400.3
190	Methyl orange	587	0.75	kg	440	528.0	633.6	728.6	801.5
191	Methyl Red	2,533	0.75	kg	1,900	2280.0	2736.0	3146.4	3461.0
192	Methylamine Solution	14	15	Ltr	210	252.0	302.4	347.8	382.5
193	Methylbenzoate	51	50	Ltr	2,533	3040.0	3648.0	4195.2	4614.7
194	Methylcyclohexane	480	0.75	Ltr	360	432.0	518.4	596.2	655.8
195	Methylene Blue	747	0.75	kg	560	672.0	806.4	927.4	1020.1
196	Methyltricosanoate	82,320	0.25	kg	20,580	24696.0	29635.2	34080.5	37488.5
197	Molybdic Acid	93	15	kg	1,400	1680.0	2016.0	2318.4	2550.2
198	morpholine	20	30	Ltr	600	720.0	864.0	993.6	1093.0
199	n - octane	41	15	ltr	620	744.0	892.8	1026.7	1129.4
200	n - octanoic Acid	58	15	ltr	874	1049.0	1258.8	1447.7	1592.4
201	N- amyl alcohol	24	25	ltr	600	720.0	864.0	993.6	1093.0
202	n- propyl Alcohol	56	50	ltr	2,800	3360.0	4032.0	4636.8	5100.5
203	N-(1-naphthyl)ethylenediamine dihydrochloride	35,490	0.25	kg	8,873	10647.0	12776.4	14692.9	16162.1
204	N,O-Bis(trimetylsily) acetamide	860	3	kg	2,580	3096.0	3715.2	4272.5	4699.7
205	n-Amyl alcohol	24	25	ltr	600	720.0	864.0	993.6	1093.0
206	n-Hepatane (HPLC Grade)	111	20	ltr	2,218	2661.3	3193.6	3672.6	4039.9
207	n-Heptane	20	75	ltr	1,533	1840.0	2208.0	2539.2	2793.1
208	n-Hexane	24	500	ltr	12,000	14400.0	17280.0	19872.0	21859.2
209	Ninhydrin	373	1.25	kg	467	560.0	672.0	772.8	850.1
210	Nitric Acid	17	20	ltr	347	416.0	499.2	574.1	631.5
211	Nitroso R Salt Solution	190	20	ltr	3,800	4560.0	5472.0	6292.8	6922.1
212	n-Octanol	510	15	ltr	7,655	9185.4	11022.5	12675.9	13943.4
213	n-Trimethylsilylimadazole	1,080	3	kg	3,240	3888.0	4665.6	5365.4	5902.0
214	Orthophosphoric Acid	15	20	ltr	299	358.4	430.1	494.6	544.1
215	o-tolidine	83	25	kg	2,084	2500.2	3000.2	3450.3	3795.3

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
216	O-Xylene	594	15	ltr	8,915	10697.4	12836.9	14762.4	16238.7
217	O-Xylene (98%)	5	30	Ltr	137	164.9	197.9	227.5	250.3
218	p- Nitrophenol	10	25	kg	261	312.6	375.1	431.4	474.5
219	P-anisoldehyde	127	3	Ltr	380	456.0	547.2	629.3	692.2
220	P-Dimethylamino Benzaldehyde	933	0.75	kg	700	840.0	1008.0	1159.2	1275.1
221	Pepsin Solution	80	5	Ltr	400	480.0	576.0	662.4	728.6
222	Perchloric Acid	53	30	Ltr	1,600	1920.0	2304.0	2649.6	2914.6
223	Petroleum Ether	20	110	Ltr	2,200	2640.0	3168.0	3643.2	4007.5
224	pH 4.01 Buffer	24	50	Ltr	1,200	1440.0	1728.0	1987.2	2185.9
225	pH 7.01 Buffer	32	50	Ltr	1,617	1940.0	2328.0	2677.2	2944.9
226	Phenol Red	587	1.25	kg	733	880.0	1056.0	1214.4	1335.8
227	Phenol Red Solution VS	29	25	Ltr	733	880.0	1056.0	1214.4	1335.8
228	Phenolphthalein	520	1.25	kg	650	780.0	936.0	1076.4	1184.0
229	Phenolphthalein solution	48	15	Ltr	720	864.0	1036.8	1192.3	1311.6
230	Phenyl Ether	190	25	kg	4,750	5700.0	6840.0	7866.0	8652.6
231	Phosphomolybdic Acid	507	10	kg	5,067	6080.0	7296.0	8390.4	9229.4
232	Phosphorus (V) Oxide(or) Phosphoric pentoxide	64	25	kg	1,600	1920.0	2304.0	2649.6	2914.6
233	Phthalic anhydride	80	15	kg	1,200	1440.0	1728.0	1987.2	2185.9
234	p-hydroxy benzoic acid	427	1.5	kg	640	768.0	921.6	1059.8	1165.8
235	Polyethylene Glycol	8	50	Ltr	375	450.0	540.0	621.0	683.1
236	Polyethylene Glycol 400	48	25	Ltr	1,200	1440.0	1728.0	1987.2	2185.9
237	Polysorbate 80	43	20	Ltr	853	1024.0	1228.8	1413.1	1554.4
238	Potassium bisulfate (Potassium hydrogen sulfate	37	50	kg	1,867	2240.0	2688.0	3091.2	3400.3
239	Potassium Bromide	59	25	kg	1,467	1760.0	2112.0	2428.8	2671.7
240	Potassium Carbonate(anhydrous)	32	25	kg	800	960.0	1152.0	1324.8	1457.3
241	Potassium Chloride (AR)	397	15	kg	5,954	7144.2	8573.0	9859.0	10844.9
242	Potassium Chloride Anhydrous	37	15	kg	560	672.0	806.4	927.4	1020.1

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
243	Potassium Chloride Std Solution (For Conductivity meter)	25	30	Ltr	760	912.0	1094.4	1258.6	1384.4
244	Potassium Chromate	37	15	kg	560	672.0	806.4	927.4	1020.1
245	Potassium Cyanate	64	15	kg	960	1152.0	1382.4	1589.8	1748.7
246	Potassium Cyanide Solution	120	10	Ltr	1,200	1440.0	1728.0	1987.2	2185.9
247	Potassium Dichromate	61	25	kg	1,533	1840.0	2208.0	2539.2	2793.1
248	Potassium Dihydrogen Phosphate	38	50	kg	1,900	2280.0	2736.0	3146.4	3461.0
249	potassium Ferricyanide	51	50	kg	2,533	3040.0	3648.0	4195.2	4614.7
250	Potassium Hexacyanoferrate (III)	93	50	kg	4,667	5600.0	6720.0	7728.0	8500.8
251	Potassium Hydrogen Sulfate	35	50	kg	1,733	2080.0	2496.0	2870.4	3157.4
252	Potassium Hydrogen Phthalate or Potassium biphthalte	48	15	kg	720	864.0	1036.8	1192.3	1311.6
253	Potassium Hydroxide	29	25	kg	733	880.0	1056.0	1214.4	1335.8
254	Potassium Iodide	51	50	kg	2,533	3040.0	3648.0	4195.2	4614.7
255	Potassium Iodobismuthate	2,400	0.75	kg	1,800	2160.0	2592.0	2980.8	3278.9
256	Potassium Nitrate	35	15	kg	520	624.0	748.8	861.1	947.2
257	Potassium Pyroantimonate	147	5	kg	733	880.0	1056.0	1214.4	1335.8
258	Potassium Pyrophosphate	33	25	kg	817	980.0	1176.0	1352.4	1487.6
259	Potassium Pyrophosphate trihydrate	47	25	kg	1,167	1400.0	1680.0	1932.0	2125.2
260	Potassium Sodium tartrate tetrahydrate	69	15	kg	1,040	1248.0	1497.6	1722.2	1894.5
261	Potassium Sulfate	37	25	kg	933	1120.0	1344.0	1545.6	1700.2
262	Potassium Tetraoxalate (Dehydrate)	69	0.75	kg	52	62.1	74.5	85.7	94.3
263	Potassium thiocyanate	61	15	kg	920	1104.0	1324.8	1523.5	1675.9
264	Propane-1,2-diol (Propylene glycol)	64	25	ltr	1,600	1920.0	2304.0	2649.6	2914.6
265	Pumice Stone	96	15	kg	1,440	1728.0	2073.6	2384.6	2623.1
266	Pyridine	73	15	ltr	1,100	1320.0	1584.0	1821.6	2003.8
267	Pyrrole	1,067	5	Ltr	5,333	6400.0	7680.0	8832.0	9715.2
268	Salicylaldehyde	163	5	Ltr	817	980.0	1176.0	1352.4	1487.6

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
269	Salicylaldehyde Azine	18,000	0.25	kg	4,500	5400.0	6480.0	7452.0	8197.2
270	Saturated Sodium Chloride Solution	21	15	Ltr	320	384.0	460.8	529.9	582.9
271	Silica Gel (Self Indicator)	21	15	kg	320	384.0	460.8	529.9	582.9
272	Silicone Oil	870	3	kg	2,610	3132.0	3758.4	4322.2	4754.4
273	Silver diethyldithio carbamate	6,133	0.25	kg	1,533	1840.0	2208.0	2539.2	2793.1
274	Silver Nitrate	653	3	kg	1,960	2352.0	2822.4	3245.8	3570.3
275	Sodium 1 nitroso 2-napthol,3,6- disulfonic Acid	2,904	2.5	kg	7,260	8712.0	10454.4	12022.6	13224.8
276	Sodium 1 Pentanesulfonate	5,880	2.5	kg	14,700	17640.0	21168.0	24343.2	26777.5
277	Sodium acetate anhydrous	64	50	kg	3,200	3840.0	4608.0	5299.2	5829.1
278	Sodium acetate trihydrate	37	50	kg	1,867	2240.0	2688.0	3091.2	3400.3
279	Sodium Benzenesulfonate	1,600	2.5	kg	4,000	4800.0	5760.0	6624.0	7286.4
280	Sodium Bitartrate Monohydrate	236	7.5	kg	1,767	2120.4	2544.5	2926.2	3218.8
281	Sodium Borate	256	25	kg	6,405	7686.0	9223.2	10606.7	11667.3
282	Sodium borate decahydrate	256	25	kg	6,405	7686.0	9223.2	10606.7	11667.3
283	Sodium Borohydride for synthesis	267	5	kg	1,333	1600.0	1920.0	2208.0	2428.8
284	Sodium Carbonate Anhydrous	35	15	kg	520	624.0	748.8	861.1	947.2
285	Sodium Chloride	13	20	kg	253	304.0	364.8	419.5	461.5
286	Sodium Citrate	19	25	kg	467	560.0	672.0	772.8	850.1
287	Sodium Citrate Dihydrate	35	15	kg	520	624.0	748.8	861.1	947.2
288	Sodium Cobaltinitrile	1,120	2.5	kg	2,800	3360.0	4032.0	4636.8	5100.5
289	Sodium diethyl dithio carbamate(Diethyl dithiocarbamate)	33	15	kg	500	600.0	720.0	828.0	910.8
290	Sodium dodecyl Sulphate	31	50	kg	1,533	1840.0	2208.0	2539.2	2793.1
291	Sodium Fluoride	48	15	kg	720	864.0	1036.8	1192.3	1311.6
292	Sodium Fluoride (99.9%)	7,600	0.75	kg	5,700	6840.0	8208.0	9439.2	10383.1
293	Sodium Hydrogen Carbonate(NaHCO3) or Sodium bicarconate	29	15	kg	440	528.0	633.6	728.6	801.5
294	Sodium Hydroxide Pellets	64	50	kg	3,200	3840.0	4608.0	5299.2	5829.1

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
295	Sodium Hypochloride	1	10	Ltr	8	9.5	11.4	13.1	14.4
296	Sodium Iodide	80	12.5	kg	1,000	1200.0	1440.0	1656.0	1821.6
297	Sodium Nitrite 99%	37	25	kg	927	1112.0	1334.4	1534.6	1688.0
298	Sodium Nitroprusside	320	5	kg	1,600	1920.0	2304.0	2649.6	2914.6
299	Sodium Oxalate	51	25	kg	1,267	1520.0	1824.0	2097.6	2307.4
300	Sodium Perchlorate	37	25	kg	927	1112.0	1334.4	1534.6	1688.0
301	Sodium Persulfate	69	20	kg	1,387	1664.0	1996.8	2296.3	2526.0
302	Sodium phosphate(Sodium dihydrogen phosphate)	37	200	kg	7,467	8960.0	10752.0	12364.8	13601.3
303	sodium sulfite anhydrous	35	25	kg	867	1040.0	1248.0	1435.2	1578.7
304	Sodium Sulphate Anhydrous	35	15	kg	520	624.0	748.8	861.1	947.2
305	Sodium Thiosulphate	21	25	kg	533	640.0	768.0	883.2	971.5
306	Sodium Thiosulphate VS	21	15	ltr	320	384.0	460.8	529.9	582.9
307	Sodium-1-octane sulfonate	1,470	5	kg	7,350	8820.0	10584.0	12171.6	13388.8
308	Starch powder	29	25	kg	733	880.0	1056.0	1214.4	1335.8
309	Starch Solution	21	15	ltr	320	384.0	460.8	529.9	582.9
310	Stock Cock Grease	16	15	kg	240	288.0	345.6	397.4	437.2
311	Strontium Chloride Hexahydrate	51	15	kg	760	912.0	1094.4	1258.6	1384.4
312	Sulfanilic Acid	280	5	kg	1,400	1680.0	2016.0	2318.4	2550.2
313	Tannic Acid	75	3	kg	225	270.0	324.0	372.6	409.9
314	Terephthalaldehyde (O-phthalaldehyde, p-phthalaldehyde)	8,240	1.25	kg	10,300	12360.0	14832.0	17056.8	18762.5
315	Tetra -n-butylammonium Hydroxide	750	20	ltr	15,000	18000.0	21600.0	24840.0	27324.0
316	Tetrabutyl ammonium hydrogen sulfate	186	25	ltr	4,650	5580.0	6696.0	7700.4	8470.4
317	Tetrabutyl ammonium Hydrogen sulphate	107	25	Ltr	2,667	3200.0	3840.0	4416.0	4857.6
318	Tetrabutyl ammonium Phosphate	288	50	kg	14,400	17280.0	20736.0	23846.4	26231.0
319	Tetrahydrofuran	120	150	Ltr	18,000	21600.0	25920.0	29808.0	32788.8
320	Tetrahydrofuran (HPLC Grade)	195	50	Ltr	9,765	11718.0	14061.6	16170.8	17787.9

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
321	Tetrahydrofuran (stabilizer free)	120	30	Ltr	3,600	4320.0	5184.0	5961.6	6557.8
322	Tetrazolium Blue Chloride	12,768	1.25	kg	15,960	19152.0	22982.4	26429.8	29072.7
323	Thioacetamide	125	5	kg	625	750.0	900.0	1035.0	1138.5
324	Thioglycollic Acid(8o%)	19	10	Ltr	193	232.0	278.4	320.1	352.2
325	Thiourea AR	44	15	kg	656	787.2	944.6	1086.3	1195.0
326	Thymol (gram)	240	0.75	kg	180	216.0	259.2	298.1	327.9
327	Thymol Blue	587	0.75	kg	440	528.0	633.6	728.6	801.5
328	Ting II Chloride pentahydrate (Stanous Chloride)	147	3	kg	440	528.0	633.6	728.6	801.5
329	Titanium dioxide	7	25	kg	184	220.2	264.2	303.9	334.3
330	Titanium trichloride	64	15	kg	960	1152.0	1382.4	1589.8	1748.7
331	Toluene In Hexane Solution	80	3	Ltr	240	288.0	345.6	397.4	437.2
332	Tribasic sodium phosphate	386	50	kg	19,320	23184.0	27820.8	31993.9	35193.3
333	Tribasic sodium phosphate dodecahydrate	386	50	kg	19,320	23184.0	27820.8	31993.9	35193.3
334	Trichloroacetic acid	187	30	kg	5,600	6720.0	8064.0	9273.6	10201.0
335	Triethanolamine	37	15	Ltr	560	672.0	806.4	927.4	1020.1
336	Triethylamine	7	30	Ltr	200	239.8	287.7	330.9	364.0
337	Triethylamine Hydrochloride(99%)	184	12.5	kg	2,300	2760.0	3312.0	3808.8	4189.7
338	Trifluoroacetic acid	22	150	Ltr	3,249	3898.8	4678.6	5380.3	5918.4
339	Trimethylamine	32	15	Ltr	474	568.8	682.6	784.9	863.4
340	Trinitrophenol (Picric Acid)	960	2.5	kg	2,400	2880.0	3456.0	3974.4	4371.8
341	Trioctylphosphine oxide	1,867	10	kg	18,667	22400.0	26880.0	30912.0	34003.2
342	Trisodium Citrate Dihydrate	19	50	kg	933	1120.0	1344.0	1545.6	1700.2
343	Tromethamine	587	5	kg	2,933	3520.0	4224.0	4857.6	5343.4
344	Vanillin	54	5	kg	271	325.2	390.2	448.8	493.7
345	Vinyl Acetate	30	25	Ltr	750	900.0	1080.0	1242.0	1366.2
346	xylene	31	50	ltr	1,533	1840.0	2208.0	2539.2	2793.1
347	Zinc Chloride	51	25	kg	1,267	1520.0	1824.0	2097.6	2307.4

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
348	Zinc granular (AR)	15	50	kg	767	920.4	1104.5	1270.2	1397.2
349	Zinc Sulphate Heptahydrate	43	15	kg	640	768.0	921.6	1059.8	1165.8
350	Zinc Sulphate VS	29	15	ltr	440	528.0	633.6	728.6	801.5
351	α-D- Glucose	250	30	kg	7,500	9000.0	10800.0	12420.0	13662.0
352	Toluene	7	10	ltr	75	89.6	107.5	123.6	136.0
353	Phenol Red indicator solution	8	12.5	ltr	96	115.2	138.2	159.0	174.9
354	Acetyl chloride	8	75	ltr	612	734.4	881.3	1013.5	1114.8
355	Tween-80 Extra Pure	14	75	ltr	1,062	1274.4	1529.3	1758.7	1934.5
356	Boron Trifluoride Ethyl Ether Complex	480	37.5	ltr	18,000	21600.0	25920.0	29808.0	32788.8
357	Copper II ethylenediamine complex 1M	29	75	ltr	2,188	2625.3	3150.4	3622.9	3985.2
358	Isopropyl Iodide	183	75	ltr	13,751	16500.6	19800.7	22770.8	25047.9
359	Anisaldehyde Extra Pure	27	37.5	ltr	1,001	1200.6	1440.7	1656.8	1822.5
360	Platinum Chloride Hydrate	91,670	0.15	kg	13,751	16500.6	19800.7	22770.8	25047.9
361	Antimony Trichloride	43	37.5	kg	1,625	1949.4	2339.3	2690.2	2959.2
362	Tetramethyl Ammonium Hydroxide Pentahydr	329	15	kg	4,938	5925.6	7110.7	8177.3	8995.1
363	Stannous Chloride Dihydrated	56	15	kg	837	1004.4	1205.3	1386.1	1524.7
364	Diphenyl Ether	13	75	ltr	938	1125.0	1350.0	1552.5	1707.8
365	Triammonium citrate	13	75	kg	938	1125.0	1350.0	1552.5	1707.8
366	Patton & Reeder reagent	283	3.75	kg	1,062	1274.4	1529.3	1758.7	1934.5
367	Diethyl Amine Hydrochloride	12	75	kg	875	1049.4	1259.3	1448.2	1593.0
368	Strontium chloride	7	75	kg	500	599.4	719.3	827.2	909.9
369	Tris Buffer	58	15	kg	875	1049.4	1259.3	1448.2	1593.0
370	Ponceau S.C I No 27195	200	3.75	kg	750	900.0	1080.0	1242.0	1366.2
371	Tetrapotassium Pyrophosphate	13	75	kg	938	1125.0	1350.0	1552.5	1707.8
372	2,3 diaminonaphthalene	452,500	0.15	kg	67,875	81450.0	97740.0	112401.0	123641.1
373	Water saturated butyl chloride	271	75	ltr	20,318	24381.0	29257.2	33645.8	37010.4
374	Trisodium phosphate	148	75	kg	11,105	13325.4	15990.5	18389.1	20228.0
375	Triphenyl Methanol	106	75	ltr	7,954	9544.5	11453.4	13171.4	14488.6

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
376	Mercuric nitrate	368	75	kg	27,563	33075.0	39690.0	45643.5	50207.9
377	Diphenyl Carbazone (Dithizone)	413	37.5	kg	15,500	18600.0	22320.0	25668.0	28234.8
378	D-Phenylalanine	7,854	3.75	kg	29,453	35343.0	42411.6	48773.3	53650.7
379	Acetic anhydride	179	75	kg	13,388	16065.0	19278.0	22169.7	24386.7
380	Chloroacetic acid	1,022	15	kg	15,326	18390.6	22068.7	25379.0	27916.9
381	placebo powder	5,051	15	kg	75,758	90909.0	109090.8	125454.4	137999.9
382	Squalane	3,297	15	ltr	49,455	59346.0	71215.2	81897.5	90087.2
383	2,2-dimethoxypropane	206	100	ltr	20,643	24771.8	29726.2	34185.1	37603.7
384	Ferrous sulfate	1,264	15	kg	18,953	22743.7	27292.5	31386.3	34525.0
385	Methylparaben	210,000	0.15	kg	31,500	37800.0	45360.0	52164.0	57380.4
386	Dehydrated hexane	92	375	ltr	34,650	41580.0	49896.0	57380.4	63118.4
387	Lanthanum oxide	533	75	kg	40,000	48000.0	57600.0	66240.0	72864.0
388	Sodium Tetraborate	51	150	kg	7,700	9239.4	11087.3	12750.4	14025.4
389	Acetone	8	50	Ltr	400	480.0	576.0	662.4	728.6
390	Diethyl Ether	52	500	Ltr	26,000	31200.0	37440.0	43056.0	47361.6
391	Hydrochloric Acid(36%)	19	100	Ltr	1,920	2304.0	2764.8	3179.5	3497.5
392	Potassium Permanganate	37	50	kg	1,867	2240.0	2688.0	3091.2	3400.3
393	Sulphuric Acid	17	50	ltr	867	1040.0	1248.0	1435.2	1578.7
394	Ethylene Dichloride	77	25	ltr	1,933	2320.0	2784.0	3201.6	3521.8
395	Lanthanum Nitrate	800	10	kg	8,000	9600.0	11520.0	13248.0	14572.8
396	Various Chemical for QC testing (powder)	1,000	50	kg	50,000	60000.0	72000.0	82800.0	91080.0
397	Various Chemical for QC testing (liquid)	300	10	ltr	3,000	3600.0	4320.0	4968.0	5464.8
					1,926,339	**2,311,607**	**2,773,928**	**3,190,017**	**3,509,019**

Pacific Medical Industries Limited

QC HPLC/GC

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
1	150mm × 4.6mm, 5µm,ODS	Pcs	302.4	2	605	726	871	1002	1102
2	250mm × 4.6mm, 5µm,ODS	Pcs	281.6	2	563	676	811	933	1026
3	150mm × 4.6mm, 5µm,C18	Pcs	302.4	2	605	726	871	1002	1102
4	250mm × 4.6mm, 5µm,VP - C8	Pcs	281.6	2	563	676	811	933	1026
5	100mm × 4.6mm, 3.5µm,C8	Pcs	235	2	470	564	677	778	856
6	250mm × 4.0mm, 5µm,Hypersil BDS C8	Pcs	338	2	676	811	973	1119	1231
7	300mm × 3.9mm, 10µm, C18	Pcs	549	2	1,098	1318	1581	1818	2000
7	300mm × 3.9mm, 10µm, u-BONDAPAK C18	Pcs	549	2	1,098	1318	1581	1818	2000
8	25cm × 4.6mmid × 5µm, peerless C18	Pcs	303.75	2	608	729	875	1006	1107
8	25cm × 4.6mm × 5µm, peerless C18	Pcs	258.67	2	517	621	745	857	942
9	25cm × 4.6mmid × 5µm, peerless silica	Pcs	281.6	2	563	676	811	933	1026
9	25cm × 4.6mm× 5µm, peerless silica,HPLC Column Coo India	Pcs	225.59	2	451	541	650	747	822
10	15cm × 4.6mmid × 5µm, Acclaim Mixed Modee WCX-1(L85)	Pcs	823.3	2	1,647	1976	2371	2727	2999
11	15cm × 3.9mmid × 5µm, Peerless C18 L(1)	Pcs	264.8	2	530	636	763	877	965
11	3.9mm x 15 cm x 5µm Peerless basic C 18	Pcs	277.83	2	556	667	800	920	1012
11	3.9mm x 15 cm x 5µm Peerless basic C 18	Pcs	241.83	2	484	580	696	801	881
12	25mm × 4.0mm, 5µm,Peerless C18	Pcs	281.6	2	563	676	811	933	1026
13	25cm × 4.6mm × 5µm, peerless silica (with porous silica)	Pcs	281.6	2	563	676	811	933	1026
14	100 × 4.6mm × 5µm, Hypersil BDS C18	Pcs	325	2	650	780	936	1076	1184
15	15cm × 4.6mm × 5µm, Peerless Basic C8 (L7)	Pcs	302.4	2	605	726	871	1002	1102
16	25cm × 4.6mm × 5µm, peerless C8 (L7)	Pcs	303.75	2	608	729	875	1006	1107
17	25cm × 4.6mm × 5µm, peerless C8 (L7)	Pcs	303.75	2	608	729	875	1006	1107
18	7,5cmx4.6mmx3µm, peerless C18 (L1)	Pcs	235	2	470	564	677	778	856

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
19	25cm × 4.6mm × 5µm, peerless CN (L10)	Pcs	303.75	2	608	729	875	1006	1107
20	25cm × 4.6mm × 5µm, peerless C18	Pcs	258.72	2	517	621	745	857	943
21	25cm × 4.6mm × 5µm, peerless C18	Pcs	281.6	2	563	676	811	933	1026
22	10cmx4.6cmx5µm, peerless Basic C18	Pcs	285.6	2	571	685	823	946	1040
22	10cmx4.6cmx5µm, peerless Basic C18	Pcs	262.4	2	525	630	756	869	956
22	10cmx4.6cmx5µm, peerless Basic C18	Pcs	262.4	2	525	630	756	869	956
22	10cmx4.6cmx5µm, peerless Basic C18	Pcs	262.4	2	525	630	756	869	956
23	20cm×4.6cmx5µm,peerless Basic C18	Pcs	303.75	2	608	729	875	1006	1107
23	20cm×4.6cmx5µm,peerless Basic C18	Pcs	258.67	2	517	621	745	857	942
24	25cm × 4.6mm × 5µm, peerless C18	Pcs	303.75	2	608	729	875	1006	1107
25	25cm × 4.6mm × 5µm, peerless C18	Pcs	303.75	2	608	729	875	1006	1107
26	25cm × 4.6mm × 5µm, peerless C18	Pcs	303.75	2	608	729	875	1006	1107
27	5cm × 4.6mm × 3µm, peerless C18	Pcs	324	2	648	778	933	1073	1180
28	25cm × 4.0mm × 5µm, peerless C8	Pcs	281.6	2	563	676	811	933	1026
29	25cm × 4.6mm × 5µm, peerless C18	Pcs	303.75	2	608	729	875	1006	1107
30	30cm × 3.9mm × 10µm, peerless C18 (L1)	Pcs	309.75	2	620	743	892	1026	1128
31	25cm × 4.6mm × 5µm, peerless C18	Pcs	281.6	2	563	676	811	933	1026
32	10cmx4.0cmx5µm, peerless Basic C18 (L1)	Pcs	285.6	2	571	685	823	946	1040
33	15cmx4.6cmx5µm, peerless Basic C8	Pcs	302.4	2	605	726	871	1002	1102
34	Halmiton R 5µm PRP 1 (150 x 4.1 mm)	Pcs	965.7	2	1,931	2318	2781	3198	3518
34	Halmiton R 5µm PRP 1 (150 x 4.1 mm)	Pcs	965.7	2	1,931	2318	2781	3198	3518
35	4.1 x 250 mm,5µm PRP 1 Halmiton	Pcs	527.69	2	1,055	1266	1520	1748	1922
36	4.6mm x 150 mm ,3µm peerless NH2(amino)	Pcs	270.48	2	541	649	779	896	985
37	4.6mm x 25cm,4µm peerless phenyl	Pcs	225.59	2	451	541	650	747	822
38	200 mmx 4.6 mm x 3µm peerless basic C 18	Pcs	286.75	2	574	688	826	950	1045
39	250mm x 4.6 mm x 8µm peerless 1000 RPS	Pcs	519.85	2	1,040	1248	1497	1722	1894

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
40	10cmx4.6cmx5µm, peerless C18	Pcs	262.4	2	525	630	756	869	956
41	250mm x 4.6mm x 5µm peerless phenyl	Pcs	258.72	2	517	621	745	857	943
42	250mm x 4.6mm x 10µm peerless C18	Pcs	258.72	2	517	621	745	857	943
42	250mm x 4.6mm x 10µm peerless C18	Pcs	225.59	2	451	541	650	747	822
43	300mm x 4.6mm x 10µm Peerless basic C18	Pcs	285.92	2	572	686	823	947	1042
44	150mm x 4.6 mm x 5µm Peerless C 18	Pcs	277.83	2	556	667	800	920	1012
44	150mm x 4.6 mm x 5µm Peerless C 18	Pcs	241.83	2	484	580	696	801	881
45	300 mm x 4.0mm x 10µm Peerless C 18	Pcs	285.92	2	572	686	823	947	1042
46	125mm x 4.6 mm x 3 µm Peerless basic C 18	Pcs	270.48	2	541	649	779	896	985
47	Sunsheller RP guard filter holder	Pcs	361.85	2	724	868	1042	1198	1318
48	SiliaChrom Plus HPLC Column SCX, 4.6x 150mm,5µm	Pcs	504	2	1,008	1210	1452	1669	1836
49	Zodiac C18 125mm x 4.0 mm x 5 µm	Pcs	150	2	300	360	432	497	546
50	Zodiac C8 250mm x 4.0 mm, 4µm	Pcs	150	2	300	360	432	497	546
51	Zodiac Phenyl -13: 250mm x 4.6, 4µm	Pcs	150	2	300	360	432	497	546
52	Zodiac 100C18 : 150mm x 4.6mm , 10µm	Pcs	200	2	400	480	576	662	729
52	Zodiac 100C18 : 150mm x 4.6mm , 10µm	Pcs	200	2	400	480	576	662	729
53	Zodiac C18 : 100mm x 8.0mm x 5µm	Pcs	454	2	908	1090	1308	1504	1654
53	Zodiac C18 : 100mm x 8.0mm x 5µm	Pcs	454	2	908	1090	1308	1504	1654
54	Zodiac 100 C18 : 250 x 4.6mm, 10µm	Pcs	200	2	400	480	576	662	729
55	Zodiac C18 -13: 250mm x 4.6mm,5µm	Pcs	200	2	400	480	576	662	729
55	Zodiac C18 -13: 250mm x 4.6mm,5µm	Pcs	200	2	400	480	576	662	729
55	Zodiac C18 -13: 250mm x 4.6mm,5µm	Pcs	200	2	400	480	576	662	729
56	SiliaChrom Plus HPLC Column C18, 4.6x 250mm,5µm,100A,	Pcs	388	2	776	931	1117	1285	1414
57	300mm × 4.0mm, 5µm,Peerless C18	Pcs	241.02	2	482	578	694	798	878
57	300mm × 4.0mm, 5µm,Peerless C18	Pcs	241.02	2	482	578	694	798	878
58	305mm × 7.75mm, 9µm,HC-75H	Pcs	984.37	2	1,969	2362	2835	3260	3586

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
58	HPLC COL HC-75 H+F 9µm 305×7.75mm	Pcs	1008.22	2	2,016	2420	2904	3339	3673
58	HPLC COL HC-75 H+F 9µm 305×7.75mm	Pcs	1008.22	2	2,016	2420	2904	3339	3673
59	4.1×250mm,5µm	Pcs	527.69	2	1,055	1266	1520	1748	1922
60	25cm×4.6mm×5µm Peerless Basic C8	Pcs	297.68	2	595	714	857	986	1085
61	12.5cm×4.6mm×3µm Peerless Basic C18	Pcs	273.35	2	547	656	787	905	996
62	12cm×4.6mm×3µm Peerless Basic C18	Pcs	273.35	2	547	656	787	905	996
63	80mm×4.0mm×5µm Peerless Basic C18	Pcs	229.92	2	460	552	662	761	838
64	HPLC COL PRP-X 100 250mm×4.6mm peek	Pcs	749.55	2	1,499	1799	2159	2483	2731
65	100mm × 8mm, 5µm,Water Resolve C18	Pcs	486.32	2	973	1167	1401	1611	1772
66	250×4.6mm×5µm Reprosil Chiral-AM	Pcs	1237.5	2	2,475	2970	3564	4099	4508
67	Partisphere SC×125×4.6mm×5µm	Pcs	464.06	2	928	1114	1336	1537	1691
68	Lichrocart Supersphere 60RP-8 250×4.0mm ×4µm	Pcs	837.75	2	1,676	2011	2413	2775	3052
69	15cm×4mm×5µm Discovery HS C18	Pcs	730.47	2	1,461	1753	2104	2419	2661
69	15cm×4mm×5µm Discovery HS C18	Pcs	730.47	2	1,461	1753	2104	2419	2661
70	100×4.6mm Spherisorb ODS 1	Pcs	412.4	2	825	990	1188	1366	1502
70	100×4.6mm Spherisorb ODS 1	Pcs	412.4	2	825	990	1188	1366	1502
71	30×4.0mm×10µm Kromasil 300	Pcs	451.14	2	902	1083	1299	1494	1644
72	150 x 4.0 mm x 10µm	Pcs	473	2	946	1135	1362	1567	1723
73	120x 4.6mm x 5µm C 18 Pursuit x RS	Pcs	648.72	2	1,297	1557	1868	2149	2363
74	4.0 x 80mm x5µm C 18	Pcs	259.54	2	519	623	747	860	946
75	30 x 4.6 mm x 3µm Peerless basic C8,	Pcs	258.67	2	517	621	745	857	942
76	Waters Nova-Pak C8 Cartridge,CoO ireland,5×100mm,4µm	Pcs	543.33	2	1,087	1304	1565	1800	1979
76	Waters Nova-Pak C8 Cartridge,CoO ireland,5×100mm,4µm	Pcs	543.33	2	1,087	1304	1565	1800	1979
77	Various types and size of columns for HPLC analysis	Pcs	500	70	35,000	42000	50400	57960	63756
1	30m ×0.25mm ID ,0.25 µm, GsBP	Pcs	589	2	1,178	1414	1696	1951	2146

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
2	30m ×0.32mm ID ,0.5 µm, GsBP	Pcs	460	2	920	1104	1325	1524	1676
3	Zebron TMZB-WAXplusTMGC cap.column 30m × 0.32mm ×0.25µm	Pcs	555	2	1,110	1332	1598	1838	2022
4	Zebron TMZB-624 GC cap.column 30m × 0.32mm ×1.8µm	Pcs	590	2	1,180	1416	1699	1954	2149
5	1.5m x 3.2 mm SS column P/W S-3	Pcs	67.87	2	136	163	195	225	247
6	GC Col : GsBP-624, 30mx 0.32 x 1.80µm	Pcs	374.73	2	749	899	1079	1241	1365
7	1.5m x 4 mm SS column P/W ,S-3	Pcs	67.87	2	136	163	195	225	247
8	GsBP-624, 75 m x 0.53 mm x 3.0µm	Pcs	235.2	2	470	564	677	779	857
9	GsBP-Inowax 30m x 0.53 mm x 1.0µm	Pcs	388.37	2	777	932	1119	1286	1415
10	1.8m x 3.0mm Glass Column P/W 20% G1 ON 100/120 Mesh Support S1D	Pcs	135.73	2	271	326	391	450	494
11	1.5m x 3.2 mm SS column P/W12% on support S1NS	Pcs	67.87	2	136	163	195	225	247
12	1.8m x 3.2 mm SS column P/W 15% G 18 On 30/ 60 Mesh support S1C	Pcs	90.45	2	181	217	260	300	330
13	0.9m x 4 mm Glass column P/W 3% G19 on support S1A	Pcs	120.61	2	241	289	347	399	439
14	GsBP 50+MS, 10m x 0.53mm x 2µm	Pcs	235.2	2	470	564	677	779	857
15	1m x 4 mm Glass column P/W acid wash salanized diatomaceous support 100/120 mesh coated with 1% w/w of cyanopropylmethylphenyl silicone fluid	Pcs	120.61	2	241	289	347	399	439
16	GsBP 624, 30m x 0.53mm x 3µm	Pcs	472.38	2	945	1134	1360	1565	1721
16	GsBP 624, 30m x 0.53mm x 3µm	Pcs	481.25	2	963	1155	1386	1594	1753
17	GsBP-5, 50m × 0.32mm , 5µm	Pcs	689.59	2	1,379	1655	1986	2284	2512
18	PhenylMethyl Deactivated Tubing,5M,0.53mm ID,0.6	Pcs	103.13	2	206	248	297	342	376
19	GsBP-5,15m×0.25mm×0.25µm	Pcs	206.25	2	413	495	594	683	751
20	GsBP-1,30m×0.53mm × 3.00µm	Pcs	429.69	2	859	1031	1238	1423	1565

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
20	GsBP-1,30m×0.53mm × 3.00µm	Pcs	429.69	2	859	1031	1238	1423	1565
21	1.0 m x 4 mm Glass Column P/W ,1% OV -225 on uniport on 100/120 Mesh	Pcs	77.34	2	155	186	223	256	282
21	1.0 m x 4 mm Glass Column P/W ,1% OV -225 on uniport on 100/120 Mesh	Pcs	77.34	2	155	186	223	256	282
22	Various types and size of columns for GC analysis	Pcs	500	20	10,000	12000	14400	16560	18216
					133,717	**160,460**	**192,552**	**221,435**	**243,578**

Pacific Medical Industries Limited

Microbial Lab Consumables

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
1	Endotoxin test kit	Set	100	40	4,000	4,800	5,760	6,624	7,286
2	Compressed Air/Gas test kit	Box	100	200	20,000	24,000	28,800	33,120	36,432
3	*Aspergillus brasiliensis*	Pcs	250	1	250	300	360	414	455
4	*Bacillus subtilis*	Pcs	250	1	250	300	360	414	455
5	*Candida albicans*	Pcs	250	1	250	300	360	414	455
6	*Escherichia coli*	Pcs	250	1	250	300	360	414	455
7	*Pseudomonas aeruginosa*	Pcs	250	1	250	300	360	414	455
8	*Salmonella enterica*	Pcs	250	1	250	300	360	414	455
9	*Staphylococcus aureus*	Pcs	250	1	250	300	360	414	455
10	*Staphylococcus epidermidis*	Pcs	250	1	250	300	360	414	455
11	*Saccharomyces cerevisiae*	Pcs	250	1	250	300	360	414	455
12	*Listeria*	Pcs	250	1	250	300	360	414	455
13	*Micrococcus luteus/ Kocuria rhizophil*	Pcs	250	1	250	300	360	414	455
14	*Mycobacterium smegmatis*	Pcs	250	1	250	300	360	414	455
15	*Bordetella bronchiseptica*	Pcs	250	1	250	300	360	414	455
16	*Lactobacillus*	Pcs	250	1	250	300	360	414	455
17	*Bifidobacterium*	Pcs	250	1	250	300	360	414	455
18	Various type of bacteria strains for antibiotic assay	Pcs	250	10	2,500	3,000	3,600	4,140	4,554
19	Various types of glasswares for micro testing	Pcs	5	500	2,500	3,000	3,600	4,140	4,554
					32,750	**39,300**	**47,160**	**54,234**	**59,657**

Pacific Medical Industries Limited

R&D Reference Standard

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
1	1,3 Thiazolidine 2,4-dicarboxylic acid RS	331800.0	0.00025	Kg	83	100	119	143	172
2	10-hydroxydecanoic acid RS	12380.0	0.005	Kg	62	74	89	107	128
3	10-Hydroxydecanoic acid RS	270900.0	0.001	Kg	271	325	390	468	562
4	1-Vinyl-2-Pyrrolidinone RS	1821750.0	0.0002	Kg	364	437	525	630	756
5	2- Methyl-5-nitroimidazole -1-ethanol RS	25872.0	0.025	Kg	647	776	931	1,118	1,341
6	2,3-Dimethylaniline RS	14600000.0	0.00005	Kg	730	876	1,051	1,261	1,514
7	2-amino-n-cyclohexyl-n-methyl benzylamine (Bromhexine Impurity C) RS	6880.0	0.005	Kg	34	41	50	59	71
8	2-Pyrrolidinone RS	2142.0	0.05	Kg	107	129	154	185	222
9	3-Ketofuside Acid RS	80000000.0	0.000005	Kg	400	480	576	691	829
10	4- Chloro 5-Sulfamoylanthranilic (Furosemide Related Compound B) RS	20517.0	0.1	Kg	2,052	2,462	2,954	3,545	4,254
11	4-Aminophenol RS	2220000.0	0.0001	Kg	222	266	320	384	460
12	4-Aminophenol RS	403200.0	0.0001	Kg	40	48	58	70	84
13	4-Epianhydrotetracycline Hydrochloride RS	29106000.0	0.000025	Kg	728	873	1,048	1,257	1,509
14	9,10-Diphenylanthracene RS	495600.0	0.00025	Kg	124	149	178	214	257
15	2-amino-5-chlorobenzophenone	128000.0	0.00025	Kg	32	38	46	55	66
16	Acetal RS	2000.0	0.02	Kg	40	48	58	69	83
17	Alprazolam RS	2750000.0	0.0002	Kg	550	660	792	950	1,140
18	Alprazolam related compound- A	5000000.0	0.00003	Kg	150	180	216	259	311

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
19	Acetaminophen Related Compound B RS	23066666.7	0.00003	Kg	692	830	996	1,196	1,435
20	Acetaminophen Related Compound C RS	13840000.0	0.00005	Kg	692	830	996	1,196	1,435
21	Acetaminophen Related Compound C RS	5397000.0	0.00005	Kg	270	324	389	466	560
22	Acetaminophen Related Compound D RS	13840000.0	0.00005	Kg	692	830	996	1,196	1,435
23	Acetaminophen Related Compound J RS	13840000.0	0.00005	Kg	692	830	996	1,196	1,435
24	Acetaminophen RS	278250.0	0.0004	Kg	111	134	160	192	231
25	Acetaminophen RS	555000.0	0.0004	Kg	222	266	320	384	460
26	Acetylcysteine EP CRS	3360000.0	0.00005	Kg	168	202	242	290	348
27	Acetylcysteine impurity C RS	16800000.0	0.00001	Kg	168	202	242	290	348
28	Acetylcysteine impurity D RS	17600000.0	0.00001	Kg	176	211	253	304	365
29	Acyclovir RS	966666.7	0.0003	Kg	290	348	418	501	601
30	Adipic Acid RS	2550000.0	0.0001	Kg	255	306	367	441	529
31	Albendazole RS	1150000.0	0.0002	Kg	230	276	331	397	477
32	Allopurinol Related Compound A RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
33	Allopurinol Related Compound B RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
34	Allopurinol Related Compound C RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
35	Allopurinol Related Compound D RS	20857142.9	0.000035	Kg	730	876	1,051	1,261	1,514
36	Allopurinol Related Compound E RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
37	Allopurinol Related Compound F RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
38	Allopurinol RS	920000.0	0.00025	Kg	230	276	331	397	477

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
39	Aceclofenac RS	1500000.0	0.0002	Kg	300	360	432	518	622
40	Aceclofenac related compound-A	38000000.0	0.00004	Kg	1,520	1,824	2,189	2,627	3,152
41	Aceclofenac related compound-B	38000000.0	0.00004	Kg	1,520	1,824	2,189	2,627	3,152
42	Aceclofenac related compound-C	38000000.0	0.00004	Kg	1,520	1,824	2,189	2,627	3,152
43	Aceclofenac related compound-D	38000000.0	0.00004	Kg	1,520	1,824	2,189	2,627	3,152
44	Aceclofenac related compound-E	38000000.0	0.00004	Kg	1,520	1,824	2,189	2,627	3,152
45	Aceclofenac related compound-F	38000000.0	0.00004	Kg	1,520	1,824	2,189	2,627	3,152
46	Aceclofenac related compound-G	38000000.0	0.00004	Kg	1,520	1,824	2,189	2,627	3,152
47	Aceclofenac related compound-H	38000000.0	0.00004	Kg	1,520	1,824	2,189	2,627	3,152
48	Aceclofenac related compound-I	38000000.0	0.00004	Kg	1,520	1,824	2,189	2,627	3,152
49	Aluminium Standard solution	19068.0	0.1	L	1,907	2,288	2,746	3,295	3,954
50	Amlodipine Besylate RS	657142.9	0.00035	Kg	230	276	331	397	477
51	Amlodipine Related Compound A RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
52	Amlodipine Related Compound C RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
53	Amlodipine Related Compound D RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
54	Amodiaquin Dihydrochloride Dihydrate RS	5540.0	0.005	Kg	28	33	40	48	57
55	Arginine Hydrochloride RS	1720000.0	0.000125	Kg	215	258	310	372	446
56	Artemether RS	2300000.0	0.0001	Kg	230	276	331	397	477
57	Artesunate RS	1150000.0	0.0002	Kg	230	276	331	397	477
58	Atenolol RS	258000.0	0.0005	Kg	129	155	186	223	267
59	Atorvastatin Calcium RS	2300000.0	0.0001	Kg	230	276	331	397	477
60	Atorvastatin Related Compound A RS	36500000.0	0.00002	Kg	730	876	1,051	1,261	1,514
61	Atorvastatin Related Compound B RS	36500000.0	0.00002	Kg	730	876	1,051	1,261	1,514

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
62	Atorvastatin Related Compound C RS	36500000.0	0.00002	Kg	730	876	1,051	1,261	1,514
63	Atorvastatin Related Compound D RS	36500000.0	0.00002	Kg	730	876	1,051	1,261	1,514
64	Atorvastatin Related Compound E RS	36500000.0	0.00002	Kg	730	876	1,051	1,261	1,514
65	Atorvastatin Related Compound H RS	36500000.0	0.00002	Kg	730	876	1,051	1,261	1,514
66	Atorvastatin Related Compound I RS	36500000.0	0.00002	Kg	730	876	1,051	1,261	1,514
67	Azithromycin RS	2250000.0	0.0002	Kg	450	540	648	778	933
68	Azithromycin related compound- F	11250000.0	0.00004	Kg	450	540	648	778	933
69	Bromazepam system suitability mixture	10500000.0	0.00004		420	504	605	726	871
70	Beclomethasone Dipropionate RS	1150000.0	0.0002	Kg	230	276	331	397	477
71	Benzoic Acid RS	168000.0	0.001	Kg	168	202	242	290	348
72	Benzyl Alcohol RS	497700.0	0.0005	Kg	249	299	358	430	516
73	Betamethasone 21-Valerate CRS	11200000.0	0.000015	Kg	168	202	242	290	348
74	Betamethasone Dipropionate RS	69000.0	0.001	Kg	69	83	99	119	143
75	Betamethasone Valerate RS	186000.0	0.001	Kg	186	223	268	321	386
76	Caffeine Std solution	2919.0	0.05	L	146	175	210	252	303
77	Calcium Carbonate RS	230000.0	0.001	Kg	230	276	331	397	477
78	Calcium Pantothanate RS	1150000.0	0.0002	Kg	230	276	331	397	477
79	Calcium Standard Solution RS	573.3	0.1	L	57	69	83	99	119
80	Cetrizine Hydrochloride RS	920000.0	0.00025	Kg	230	276	331	397	477
81	Cetrizine Related Compound A RS	40250000.0	0.00002	Kg	805	966	1,159	1,391	1,669
82	Cetrizine Related Compound B RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
83	Cetrizine Related Compound C RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
84	Chlormipene Related compound A RS	8050000.0	0.0001	Kg	805	966	1,159	1,391	1,669

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
85	Chlorpheniramine Maleate RS	785440.0	0.000125	Kg	98	118	141	170	204
86	Cholecalciferol RS	7833333.3	0.00003	Kg	235	282	338	406	487
87	Cimetidine RS	1150000.0	0.0002	Kg	230	276	331	397	477
88	Ciprofloxacin ethylenediamine analog RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
89	Ciprofloxacin Hydrochloride RS	1212500.0	0.0004	Kg	485	582	698	838	1,006
90	Clarithromycin RS	2300000.0	0.0001	Kg	230	276	331	397	477
91	Clarithromycin Related Compound A RS	14600000.0	0.00005	Kg	730	876	1,051	1,261	1,514
92	Carvedilol RS	3000000.0	0.0002	Kg	600	720	864	1,037	1,244
93	Carvedilol related compound- A	27250000.0	0.00004	Kg	1,090	1,308	1,570	1,884	2,260
94	Carvedilol related compound- B	27250000.0	0.00004	Kg	1,090	1,308	1,570	1,884	2,260
95	Carvedilol related compound- C	27250000.0	0.00004	Kg	1,090	1,308	1,570	1,884	2,260
96	Carvedilol related compound- D	27250000.0	0.00004	Kg	1,090	1,308	1,570	1,884	2,260
97	Carvedilol system suitability mixture RS	27250000.0	0.00004	Kg	1,090	1,308	1,570	1,884	2,260
98	Clopidogrel Bisulfate RS	11000000.0	0.0002	Kg	2,200	2,640	3,168	3,802	4,562
99	Clopidogrel related compound A RS	100000000.0	0.00002	Kg	2,000	2,400	2,880	3,456	4,147
100	Clopidogrel related compound B RS	100000000.0	0.00002	Kg	2,000	2,400	2,880	3,456	4,147
101	Clopidogrel related compound C RS	100000000.0	0.00002	Kg	2,000	2,400	2,880	3,456	4,147
102	Clonazepam RS	1325000.0	0.0002	Kg	265	318	382	458	550
103	Clonazepam related compound- A	41750000.0	0.00004	Kg	1,670	2,004	2,405	2,886	3,463
104	Clonazepam related compound- B	41750000.0	0.00004	Kg	1,670	2,004	2,405	2,886	3,463
105	Clonazepam related compound- C	41750000.0	0.00004	Kg	1,670	2,004	2,405	2,886	3,463
106	Cyanocobalamin RS	1533333.3	0.00015	Kg	230	276	331	397	477

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
107	Celecoxib RS	8120000.0	0.0002	Kg	1,624	1,949	2,339	2,806	3,368
108	Celecoxib related compound- A	152000000.0	0.00004	Kg	6,080	7,296	8,755	10,506	12,607
109	Celecoxib related compound- B	40650000.0	0.00004	Kg	1,626	1,951	2,341	2,810	3,372
110	Diazepam RS	8130000.0	0.0002	Kg	1,626	1,951	2,341	2,810	3,372
111	Diazepam related compound- A	15500000.0	0.00004	Kg	620	744	893	1,071	1,286
112	Diazepam related compound- B	15500000.0	0.00004	Kg	620	744	893	1,071	1,286
113	D- Panthenol RS	2614.5	0.1	L	261	314	376	452	542
114	Decosahexaenoic Acid ethyl ester(DHA) RS	106000.0	0.001	Kg	106	127	153	183	220
115	Dexamethasone Acetate RS	1200000.0	0.0002	Kg	240	288	346	415	498
116	Dexamethoasone RS	1480000.0	0.000125	Kg	185	222	266	320	384
117	Dextran RS	1140.0	0.1	Kg	114	137	164	197	236
118	Dextromethophan hydrobromide RS	460000.0	0.0005	Kg	230	276	331	397	477
119	Dextrose RS	460000.0	0.0005	Kg	230	276	331	397	477
120	Diaveridine Crystalline RS	327600.0	0.00025	Kg	82	98	118	142	170
121	Diaveridine RS	9400000.0	0.000025	Kg	235	282	338	406	487
122	Diclofenac Potassium RS	750000.0	0.0002	Kg	150	180	216	259	311
123	Diclofenac Related Compound A RS	29200000.0	0.000025	Kg	730	876	1,051	1,261	1,514
124	Diclofenac Sodium RS	1150000.0	0.0002	Kg	230	276	331	397	477
125	Diethyl pthalate RS	2150000.0	0.0002		430	516	619	743	892
126	Diethanolamine Fusidate RS	3750000.0	0.0002	Kg	750	900	1,080	1,296	1,555
127	Diethylene Glycol RS	1150000.0	0.0002	L	230	276	331	397	477
128	Dihydroartemisinin RS	512400.0	0.001	Kg	512	615	738	885	1,063

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
129	Dimethyl 4,4' - Biphenyldicarboxylate RS	5103.0	0.05	Kg	255	306	367	441	529
130	Dimethyl 7,7' dimethoxy-4,4'bibenzol[d][1,3]dioxole 55'dicarboxylate RS	4998000.0	0.000025	Kg	125	150	180	216	259
131	Dimethyl Sulfoxide RS	101666.7	0.003	Kg	305	366	439	527	632
132	Dithizone RS	7260.0	0.01	Kg	73	87	105	125	151
133	D-L alpha Tocopherol Acetate RS	224000.0	0.0001	Kg	22	27	32	39	46
134	Dry Aluminium Hydroxide Gel RS	1150000.0	0.0002	Kg	230	276	331	397	477
135	Esomeprazole magnesium RS	2625000.0	0.0002		525	630	756	907	1,089
136	Econazole Nitrate RS	920000.0	0.00025	Kg	230	276	331	397	477
137	Eicosapentaenoic acid ethyl ester (EPA) RS	159000.0	0.001	Kg	159	191	229	275	330
138	Enalapril Maleate RS	1150000.0	0.0002	Kg	230	276	331	397	477
139	Enalaprilate RS	616666.7	0.0003	Kg	185	222	266	320	384
140	Ergocalciferol RS	8333333.3	0.00003	Kg	250	300	360	432	518
141	Erythromycin B RS	2709000.0	0.0001	Kg	271	325	390	468	562
142	Erythromycin C Reference Standard	10836000.0	0.000025	Kg	271	325	390	468	562
143	Erythromycin Related Compound N(N-demethylerythromycinA) RS	41034000.0	0.00005	Kg	2,052	2,462	2,954	3,545	4,254
144	Erythromycin RS	920000.0	0.00025	Kg	230	276	331	397	477
145	Erythromycin Stearate RS	1150000.0	0.0002	Kg	230	276	331	397	477
146	Ethyl Paraben RS	1150000.0	0.0002	Kg	230	276	331	397	477
147	Ethylene Glycol RS	117400.0	0.0005	L	59	70	85	101	122
148	Ethylene oxide RS	91875.0	0.0012	L	110	132	159	191	229

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
149	Ethylene oxide Stock Sol RS	147875.0	0.0012	L	177	213	256	307	368
150	Fluocinolone Acetonide RS	1150000.0	0.0002	kg	230	276	331	397	477
151	Fluocinonide RS	1150000.0	0.0002	kg	230	276	331	397	477
152	Folic Acid Related Compound A RS	4700000.0	0.00005	kg	235	282	338	406	487
153	Folic Acid RS	460000.0	0.0005	kg	230	276	331	397	477
154	Formic Acid RS	191666.7	0.0012	L	230	276	331	397	477
155	Fructose RS	1560000.0	0.000125	kg	195	234	281	337	404
156	Furosemide RS	22050.0	0.005	kg	110	132	159	191	229
157	Garlic Oil RS	2000.0	0.02	Kg	40	48	58	69	83
158	Gentamicin Sulfate RS	60400.0	0.001	kg	60	72	87	104	125
159	Gliclazide CRS	8400000.0	0.00002	kg	168	202	242	290	348
160	Gliclazide Impurity B CRS	5418000.0	0.00005	Kg	271	325	390	468	562
161	Gliclazide Impurity F CRS	5418000.0	0.00005	Kg	271	325	390	468	562
162	Guanine RS	2350000.0	0.0001	kg	235	282	338	406	487
163	Hydrochlorothiazide RS	323000.0	0.0002	kg	65	78	93	112	134
164	Ibuprofen impurity B RS	36500000.0	0.00002	Kg	730	876	1,051	1,261	1,514
165	Ibuprofen RS	306666.7	0.00075	kg	230	276	331	397	477
166	Imidazole RS	3650000.0	0.0002	kg	730	876	1,051	1,261	1,514
167	Irbesartan Related compound (A) RS	29200000.0	0.000025	kg	730	876	1,051	1,261	1,514
168	Irbesartan RS	1150000.0	0.0002	kg	230	276	331	397	477
169	Iron (Fe) Standard Solution	7627.4	0.25	L	1,907	2,288	2,746	3,295	3,954
170	Ketoconazole RS	1150000.0	0.0002	kg	230	276	331	397	477
171	L- Arginine RS	525.0	0.2	kg	105	126	151	181	218
172	Lansoprazole RS	1533333.3	0.00015	kg	230	276	331	397	477

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
173	L-Cysteine RS	1155000.0	0.0001	kg	116	139	166	200	240
174	L-Cystine RS	420000.0	0.0005	kg	210	252	302	363	435
175	Levocetrizine dihydrochloride RS	1150000.0	0.0002	kg	230	276	331	397	477
176	Levofloxacin Hemihydrate RS	515000.0	0.0002	kg	103	124	148	178	214
177	Levofloxacin related compound-A	63333333.3	0.00003	kg	1,900	2,280	2,736	3,283	3,940
178	Levofloxacin related compound-B	63000000.0	0.00003	kg	1,890	2,268	2,722	3,266	3,919
179	Lorazepam RS	27750000.0	0.0002	kg	5,550	6,660	7,992	9,590	11,508
180	Lorazepam related compound-A	77875000.0	0.00004	kg	3,115	3,738	4,486	5,383	6,459
181	Lorazepam related compound-B	77875000.0	0.00004	kg	3,115	3,738	4,486	5,383	6,459
182	Lorazepam related compound-C	77875000.0	0.00004	kg	3,115	3,738	4,486	5,383	6,459
183	Lorazepam related compound-D	77875000.0	0.00004	kg	3,115	3,738	4,486	5,383	6,459
184	Lorazepam related compound-E	77875000.0	0.00004	kg	3,115	3,738	4,486	5,383	6,459
185	Lincomycin Hydrochloride RS	1150000.0	0.0002	kg	230	276	331	397	477
186	L-Lysine Hydrochloride RS	1325000.0	0.0002	kg	265	318	382	458	550
187	Loperamide Hydrochloride RS	1150000.0	0.0002	kg	230	276	331	397	477
188	Loperamide trans-N-oxide (Lopreamide related compound- F	99750000.0	0.00004	kg	3,990	4,788	5,746	6,895	8,274
189	Loratadine RS	1925000.0	0.0002	kg	385	462	554	665	798
190	Losartan Potassium RS	1533333.3	0.00015	kg	230	276	331	397	477
191	L-Tyrosine RS	3465000.0	0.00005	kg	173	208	249	299	359
192	Lysozyme Chloride RS	65100.0	0.001	kg	65	78	94	112	135
193	Mebendazole RS	1150000.0	0.0002	kg	230	276	331	397	477
194	Mebendazole related compund-D	153000000.0	0.00004	kg	6,120	7,344	8,813	10,575	12,690
195	Mefenamic Acid RS	1150000.0	0.0002	kg	230	276	331	397	477

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
196	Mefloquine HCL RS	2300000.0	0.0001	kg	230	276	331	397	477
197	Metformin Hydrochloride RS	1350000.0	0.0002	kg	270	324	389	467	560
198	Metformin related compound- A	75000000.0	0.00004	kg	3,000	3,600	4,320	5,184	6,221
199	Nitrazepam RS	1725000.0	0.0002	kg	345	414	497	596	715
200	Nordazepam RS	10500000.0	0.00004	kg	420	504	605	726	871
201	Norfloxacin RS	1150000.0	0.0002	kg	230	276	331	397	477
202	Norfloxacin related compound-A	100000000.0	0.00003	kg	3,000	3,600	4,320	5,184	6,221
203	Norfloxacin related compound-E	100000000.0	0.00003	kg	3,000	3,600	4,320	5,184	6,221
204	Norfloxacin related compound-H	100000000.0	0.00003	kg	3,000	3,600	4,320	5,184	6,221
205	Norfloxacin related compound-K	100000000.0	0.00003	kg	3,000	3,600	4,320	5,184	6,221
206	Omeprazole RS	1190000.0	0.0002	kg	238	286	343	411	494
207	Olanzapine RS	11660000.0	0.0002	kg	2,332	2,798	3,358	4,030	4,836
208	Olanzapine related compound-A	76025000.0	0.00004	kg	3,041	3,649	4,379	5,255	6,306
209	Olanzapine related compound-B	76025000.0	0.00004	kg	3,041	3,649	4,379	5,255	6,306
210	Ofloxacin RS	2500000.0	0.0002	kg	500	600	720	864	1,037
211	Ofloxacin related compound-A RS	63333333.3	0.00003	kg	1,900	2,280	2,736	3,283	3,940
212	O-toluene sulfonamide RS	1825000.0	0.0002	kg	365	438	526	631	757
213	Palmitate Acid RS	1500000.0	0.0005	kg	750	900	1,080	1,296	1,555
214	Palmitic acid RS	444000.0	0.0005	kg	222	266	320	384	460
215	Parbendazole (Internal STD) RS	1150000.0	0.0002	kg	230	276	331	397	477
216	Phenylephrine HCl RS	1150000.0	0.0002	kg	230	276	331	397	477
217	Potassium Standard Solution RS	19068.0	0.1	L	1,907	2,288	2,746	3,295	3,954
218	Povidone RS	2300000.0	0.0001	kg	230	276	331	397	477
219	Pyridoxine Hydrochloride RS	1150000.0	0.0002	kg	230	276	331	397	477

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
220	Quercetin RS	400000.0	0.0005	kg	200	240	288	346	415
221	Quetiapine Fumarate RS	2750000.0	0.00002	kg	55	66	79	95	114
222	Ranitidine HCL RS	1150000.0	0.0002	kg	230	276	331	397	477
223	Ranitidine Related Compound A RS	14600000.0	0.00005	kg	730	876	1,051	1,261	1,514
224	Ranitidine Related Compound B RS	14600000.0	0.00005	kg	730	876	1,051	1,261	1,514
225	Residual Solvent Class-1 RS	191666.7	0.0012	L	230	276	331	397	477
226	Residual Solvent Class-2-1,4Dioxane RS	191666.7	0.0012	L	230	276	331	397	477
227	Residual Solvent Class-2-Methylcyclohexane RS	191666.7	0.0012	L	230	276	331	397	477
228	Residual Solvent Class-2-Mixture A RS	191666.7	0.0012	L	230	276	331	397	477
229	Residual Solvent Class-2-Mixture B RS	191666.7	0.0012	L	230	276	331	397	477
230	Retinol Acetate (Vitamin A) CRS	336000.0	0.0005	Kg	168	202	242	290	348
231	Retinol palmitate RS	603800.0	0.0001	Kg	60	72	87	104	125
232	Retinyl Acetate RS	460000.0	0.0005	Kg	230	276	331	397	477
233	Retinyl Palmitate RS	4600000.0	0.00005	Kg	230	276	331	397	477
234	Riboflavin RS	460000.0	0.0005	Kg	230	276	331	397	477
235	Rosuvastatin Calcium RS	586666.7	0.0003	Kg	176	211	253	304	365
236	Roxithromycin RS	735040.0	0.000125	Kg	92	110	132	159	191
237	Saccharim Sodium RS	2300000.0	0.0001	Kg	230	276	331	397	477
238	Sildenafil Citrate RS	4850000.0	0.0001	Kg	485	582	698	838	1,006
239	Sildenafil Related compound A RS	80500000.0	0.00001	Kg	805	966	1,159	1,391	1,669
240	Sodium L-Lactate RS	138600.0	0.001	Kg	139	166	200	240	287
241	Sodium Starch Glycolate Type A RS	575000.0	0.0004	Kg	230	276	331	397	477
242	Sodium Starch Glycolate Type B RS	575000.0	0.0004	Kg	230	276	331	397	477

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
243	Sodium Sulfate Anhydrous RS	230000.0	0.001	Kg	230	276	331	397	477
244	Sodium Sulfite RS	47100.0	0.001	Kg	47	57	68	81	98
245	Stearic Acid RS	210000.0	0.0005	Kg	105	126	151	181	218
246	Stearic Acid RS	444000.0	0.0005	Kg	222	266	320	384	460
247	Sucrose RS	2300000.0	0.0001	Kg	230	276	331	397	477
248	Sulfamethoxazole RS	1150000.0	0.0002	Kg	230	276	331	397	477
249	Sulfanilamide RS	46000.0	0.005	Kg	230	276	331	397	477
250	Sitagliptine phosphate RS	2305000.0	0.0002	Kg	461	553	664	797	956
251	Sitagliptine phosphate system suitability mixture	76050000.0	0.00004	Kg	3,042	3,650	4,380	5,257	6,308
252	Tadalafil RS	7795000.0	0.0002	Kg	1,559	1,871	2,245	2,694	3,233
253	Telmisartan Related Compound A RS	36500000.0	0.00002	Kg	730	876	1,051	1,261	1,514
254	Telmisartan Related Compound B RS	48666666.7	0.000015	Kg	730	876	1,051	1,261	1,514
255	Telmisartan RS	1150000.0	0.0002	Kg	230	276	331	397	477
256	Terbinafine Hydrochloride RS	1150000.0	0.0002	Kg	230	276	331	397	477
257	Testosterone Propionate RS	375000.0	0.0002	Kg	75	90	108	130	156
258	Tetracycline HCL RS	1150000.0	0.0002	Kg	230	276	331	397	477
259	Thiamine Hydrochloride RS	1150000.0	0.0002	Kg	230	276	331	397	477
260	Thiamine Nitrate CRS	11200000.0	0.000015	Kg	168	202	242	290	348
261	Triamcinolone Acetonide STD RS	460000.0	0.0005	Kg	230	276	331	397	477
262	Trypsin RS	1680000.0	0.0001	Kg	168	202	242	290	348
263	Trizolam RS	35375000.0	0.00004	Kg	1,415	1,698	2,038	2,445	2,934
264	L- Tyrosine RS	2230000.0	0.0002	Kg	446	535	642	771	925
265	Tramadol HCL RS	6155000.0	0.0002	Kg	1,231	1,477	1,773	2,127	2,553

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
266	Tramadol related compound- A	76175000.0	0.00004	Kg	3,047	3,656	4,388	5,265	6,318
267	Tramadol related compound- B	76175000.0	0.00004	Kg	3,047	3,656	4,388	5,265	6,318
268	Zolpidem tartarate RS	8170000.0	0.0002	Kg	1,634	1,961	2,353	2,824	3,388
269	Zolpidem tartarate related compound- A	30850000.0	0.00004	Kg	1,234	1,481	1,777	2,132	2,559
270	Various Reference standard for Laboratory testing	2500.0	1	Kg	2,500	3,000	3,600	4,320	5,184
271	Various Impurity standard for Laboratory testing	24333.3	1	Kg	24,333	29,200	35,040	42,048	50,458
					224,149	**268,978**	**322,774**	**387,329**	**464,794**

Pacific Medical Industries Limited

~~R&D Reference Standard~~ R and D HPLC/GC Columns

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
1	150mm × 4.6mm, 5μm,ODS	Pcs	302.4	3.00	907	1,089	1,306	1,568	1,881
2	250mm × 4.6mm, 5μm,ODS	Pcs	281.6	3.00	845	1,014	1,217	1,460	1,752
3	150mm × 4.6mm, 5μm,C18	Pcs	302.4	3.00	907	1,089	1,306	1,568	1,881
4	250mm × 4.6mm, 5μm,VP - C8	Pcs	281.6	3.00	845	1,014	1,217	1,460	1,752
5	100mm × 4.6mm, 3.5μm,C8	Pcs	235	3.00	705	846	1,015	1,218	1,462
6	250mm × 4.0mm, 5μm,Hypersil BDS C8	Pcs	338	3.00	1,014	1,217	1,460	1,752	2,103
7	300mm × 3.9mm, 10μm, C18	Pcs	549	3.00	1,647	1,976	2,372	2,846	3,415
8	300mm × 3.9mm, 10μm, u-BONDAPAK C18	Pcs	549	3.00	1,647	1,976	2,372	2,846	3,415
9	25cm × 4.6mmid × 5μm, peerless C18	Pcs	303.75	3.00	911	1,094	1,312	1,575	1,890
10	25cm × 4.6mm × 5μm, peerless C18	Pcs	258.67	3.00	776	931	1,117	1,341	1,609
11	25cm × 4.6mmid × 5μm, peerless silica	Pcs	281.6	3.00	845	1,014	1,217	1,460	1,752
12	25cm × 4.6mm× 5μm, peerless silica,HPLC Column Coo India	Pcs	225.59	3.00	677	812	975	1,169	1,403
13	15cm × 4.6mmid × 5μm, Acclaim Mixed Modee WCX-1(L85)	Pcs	823.3	3.00	2,470	2,964	3,557	4,268	5,122
14	15cm × 3.9mmid × 5μm, Peerless C18 L(1)	Pcs	264.8	3.00	794	953	1,144	1,373	1,647
15	3.9mm x 15 cm x 5μm Peerless basic C 18	Pcs	277.83	3.00	833	1,000	1,200	1,440	1,728
16	3.9mm x 15 cm x 5μm Peerless basic C 18	Pcs	241.83	3.00	725	871	1,045	1,254	1,504

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
17	25mm × 4.0mm, 5μm,Peerless C18	Pcs	281.6	3.00	845	1,014	1,217	1,460	1,752
18	25cm × 4.6mm × 5μm, peerless silica (with porous silica)	Pcs	281.6	3.00	845	1,014	1,217	1,460	1,752
19	100 × 4.6mm × 5μm, Hypersil BDS C18	Pcs	325	3.00	975	1,170	1,404	1,685	2,022
20	15cm × 4.6mm × 5μm, Peerless Basic C8 (L7)	Pcs	302.4	3.00	907	1,089	1,306	1,568	1,881
21	25cm × 4.6mm × 5μm, peerless C8 (L7)	Pcs	303.75	3.00	911	1,094	1,312	1,575	1,890
22	25cm × 4.6mm × 5μm, peerless C8 (L7)	Pcs	303.75	3.00	911	1,094	1,312	1,575	1,890
23	7,5cmx4.6mmx3μm, peerless C18 (L1)	Pcs	235	3.00	705	846	1,015	1,218	1,462
24	25cm × 4.6mm × 5μm, peerless CN (L10)	Pcs	303.75	3.00	911	1,094	1,312	1,575	1,890
25	25cm × 4.6mm × 5μm, peerless C18	Pcs	258.72	3.00	776	931	1,118	1,341	1,609
26	25cm × 4.6mm × 5μm, peerless C18	Pcs	281.6	3.00	845	1,014	1,217	1,460	1,752
27	10cmx4.6cmx5μm, peerless Basic C18	Pcs	285.6	3.00	857	1,028	1,234	1,481	1,777
28	10cmx4.6cmx5μm, peerless Basic C18	Pcs	262.4	3.00	787	945	1,134	1,360	1,632
29	10cmx4.6cmx5μm, peerless Basic C18	Pcs	262.4	3.00	787	945	1,134	1,360	1,632
30	10cmx4.6cmx5μm, peerless Basic C18	Pcs	262.4	3.00	787	945	1,134	1,360	1,632
31	20cm×4.6cmx5μm,peerless Basic C18	Pcs	303.75	3.00	911	1,094	1,312	1,575	1,890
32	20cm×4.6cmx5μm,peerless Basic C18	Pcs	258.67	3.00	776	931	1,117	1,341	1,609
33	25cm × 4.6mm × 5μm, peerless C18	Pcs	303.75	3.00	911	1,094	1,312	1,575	1,890
34	25cm × 4.6mm × 5μm, peerless C18	Pcs	303.75	3.00	911	1,094	1,312	1,575	1,890
35	25cm × 4.6mm × 5μm, peerless C18	Pcs	303.75	3.00	911	1,094	1,312	1,575	1,890
36	5cm × 4.6mm × 3μm, peerless C18	Pcs	324	3.00	972	1,166	1,400	1,680	2,016
37	25cm × 4.0mm × 5μm, peerless C8	Pcs	281.6	3.00	845	1,014	1,217	1,460	1,752
38	25cm × 4.6mm × 5μm, peerless C18	Pcs	303.75	3.00	911	1,094	1,312	1,575	1,890

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
39	30cm × 3.9mm × 10µm, peerless C18 (L1)	Pcs	309.75	3.00	929	1,115	1,338	1,606	1,927
40	25cm × 4.6mm × 5µm, peerless C18	Pcs	281.6	3.00	845	1,014	1,217	1,460	1,752
41	10cmx4.0cmx5µm, peerless Basic C18 (L1)	Pcs	285.6	3.00	857	1,028	1,234	1,481	1,777
42	15cmx4.6cmx5µm, peerless Basic C8	Pcs	302.4	3.00	907	1,089	1,306	1,568	1,881
43	Halmiton R 5µm PRP 1 (150 x 4.1 mm)	Pcs	965.7	3.00	2,897	3,477	4,172	5,006	6,007
44	Halmiton R 5µm PRP 1 (150 x 4.1 mm)	Pcs	965.7	3.00	2,897	3,477	4,172	5,006	6,007
45	4.1 x 250 mm,5µm PRP 1 Halmiton	Pcs	527.69	3.00	1,583	1,900	2,280	2,736	3,283
46	4.6mm x 150 mm ,3µm peerless NH2(amino)	Pcs	270.48	3.00	811	974	1,168	1,402	1,683
47	4.6mm x 25cm,4µm peerless phenyl	Pcs	225.59	3.00	677	812	975	1,169	1,403
48	200 mmx 4.6 mm x 3µm peerless basic C 18	Pcs	286.75	3.00	860	1,032	1,239	1,487	1,784
49	250mm x 4.6 mm x 8µm peerless 1000 RPS	Pcs	519.85	3.00	1,560	1,871	2,246	2,695	3,234
50	10cmx4.6cmx5µm, peerless C18	Pcs	262.4	3.00	787	945	1,134	1,360	1,632
51	250mm x 4.6mm x 5µm peerless phenyl	Pcs	258.72	3.00	776	931	1,118	1,341	1,609
52	250mm x 4.6mm x 10µm peerless C18	Pcs	258.72	3.00	776	931	1,118	1,341	1,609
53	250mm x 4.6mm x 10µm peerless C18	Pcs	225.59	3.00	677	812	975	1,169	1,403
54	300mm x 4.6mm x 10µm Peerless basic C18	Pcs	285.92	3.00	858	1,029	1,235	1,482	1,779
55	150mm x 4.6 mm x 5µm Peerless C 18	Pcs	277.83	3.00	833	1,000	1,200	1,440	1,728
56	150mm x 4.6 mm x 5µm Peerless C 18	Pcs	241.83	3.00	725	871	1,045	1,254	1,504
57	300 mm x 4.0mm x 10µm Peerless C 18	Pcs	285.92	3.00	858	1,029	1,235	1,482	1,779

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
58	125mm x 4.6 mm x 3 µm Peerless basic C 18	Pcs	270.48	3.00	811	974	1,168	1,402	1,683
59	Sunsheller RP guard filter holder	Pcs	361.85	3.00	1,086	1,303	1,563	1,876	2,251
60	SiliaChrom Plus HPLC Column SCX, 4.6x 150mm,5µm	Pcs	504	3.00	1,512	1,814	2,177	2,613	3,135
61	Zodiac C18 125mm x 4.0 mm x 5 µm	Pcs	150	3.00	450	540	648	778	933
62	Zodiac C8 250mm x 4.0 mm, 4µm	Pcs	150	3.00	450	540	648	778	933
63	Zodiac Phenyl -13: 250mm x 4.6, 4µm	Pcs	150	3.00	450	540	648	778	933
64	Zodiac 100C18 : 150mm x 4.6mm , 10µm	Pcs	200	3.00	600	720	864	1,037	1,244
65	Zodiac 100C18 : 150mm x 4.6mm , 10µm	Pcs	200	3.00	600	720	864	1,037	1,244
66	Zodiac C18 : 100mm x 8.0mm x 5µm	Pcs	454	3.00	1,362	1,634	1,961	2,354	2,824
67	Zodiac C18 : 100mm x 8.0mm x 5µm	Pcs	454	3.00	1,362	1,634	1,961	2,354	2,824
68	Zodiac 100 C18 : 250 x 4.6mm, 10µm	Pcs	200	3.00	600	720	864	1,037	1,244
69	Zodiac C18 -13: 250mm x 4.6mm,5µm	Pcs	200	3.00	600	720	864	1,037	1,244
70	Zodiac C18 -13: 250mm x 4.6mm,5µm	Pcs	200	3.00	600	720	864	1,037	1,244
71	Zodiac C18 -13: 250mm x 4.6mm,5µm	Pcs	200	3.00	600	720	864	1,037	1,244
72	SiliaChrom Plus HPLC Column C18, 4.6x 250mm,5µm,100A,	Pcs	388	3.00	1,164	1,397	1,676	2,011	2,414
73	300mm × 4.0mm, 5µm,Peerless C18	Pcs	241.02	3.00	723	868	1,041	1,249	1,499
74	300mm × 4.0mm, 5µm,Peerless C18	Pcs	241.02	3.00	723	868	1,041	1,249	1,499
75	305mm × 7.75mm, 9µm,HC-75H	Pcs	984.37	3.00	2,953	3,544	4,252	5,103	6,124
76	HPLC COL HC-75 H+F 9µm 305×7.75mm	Pcs	1008.22	3.00	3,025	3,630	4,356	5,227	6,272
77	HPLC COL HC-75 H+F 9µm 305×7.75mm	Pcs	1008.22	3.00	3,025	3,630	4,356	5,227	6,272
78	4.1×250mm,5µm	Pcs	527.69	3.00	1,583	1,900	2,280	2,736	3,283

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
79	25cm×4.6mm×5μm Peerless Basic C8	Pcs	297.68	3.00	893	1,072	1,286	1,543	1,852
80	12.5cm×4.6mm×3μm Peerless Basic C18	Pcs	273.35	3.00	820	984	1,181	1,417	1,700
81	12cm×4.6mm×3μm Peerless Basic C18	Pcs	273.35	3.00	820	984	1,181	1,417	1,700
82	80mm×4.0mm×5μm Peerless Basic C18	Pcs	229.92	3.00	690	828	993	1,192	1,430
83	HPLC COL PRP-X 100 250mm×4.6mm peek	Pcs	749.55	3.00	2,249	2,698	3,238	3,886	4,663
84	100mm × 8mm, 5μm,Water Resolve C18	Pcs	486.32	3.00	1,459	1,751	2,101	2,521	3,025
85	250×4.6mm×5μm Reprosil Chiral-AM	Pcs	1237.5	3.00	3,713	4,455	5,346	6,415	7,698
86	Partisphere SC×125×4.6mm×5μm	Pcs	464.06	3.00	1,392	1,671	2,005	2,406	2,887
87	Lichrocart Supersphere 60RP-8 250×4.0mm ×4μm	Pcs	837.75	3.00	2,513	3,016	3,619	4,343	5,211
88	15cm×4mm×5μm Discovery HS C18	Pcs	730.47	3.00	2,191	2,630	3,156	3,787	4,544
89	15cm×4mm×5μm Discovery HS C18	Pcs	730.47	3.00	2,191	2,630	3,156	3,787	4,544
90	100×4.6mm Spherisorb ODS 1	Pcs	412.4	3.00	1,237	1,485	1,782	2,138	2,565
91	100×4.6mm Spherisorb ODS 1	Pcs	412.4	3.00	1,237	1,485	1,782	2,138	2,565
92	30×4.0mm×10μm Kromasil 300	Pcs	451.14	3.00	1,353	1,624	1,949	2,339	2,806
93	150 x 4.0 mm x 10μm	Pcs	473	3.00	1,419	1,703	2,043	2,452	2,942
94	120x 4.6mm x 5μm C 18 Pursuit x RS	Pcs	648.72	3.00	1,946	2,335	2,802	3,363	4,036
95	4.0 x 80mm x5μm C 18	Pcs	259.54	3.00	779	934	1,121	1,345	1,615
96	30 x 4.6 mm x 3μm Peerless basic C8,	Pcs	258.67	3.00	776	931	1,117	1,341	1,609
97	Waters Nova-Pak C8 Cartridge,CoO ireland,5×100mm,4μm	Pcs	543.33	3.00	1,630	1,956	2,347	2,817	3,380
98	Waters Nova-Pak C8 Cartridge,CoO ireland,5×100mm,4μm	Pcs	543.33	3.00	1,630	1,956	2,347	2,817	3,380

S.No.	Description	Unit	Est.Price/Unit(USD)	Qty	Year 1 (USD)	Year 2 (USD)	Year 3 (USD)	Year 4 (USD)	Year 5 (USD)
99	Various types and size of columns for HPLC analysis	Pcs	500	10.00	5,000	6,000	7,200	8,640	10,368
100	Zebron TMZB-624 GC cap.column 30m × 0.32mm ×1.8μm	Pcs	590	2.00	1,180	1,416	1,699	2,039	2,447
101	GsBP-624, 75 m x 0.53 mm x 3.0μm	Pcs	235.2	2.00	470	564	677	813	975
102	GsBP 624, 30m x 0.53mm x 3μm	Pcs	472.38	2.00	945	1,134	1,360	1,633	1,959
103	Various types and size of columns for GC analysis	Pcs	500	5.00	2,500	3,000	3,600	4,320	5,184
					121,975	**146,370**	**175,644**	**210,772**	**252,927**

၄။ FDA ဆေးဝါးထုတ်လုပ်ခွင့်လိုင်စင် နှင့် DRC ရရှိမှု အခြေအနေ

Pacific Medical Industries Ltd.

Head Office : No. 408/410,#07th floor, Samsung Plaza, Mahabandoola street, Kyauktada Tsp. Yangon, Myanmar. Tel: (95-1)391644~50,249592~3,Fax (95-1)249718

Factory : No. 209,210,211, Corner of Khun It Thar Minthar street and Kannar street, City of Industry, Dagon Seikkan Tsp.,Yangon, Myanmar. Tel: (95-1) 592223,592124.

သို့

အတွင်းရေးမှူး
မြန်မာနိုင်ငံ ရင်းနှီးမြှုပ်နှံမှုကော်မရှင်

ရက်စွဲ၊ ၊၂၀၁၉ ခုနှစ်၊ မတ်လ(၁၉)ရက်

အကြောင်းအရာ။ ။ ဆေးဝါးထုတ်လုပ်ခွင့် လိုင်စင်ရရှိမှု အခြေအနေတင်ပြခြင်း။

Pacific Medical Industries Ltd ၏ MIC သို့ မူလ တင်ပြထားသည့် Proposal တွင် Tablet, Hard Capsule, Soft Capsule, Liquid Syrup, Dry Syrup & Powder, Cream & Ointments စသဖြင့် အဆင့်ဆင့် ထုတ်လုပ်သွားရန် တင်ပြထားခဲ့ပြီး ဖြစ်ပါသည်။ လက်ရှိတွင် ပထမအဆင့် ထုတ်လုပ်မည့် အစီအစဉ်အရ မြန်မာနိုင်ငံ စားသောက်ကုန်နှင့် ဆေးဝါး အရေးအသွေး စစ်ဆေးရေးဌာန FDA သို့ တင်ပြထားပြီး FDA မှ ခွင့်ပြု ထုတ်ပေးသော ဆေးဝါးမှတ်ပုံတင် လက်မှတ် DRC အရ Tablet (၁၈)မျိုးနှင့် Capsule (၀) မျိုးတို့မှာ DRC No. ရရှိခဲ့ပြီးကျန် Tablet/Capsule (၃၉) မျိုးမှာလည်း DRC နံပါတ် ရရန် လျှောက် ထားဆဲဖြစ်ပါသည်။ အသေးစိတ် စာရင်းအား ပူးတွဲပါအတိုင်းတင်ပြအပ်ပါသည်။

အဆိုပါ ဆေးဝါးများအား ဦးစွာပထမအနေနှင့် ပြည်တွင်းတွင်သာ ၁၀၀ ရာခိုင်နှုန်းဖြန့်ချိမည်ဖြစ်ပြီးနောင်တစ်ချိန် ဈေးကွက်ရရှိမှုပေါ်မူတည်၍ ပြည်ပနိုင်ငံများသို့လည်း တင်ပို့ရောင်းချမည့် အစီအစဉ်များ ရှိပါကြောင်း တင်ပြအပ်ပါသည်။

လေးစားစွာဖြင့်

ဦးဇော်မိုးနိုင်
Managing Director
Pacific Medical Industries Ltd.,

GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG MANUFACTURER LICENCE

In accordance with Section (5) Sub-section (h) of the National Drug Law, the Drug Manufacturer Licence has been granted to Pacific Medical Industries Ltd

No.408,410,#07th Floor,Samsung Plaza,Mahabandoola Street,

Kyauktada Township,Yangon.

To manufacture the drugs as specified in the attached schedule under supervision of expert staff,

1. U Zaw Moe Khine M B A - BS (Owner)
2. Dr. Tin Sandar Zaw M.B.,B.S, M.Pharm
3. Dr. Htet Htet Lin Ph.D(Env Biotech)
4. Daw April Lwin B. Pharm

at the premises of No.209,210,211,Corner of Khun It Thar Minthar Street and Kannar Street, City of Industry, Dagon Seikkan Township, Yangon.

The Licence shall be valid until November,2020 unless earlier suspended or revoked.

Licence No 2011 PL 0002

Date of issue 20th November,2017

24/11/17

(Secretary)

Dr. Than Htut

Director General

Department of Food and Drug Administration

NO.	Product Name (brand name)	Dosage Form	Sales category (POM, OTC,etc)	Myanmar Drug Registration No.
1	MEDIGESIC	Tablet	OTC	DRC.No. 2307L541
2	ALMOBEST	Tablet	POM	DRC.No. 2307L552
3	BACTMYCIN	Capsule	POM	DRC.No. 2309L543
4	DIGLID	Tablet	POM	DRC.No. 2309L546
5	ATOSTAT 20	Tablet	POM	DRC.No. 2309L558
6	ATOSTAT 10	Tablet	POM	DRC.No. 2309L557
7	MUCOVAN	Tablet	OTC	DRC.No. 2309L545
8	MEZONE	Tablet	POM	DRC.No. 2309L556
9	ZYLONOL	Tablet	POM	DRC.No. 2307L539
10	VASOTAN - L25	Tablet	POM	DRC.No. 2307L537
11	VASOTAN - L50	Tablet	POM	DRC.No. 2307L538
12	SEPRIM	Tablet	POM	DRC.No. 2309L560
13	MEDFORMIN	Tablet	POM	DRC.No. 2307L536
14	IMLOMIDE	Tablet	POM	DRC.No. 2309L544
15	CIPROXA 500	Tablet	POM	DRC.No. 2309L550
16	CIPROXA 250	Tablet	POM	DRC.No. 2309L551
17	LEFLOXA 500	Tablet	POM	DRC.No. 2309L548
18	ADVIL-400	Tablet	POM	DRC.No. 2309L549
19	CARDISAFE	Tablet	POM	DRC.No. 2309L559

DRC Submited List

Sr.No.	Product Name	Generic Name	DRC No.	DRC Approval Communicated to stake holders
(39) Items Submited to FDA				
20	Prednin	Prednisolone 5 mg Tablet		
21	Volfenac	Diclofenac Sodium 50 mg Tablet		
22	ADVIL 200	Ibuprofen 200 mg Tablet		
23	Mefenal	Mefemic acid 250 mg Tablet		
24	Ofloxa	Ofloxacillin 200 mg Tablet		
25	Lefloxa 250	Levofloxacin 250 mg Caplet		
26	ANCLOCIN	Aeeclofenae 100 mg Tablet		
27	ERYTHROBEST 250	Erythromycin Stcarate 250 mg tablet		
28	NORFLOXA 400	Norfloxaein 400 mg Caplet		
29	KOZEN	Scrratiopcptidasc 10 mg tablet		
30	VASOTAN-1	Irbestartan Tablet 150 mg Tablet		
31	MEBENZA	Mebendazole 500 mg Caplet		
32	ZOVIVIR	Acyclovir 200 mg tablet		
33	VASOTEC 5	Fnalapril maleate 5 mg		
34	BENTRAX	Albendazole 400 mg tablet		
35	CARDILOL 3.125	Carvedilol 3.125 mg Tablet		
36	CARDILOL 6.25	Carvedilol 6.25 mg Tablet		
37	AIR-MAG	Aluminum Hydroxide 200 mg & Magnesium Hydroxide 200 mg Chewable Tablets		
38	STRESS FREE	Vitamin B complex and Vitamin C Caplets		
39	ZYTRIZ	Cetrizine dihydrochloride 10 mg tablet		

DRC Submited List

Sr.No.	Product Name	Generic Name	DRC No.	DRC Approval Communicated to stake holders
40	CRESVASTATIN 20	Rosuvastatin Calcium 20 mg Tablet		
41	CRESVASTATIN 10	Rosuvastatin Calcium 10 mg Tablet		
42	CARDILOL 12.5	Carvedilol 12.5 Tablet		
43	LEVOPACTRINE 5	Levocetrizine 5mg Tablet		
44	LEVOPACTRINE 10	Levocetrizine 10mg Tablet		
45	ESOFIC 20	Esomeprazole 20 mg Tablet		
46	PACIGREL	Clopidrogel 75 mg Tablet		
47	DONPERIPAC 10	Domperidone 10mg Tablet		
48	MONTEFIC 5	Montelukast 5mg Tablet		
49	MONTEFIC 10	Montelukast 10mg Tablet		
50	AZITHROFIC 250	Azithromycin 250mg Tablet		
51	AZITHROFIC 500	Azithromycin 500mg Tablet		
52	ANCLOCIN 200	Aceclofenac SR Tablets 200mg		
53	PANTOFIC 40	Pantoprazole Enteric coated tablets 40mg		
54	CELECOFIC 100	Celecoxib 100 mg Capsule		
55	ALMOBEST 10	Amlodipine Tablets USP 10mg		
56	Sitafic 50	Sitagliptin 50 mg Tablet		
57	Sitafic 100	Sitagliptin 100 mg Tablet		
58	Pacium 500	Calcium carbonate Tablet 500mg		

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub—section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **MEDIGESIC**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Tablet

Presentation: Blister pack of 10 x 10 tablets in a carton box

Therapeutic Category: Analgesic, Antipyretic

Strength & Composition: Each tablet contains Paracetamol 500mg.

Sales Category: Over The Counter Medicine

This certificate shall be valid until July, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (3/2018)

Registration No: 2307L541

Date of issue: 13th July, 2018

Signature: 21.9.18

Name: Professor Dr. Khin Zaw

Designation: Secretary

Box size:
108 x 60 x 43 (mm)
Blister size:
42 x 102 (mm)
Process Color
Pantone 638 C
Pantone Dark Blue C

MEDiGESiC

Paracetamol 500 mg

MEDiGESiC
Paracetamol 500 mg

Compositions: Each Tablet contains Paracetamol 500mg.

Dosage Adults: 0.5 to 1g every 4 to 6 hours up to a Maximum of 4g daily.
For long term therapy, daily doses not to exceed 2.6g
unless the patients is monitored.

Children: Under 3 months: 10mg/kg body wt (5 mg/kg body wt if jaundiced)
3 months to 1 year 60 to 120mg
1 to 5 years 120 to 250mg
6 to 12 years 250 to 500mg.
These dosage may be given 3 to 4 times daily.

Paracetamol 500 mg
MEDiGESiC

Storage: Store below 30 °C in a dry place. Protect from light.

READ INSERT PAPER CAREFULLY BEFORE USING.
KEEP OUT OF REACH OF CHILDREN.


Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp, Yangon, Myanmar.

website: www.aa.com.mm

Reg. No.:

501112

Ver.1701


MEDiGESiC
Paracetamol 500 mg
Myanmar Reg. No:

Ver.1601

MEDiGESiC

Paracetamol USP 500 mg

PARACETAMOL TABLETS USP

COMPOSITION: Each uncoated tablet contains Paracetamol USP 500mg.

CHEMISTRY: Acetaminophen; N-acetyl-p-amino-phenol

PHARMACOLOGICAL CATEGORY: Analgesic and Antipyretic agent.

PHARMACOLOGY: The analgesic and antipyretic actions of paracetamol are similar to those of the salicylates. Analgesia is mediated peripherally and also centrally by inhibition of prostaglandin synthesis, whereas antipyresis is produced by a central action on the hypothalamic regulatory center.
Pharmacokinetics: Paracetamol is readily absorbed from the GIT with peak plasma concentration occurring about 10-60 min after oral administration.
Paracetamol is distributed into most body tissues. Plasma protein binding is negligible. Paracetamol is metabolized predominantly in the liver and excreted in the urine mainly as the glucuronide and sulpate conjugate. The elimination half life varies from about 1-3 hours.

INDICATIONS AND USES: Paracetamol is indicated for the relief of painful disorders such as headache, dysmenorrhea, conditions involving musculoskeletal pain, myalgias, and neuralgias. It is also indicated as an fever, such as the common cold and viral infections. Paracetamol is an effective analgesic after dental work and tooth extractions, and in teething.

CONTRAINDICATOINS: Paracetamol is contraindicated in patients hypersensitive to this drug.

SIDE EFFECTS/ADVERSE REACTIONS: Side effects of paracetamol are rare and usually mild, though haematological reactions including Thrombocytopenia, Leucopenia, Pancytopenia, Neutropenia and Agranulocytosis have been reported. Skin rashes and other hypersensitivity reactions occur occasionally.

PRECAUTIONS AND WARNINGS: Chronic use should be avoided. It should not be taken for more than 10 consecutive days, unless directed. Exercise caution in patients with impaired kidney and liver function, in patients taking other drugs that affect the liver.

DRUG INTERACTIONS: Paracetamol potentiates the effect of oral anticoagulants. Anticholinergics, and narcotics may decrease the rate of absorption of paracetamol. Absorption is increased by metoclopramide. Excretion may be affected and plasma concentrations altered when administered with Probenecid.

USE IN PREGNANCY AND LACTATION: The drug may cause birth defects and interfere with the development of the fetus, therefore pregnant women should consult doctor before taking it. Since paracetamol is excreted in breast milk caution should be exercised in nursing mothers.

DOSAGE AND ADMINISTRATION: Adults: 0.5 to 1 g every 4 to 6 hours up to a maximum of 4g daily. For long term therapy, daily dose not to exceed 2.6 g, unless the patient is monitored.
Infants: Under 3 months: 10mg/kg body wt (5mg/kg body wt if jaundiced)
3 months to 1 year: 60 to 120mg
1 to 5 years: 120 to 250mg
6 to 12 years: 250 to 500mg. These dosage may be given 3 to 4 times daily.

OVERDOSAGE, SYMPTOMS AND ANTIDOTE: The consequence of over dosage may be serious. Ingestion of as little as 10 to 50g of paracetamol may cause severe hepatocellular necrosis and less often renal tubular necrosis.
Symptoms include nausea, vomiting, lethargy, sweating, abdominal pain. Hepatic failure, encephalopathy, coma and death may result.
Treatments: Patient must be hospitalized, Gastric lavage should be carried out. Activated charcoal may be given. Magnesium or Sodium sulphate may be instilled into stomach after lavage. Early administration of compounds supplying sulfhydryl groups may prevent or minimize hepatic damage. Oral and IV administration of Acetylcysteine has been used.

STORAGE: Store below 25°C, in a dry place.

Reg No.:

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

501113

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **ALMOBEST**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Tablet

Presentation: Blister pack of 10 x 10 tablets in a carton box.

Therapeutic Category: Antihypertensive

Strength & Composition: Each tablet contains Amlodipine besilate eq. to Amlodipine 5mg.

Sales Category: Prescription Only Medicine

This certificate shall be valid until September 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)


Registration No: 2309[illegible]552

Date of issue: 2[illegible]th September, 2018

Signature:

Name: Professor Dr. Khin Zaw

Designation: Secretary


Almobest
Tab.
Amlodipine USP 5mg
PACIFIC
10 X 10 Tablets
Almobest
Amlodipine USP 5mg
COMPOSITION:
Amlodipine besilate equivalent to amlodipine 5mg per each tablet.
STORAGE:
Store in a dry place. Protect from light, not exceeding 30°C.
DOSAGE:
As directed by physician.
READ INSERT PAPER CAREFULLY BEFORE USE HYPERTENSION.
KEEP OUT OF REACH OF CHILDREN.


Almobest
Tab.
Amlodipine USP 5mg
10 X 10 Tablets
Batch No. : 081701
Mfg Date : 08/2017
Exp. Date : 08/2020
Manufactured by:
Pacific Medical Industries Ltd.
website: www.aa.com.mm
Almobest
Amlodipine USP 5mg




Almobest
Amlodipine 5mg

Ver.1701

Almobest Tab.

Amlodipine USP 5mg

Composition: Each uncoated tablet contains:
Amlodipine Besilate Eq. to Amlodipine...............5mg
DESCRIPTION: Amlodipine is a long-action calcium channel blocker (dihydropyridine class) used as an anti-hypertensive and in the treatment of angina.
PHARMACOLOGY: ALMOBEST is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.
The mechanism of the antihypertensive action of ALMOBEST is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which ALMOBEST relieves angina has not been fully determined but ALMOBEST reduces total ischaemic burden by the following two actions.
1) ALMOBEST dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.
2) The mechanism of action of ALMOBEST also probably involves dilatation of the main coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal's or variant angina).
In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of administration.
ALMOBEST has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.
Use in Patients with Heart Failure: Haemodynamic studies and exercise based controlled clinical trails in NYHA Class II-IV heart failure patients have shown that ALMOBEST did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.
A placebo controlled study (PRAISE) designed to evaluate patients in NYHA III and IV heart failure without clinical symptoms or objective findings suggestive or underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics. ALMOBEST had no effect on total cardiovascular mortality. In this same population ALMOBEST was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.
A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trail (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10mg/d (calcium channel blocker) or lisinopril 10-40mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25mg/d in mild to moderate hypertension. A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stoke › 6 months prior to enrollment, or documentation of other atherosclerotic CVD (over all 51.5%), type 2 diabetes (36.1%), HDL-C <35mg/Dl (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).
The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95%CI (0.90-1.07) p=0.65. Among Secondary Endpoints, the incidence of health failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2%% vs RR 1.38, 95% CI [1.25-1.52] p‹0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89-1.02] p=0.20.
In a study involving 268 children age 6-17 years with predominantly secondary hypertension, comparison of a 2.5mg dose, and 5.0mg dose of amlodipine with placebo, showed that both reduced Systolic Blood Pressure significantly more than placebo. The difference between the two doses was not statistically significant.
The long-term effects of amlodipine on growth, puberty and general development have not been studied. The long-term efficacy of amlodipine on therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood has also not been established.
Pharmacokinetic Properties
Absorption, distribution, plasma protein binding: After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post done. Absolute bioavailability has been estimated to be between 64 and 80 %. The volume of distribution is approximately21 l/kg. In vitro studies have shown that approximately 97.5 % of circulating amlodipine is bound to plasma proteins.
Biotransformation/elimination: The terminal plasma elimination half life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10 % of the parent compound and 60 % of metabolites excreted in the urine.
Used in the elderly: The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.
Therapeutic Indications
Hypertension.
Prophylaxis of chronic stable angina pectoris.
Prinzmetal's (variant) angina when diagnosed by a cardiologist.
In hypertensive patients, ALMOBEST has been used in combination with a thiazide diuretic, alpha blocker, beta-adrenoceptor blocking agent, or an angiotensin converting enzyme inhibitor. For angina, ALMOBEST may be used as monotherapy or, in combination with other antianginal drugs is patient with angina that is refractory to nitrates and/or adequate doses of beta blockers.
ALMOBEST is well tolerated in patients with heart failure and a history of hypertension or ischaemic heart disease.
Posology and method of administration
In adult: For both hypertension and angina the usual initial dose is 5gm ALMOBEST once daily which may be increased to a maximum dose of 10mg depending on the individuel patient's response.
No dose adjustment of ALMOBEST is required upon concomitant administration of thiazide diuretics, beta blockers, and angiotensin-converting enzyme inhibitors.
Use in children: Not recommended.
Use in elderly: ALMOBEST, used at similar doses in elderly or younger patients, is equally well tolerated. Therefore normal dosage regimens are recommended.
Patients with hepatic impairment: See section "Special warnings and special precautions for use".
Patients with renal impairment: Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment, therefore the normal dosage is recommended. Amlodipine is not dailysable.
Contraindications:
ALMOBEST is contra-indicated in patients with a known sensitivity to dihydropyridines, amlodipine or any of the excipients.
ALMOBEST should not be used in cardiogenic shock, clinically significant aortic stenosis, unstable angina (excluding Prinzmetal's angina).
Specia warnings and precautions for use
Use in patients with heart failure: In a long term, placebo controlled study (PRISE-2) of ALMOBEST, in patients with NYHA III and IV heart failure of nonischeemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo. See section "Pharamacodynamic Properties".
Use in patients with impaired hepatic function: As with all calcium antagonists, amlodipine's half-life is prolonged in patients with impaired liver function and dosage recommendations have not been established. The drug should therefore be administered with caution in these patients.
There are no data to support the use of ALMOBEST alone, during or within one month of a myocardial infarction.
The safety and efficacy of ALMOBEST in hypertensive crisis has not been established.
Drug interactions: ALMOBEST has been safely administered with thiazide diuretics, alpha blockers, beta blockers, angiotensin-converting enzyme

inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycaemic drugs.
In vitro data from studies with human plasma, indicate that amlodipine has no effect on protein binding of digoxin, phenytoin, warfarin or indomethacin.
Special studies: Effect of each agents on amlodipine
Cimetidine: Co-administration of ALMOBEST with cimetidine did not alter the pharmacokinetics of ALMOBEST.
Grapefruit Juice: Co-administration of 240ml of grapefruit juice with a single oral dose of ALMOBEST 10mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of ALMOBEST.
Sildenafil: When ALMOBEST and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.
Pregnancy & Lactation: Although some dihydropyridine compounds have been found to be teratogenic in animals, data in the rat and rabbit for amlodipine provide no evidence for a teratogenic effect. There is, however, no clinical experience with the preparation in pregnancy or lactation. Accordingly, ALMOBEST should not be administered during pregnancy or lactation, or to women of childbearing potential unless effective contraception is used.
Effects on ability to drive and use machines
Clinical experience with ALMOBEST indicates that therapy is unlikely to impair a patient's ability to drive or use machinery.
Undesirable effects: Adverse events that have been reported in amlodipine trials are categorized below, according to system organ class and frequency. Frequencies are defined as: very common (>10%); common (>1%, ≤10%); uncommon (>0.1%, ≤1%); rare (>0.01%, ≤0.1%) and very rare (≤0.01%)

Blood and the Lymphatic System Disorders	thrombocytopenia	Very rare
Immune System Disorders	allergic reaction	Very rare
Metabolism and Nutrition Disorders	hyperglycaemia	Very rare
Psychiatric Disorders	insomnia, mood changes	Uncommon
Nervous System Disorders	somnolence, dizziness, headache	Common
	tremor, taste perversion, syncope, hypoaesthesia, paraesthesia	Uncommon
	peripheral neuropathy	Very rare
Eye Disorders	visual disturbances	Uncommon
Ear and Labyrinth Disorders	tinnitus	Uncommon
Cardiac Disorders	palpitations	Common
	myocardial infarction, arrhythmia, ventricular tachycardia and atrial fibrillation	Very rare
Vascular Disorders	flushing	Common
	hypotension	Uncommon
	vasculitis	Very rare
Respiratory, Thoracic and Mediastinal Disorders	dyspnoea, rhinitis	Uncommon
	coughing	Very rare
Gastrointestinal Disorders	abdominal pain, nausea	Common
	vomiting, dyspepsia, altered bowel habits, dry mouth	Uncommon
	pancreatitis, gastritis, gingival hyperplasia	Very rare
Hepato-biliary Disorders	hepatitis, jaundice and hepatic enzyme elevations(mostly consistent with cholestasis)	Very rare
Skin and Subcutaneous Tissue Disorders	alopecia, purpura, skin discolouration, increased sweating, pruritus, rash	Uncommon
	angioedema, erythema multiforme, urticaria	Very rare
Musculoskeletal and Connective Tissue Disorders	arthralgia, myalgia, muscle cramps, back pain	Uncommon
	micturition disorder, nocturia, increased urinary frequency	Uncommon
Reproductive System and Breast Disorders	impotence, gynaecomastia	Uncommon
General Disorders and Administration Site Conditions	oedema, fatigue	Common
	chest pain, asthenia, pain, malaise	Uncommon
Investigation	weight increase, weight decrease	Uncommon

Overdose: Available data suggest that gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.
Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine 10mg has been shown to significantly decrease amlodipine absorption. Gastric lavage may be worthwhile in some cases. Clinically significant hypotension due to ALMOBEST overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade. Since ALMOBEST is highly protein-bound, dialysis is not likely to be of benefit.
Incompatibilities: None
Shelf life: 36 months
Special precautions for storage:
Keep medicines out of the reach of children.
Store below 30°C, protected from light.
Presentation: Alu Blister pack of 10x10 tablets

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

Website: www.aa.com.mm 501015

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.,

Address: 408/410, Mahabandoola St, #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **BACTMYCIN**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Capsule

Presentation: Blister pack of 2 x 10 capsules in a carton box.

Therapeutic Category: Anti-infective

Strength & Composition: Each capsule contains Lincomycin HCl eq. to Lincomycin 500mg.

Sales Category: Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No: 2309L5431

Date of issue: 24th September, 2018

Signature: [signature] 9.11.18

Name: Professor Dr. Khin Zaw

Designation: Secretary

BACTMYCIN

Lincomycin USP 500mg

BACTMYCIN
Lincomycin USP 500mg

PACIFIC

2 x 10 Capsules

Composition:
Each capsule contains Lincomycin HCl equivalent to Lincomycin 500 mg.
Storage:
Store in a dry place. Protect from light., not exceeding 30°C.
Dosage:
As directed by physician.

READ INSERT PAPER CAREFULLY BEFORE USING
KEEP OUT OF REACH OF CHILDREN.

BACTMYCIN
Lincomycin USP 500mg


BACTMYCIN
Lincomycin USP 500mg

PACIFIC

2 x 10 Capsules

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
website: www.aa.com.mm

Batch No. : 082017
Mfg. Date. : 08/2017
Exp. Date : 08/2020




BACTMYCIN
Lincomycin 500mg
Pacific Medical Industries Ltd.
Batch No. : 081701
Mfg. Date : 08/2017
Exp. Date : 08/2020

Ver.1701

BACTMYCIN
Lincomycin USP 500mg

(DESCRIPTION): BACTMYCIN capsule 500mg is cap-dark blue,body-light blue filled with white powder.

(COMPOSITIONS): Each capsule contains 500mg Lincomycin as the hydrochloride.

(INDICATION AND USAGE): Treatment of the following infections when caused by susceptible straints of gram-positive aerobes, eg streptococci, pneumococci and staphylococci, or by susceptible anaerobic bacteria. Upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. Effectiveness in the treatment of mastroditis would be anticipated. Lower respiratory infections including acute bronchitis and pneumonia. Skin and soft tissue infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections, conditions like erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible microorganisms, respond to lincomycin therapy. Bone and joint infections including osteomyelitis and septic arthritis. Septicemia and Endocarditis: Selected cases of septicemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. However, bactericidal drugs are often preferred for these infections.

(DOSAGE AND ADMINISTRATION)
Adult
Moderately severe infection: Take 500 mg every 8 hours.
Severe infection: Take 500 mg every six hours.
Children: 30mg/kg every 6-8 hours depending on the severity of the infection
Note: In cases of β-haemolytic streptococcal infection, treatment with BACTMYCIN should continue for at least 10 days to diminish the likelihood of subsequent rheumatic fever or glomerulonephritis.

(CONTRA-INDICATIONS, WARNING, etc.)
Contra-Indications: Patients previously found to be sensitive to lincomycin.
Precautions
The clinical spectrum varies from mild, watery diarrhea to severe persistent diarrhea, leukocytosis, fever, severe abdominal cramps which may be associated with the passage of blood and mucus which, if allowed to progress, may produce peritonitis, shock and toxic megacolon. The diagnosis of antibiotic-associated colitis is usually made by the endoscopic demonstration of pseudomembranous colitis and may be further confirmed by culture of the stool for Clostridum difficile on selective media and assay of the stool specimen for the toxin(s) of the C.difficile.
Onset of antibiotic-associated colitis has occurred during the administration or even 2 or 3 weeks following administration of the antibiotic. The disease is more likely to take a more severe course in older patients or in patients who are debilitated. In case of occurrence of mild antibiotic-associated colitis, discontinuance of lincomycin is recommended. Treatment with cholestyramine and colestipol resins is recommended as these products have been shown to bind to toxin in vitro. The recommended dosage for cholestyramine is 4g given 3-4 times daily and for colestipol, 5g given 3 times daily. When serve antibiotic-associated colitis occurs, this has to be treated with appropriate fluid electrolyte and

protein supplementation. Studies has also indicated that a toxin(s) produced by Clostridia (especially C.difficile) is/(are) the principal direct cause of antibiotic-associated colitis. Clostridium is usually sensitive in vitro to vancomycin. When 125~500mg vancomycin 4 times daily is administered for 7~10 days, there is a rapid observed disappearance of the toxin from feacal samples and a coincident clinical recovery from diarrhea. In some cases, colitis may re-occur after cessation of vancomycin treatment. Cholestyramine and colestipol resins bind to vancomycin in vitro. If both a resin and vancomycin are to be administrated concurrently, it may be advisable to separate the time of administration of each drug. As an alternative therapy, oral bacitracin 25,000 units 4 times daily for 7~19 days could be considered. Drugs which cause bowel stasis should be avoided. Caution should exercised in prescribing lincomycin doses in patients with a history of GI disease, particularly colitis. Although lincomycin appears to diffuse into cerebrospinal fluid, levels of lincomycin in the CSF may be inadequate for the treatment of meningitis. Thus, it should not be used in the treatment of meningitis.

If lincomycin antibiotic therapy is prolonged, liver and kidney function tests should be performed. The use of lincomycin may result in an overgrowth of nonsusceptible organisms, particularly yeasts. Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular-blocking agents. Therefore, it should be used with caution in patients receiving such agents. Lincomycin should be administered with caution in atopic individuals. Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum lincomycin levels monitored during high-dose therapy.

Use in pregnancy & lactation: Safety for use in pregnancy has not been established. Lincomycin has been reported to appear in breast milk in ranges from 0.5-2.4 µg/mL.

Adverse reactions: Gastrointestinal: Nausea, vomiting, abdominal distress and persistent diarrhea (see Precautions) and, with oral preparation, esophagitis.

Hematopoietic : Neutropenia, leukopenia, agranulocytosis and thrombocytopenic purpura have been reported. There have been reports of aplastic anemia and pancytopenia in which lincomycin could not be ruled out as the causative agent.

Hypersensitivity Reactions : Angioneurotic edema, serum-sickness and anaphylaxis have been reported, some of these patients sensitive to penicillin.

Rare instances of erythema multiforme, some resembling Stevens-Johnson sundrome, have been associated with lincomycin administration.

Skin and Mucous membranes : Pruritus, skin rashes urticaria vaginitis and rare instances of exfoliative and vesiculobullous dermatitis have been reported.

Liver : Jaundice and abnormal liver function tests (particularly elevation of serum transaminase) have been observed during lincomycin therapy.

(STORAGE CONDITION)

Store at room temperature with well closed and light-resistant container.

(HOW SUPPLIED) 100 Caps.

Manufactured by:

Pacific Medical Industries Ltd.

City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

501074

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.,

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **DIGLID**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Tablet

Presentation: Blister pack of 10 x 10 tablets in a carton box.

Therapeutic Category: Antidiabetic

Strength & Composition: Each film-coated tablet contains Gliclazide USP 80mg.

Sales Category: Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No: 2309L546


Date of issue: 24th September, 2018

Signature:

Name: Professor Dr. Khin Zaw

Designation: Secretary


DiGLiD
Gliclazide USP 80 mg
PACIFIC
10 x 10 Tablets
DiGLiD
Gliclazide USP 80 mg
COMPOSITION: Each tablet contains: Gliclazide USP 80mg
DOSAGE & ADMINISTRATION: Carefully read enclosed leaflet.
STORAGE: Keep in airtight, light-resistant container, not exceeding 30°C
- Keep out of reach of children.
- Read enclosed leaflet carefully before use. "Read the enclosed leaflet"



DiGLiD
Gliclazide USP 80 mg
10 x 10 Tablets
PACIFIC
DiGLiD
Gliclazide USP 80 mg
Batch No. : 081701
Mfg. Date : 08/2017
Exp Date : 08/2020
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
website: www.aa.com.mm

Ver.1701

DiGLiD

Gliclazide USP 80 mg

DIGLID tablet (Gliclazide)

(PROPERTIES)

Diglid is a hypoglycaemic sulfonylurea which stimulate insulin secretion by the pancreas. Its action on insulin secretion is mainly due to the restoration of the early phase, resulting in a physiological release of insulin. In addition to this pancreatic action, it has been demonstrated that Diglid administration improves the metabolic utilization of glucose at a peripheral level. This extrapancreatic action is not due to a modification in the number of insulin receptors, but may be due to the potentiation of the post-receptor pathways. Thus, Diglid restores glycaemic control throughout 24 hours. It normalizes fasting and postprandial blood sugar.

In man, apart from having hypoglycaemic effect, Diglid has been shown to reduce platelet hyperadhesiveness and hyperaggregation and to increase fibrinolytic activity. (These factors are thought to be implicated in the pathogenesis of the long-term complications of diabetes mellitus).

Controlled studies in patients with diabetic retinopathy suggest that these effects of Diglid are beneficial in showing down the progression of retinopathy.

COMPOSITION: Each tablet contains

Gliclazide USP 80mg

Excipients: Corn starch, Lactose, Povidone, Talc, Magnesium Stearate,

APPEARANCE: White round film-coated tablet.

INDICATION: Non-insulin-dependents mellitus.

DOSAGE AND ADMINISTRATION: The total daily dose may vary from 1-4 tabs taken orally. The dose should be adjusted according to the individual patient's response, commencing with 40-80 mg daily and increasing until adequate control is achieved. A single dose should not exceed 160 mg and when higher doses are required, a twice-daily split dosage is advised and should be divided according to the main meals of the day.

In the majority of cases, 2 tabs/day with meals; 1 tab with breakfast, 1 tab with dinner.

For the elderly diabetic, the starting dose should be ½ tab in the evening.

CAUTIONS:

- Over dosage: The symptom to be expected of overdose would be hypoglycaemia. The treatment is gastric lavage and correction of the hypoglycaemia by appropriate means with continued monitoring of the patient's blood sugar until the effect of the drug has ceased.
- Precautions: Care should be exercised in patients with hepatic and/ or renal impairment and a small starting dose should be used with careful patient monitoring. As with other sulfonylureas hypoglycaemia will occur if the patient's dietary intake is reduced or if they are receiving a larger dose of Diglid than required.

CONTRAINDICATIONS: Diglid should not be used alone in insulin-dependent diabetes; diabetes complicated by ketosis and acidosis; pregnancy; diabetics undergoing surgery, after severe trauma or during infections, patients known to have hypersensitivity to other sulfonylureas and related drugs.

SIDE EFFECTS: Diglid is generally well tolerated., Nausea, headache, rashes and gastrointestinal disturbances have been reported.

Immediately inform your physician of the side effects, if any.

DRUG INTERACTIONS: Potentiation of the hypoglycaemic action of Diglid may occur with the concomitant administration of sulfonamides, salicylates, phenylbutazone, B-adrenoreceptor blocking agents, MAOIs, ketoconazole and miconazole.

Diminution of hypoglycaemic action of Diglid may occur with the concomitant administration of thiazide diuretics, corticosteroids and oestrogens.

Adjustment of dosage of hypoglycaemic agents may be required in patients suffering from intercurrent infections, traumas, shock or after anaesthesia.

When major surgery is to be performed, insulin therapy should be substituted for oral hypoglycaemics.

SPECIFICATION: BP

SHELF LIFE: Expiry 3 years from manufacturing date

WARNING: Do not administer if the medicine has expired or the tablet colour has changed. The medicine is under prescription only. Keep out of reach of children.

PACKING UNITS: 10 tablets/blister; 10 blisters/box.

STORAGE: Keep in airtight, light-resistant container.

Reg.No.:

Read the leaflet carefully before use.


For further information, consult with your physician.

Manufactured by:


PACIFIC **Pacific Medical Industries Ltd.**

City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm 501044



Manufactured by:
Pacific Medical Industries Ltd.
DiGLiD
Gliclazide 80 mg
Batch No : 081701
Mfg Date : 08/2017
Exp Date : 08/2020



THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name	Pacific Medical Industries Ltd.
Address	408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar
Name of product	**ATOSTAT 20**
Manufacturer	Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar
Dosage form	Tablet
Presentation	Alu-Alu blister pack of 3 x 10 tablets in a carton box.
Therapeutic Category	Lipid regulating agent
Strength & Composition	Each film-coated tablet contains Atorvastatin Calcium eq. to Atorvastatin USP 20mg.
Sales Category	Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No 2009L558

Date of issue 24th September, 2018

Signature	28.11.18
Name	Professor Dr. Khin Zaw
Designation	Secretary

COMPOSITION: Each tablet contains
Atorvastatin Calcium equivalent to Atorvastatin 20 mg.

STORAGE:
Store in a dry place. Protect from light, not exceeding 30°C.

READ INSERT PAPER CAREFULLY BEFORE USE.
KEEP OUT OF REACH OF CHILDREN.

ATOSTAT 20

Atorvastatin USP 20 mg

PACIFIC

3x10 Tablets

ATOSTAT 20
Atorvastatin USP 20 mg

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

Batch No.	: 081701
Mfg. Date.	: 08/2017
Exp. Date.	: 08/2020

ATOSTAT 20
Atorvastatin USP 20 mg
ATOSTAT 20
Atorvastatin USP 20 mg
3x10 Tablets
PACIFIC

ATOSTAT 20

Atorvastatin 20 mg

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
www.aa.com.mm

ATOSTAT 20
Atorvastatin 20 mg
Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
www.aa.com.mm
ATOSTAT 20
Atorvastatin 20 mg
Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
www.aa.com.mm
ATOSTAT 20
Atorvastatin 20 mg
Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
www.aa.com.mm
ATOSTAT 20
Atorvastatin 20 mg
Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
ATOSTAT

Batch No. : 081701
Mfg. Date. : 08/2017
Exp. Date. : 08/2020

Ver.1701

ATOSTAT 20

Atorvastatin USP 20 mg

Composion: Each film-coated tablet contains: Atorvastatin Calcium Eq. To Atorvastain .... 20 mg

PHARMACOLOGY

Pharmacodynamic: Atorvastatin as well as some of its metabolites are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage rather than systemic drug concentration correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response.

Mechanism of Action: Atrovastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzymeA to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.

Pharmacokinetic Properties

Absorption: Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug sbsorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC. LDL-C reduction is similar whether atorvastatin is given with or without food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration.

Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin is likely to be secreted in human milk.

Metabolism: Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importanco of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.

Excretion: Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.

Therapeutic indications

Hypercholesterolaemia: Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol, LDL-cholesterol, apoliporprotein B, and triglycerides in adults and children aged 10 years and older with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other nonpharmacological measures is inadequate.

Atorvastatin is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol, LDL-cholesterol , and apolipoprotein B in patients with homozygous familial hypercholesterolaemia when response to these is inadequate.

Primary prevention in type II diabetes: Atorvastatin is indicated for reducing the risk of cardiovascular events in diabetic patients with at least 1 additional risk factor, without clinically evident coronary heart disease irrespective of whether cholesterol is raised.

Posology and method of administration: The patient should be placed on a standard cholesterol-lowering diet before receiving atorvastatin and should continue on this diet during treatment with atorvastatin.

Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb): The recommended starting dose of atorvastatin is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40mg once daily. The dosage range of atorvastatin is 10 to 80 mg once daily atorvastatin can be administered as a single dose at any time of the day, with or without food. The starting dose or maintenance dose of atorvastatin should be individualized according to patient characteristics such as goal of therapy and response. After initiation and/or upon titration of atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.

Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should total-C be used to monitor therapy.

Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age): The recommended starting does of atorvastatin is 10mg/day; the maximum recommended dose is 20mg/day (doses greater than 20mg have not been studied in this patient population). Dose should be individualized according to the recommended goal of therapy. Adjustments should be made at intervals of 4weeks or more.

Ver.1701

ATOSTAT 20

Atorvastatin USP 20 mg

Composion: Each film-coated tablet contains: Atorvastatin Calcium Eq. To Atorvastain .... 20 mg

PHARMACOLOGY

Pharmacodynamic: Atorvastatin as well as some of its metabolites are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage rather than systemic drug concentration correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response.

Mechanism of Action: Atrovastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzymeA to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.

Pharmacokinetic Properties

Absorption: Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug sbsorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC. LDL-C reduction is similar whether atorvastatin is given with or without food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration.

Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin is likely to be secreted in human milk.

Metabolism: Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importanco of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.

Excretion: Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.

Therapeutic indications

Hypercholesterolaemia: Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol, LDL-cholesterol, apoliporprotein B, and triglycerides in adults and children aged 10 years and older with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other nonpharmacological measures is inadequate.

Atorvastatin is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol, LDL-cholesterol , and apolipoprotein B in patients with homozygous familial hypercholesterolaemia when response to these is inadequate.

Primary prevention in type II diabetes: Atorvastatin is indicated for reducing the risk of cardiovascular events in diabetic patients with at least 1 additional risk factor, without clinically evident coronary heart disease irrespective of whether cholesterol is raised.

Posology and method of administration: The patient should be placed on a standard cholesterol-lowering diet before receiving atorvastatin and should continue on this diet during treatment with atorvastatin.

Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb): The recommended starting dose of atorvastatin is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40mg once daily. The dosage range of atorvastatin is 10 to 80 mg once daily atorvastatin can be administered as a single dose at any time of the day, with or without food. The starting dose or maintenance dose of atorvastatin should be individualized according to patient characteristics such as goal of therapy and response. After initiation and/or upon titration of atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.

Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should total-C be used to monitor therapy.

Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age): The recommended starting does of atorvastatin is 10mg/day; the maximum recommended dose is 20mg/day (doses greater than 20mg have not been studied in this patient population). Dose should be individualized according to the recommended goal of therapy. Adjustments should be made at intervals of 4weeks or more.

Homozygous Familial Hypercholesterolemia: The dosage of atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.
Concomitant Therapy: Atorvastatin may be used in combination with a bile acid binding resin for additive effect. The combination of HMG-CoA reductase inhibitors and fibrates should generally be avoided.
Dosage in Patients with Renal Insufficiency: Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary
Contraindication: Active liver disease or unexplained persistent elevations of serum transaminases. Hypersensitivity to any component of this medication.
Special warning and precautions for use
Warning: Liver Dysfunction HMG-CoA reductase inhibitors, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (>3 times the upper limit of normal [ULN]occurring on 2 or more occasions) in serum transaminases occured in 0.7% of patients who received atorvastatin in clinical trials. The incidence il these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.
Precautions
General: Before instituting therapy with atorvastatin, an attempt should be made to control hypercholesterolemia with appropriate diet, exercise, and weight reduction in obese patients, and to treat other underlying medical problems.
Drug Interactions: The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic), erythromycin, azole antifungals.
Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%. However, LDL-C reduction was not altered.
Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.
Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered. However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.
Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%. Patients taking digoxin should be monitored approximately.
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%. These increases should be considered when selecting an oral contraceptive for woman taking atorvastatin.
Warfarin: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment
Pregnancy and lactation: Atherosclerosis is a chronic process and discontinuation of liquid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, HMG-CoA reductase inhibitors are contraindicated during pregnancy and in nursing mothers. ATORVASTATIN SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant becomes pregnant while taking this drug, therapy should be discontinued and the patient apprised of the potential hazard to the fetus.
Effects on ability to drive and use machine: This medicine is presumed to be safe or unlikely to produce an effect.
Undesirable effects: Adverse reactions have usually been mild and transient. Less than 2% of patients were discontinued from clinical trails due to side effects attributed to Atorvastatin.
The most frequent (1% or more) adverse effects associated with Atorvastatin therapy, in patients participating in controlled clinical studies were:
Psychiatric Disorders: insomnia
Nervous System Disorders: headache
Gastrointestinal Disorders: abdominal pain, dyspepsia, nausea, flatulence, constipation, diarrhoea
Musculoskeletal and Connective Tissue Disorders: myalgia
General Disorders and Administration Site Conditions: asthenia
Overdose: These is no specific treatment for atorvastatin overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as repuired. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.
Incompatibilities: None
Shelf life: 24 months
Special precautions for storage: Store below 30°C. Protect from light.
Keep all medicines out of reach of children.
Presentation: Blister pack of 3 x 10 tablets, 10 x 10 tablets

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm 501018

Homozygous Familial Hypercholesterolemia: The dosage of atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.
Concomitant Therapy: Atorvastatin may be used in combination with a bile acid binding resin for additive effect. The combination of HMG-CoA reductase inhibitors and fibrates should generally be avoided.
Dosage in Patients with Renal Insufficiency: Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary
Contraindication: Active liver disease or unexplained persistent elevations of serum transaminases. Hypersensitivity to any component of this medication.
Special warning and precautions for use
Warning: Liver Dysfunction HMG-CoA reductase inhibitors, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (>3 times the upper limit of normal [ULN]occurring on 2 or more occasions) in serum transaminases occured in 0.7% of patients who received atorvastatin in clinical trials. The incidence il these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.
Precautions
General: Before instituting therapy with atorvastatin, an attempt should be made to control hypercholesterolemia with appropriate diet, exercise, and weight reduction in obese patients, and to treat other underlying medical problems.
Drug Interactions: The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic), erythromycin, azole antifungals.
Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%. However, LDL-C reduction was not altered.
Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.
Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered. However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.
Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%. Patients taking digoxin should be monitored approximately.
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%. These increases should be considered when selecting an oral contraceptive for woman taking atorvastatin.
Warfarin: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment
Pregnancy and lactation: Atherosclerosis is a chronic process and discontinuation of liquid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, HMG-CoA reductase inhibitors are contraindicated during pregnancy and in nursing mothers. ATORVASTATIN SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant becomes pregnant while taking this drug, therapy should be discontinued and the patient apprised of the potential hazard to the fetus.
Effects on ability to drive and use machine: This medicine is presumed to be safe or unlikely to produce an effect.
Undesirable effects: Adverse reactions have usually been mild and transient. Less than 2% of patients were discontinued from clinical trails due to side effects attributed to Atorvastatin.
The most frequent (1% or more) adverse effects associated with Atorvastatin therapy, in patients participating in controlled clinical studies were:
Psychiatric Disorders: insomnia
Nervous System Disorders: headache
Gastrointestinal Disorders: abdominal pain, dyspepsia, nausea, flatulence, constipation, diarrhoea
Musculoskeletal and Connective Tissue Disorders: myalgia
General Disorders and Administration Site Conditions: asthenia
Overdose: These is no specific treatment for atorvastatin overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as repuired. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.
Incompatibilities: None
Shelf life: 24 months
Special precautions for storage: Store below 30°C. Protect from light.
Keep all medicines out of reach of children.
Presentation: Blister pack of 3 x 10 tablets, 10 x 10 tablets

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm 501

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub—section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: ATOSTAT 10

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Tablet

Presentation: Alu-Alu blister pack of 10 x 10 tablets in a carton box.

Therapeutic Category: Lipid regulating agent

Strength & Composition: Each film-coated tablet contains Atorvastatin Calcium eq. to Atorvastatin USP 10mg.

Sales Category: Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No: 2809L557

Date of issue: 24th September, 2018

Signature: [signature] 28.11.18

Name: Professor Dr. Khin Zaw

Designation: Secretary

Batch No. : 081701
Mfg. Date. : 08/ 2017
Exp. Date. : 08/ 2020

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

ATOSTAT 10

Atorvastatin USP 10mg

ATOSTAT 10
Atorvastatin USP 10mg

PACIFIC 10 x 10 Tablets

COMPOSITION: Each tablet contains
Atorvastatin Calcium equivalent to Atorvastatin 10mg.

STORAGE:
Store in a dry place. Protect from light, not exceeding 30°C.

READ INSERT PAPER CAREFULLY BEFORE USE.
KEEP OUT OF REACH OF CHILDREN.

10 x 10 Tablets PACIFIC
ATOSTAT 10
Atorvastatin USP 10mg
Atorvastatin USP 10mg
ATOSTAT 10

ATOSTAT 10

Atorvastatin 10mg

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
www.aa.com.mm

ATOSTAT 10

Atorvastatin 10mg

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
www.aa.com.mm

ATOSTAT 10

Atorvastatin 10mg

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
www.aa.com.mm

ATOSTAT 10

Atorvastatin 10mg

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
www.aa.com.mm

ATOSTAT 10

Atorvastatin 10mg

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

Batch No. : 081701
Mfg. Date. : 08/2017
Exp. Date. : 08/2020

Ver.1701

ATOSTAT 10

Atorvastatin USP 10 mg

Composion: Each film-coated tablet contains: Atorvastatin Calcium Ep. To Atorvastain 100mg

PHARMACOLOGY

Pharmacodynamic: Atorvastatin as well as some of its metabolites are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage rather than systemic drug concentration correlates better with LDL-C reduction. Individualization of drug dosago should be based on therapeutic response.

Mechanism of Action: Atrovastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzymeA to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and apolipoprotein B (apo B) promote human atherosclerosis and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.

Pharmacokinetic Properties

Absorption: Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug sbsorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether atorvastatin is given with or without food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration.

Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin is likely to be secreted in human milk.

Metabolism: Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following coadministration with erythromycin, a known inhibitor of this isozyme. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.

Excretion: Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.

Therapeutic indications

Hypercholesterolaemia: Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol, LDL-cholesterol, apoliporprotein B, and triglycerides in adults and children aged 10 years and older with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other nonpharmacological measures is inadequate.

Atorvastatin is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol, LDL-cholesterol, and apolipoprotein B in patients with homozygous familial hypercholesterolaemia when response to these is inadequate.

Primary prevention in type II diabetes: Atorvastatin is indicated for reducing the risk of cardiovascular events in diabetic patients with at least 1 additional risk factor, without clinically evident coronary heart disease irrespective of whether cholesterol is raised.

Posology and method of administration: The patient should be placed on a standard cholesterol-lowering diet before receiving atorvastatin and should continue on this diet during treatment with atorvastatin.

Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb): The recommended starting dose of atorvastatin is 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40mg once daily. The dosage range of atorvastatin is 10 to 80 mg once daily atorvastatin can be administered as a single dose at any time of the day, with or without food. The starting dose or maintenance dose of atorvastatin should be individualized according to patient characteristics such as goal of therapy and response. After initiation and/or upon titration of atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.

Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assoss treatment response. Only if LDL-C levels are not available, should total-C be used to monitor therapy.

Heterozygous Familial Hypercholesterolemia In Pediatric Patients (10-17 years of age): The recommended starting does of atorvastatin is 10mg/day; the maximum recommended dose is 20mg/day (doses greater than 20mg have not been studied in this patient population). Dose should be individualized according to the recommended goal of therapy. Adjustments should be made at intervals of 4weeks or more.

Homozygous Familial Hypercholesterolemia: The dosage of atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin ... 'd be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if ... treatments are unavailable.

Concomitant Therapy: Atorvastatin may be used in combination with a bile acid binding resin for additive effect. The combination of HMG-CoA reductase inhibitors and fibrates should generally be avoided.

Dosage In Patients with Renal Insufficiency: Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary

Contraindication: Active liver disease or unexplained persistent elevations of serum transaminases. Hypersensitivity to any component of this medication.

Special warning and precautions for use

Warning: Liver Dysfunction HMG-CoA reductase inhibitors, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (>3 times the upper limit of normal [ULN]occurring on 2 or more occasions) in serum transaminases occured in 0.7% of patients who received atorvastatin in clinical trials. The incidence if these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.

Precautions

General: Before instituting therapy with atorvastatin, an attempt should be made to control hypercholesterolomia with appropriate diet, oxercise, and weight reduction in obese patients, and to treat other underlying medical problems.

Drug Interactions: The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic), erythromycin, azole antifungals.

Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%. However, LDL-C reduction was not altered.

Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.

Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered. However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.

Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.

Digoxin: When multiplo doses of atorvastatin and digoxin wero coadministered, steady-state plasma digoxin concentrations increased by approximately 20%. Patients taking digoxin should be monitored approximately.

Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.

Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%. These increases should be considered when selecting an oral contraceptive for woman taking atorvastatin.

Warfarin: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment

Pregnancy and lactation: Atherosclerosis is a chronic process and discontinuation of liquid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, HMG-CoA reductase inhibitors are contraindicated during pregnancy and in nursing mothers. ATORVASTATIN SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, therapy should be discontinued and the patient apprised of the potential hazard to the fetus.

Effects on ability to drive and use machine: This medicine is presumed to be safe or unlikely to produce an effect.

Undesirable effects: Adverse reactions have usually been mild and transient. Less than 2% of patients were discontinued from clinical trails due to side effects attributed to Atorvastatin.

The most frequent (1% or more) adverse effects associated with Atorvastatin therapy, in patients participating in controlled clinical studies were:

Psychiatric Disorders: insomnia

Nervous System Disorders: headache

Gastrointestinal Disorders: abdominal pain, dyspepsia, nausea, flatulence, constipation, diarrhoea

Musculoskeletal and Connective Tissue Disorders: myalgia

General Disorders and Administration Site Conditions: asthenia

Overdose: These is no specific treatment for atorvastatin overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as repuired. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.

Incompatibilities: None

Shelf life: 24 months

Special precautions for storage: Store below 30°C. Protect from light.

Keep all medicines out of reach of children.

Presentation: Blister pack of 3 x 10 tablets, 10 x 10 tablets

Manufactured by:

Pacific Medical Industries Ltd.

City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

501018

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **MUCOVAN**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Tablet

Presentation: Blister pack of 10 x 10 tablets in a carton box.

Therapeutic Category: Mucolytic

Strength & Composition: Each tablet contains Bromhexine hydrochloride USP 8mg.

Sales Category: Over The Counter Medicine

This certificate shall be valid until September 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No: 2309[illegible]545


Date of issue: 24th September, 2018

Signature:

Name: Professor Dr. Khin Zaw

Designation: Secretary


MUCOVAN
Bromhexine HCl 8 mg


website: www.aa.com.mm
Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
Batch No. : 111701
Mfg. Date : 11/2017
Exp. Date : 11/2020
MUCOVAN
Bromhexine HCl USP 8 mg
PACIFIC
10 X 10 Tablets


MUCOVAN
Bromhexine HCl USP 8 mg
PACIFIC
10 X 10 Tablets
MUCOVAN
Bromhexine HCl USP 8 mg
DOSAGE & ADMINISTRATION: Taken after meals:
Adult, children > 12 years: 1 tablet 3 times daily.
Children from 6-12 years: 1/2 tablet 3 times daily.
Children from 2-<6 years: 1/2 tablet 2 times daily.
STORAGE: Store in a cool, dry place. Protect from light, not exceeding 30°C
- Keep out of reach of children.
- Read enclosed leaflet carefully before use. "Read the enclosed leaflet"



Ver.1701

MUCOVAN

Bromhexine HCl USP 8 mg

MUCOVAN Tablet

COMPOSITIONS: Bromhexine hydrochloride 8 mg
Excipients sq. for 1 tablet.

ACTIONS:
Bromhexine is a synthetic derivative of the herbal active ingredient Vasicine. Preclinically, it has been shown to increase the proportion of serous bronchial secretion. Bromhexine enhances mucus transport by reducing mucus viscosity and by activating the ciliated epithelium (mucocillary clearance).

INDICATIONS:
Mucolytic in acute or chronic inflammatory conditions of larynx, trachea, bronchi and lung, bronchiectasis, pneumoconiosis.

DOSAGE & ADMINISTRATION:
Taken after meals:
Adults, children>12 years : 1 tablet 3 times daily.
Children from 6-12 years : ½ tablet 3 times daily.
Children from 2<6 years : ½ tablet 2 times daily.

CONTRA-INDICATIONS:
Hypersensitivity to Bromhexine.
Pregnancy, lactation.

SIDE-EFFECTS:
Mild gastrointestinal side-effects (e.g., nausea, vomiting,...) have been reported.
Inform your doctor about side-effects when using this medicine.

PRECAUTIONS:
Patients being treated with MUCOVAN should be notified of an expected increase in the flow of secretions.

INTERACTIONS:
Administration of Bromhexine together with antibiotics (Amoxicillin, Cefuroxime, Erythromycin, Doxycycline) leads to higher antibiotic concentrations in the lung tissue.

SHELF-LIFE:
36 months from the manufacturing date.
Never use after the expiry date clearly indicated on the outer packaging.

STORAGE:
Store in a cool, dry place. Protect from light.

PRESENTATION:
Blister of 10 tablets. Box of 10 blisters.
Blister of 20 tablets. Box of 10 blisters.

MYANMAR REGISTRATION No.

Read the directions carefully before use.
For further information, please refer to your doctor.

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.ae.com.mm

501050

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub—section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **MEZONE**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Tablets

Presentation: Blister pack of 10 x 10 tablets in a carton box.

Therapeutic Category: Anti-inflammatory (Corticosteroid)

Strength & Composition: Each tablet contains Dexamethasone acetate USP 0.5mg.

Sales Category: Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No: 2809L556

Date of issue: 24th September, 2018

Signature: [signature] 28.11.18

Name: Professor Dr. Khin Zaw

Designation: Secretary





MEZONE
Dexamethasone
Acetate USP 0.5 mg
PACIFIC
10 x 10 Tablets
MEZONE
Dexamethasone
Acetate USP 0.5 mg
COMPOSITION:
Dexamethasone acetate 0.5mg
DOSAGE & ADMINISTRATION:
As prescribed by physician.
- Recommended dosage: Oral route; Taken after meals.
+ Adults: 1-6 tablets daily.
+ Children: ½-4 tablets daily.
Do not stop administration abruptly but reduce the dosage gradually.
STORAGE:
Store in a dry place, protect from light, not exceeding 30°C


Batch No. : 091701
Mfg. Date. : 09/2017
Exp. Date. : 09/2020
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
website: www.aa.com.mm
MEZONE
Dexamethasone Acetate USP 0.5 mg
10 x 10 Tablets
PACIFIC
MEZONE
Dexamethasone Acetate USP 0.5 mg


MEZONE
MEZONE
MEZONE
Batch No. : 091701
Mfg. Date. : 09/2017
Exp. Date. : 09/2020

Ver.1701

MEZONE

COMPOSITIONS: Dexamethasone acetate 0.5mg. Excipients sq. for 1 tablet

ACTIONS: Dexamethasone is a steroidal anti-inflammatory drug. It is used principally because of its anti-inflammatory and immunosuppressive effects. Its metabolic effect and sodium retention are weaker than those of hydrocortisone.

INDICATIONS:

-Treatment of status asthmaticus, laryngitis stridulosa, severe allergic conditions: giant urticarias, eczema, serum sickness
-Arthritis, polyarthritis.
-Adrenal insufficiency.
-It is used in combination with other therapy in treatment of cerebral edema, shock due to various causes, adjunctive therapy in bacterial meningitis.
-It is given antenatally to mothers at risk of premature delivery in order to hasten fetal lung maturation and help prevent neonatal respiratory distress syndrome.

DOSAGE & ADMINISTRATION: -As prescribed by physician. -Recommended dosage:

Oral route: +Adults: 1-6 tablets daily. +Children: ½-4 tablets daily.
Taken after meals. Do not stop administration abruptly but reduce the dosage gradually.

CONTRA-INDICATIONS: -Hypersensitivity to Dexamethasone.
-Systemic fungal infections, viral infections, uncontrolled tuberculous or gonorrheal infections, severely deformed joints.

PRECATIONS: -In patients with osteoporosis, fresh intestinal surgery, psychotic disorder, peptic ulcers, diabetes mellitus, hypertension, cardiac insufficiency and renal insufficiency

SIDE-EFFECTS: -Water and electrolytes balance disturbance, endocrine and metabolism disturbance such as glucose tolerance, growth retardation in children, peptic ulceration, ulceration hemorrhage, dermolysis.
Inform your doctor about side-effects when using this medicine.

INTERACTIONS:

-Do not take concomitantly with Barbiturates, Phenytoin, Rifampicin, Rifabutin, Carbamazepine, Ephedrine, Aminoglutethimide.

SHELF-LIFE: -24 months from the manufacturing date
Never use after the expiry date clearly indicated on the outer packaging.

STORAGE: Store in a dry place, not exceeding 30°C. Protect from light.

PRESENTATION: Blister of 10 tablets. Box of 10 blisters

MYANMAR REGISTRATION No.

Read the directions carefully before use. For further information, please refer to your doctor

PACIFIC

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp. Yangon, Myanmar

website: www.aa.com.mm

501041

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub—section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name	Pacific Medical Industries Ltd.
Address	408/410, Mahabandoola St. #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar
Name of product	ZYLONOL
Manufacturer	Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar
Dosage form	Tablet
Presentation	Blister pack of 10 x 10 tablets in a carton box.
Therapeutic Category	Antigout
Strength & Composition	Each tablet contains Allopurinol 100mg
Sales Category	Prescription Only Medicine

This certificate shall be valid until July 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (3/2018)


Registration No [illegible]L539

Date of issue 13th July, 2018.

Signature 14.9.18


Name Professor Dr. Khin Zaw

Designation Secretary


Zylonol
Allopurinol USP 100 mg Tab.
10 x 10 Tablets
PACIFIC
Zylonol
Allopurinol USP 100 mg Tab.
COMPOSITION:
Each tablet contains Allopurinol 100 mg.
STORAGE:
Store in a well-closed container at room temperature, not exceeding 30°C
READ INSERT PAPER CAREFULLY BEFORE USING
KEEP OUT OF REACH OF CHILDREN.




Zylonol
Allopurinol 100 mg Tab.


Website: www.aa.com.mm
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
Manufactured by:
Batch No. : 091701
Mfg. Date.: 09/2017
Exp. Date. : 09/2020
Zylonol
Allopurinol USP 100 mg Tab.
PACIFIC
10 x 10 Tablets
Zylonol
Allopurinol USP 100 mg Tab.

Ver.1701

Zylonol

Allopurinol USP 100 mg Tab.

Composition: Each tablet contains Allopurinol..100mg
Description: White and round tablet
Indication: The management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
The management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.
Treatment with Allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present.
The management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800mg/day in male patients and 750mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
Dosage and Administration: Adult: The dosage of Allopurinol to accomplish full control of gout and to lower serum uric acid to normal or nearnormal levels varies with the severity of the disease. The average is 200-300 mg/day for patients with mild gout and 400-600 mg/day for those with moderately severe tophaceous gout. The appropriate dosage may be administered in divided doses or as a single equivalent dose with the 300mg tablet. Dosage requirement in excess of 300mg should be administered in divided doses.
The minimal effective dosage is 100-200mg daily and the maximal recommended dosage is 800mg daily. To reduce the possibility of flare-up of acute gouty attacks, it is recommended that the patient start with a low dose of Allopurinol (100mg daily) and increase at weekly intervals by 100mg until a serum uric acid level of 6mg/dL or less is attained but without exceeding the maximal recommended dosage. Normal serum urate levels are usually achieved in 1-3 weeks. The upper limit of normal is about 7mg/dL for men and postmenopausal women and 6mg/dL for premenopausal women. Too much reliance should not be placed on a single serum uric acid determination since, for technical reasons, estimation of uric acid may be difficult. By selecting the appropriate dosage and, in certain patients, using uricosuric agents concurrently, it is possible to reduce serum uric acid to normal or, if desired, to as low as 2-3mg/dL and keep it there indefinitely.
Since Allopurinol and its metabolites are primarily eliminated only by the kidney, accumulation of the drug can occur in renal failure, and the dose of Allopurinol should consequently be reduced. With a creatinine clearance of 10-20mL/min, a daily dosage of 100-200mg of Allopurinol is suitable. When the creatinine clearance is less than 10mL/min, the daily dosage should not exceed 100mg. With extreme renal impairment (creatinine clearance less than 3mL/min) the intervals between doses may also need to be lengthened. If facilities are available to monitor plasma oxipurinol concentrations, the dose should be adjusted to maintain plasma oxipurinol levels below 100μmol/L (15.2mg/L).
Precautions:
1.Warning:
ALLOPURINOL SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF SKIN RASH OR OTHER SIGNS WHICH MAY INDICATE AN ALLERGIC REACTION.
2.Contraindications:
1)Children (except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome)
2)Nursing mothers
3)Patients with a know hypersensitivity to any of its ingredients
4)Patients who have developed a severe reaction to Allopurinol should not be restarted on the drug
5)Patients with mild uricemia without symptom (uric acid <90mg/L)
3.Careful administration:
1)Patients with hepatic impairment
2)Patients with renal failure
3)Pregnancy
4)The elderly
5)Patients who are taking mercaptopurine and azathioprine
6)Patients under treatment for hypertension or cardiac insufficiency, for example with diuretics or ACE inhibitors, may have some concomitant impairment of renal function and allopurinol should be used with care in this group.
7)Patients with disorder of hematopoiesis
4. Adverse reactions: Data upon which the following estimates of incidence of adverse reactions are made are derived from experiences reported in the literature, unpublished clinical trials and voluntary reports since marketing of Allopurinol began. Past experience suggested that the most frequent event following the initiation of Allopurinol treatment was an increase in acute attacks of gout (average 6% in early studies). An analysis of current usage suggests that the incidence of acute gouty attacks has diminished to less than 1%. The explanation for this decrease has not been determined but may be due in part to initiating therapy more gradually.
The most frequent adverse reaction to Allopurinol is skin rash. Skin reactions can be severe and sometimes fatal. Therefore, treatment with Allopurinol should be discontinued immediately if a rash develops. Some patients with the most severe reaction also had fever, chills, arthralgias, cholestatic jaundice, eosinophilia and mild leukocytosis or leukopenia. Among 55 patients with gout treated with Allopurinol for 3 to 34 months (average greater than 1 year) and followed prospectively, Rundles observed that 3% of patients developed a type of drug reaction which was predominantly a pruritic maculopapular skin eruption, sometimes scaly or exfoliative. However, with current usage, skin reactions have been observed less frequently than 1%. The explanation for this decrease is not obvious. The incidence of skin rash may be increased in the presence of renal insufficiency. The frequency of skin rash among patients receiving ampicillin or amoxicillin concurrently with Allopurinol has been reported to be increased.
Most Common Reactions*:
Probably Causally Related:
Gastrointestinal: diarrhea, nausea, alkaline phosphatase increase, SGOT/SGPT increase
Metabolic and Nutritional: acute attacks of gout
Skin and Appendages: rash, maculopapular rash
*Early clinical studies and incidence rates from early clinical experience with Allopurinol suggested that these adverse reactions were found to occur at a rate of greater than 1%. The most frequent event observed was acute attacks of gout following the initiation of therapy. Analyses of current usage suggest that the incidence of these adverse reactions is now less than 1%. The explanation for this decrease has not been determined, but it may be due to following recommended usage.
Incidence Less Than 1%
Probably Causally Related:
Body As a Whole: ecchymosis, fever, headache
Cardiovascular: necrotizing angiitis, vasculitis
Gastrointestinal: hepatic necrosis, granulomatous hepatitis, hepatomegaly, hyperbilirubinemia, cholestatic jaundice, vomiting, intermittent abdominal pain, gastritis, dyspepsia
Hemic and Lymphatic: thrombocytopenia, eosinophilia, leukocytosis, leukopenia
Musculoskeletal: myopathy, arthralgias
Nervous: peripheral neuropathy, neuritis, paresthesia, somnolence
Respiratory: epistaxis

Skin and Appendages: erythema multiforme exudativum (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), hypersensitivity vasculitis, purpura, vesicular bullous dermatitis, exfoliative dermatitis, eczematoid dermatitis, pruritus, urticaria, alopecia, onycholysis, lichen planus
Special Senses: taste loss/ perversion
Urogenital: renal failure, uremia
Incidence Less Than 1%
Causal Relationship Unknown:
Body As a Whole: malaise
Cardiovascular: pericarditis, peripheral vascular disease, thrombophlebitis, bradycardia, vasodilation
Endocrine: Infertility (male), hypercalcemia, gynecomastia (male)
Gastrointestinal: hemorrhagic pancreatitis, gastrointestinal bleeding, stomatitis, salivary gland swelling, hyperlipidemia, tongue edema, anorexia
Hemic and Lymphatic: aplastic anemia, agranulocytosis, eosinophilic fibrohistiocytic lesion of bone marrow, pancytopenia, prothrombin decrease, anemia, hemolytic anemia, reticulocytosis, lymphadenopathy, lymphocytosis
Musculoskeletal: myalgia
Nervous: optic neuritis, confusion, dizziness, vertigo, foot drop, decrease in libido, depression, amnesia, tinnitus, asthenia, insomnia
Respiratory: bronchospasm, asthma, pharyngitis, rhinitis
Skin and Appendages: furunculosis, facial edema, sweating, skin edema
Special Sense: cataracts, macular retinitis, iritis, conjunctivitis, amblyopia
Urogenital: nephritis, impotence, primary hematuria, albuminuria

5. General precautions:
1)Allopurinol should be withdrawn immediately when a skin rash or other evidance of sensitivity occurs.
2)Allopurinol treatment should not be started until an acute attack of gout has completely subsided, as further attacks may be precipitated
3)In the early stages of treatment with Allopurinol as with uricosuric agents, an acute attack of gouty arthritis may be precipitated. Therefore, it is advisable to give prophylaxis with a suitable anti-inflammatory agent or colchicine for at least one month. The literature should be consulted for details of appropriate dosage and precautions and warnings. It is recommended that the patient start with a low dose of Allopurinol (100mg daily) and increase at weekly intervals by 100mg until a serum uric acid level of 6 mg/dL or less is attained but without exceeding the maximum recommended dose (800mg per day). If acute attacks develop in patients receiving allopurinol, treatment should continue at the same dosage while the acute attack is treated with a suitable anti-inflammatory agent.
4)A fluid intake sufficient to yield a daily urinary output of at least two liters and the maintenance of a neutral or, preferably, slightly alkaline urine are desirable to (1) avoid the theoretical possibility of formation of xanthine calculi under the influence of therapy with Allopurinol and (2) help prevent renal precipitation of urates in patients receiving concomitant uricosuric agents.
5)Since adverse reactions such as somnolence, vertigo and ataxia have been reported in patients receiving allopurinol, patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that allopurinol does not adversely affect performance.
6)Periodic liver function tests are recommended during the early stages of therapy.
7)The dosage should be adjusted by monitoring serum urate concentrations and urinary urate/uric acid levels at appropriate intervals.

6. Drugs interactions:
1)Azathioprine is metabolised to 6-mercaptopurine which is inactivated by the action of xanthine oxidase. When 6-mercaptopurine or azathioprine is given concurrently with Allopurine, only one-quarter of the usual dose of 6-mercaptopurine or azathioprine should be given because inhibition of xanthine oxidase will prolong their activity.
2)If Allopurinol is given concomitantly with chlorpropamide when renal function is poor, there may be an increased risk of prolonged hypoglycaemic activity because allopurinol and chlorpropamide may compete for excretion in the renal tubule. There have been rare reports of increased affect of warfarin and other coumarin anticoagulants when co-administered with allopurinol, therefore, all patients receiving anticoagulants must be carefully monitored.
3)In aminal test, there is a report that hepatic iron uptake may be increased in combination use with iron supplements.
4)Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease (other than leukaemia), in the presence of allopurinol.
5)Allopurinol may inhibit hepatic oxidation of phenytoin but the clinical significance has not been demonstrated.
6)Reports suggest that the plasma concentration of ciclosporin may be increased during concomitant treatment with allopurinol. The possibility of enhanced ciclosporin toxicity should be considered if the drugs are co-administered.
7)Inhibition of the metabolism of theophylline has been reported. The mechanism of the interaction may be explained by xanthine oxidase being involved in the biotransformation of theophylline in man. Theophylline levels should be monitored in patients starting or increasing allopurinol therapy.
8)Evidence suggests that the plasma half-life of vidarabine is increased in the presence of allopurinol. When the two products are used concomitantly extra vigilance is necessary, to recognise enhanced toxic effects.
9)An increase in frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs. The cause of the reported association has not been established. However, it is recommended that in patients receiving allopurinol an alternative to ampicillin or amoxicillin is used where available
10)Oxipurinol, the major metabolite of allopurinol and itself therapeutically active is excreted by the kidney in a similar way to urate. Hence, drugs with uricosuric activity such as probenecid or large doses of salicylate may accelerate the excretion of oxipurinol. This may decrease the therapeutic activity of Allopurinol, but the significance needs to be assessed in each case.
11)It may enhance the action of salicylate.

7. Use in Pregnancy • Nursing Mothers
1)Teratogenesis has not been observed in animal test. Allopurinol should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.
2)Reports indicate that allopurinol and oxipurinol are excreted in human breast milk. Therefore Allopurinol should not be used in nursing mothers.

8. Use in Children: Safety in Children have not been established.

9. Use in the Elderly: In the absence of specific data, the lowest dosage which produces satisfactory urate reduction should be used.

10. Caution for storage :
1)Keep out of children's rach.
2)Don't take this drug in another case in order to protect from misusing and preserve quality of drug.

Storage: Store in a well-closed container at room temperature.
Package Units: 100 Tabs.

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm 501009

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub—section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **VASOTAN L 25**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Tablet

Presentation: Blister pack of 10 x 10 tablets in a carton box

Therapeutic Category: Antihypertensive

Strength & Composition: Each film coated tablet contains Losartan Potassium USP 25mg

Sales Category: Prescription Only Medicine

This certificate shall be valid until July, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (3/2018)


Registration No: 2[illegible]7L537


Date of issue: 13th July, 2018

Signature: [signature] 14.9.18

Name: Professor Dr. Khin Zaw

Designation: Secretary


Vasotan-L 25
Losartan Potassium Tablets 25 mg
PACIFIC
10x10 Tablets
Vasotan-L 25
Losartan Potassium Tablets 25 mg
Batch. No. : 091701
Mfg. Date. : 09/2017
Exp. Date. : 09/2020
Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
website: www.aa.com.mm


COMPOSITION:
Each film-coated tablet contains: Losartan Potassium USP 25 mg
INDICATION:
Vasotan-L 25 is indicated for the treatment of hypertension.
DOSAGE & ADMINISATRATION:
As directed by the Physician.
STORAGE:
Store in a dry at temperature below 30°C.
Vasotan-L 25
Losartan Potassium Tablets 25 mg
PACIFIC
10x10 Tablets
Vasotan-L 25
Losartan Potassium Tablets 25 mg




Vasotan-L 25
Vasotan-L 25
Vasotan-L 25
Vasotan-L 25
Batch No.
Mfg. Date
Exp. Date

VASOTAN – L 25/50

(LOSARTAN POTASSIUM TABLETS 25/ 50 mg)

COMPOSITION

VASOTAN - L25

Each Film coated tablet contains:
Losartan potassium USP 25 mg
Colour: Titanium Dioxide.

VASOTAN – L50

Each Film coated tablet contains:
Losartan potassium USP 50 mg.
Colour: Titanium Dioxide & Red Oxide of Iron.

PHARMACOLOGY

Pharmacodynamic properties

Losartan is a non-peptide angiotensin II receptor antagonist with high affinity and. selectivity for the AT receptor, without binding to or blocking other hormone receptors or ion channels important in cardiovascular regulation. Angiotensin II is a potent vasoconstrictor, a primary active hormone of the renin angiotensin system, and a major determinant of the pathophysiology of hypertension. Losartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by inhibiting the binding of angiotensin II to the AT receptor.

Pharmacokinetic properties

Following oral administration, bioavailability is approximately 33%. It undergoes first-pass metabolism to form an active carboxylic acid metabolite, (which has greater pharmacological activity than losartan) and some inactive metabolites. About 14% of an intravenously or orally administered dose is converted to its active metabolite. The mean peak concentrations of losartan and its active metabolite are reached in 1 hour and 3-4 hours, respectively.

Both losartan and the carboxylic acid metabolite are greater than, or equal to 99% bound to plasma proteins. The distribution volume of losartan is 34 liters .The terminal half-life of losartan is 2 hours and of its active metabolite is 6-9 hours. Losartan is excreted in the urine, and in the faeces, as unchanged drug and metabolites. Following oral dosing, about 35% of the dose is excreted in the urine and about 60% in the faeces. Neither losartan nor the active metabolite can be removed by haemodialysis. Plasma concentrations of losartan are not altered in patients with impaired renal function and a creatinine clearance above 10 ml/min. Compared to patients with normal renal function, the AUC for losartan is approximately 2-fold greater in patients on haemodialysis.

INDICATIONS:

VASOTAN – L 25/50 is indicated for the treatment of hypertension.

WARNING

Women of childbearing age should ensure adequate contraception.

VASOTAN – L 25/50 is contra-indicated in pregnancy and should be used with care, i; at all, during breast-feeding.

VASOTAN – L 25/50 should be used with caution in patients with bilateral renal artery stenosis or stenosis of an artery 10 a single kidney, aortic valve stenosis or hypertrophic obstructive cardiomyopathy.

Symptomatic hypotension may occur after initiation of VASOTAN – L 25/50. Reduced doses must be considered in patients with Hepatic impairment.

DOSAGE AND DIRECTIONS FOR USE

Hypertension

Adult Hypertensive

Dosing must be individualized. The usual starting dose of VASOTAN - L25/50 is 50 mg once daily. A dose of 25 mg may be used in patients with possible depletion of intravascular volume (e.g. patients treated with diuretics) and patients with a history of hepatic impairment. VASOTAN – L 25/50 can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg.

If the antihypertensive effect measured at trough using once-a-day dosing is inadequate, a twice-a-day regimen at the same total daily dose or an increase in dose may give a more satisfactory response. The effect of losartan is substantially present within one weed but in some studies the maximal effect occurred in 3-6 weeks.

If blood pressure is not controlled by losartan alone, a low dose of a diuretic may be added.

No initial dosage adjustment is necessary for elderly patients or for patients with renal impairment, including patients on dialysis.

Pediatric hypertensive patient's ≥ 6 years of age

The usual recommended starting dose is 0.7 mg/kg once daily (up to 50 mg total). Dosage should be adjusted according to blood pressure response.

Doses above 1.4 mg/kg (or in excess of 100 mg) daily have not been studied in pediatric patients. Losartan is not recommended in pediatric patients < 6 years of age or in pediatric patients with glomerular filtration rate < 30mL/min/1.73m²

Hypertensive patients with left ventricular hypertrophy

The usual starting dose is 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should be added and/or the dose of VASOTAN - L25/50 should be increased to 100 mg once daily followed by an increase in hydrochlorothiazide to 25 mg once daily based on blood pressure response.

Nephropathy in type 2 diabetic patients

The usual starting dose is 50 mg once daily. The dose should be increased to 1 00 mg once daily based on blood pressure response.

CONTRA-INDICATIONS:

Hypersensitivity to losartan of any of the components of this product.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:

Interactions:

Combinations containing any of the following medications, depending on the amount present, may also interact with VASOTAN - L25/50.

Non-steroidal anti-inflammatory drugs (NSAIDs) may antagonize the antihypertensive effect of VASOTAN – L 25/50.

Concurrent use with sympathomimetic may reduce the antihypertensive effects of VASOTAN – L 25/50.

Potassium-sparing diuretics, potassium containing medication or potassium supplements used concurrently with VASOTAN – L 25/50 may result in hyperkalemia since reduction of aldosterone production induced by VASOTAN – L 25/50 may lead to elevation of serum potassium.

PREGNANCY AND LACTATION:

death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypo plastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.

These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester.

Mothers whose embryos and fetuses are exposed to an angiotensin II receptor antagonist only during the first trimester should be so informed.

Nonetheless, when patients become pregnant, physicians should have the patient discontinue the use of VASOTAN – L 25/50 as soon as possible.

VASOTAN – L 25/50 should be discontinued as soon as possible, when pregnancy is suspected.

VASOTAN – L 25/50 should not be used in pregnancy as teratogenicity has been shown in experimental animals.

Lactation: Safety has not been established.

Side Effects:

The following side-effects may occur:

Blood and lymphatic System disorders:

The following side effects have been reported and frequencies are unknown:
Symptomatic anemia, neutropenia

Nervous system disorders:

More frequent: Headache
Less frequent: Dizziness
Rare: Insomnia
The following side effect has been reported and frequencies are unknown:
Migraine

Cardiac disorders:

The following side effects have been reported and frequencies are unknown:
Palpitations, tachycardia

Vascular disorders:

The following side effect has been reported and frequencies are unknown:
Hypotension

Respiratory, thoracic and mediastinal disorders:

Less frequent: Cough, nasal congestion, pharyngitis, upper respiratory infection
Rare: Sinus disorder

Gastrointestinal disorders:

Less frequent: Diarrhoea
The following side effects have been reported and frequencies are unknown.:
Dyspepsia, nausea, acute pancreatitis, abdominal pain, taste disturbances complete taste loss

Hepato-biliary disorders:

The following side effects have been reported and frequencies are unknown :
Severe acute hepatotoxicity, cholestasis

Skin and subcutaneous tissue disorders:

The following side effects have been reported and frequencies are unknown:
Urticaria, rash, atypical cutaneous lymphoid infiltrates. Angioedema (involving swelling of the face, lips, and/or tongue) has been reported in patients treated with VASOTAN - L25/50.

Musculoskeletal, connective tissue and bone disorders:

Less frequent: Back pain
Rare: Muscle cramps, leg pain,
The following side effects have been reported and frequencies are unknown:
Myalgia

Renal and urinary disorders:

The following side effects have been reported and frequencies are unknown:
Impaired renal function

General disorders and administrative site conditions:

Less frequent: Fatigue
The following side effect has been reported and frequencies are unknown:
Chest pain, oedema/swelling, asthenia

KOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

The symptoms of an over dosage of VASOTAN – L 25/50 would be hypotension and tachycardia.

Bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted.

Neither VASOTAN – L 25/50 nor the active metabolite can be removed by haemodialysis.

STORAGE INSTRUCTIONS:

Store in a dry place at temperature below 30°C.
Keep out of reach of children.

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp, Yangon, Myanmar

Website: www.aa.com.mm

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **VASOTAN-L 50**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Tablet

Presentation: Blister pack of 10 x 10 tablets in a carton box

Therapeutic Category: Antihypertensive

Strength & Composition: Each film coated tablet contains Losartan Potassium USP 50mg

Sales Category: Prescription Only Medicine

This certificate shall be valid until July 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (3/2018)


Registration No: 2807L538

Date of issue: 13th July, 2018


Signature: [signature] 14.9.18

Name: Professor Dr. Khin Zaw

Designation: Secretary



Batch. No. : 091701
Mfg. Date. : 09/2017
Exp. Date. : 09/2020
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
website: www.aa.com.mm
Vasotan-L 50
Losartan Potassium Tablets 50 mg
PACIFIC
10x10 Tablets
Vasotan-L 50
Losartan Potassium Tablets 50 mg


Vasotan-L 50
Losartan Potassium Tablets 50 mg
PACIFIC
10x10 Tablets
Vasotan-L 50
Losartan Potassium Tablets 50 mg
COMPOSITION:
Each film-coated tablet contains: Losartan Potassium USP 50 mg
INDICATION:
Vasotan-L 50 is indicated for the treatment of hypertension.
DOSAGE & ADMINISATRATION:
As directed by the Physician.
STORAGE:
Store in a dry at temperature below 30°C.


Losartan Potassium Tablets 50 mg
Vasotan-L 50
Losartan Potassium Tablets 50 mg
Vasotan-L 50
Losartan Potassium Tablets 50 mg
Vasotan-L 50
Losartan Potassium Tablets 50 mg
Batch. No. : 091701
Mfg. Date. : 09/2017
Exp. Date. : 09/2020



death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypo plastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.
These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester.
Mothers whose embryos and fetuses are exposed to an angiotensin II receptor antagonist only during the first trimester should be so informed.
Nonetheless, when patients become pregnant, physicians should have the patient discontinue the use of VASOTAN – L 25/50 as soon as possible.
VASOTAN – L 25/50 should be discontinued as soon as possible, when pregnancy is suspected.
VASOTAN – L 25/50 should not be used in pregnancy as teratogenicity has been shown in experimental animals.

Lactation: Safety has not been established.

Side Effects:

The following side-effects may occur:

Blood and lymphatic System disorders:

The following side effects have been reported and frequencies are unknown:
Symptomatic anemia, neutropenia

Nervous system disorders:

More frequent: Headache
Less frequent: Dizziness
Rare: Insomnia
The following side effect has been reported and frequencies are unknown:
Migraine

Cardiac disorders:

The following side effects have been reported and frequencies are unknown:
Palpitations, tachycardia

Vascular disorders:

The following side effect has been reported and frequencies are unknown:
Hypotension

Respiratory, thoracic and mediastinal disorders:

Less frequent: Cough, nasal congestion, pharyngitis, upper respiratory infection
Rare: Sinus disorder

Gastrointestinal disorders:

Less frequent: Diarrhoea
The following side effects have been reported and frequencies are unknown.:
Dyspepsia, nausea, acute pancreatitis, abdominal pain, taste disturbances complete taste loss

Hepato-biliary disorders:

The following side effects have been reported and frequencies are unknown :
Severe acute hepatotoxicity, cholestasis

Skin and subcutaneous tissue disorders:

The following side effects have been reported and frequencies are unknown:
Urticaria, rash, atypical cutaneous lymphoid infiltrates. Angioedema (involving swelling of the face, lips, and/or tongue) has been reported in patients treated with VASOTAN - L25/50.

Musculoskeletal, connective tissue and bone disorders:

Less frequent: Back pain
Rare: Muscle cramps, leg pain,
The following side effects have been reported and frequencies are unknown:
Myalgia

Renal and urinary disorders:

The following side effects have been reported and frequencies are unknown:
Impaired renal function

General disorders and administrative site conditions:

Less frequent: Fatigue
The following side effect has been reported and frequencies are unknown:
Chest pain, oedema/swelling, asthenia

KOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

The symptoms of an over dosage of VASOTAN – L 25/50 would be hypotension and tachycardia.
Bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted.
Neither VASOTAN – L 25/50 nor the active metabolite can be removed by haemodialysis.

STORAGE INSTRUCTIONS:

Store in a dry place at temperature below 30°C.
Keep out of reach of children.

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp, Yangon, Myanmar

Website: www.aa.com.mm

VASOTAN – L 25/50

(LOSARTAN POTASSIUM TABLETS 25/ 50 mg)

COMPOSITION

VASOTAN - L25
Each Film coated tablet contains:
Losartan potassium USP 25 mg
Colour: Titanium Dioxide.
VASOTAN – L50
Each Film coated tablet contains:
Losartan potassium USP 50 mg.
Colour: Titanium Dioxide & Red Oxide of Iron.

PHARMACOLOGY

Pharmacodynamic properties

Losartan is a non-peptide angiotensin II receptor antagonist with high affinity and selectivity for the AT receptor, without binding to or blocking other hormone receptors or ion channels important in cardiovascular regulation. Angiotensin II is a potent vasoconstrictor, a primary active hormone of the renin angiotensin system, and a major determinant of the pathophysiology of hypertension. Losartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by inhibiting the binding of angiotensin II to the AT receptor.

Pharmacokinetic properties

Following oral administration, bioavailability is approximately 33%. It undergoes first-pass metabolism to form an active carboxylic acid metabolite, (which has greater pharmacological activity than losartan) and some inactive metabolites. About 14% of an intravenously or orally administered dose is converted to its active metabolite. The mean peak concentrations of losartan and its active metabolite are reached in 1 hour and 3-4 hours, respectively.
Both losartan and the carboxylic acid metabolite are greater than, or equal to 99% bound to plasma proteins. The distribution volume of losartan is 34 liters .The terminal half-life of losartan is 2 hours and of its active metabolite is 6-9 hours. Losartan is excreted in the urine, and in the faeces, as unchanged drug and metabolites. Following oral dosing, about 35% of the dose is excreted in the urine and about 60% in the faeces. Neither losartan nor the active metabolite can be removed by haemodialysis. Plasma concentrations of losartan are not altered in patients with impaired renal function and a creatinine clearance above 10 ml/min. Compared to patients with normal renal function, the AUC for losartan is approximately 2-fold greater in patients on haemodialysis.

INDICATIONS:

VASOTAN – L 25/50 is indicated for the treatment of hypertension.

WARNING

Women of childbearing age should ensure adequate contraception.
VASOTAN – L 25/50 is contra-indicated in pregnancy and should be used with care, i; at all, during breast-feeding.
VASOTAN – L 25/50 should be used with caution in patients with bilateral renal artery stenosis or stenosis of an artery 10 a single kidney, aortic valve stenosis or hypertrophic obstructive cardiomyopathy.
Symptomatic hypotension may occur after initiation of VASOTAN – L 25/50. Reduced doses must be considered in patients with Hepatic impairment.

DOSAGE AND DIRECTIONS FOR USE

Hypertension

Adult Hypertensive

Dosing must be individualized. The usual starting dose of VASOTAN - L25/50 is 50 mg once daily. A dose of 25 mg may be used in patients with possible depletion of intravascular volume (e.g. patients treated with diuretics) and patients with a history of hepatic impairment. VASOTAN – L 25/50 can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg.
If the antihypertensive effect measured at trough using once-a-day dosing is inadequate, a twice-a-day regimen at the same total daily dose or an increase in dose may give a more satisfactory response. The effect of losartan is substantially present within one weed but in some studies the maximal effect occurred in 3-6 weeks. ·
If blood pressure is not controlled by losartan alone, a low dose of a diuretic may be added.
No initial dosage adjustment is necessary for elderly patients or for patients with renal impairment, including patients on dialysis.
Pediatric hypertensive patient's ≥ 6 years of age
The usual recommended starting dose is 0.7 mg/kg once daily (up to 50 mg total). Dosage should be adjusted according to blood pressure response.
Doses above 1.4 mg/kg (or in excess of 100 mg) daily have not been studied in pediatric patients. Losartan is not recommended in pediatric patients < 6 years of age or in pediatric patients with glomerular filtration rate < 30mL/min/1.73m^2
Hypertensive patients with left ventricular hypertrophy
The usual starting dose is 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should be added and/or the dose of VASOTAN – L25/50 should be increased to 100 mg once daily followed by an increase in hydrochlorothiazide to 25 mg once daily based on blood pressure response.
Nephropathy in type 2 diabetic patients
The usual starting dose is 50 mg once daily. The dose should be increased to I 00 mg once daily based on blood pressure response.

CONTRA-INDICATIONS:

Hypersensitivity to losartan of any of the components of this product.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:

Interactions:

Combinations containing any of the following medications, depending on the amount present, may also interact with VASOTAN - L25/50.
Non-steroidal anti-inflammatory drugs (NSAIDs) may antagonize the antihypertensive effect of VASOTAN – L 25/50.
Concurrent use with sympathomimetic may reduce the antihypertensive effects of VASOTAN – L 25/50.
Potassium-sparing diuretics, potassium containing medication or potassium supplements used concurrently with VASOTAN – L 25/50 may result in hyperkalemia since reduction of aldosterone production induced by VASOTAN – L 25/50 may lead to elevation of serum potassium.

PREGNANCY AND LACTATION:

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub—section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name	Pacific Medical Industries Ltd.
Address	408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar
Name of product	**SEPRIM**
Manufacturer	Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar
Dosage form	Tablet
Presentation	Blister pack of 10 x 10 tablets in a carton box
Therapeutic Category	Anti-infective
Strength & Composition	Each tablet contains Sulfamethoxazole 400mg and Trimethoprim 80mg
Sales Category	Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No 2309B560


Date of issue 24th September, 2018

Signature

Name Professor Dr. Khin Zaw

Designation Secretary




Rx PRESCRIPTION DRUG
SEPRiM
Sulfamethoxazole 400 mg
Trimethoprim 80 mg
PACIFIC
10 x 10 tablets
SEPRiM
Sulfamethoxazole 400 mg
Trimethoprim 80 mg
Compositions: Each tablet contains
Sulfamethoxazole 400 mg and
Trimethoprim 80 mg.
Dosage: Taken with plenty of water during meals:
Adults: 1-2 tablets twice daily.
Children: 1/2-1 tablet twice daily. Or as prescribed by physician.

Storage: Store below 30°C in airtight and well-closed containers.
Protect from light.

READ INSERT PAPER CAREFULLY BEFORE USING.
KEEP OUT OF REACH OF CHILDREN.

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

Batch No. : 081701
Mfg. Date : 08/2017
Exp. Date : 08/2020

website: www.aa.com.mm

Rx PRESCRIPTION DRUG

SEPRiM

Sulfamethoxazole 400 mg
Trimethoprim 80 mg

PACIFIC

10 x 10 tablets

SEPRiM
Sulfamethoxazole 400 mg
Trimethoprim 80 mg



Ver.1701

SEPRiM tab

Sulfamethoxazole 400 mg
Trimethoprim 80 mg

COMPOSITION: Each tablet contains:

Trimethoprim	80mg
Sulfamethoxazole	400mg

PHARMACOLOGICAL CLASSIFICATION:
A 20.2 Antimicrobial (Chemotherapeutic) Agents. (Other than antibiotics).

PHARMACOLOGICAL ACTION: SEPRIM exerts its bactericidal action by the sequential blockade of two enzymes intervening in the biosynthesis of folinic acid in the micro-organism. SEPRIM is bactericidal at concentrations at which the active ingredients trimethoprim and sulfamethoxazole, are usually bacteriostatic. It is therefore often active against organisms resistant to one of the active ingredients thereby minimizing the risk of bacterial resistance.

INDICATIONS: SEPRIM is effective against a wide range of Gram-positive and Gram-negative organisms. It is indicated for:
1. Upper and lower respiratory tract infections e.g. acute and chronic bronchitis, bronchiectasis, tonsillitis, sinusitis and pharyngitis, otitis media, pneumonia and pneumocystis corinii pneumonitis (see Precautions).
2. Renal and urinary tract infection e.g pyelitis, pyelonephritis, urethritis, acute and chronic cystitis and cystopyelitis, including prostatitis.
3. Gastro-intestinal tract infections e.g. enteritis, typhoid and paratyphoid fever, typhoid carriage, bacillary dysentery and cholera (as an adjunct to fluid and electrolyte replacement).
4. Genital tract infections – both male and female including gonococcal infections.
5. Skin infections e.g. pyoderma, boils, furuncles, abscesses.
6. Other bacterial infections – acute brucellosis, mycetoma except those caused by true fungi, nocardiosis, acute and chronic osteomyelitis.

CONTRA-INDICATIONS: SEPRIM is contra-indicated in patients suffering for porphyria, liver parenchymal damage, megaloblastic anaemia due to folic acid deficiency, severe renal insufficiency, and a history of hypersensitivity to sulfonamides or trimethoprim. SEPRIM should not be administered during pregnancy, to women prior to delivery, or to nursing mothers. It should also not be used in premature or newborn infants during the first few weeks of life.

WARNING: A high incidence of side-effects occurs in immunocompromised patients, such as those suffering from Aids or patients receiving immunosuppressive therapy. The adverse effects include skin rash, recurrent fever, neutropenia, thrombocytopenia and raised liver enzyme values
SEPRIM may cause the occurrence of erythema multiforme, toxic dermal necrolysis and allergic vasculitis. Treatment should be discontinued immediately when a rash appears because of the danger of severe allergic reactions.

DOSAGE AND DIRECTIONS FOR USE:
Children 6-12 years: One tablet every 12 hours after meals.
Adults and Children over 12 years: The usual dose is two tablets every 12 hours after meals. The maximum dose (for particularly severe cases) is three tablets every 12 hours. The minimum dosage for long-term treatment (longer than 14 days) is one tablet every 12 hours

SIDE-EFFECTS AND SPECIAL PRECAUTIONS: Hypersensitivity reactions particularly involving the skin are among the most common adverse effects of SEPRIM and are usually due to the sulfamethoxazole component. The Stevens-Johnson and Lyell's syndromes have been reported.
Adverse effects on the gastro-intestinal tract may also occur fairly frequently
Sulfamethoxazole: Sulfamethoxazole may cause nausea, vomiting and diarrhoea.
Hypersensitivity reactions may occur. Those involving the skin include rashes, photosensitivity reactions, exfoliative dermatitis, toxic epidermal necrolysis (Lyell's syndrome), and erythema nodosum. A severe potentially fatal form of erythema multiforme, associated with widespread lesions of the skin and mucous membranes, termed the Stevens-Johnson syndrome, may occur.
Systemic lupus erythematosus, particularly exacerbations of pre-existing disease, has also been reported. Nephrotoxic reactions, which may result in renal failure, have been attributed to hypersensitivity to sulfamethoxazole. Lumbar pain, haematuria, oliguria, and anuria may occur due to crystallisation in the urine of sulfamethoxazole or its less soluble acetylated metabolite.
Blood disorders, mostly as a result of hypersensitivity reactions, may occur and include agranulocytosis, aplastic anaemia, thrombocytopenia, leucopenia, hypoprothrombinaemia, and eosinophilia. Acute haemolytic anaemia often associated with glucose-6-phosphate dehydrogenase deficiency may occur.
Other side-effects which may be manifestations of a generalised hypersensitivity reaction to sulfamethoxazole include a syndrome resembling serum sickness, hepatotoxic reactions, myocarditis, pancreatitis, pulmonary eosinophilia, and vasculitis including polyarteritis nodosa.
Anaphylaxis has been reported.
Sulfamethoxazole may cause cyanosis due to methaemoglobinaemia or sulphaemoglobinaemia
Other side-effects include effects on the eyes such as optic neuropathy or transient myopia, fever, hypothyroidism, and neurological reactions including ataxia, dizziness, fatigue, headache, insomnia, peripheral neuritis, and vertigo. Sulfamethoxazole may cause alterations of the bacterial flora in the gastro-intestinal tract. There is, therefore, the possibility that pseudomembranous colitis may occur.
Slow acetylators of sulfamethoxazole may be at greater risk of adverse reactions than fast acetylators.

Trimethoprim: Side-effects caused by trimethoprim include pruritus, skin rash, fever, nausea, vomiting, and sore mouth.

Precautions: It should be given with caution to patients with actual or possible folate deficiency because of possible interference with human folate metabolism by trimethoprim, and administration of folinic acid could be considered.
It should also be used with caution in patients receiving pyrimethamine as they may develop megaloblastic anaemia due to the trimethoprim component.
Adverse effects on the blood may be more severe in malnourished or elderly patients, there also appears to be an increased risk of thrombocytopenia in elderly patients concurrently receiving diuretics, mainly thiazides. All patients receiving prolonged treatment with Purbac should be given regular blood examinations.
It should be used cautiously and in reduced dosage in patients with impaired renal function. Because of the risk of crystalluria, an adequate fluid intake should be maintained and the administration of alkalis may be necessary if very large doses are used.

PRESENTATON: 100 tablets/box

STORAGE: Store below 30°C in airtight and well-closed containers. Protect from light.
KEEP OUT OF REACH OF CHILDREN.

Reg. No:

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

501123

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub—section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name Pacific Medical Industries Ltd.

Address 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product **MEDFORMIN**

Manufacturer Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form Tablet

Presentation Blister pack of 10 x 10 tablets in a carton box

Therapeutic Category Antidiabetic

Strength & Composition Each film-coated tablet contains Metformin Hydrochloride 500mg

Sales Category Prescription Only Medicine

This certificate shall be valid until July, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (3/2018)

Registration No [illegible]L536

Date of issue 13th July, 2018

Signature 14.9.18

Name Professor Dr. Khin Zaw

Designation Secretary

Each tablet contains: Metformin Hydrochloride 500 mg

- Dosage: As directed by the Physician.

Keep out of the reach of children

Batch No. : 091701

Mfg. Date. : 092017

Exp. Date. : 092020

Medformin Tablet

Metformin Hydrochloride 500 mg

10x10 Tablets

Medformin Tablet

Metformin Hydrochloride 500 mg

PACIFIC

Manufactured by:

Pacific Medical Industries Ltd.

City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

• Indication: Metformin as monotherapy, is indicated as an adjunct to diet to lower blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily managed on diet alone. Metformin may be used concomitantly with a sulfonylurea when a Sulfonylurea alone does not result in adequate glycemic control.

10x10 Tablets

Medformin Tablet

Metformin Hydrochloride 500 mg

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

Medformin Tablet
Metformin Hydrochloride 500 mg


Medformin Tablet
Metformin Hydrochloride 500 mg
Manufactured by
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikan Tsp., Yangon, Myanmar.
website: www.aa.com.mm
Medformin Tablet
Metformin Hydrochloride 500 mg
Manufactured by
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikan Tsp., Yangon, Myanmar.
website: www.aa.com.mm
Medformin Tablet
Metformin Hydrochloride 500 mg
Manufactured by
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikan Tsp., Yangon, Myanmar.
website: www.aa.com.mm
Medformin Tablet
Metformin Hydrochloride 500 mg
Manufactured by
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikan Tsp., Yangon, Myanmar.
website: www.aa.com.mm
Batch No. : 091701
Mfg. Date. : 092017
Exp. Date. : 092020



Medformin

Metformin HCL 500 mg

Composition:
Each tablet contains: Metformin hydrochloride 500mg

Indications:
Medformin is indicated in the control of type 2 diabetes mellitus i.e. Non Insulin dependent Diabetes Mellitus (NIDDM) especially in overweight patients. It can be given alone as initial therapy or as combination therapy with sulfonylurea. It can also be used as adjunct therapy in Insulin dependent Diabetes Mellitus (IDDM), especially in overweight patients

Dosage & Administration:
Adults: 500 mg every 8 hours after food. Maximum 3 gm in divided doses per day.
Children: Not recommended children.
Take exactly as directed by your doctor. If you do not understand these direction, ask your pharmacist nurse or doctor to explain the instructions to you.
Take each dose of Pacformin with a full glass of water
Take with a meal to reduce nausea, diarrhea and upset stomach that may occur with metformin therapy. These symptoms may be more likely to occur during the first few weeks of therapy.

Side effects.
Side effects of Metformin include diarrhea, abdominal discomfort, nausea and vomiting, dizziness, rash, metallic taste and anorexia. These are usually minimized by a gradual increase in the dosage of the drug and taking with meals

Contra indication:
Medformin is contraindicated in renal disease or dysfunction as suggested by serum creatinine of 1.5mg/dl or higher in men or 1.4mg/dl or higher in women, acute or chronic metabolic acidosis including diabetic ketoacidosis and diabetic coma, congestive heart failure, alcoholism and hypersensitivity to any component of the drug. It is preferable to use insulin in pregnant female patients.

Interaction:
<u>Alcohol</u>
Potentiates effect of metformin on lactate metabolism.
Cationic drugs like amiloride, digoxin, quinidine may increase metformin serum concentration by competing for tubular secretion
<u>Cimetidine.</u>
This increases the serum concentration of metformin
It is important to closely monitor blood glucose when starting or ending the use of agents that produce hyperglycaemia such as calcium channel blockers, corticosteroids, diuretics, estrogens

Precautions:
<u>Lactic acidosis:</u>
Lactic acidosis is a rare, but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation. Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure. The incidence of lactic acidosis can and should be reduced by assessing also other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any condition associated with hypoxia.

<u>Renal function.</u>
As metformin is excreted by the kidney, serum creatinine levels should be determined before initiating treatment and regularly thereafter
* at least annually in patients with normal renal function,
* at least two to four times a year in patients with serum creatinine levels at the upper limit of normal and in elderly subjects
Decreased renal function in elderly subjects is frequent and asymptomatic. Special caution should be exercised in situations where renal function may become impaired

<u>Administration of iodinated contrast agent.</u>
As the intravascular administration of iodinated contrast materials in radiologic studies can lead to renal failure, metformin should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal.

<u>Surgery:</u>
Metformin hydrochloride should be discontinued 48 hours before elective surgery with general anaesthesia and should not be usually resumed earlier than 48 hours afterwards.

Overdosage:
Hypoglycaemia has not been seen with metformin doses of up to 85g, although lactic acidosis has occurred in such circumstances. High overdose or concomitant risks of metformin may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and metformin is haemodialysis

Storage:
Store below 25°C. Protect from light and moisture
KEEP OUT OF REACH OF CHILDREN

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar

website: www.aa.com.mm

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name	Pacific Medical Industries Ltd.,
Address	408/410, Mahabandoola St, #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar
Name of product	**IMLOMIDE**
Manufacturer	Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar
Dosage form	Tablet
Presentation	Blister pack of 10 x 10 tablets in a carton box.
Therapeutic Category	Antidiarrhoea
Strength & Composition	Each tablet contains Loperamide hydrochloride 2mg.
Sales Category	Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)


Registration No. 2309L744


Date of issue 24th September, 2018

Signature 9.11.18

Name Professor Dr. Khin Zaw

Designation Secretary


IMLOMIDE Tab
Loperamide Hydrochloride 2mg
10x10 Tablets
IMLOMIDE Tab
Loperamide Hydrochloride 2mg
Manufactured by:
Pacific Medical Industries Ltd
City of Industry, Dagon Seikkan Tsp.
website: www.aa.
Keep out of reach of children
Batch No.: 101701
Mfg. Date: 10 /2017
Exp. Date: 10 /2020




IMLOMIDE Tab
Loperamide Hydrochloride 2 mg
Manufactured by:
Pacific Medical Industries Ltd.


10x10 Tablets
IMLOMIDE Tab
Loperamide Hydrochloride 2mg
Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp.
website: www.aa.com.mm
IMLOMIDE Tab
Loperamide Hydrochloride 2mg

IMLOMIDE Tab.

Loperamide Hydrochloride 2 mg

COMPOSITION:
Each tablet contains Loperamide hydrochloride 2mg.
PHARMACOLOGICAL CLASSIFICATION:
A.11.9 Medicines acting on gastro-intestinal tract. Antidiarrhoeals.
PHARMACOLOGICAL ACTION:
Loperamide hydrochloride tablets inhibits hypermotility by direct action on the bowel wall. Its inhibition of peristalsis is the result of decreasing the activity of both the longitudinal muscles (preparatory and reflex phase) and the circular muscles (reflex phase).
Loperamide hydrochloride tablets normalizes the stool in both acute and chronic diarrhoea.
Loperamide hydrochloride tablets is incompletely absorbed from the gut, and it is almost completely metabolized in the liver where it is conjugated and excreted via the bile. Loperamide hydrochloride tablets is mainly eliminated via the faeces.
INDICATIONS:
Adults and children 6 years and older: Loperamide hydrochloride tablets is indicated for the control and symptomatic relief of acute and chronic nonspecific diarrhoea and inhibition of peristalsis and slowing intestinal transit time in patients with ileostomies, colostomies and other intestinal resections.
Children below 6 years of age: Loperamide hydrochloride tablets is indicated for inhibition of peristalsis and slowing intestinal transit time.
CONTRA-INDICATIONS:
Loperamide hydrochloride tablets is contra-indicated in patients with a known hypersensitivity to the medicine.
Loperamide hydrochloride tablets is contra-indicated in infants under 24 months of age.
Since treatment of diarrhoea with Loperamide hydrochloride tablets is only symptomatic, diarrhoea should be treated causally, whenever causal treatment is available. Loperamide hydrochloride tablets should not be used as the primary therapy in acute dysentery, which is characterised by blood in stools and high fever.
Loperamide hydrochloride tablets must not be used in patients with acute ulcerative colitis or pseudomembranous colitis associated with broad spectrum antibiotics. In general, Loperamide hydrochloride tablets should not be used when inhibition of peristalsis is to be avoided and must be discontinued promptly if constipation, abdominal distension or symptoms and signs suggestive of ileus develop. Loperamide administration may precipitate toxic megacolon in patients with inflammatory bowel disease.
The safety of use during pregnancy and lactation has not been established.
DOSAGE AND DIRECTIONS FOR USE:
Loperamide hydrochloride tablets should not be used in infants under 2 years. The tablets, however, are not suited for children under 6 years of age.
Acute non-specific diarrhoea:
For adults and children of 6 years and older: 2 tablets (adults) or 1 tablet (children) as an initial dose followed by 1 tablet after each subsequent loose stool.
Do not exceed the following maximum daily dosages.

WEIGHT IN KILOGRAMS (kg)	MAXIMUM DAILY DOSE
from 14 kg	2 tablets
from 20 kg	3 tablets
from 27 kg	4 tablets
from 34 kg	5 tablets
from 40 kg	6 tablets
from 47 kg	7 tablets
from 54 kg	8 tablets

***Important:** As soon as diarrhoea is under control, stop dosage.*
In acute diarrhoea, if clinical improvement is not observed within 48 hours, the administration of LOPERAMIDE HYDROCHLORIDE TABLETS should be discontinued and patients should be advised to consult their doctor.
Chronic non-specific diarrhoea (consult your doctor):
With individually adjusted dosage it is usually possible to obtain a virtually normal bowel movement.
The initial dose is 2 tablets daily for adults and 1 tablet daily for children of 6 years and over.
The initial dose should be adjusted until 1 - 2 solid stools per day are obtained. This is usually achieved on a maintenance dose of 1 - 6 tablets.
If constipation occurs, the dosage should be decreased.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Reversible paralytic ileus may occur.
Constipation and or abdominal distension, dry mouth, abdominal pain or discomfort and other gastro-intestinal disturbances, (e.g. nausea and vomiting), drowsiness or dizziness and fatigue may occur. Urinary retention has been reported less frequently.
Hypersensitivity reactions such as skin rash and urticaria and less frequently cases of anaphylactic shock and bullous eruption including Toxic Epidermal Necrolysis. Other medications may have caused or contributed to some of these cases.
Precautions:
In patients with diarrhoea, especially in infants, fluid and electrolyte depletion may occur. In such cases administration of appropriate fluid and electrolyte replacement (oral rehydration therapy (ORT)) is the most important measure. Loperamide hydrochloride tablets should not be given to children less than 6 years of age without medical prescription and supervision.
Loperamide hydrochloride tablets is not recommended for routine use in acute or chronic diarrhoea in children under the age of 6 years.
Patients with hepatic dysfunction should be monitored closely for signs of central nervous system toxicity because of the high first-pass metabolism.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Overdosage (including relative overdosage due to hepatic dysfunction) may lead to constipation, urinary retention, ileus and depression of the central nervous system (e.g. stupor, coordination abnormality, somnolence, miosis, muscular hypertonia, respiratory depression). Children may be more sensitive to central nervous system effects of loperamide than adults. Convulsions have been reported in children under the age of 2 years.
Excessive inhibition of peristalsis with nausea and dryness of the mouth.
Treatment is symptomatic and supportive. Naloxone can be given as an antidote. Since the duration of action of Loperamide hydrochloride tablets is longer than that of naloxone (1 to 3 hours) repeated treatment with naloxone may be indicated. Therefore, the patient should be monitored closely for at least 48 hours in order to detect possible central nervous system depression.
STORAGE INSTRUCTIONS:
Store below 25°C. Protect from light.
KEEP OUT OF REACH OF CHILDREN.

Read the directions carefully before use.
For further information, please refer to your doctor.

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name	Pacific Medical Industries Ltd.
Address	408/410, Mahabandoola St. #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar
Name of product	**CIPROXA 500**
Manufacturer	Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar
Dosage form	Tablet
Presentation	Blister pack of 10 x 10 tablets in a carton box.
Therapeutic Category	Anti-infective
Strength & Composition	Each film coated tablet contains Ciprofloxacin HCl 500mg.
Sales Category	Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No	23092550
Date of issue	24th September, 2018

Signature	[signature] 16.11.18
Name	Professor Dr. Khin Zaw
Designation	Secretary

10x10 Tablets

CIPROXA 500 Tablet

Ciprofloxacin HCL 500 mg

CIPROXA 500 Tablet

Ciprofloxacin HCL 500 mg

[DOSAGE AND ADMINISTRATION]
See the insert

[CONTRA-INDICATIONS WARNINGS, etc]
See the insert

[STORAGE CONDITION]
Store at room temperature

[HOW SUPPLIED]
100 TABLETS

Batch No. : 091701
Mfg. Date. : 09/ 2017
Exp. Date. : 09/ 2020

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

10x10 Tablets

CIPROXA 500 Tablet

Ciprofloxacin HCL 500 mg

[DESCRIPTION]

CIPROXA Tablet (Ciprofloxacin HCL 500 mg) is white and film coated oblong tablet.

[INGREDIENTS]

Ciprofloxacin HCL USP .... 582 mg
(as Ciprofloxacin HCL 500 mg)


[INDICATION AND USAGE]

Ciprofloxacin is used in adults for the treatment of urinary tract infections, lower respiratory tract infections, skin and skin structure infections, or bone and joint infections caused by susceptible bacteria. (See the insert)

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.ae.com.mm




Ciprofloxacin HCL 500 mg
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
CIPROXA 500 Tablet
Ciprofloxacin HCL 500 mg
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
CIPROXA 500 Tablet
Ciprofloxacin HCL 500 mg
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
Batch No. : 091701
Mfg. Date. : 09/ 2017
Exp. Date. : 09/ 2020

CIPROXA 250/500 mg

Ciprofloxacin HCL (USP)

[DESCRIPTION]: CIPROXA 250/500 mg , is yellow and film cooled oblong tablet. 500mg is white and film coated oblong tablet.
[INGREDIENTS] in each tablet
Ciprofloxacin HCL (USP) .... 291 mg (as Ciprofloxacin 250mg)
Ciprofloxacin HCL (USP) .... 582 mg (as Ciprofloxacin 500nng)
[INDICATION AND USAGE]
For the treatment of infections caused by susceptible strains of the designated microorganism in the conditions listed below.
Please see the DOSAGE AND ADMINISTRATION for specific recommendations.
Lower Respiratory Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae. Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae , Haemophilus porainfluenzae , or Streptococcus pneumoniae.
Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Protous vulgaris, Providencia stuartii , Morgonella morganii. Citrobacter freundii, Pseudomonas aeruginosa, staphylococcus aureus, Staphylococcus epidermidis, or Streptococcus pyogens.
Bone and Joint Infection caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginoso.
Urinary Tract Infections caused by Eschericbia coli. Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterocuteus faecalis.
Infectious Diarrhoea caused by Escherichia coli (Enter toxigenic strains) Campylobacter jejuni , Shigella flexneri or shigella sonnei , when antibacterial therapy is indicated.

[DOSAGE AND ADMINISTRATION]
The usual adult dosage for patients with urinary tract infections is 250mg every 12 hours. For patients with complicated infections caused by organisms not highly susceptible, 500mg may be: administered every 12 hours. Lower respiratory tract infections, skin and skin structure infections, and bone and joint infections may be treated with 500mg every 12 hours. For more severe or complicated infections, a dosage of 750 mg may be given every 12 hours. The recommended dosage for infectious Diarrhoea is 500mg every 12 hours.

DOSAGE GUIDELINES

Location of Infection	Type of Severity	Unit Dose	Frequency	Dolly Dose
Urinary Tract	Mild/ Moderate	250mg	q 12 h	500mg
	Severe/ Complicated	500mg	q 12 h	1000mg
Lower Respiratory Tract; Bone and Joint;	Mild/ Moderate	500mg	q 12 h	1000mg
Skin & Skin Structure	Severe/ Complicated	750mg	q 12 h	1500mg
Infectious Diarrhoea	Mild/ Moderate/ Severe	500mg	q 12 h	1000mg

The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative organism, the integrity of the patients host-defense mechanisms, and the status of renal function and hepatic function.
The duration of treatment depends upon the severity of infection. Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration 7 to 14 days; however, for severe and complicated infections more prolonged therapy may be required. Bone & Joint infections may require treatment for 4 to 6 weeks or longer. Infectious Diarrhoea may be treated for 5 - 7 days.
Concurrent Use with Antacids or Multivalent Cations: Concurrent administration of Ciprofloxacin with sucralfate or divalent and trivalent cations such as iron or antacids containing magnesium, aluminum, or calcium may substantially interfere with the absorption of Ciprofloxacin, resulting in serum and urine levels considerably lower than desired. Therefore, concurrent administration of these agents with ciprofloxacin should be avoided. However, usual dietary intake of calcium has not been shown to after the bioavailability studies trove shown that antacid may be administered either 2 hours after or 6 hours before Ciprofloxacin dosing without a significant decrease bioavailability Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of Ciprofloxacin.
Impaired Renal Function: Ciprofloxacin is eliminated primarily by renal excretion; however the drug o also metabolized and partially cleared through the biliary system of the lower and through the intestine. These alternate pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction. The following table provides dosage guidelines for use in patients with renal impairment; however, monitoring of serum drug levels provides the most reliable basis for dosage adjustment:
RECOMMENDED STARTING AND MAINTENANCE DOSES FOR PATIENTS WITH IMPAIRED RENAL FUNCTION

Creatinine Clearance (ml/min)	Dose	
>50	See Usual Dosage	
30-50	250-500 mg	q 12 h
5-29	250-500 mg	q 18 h
Patients on hemodialysis Or peritoneal dialysis	250- 500 mg (after dialysis)	q 24 h

When only the serum creatinine concentration is known, the following formula may be used to estimate creatinine clearance.

$$\text{Men: creatinine clearance (ml/min)} = \frac{\text{Weight (kg)} \times (140\text{-age})}{72 \times \text{serum creatinine (mg/dl)}}$$

Women: 0.85 x the value calculated for men
The serum creatinine should represent a steady state of· renal function. In patients with severe infections and severe renal impairment a unit dose of 750mg may be administered at the intervals noted above; however, patients should be carefully monitored and the serum Ciprofloxacin concentration should be measured periodically. Peak concentrations (l -2 hours after dosing) should generally range from 2 to 4μg/ml. For patients with changing renal function or for patients with renal impairment and hepatic insufficiency, measurement of serum concentrations of Ciprofloxacin will provide additional guidance for adjusting dosage.
[CONTRA-INDICATIONS WARNINGS, etc]
Contra- Indications: Ciprofloxacin is contra-indicated in patients who have shown hypersensitivity to ciprofloxacin or other quinolones. Ciprofloxacin is also contra-indicated in children and growing adolescents except where the benefits of treatment exceed the risks.

Warning and precautions: Ciprofloxacin should be used with caution in epileptics and patients with a history of CNS disorders and only if the benefits of treatment are considered to outweigh- the risk of possible CNS side-effects.
Ciprofloxacin could result in on impairment of the patient's ability to drive or operate machinery, particularly in conjunction with alcohol.
Crystal Luria related to the use of ciprofloxacin has been reported. Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.
Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity are prone to hemolytic reactions with quinolones, and so ciprofloxacin should be used with caution.
Drug Interactions: Ciprofloxacin Tablets should not be administered within 4 hours of medications containing magnesium, aluminum or iron salts as interference with absorption may occur, when appropriate patients should be advised not to self-medicate with antaci.ds or iron-containing preparations during therapy with Ciprofloxacin.
Increased plasma levels of theophylline have been observed following concurrent administration with ciprofloxacin. It is recommended that the dose of theophylline should be reduced and plasma levels of theophylline monitored .When monitoring of plasma levels is not possible. the use of ciprofloxacin should be avoided in patients receiving theophylline. Particular caution is advised in those patients with convulsive disorders.
Prolongation of bleeding time has been reported during concomitant administration of ciprofloxacin and anticoagulants. Animal data have shown that high doses of quinolones in combination with some non-steroidal anti-inflammatory drugs (e .g . fenbuten , but not acetylsalicyclic acid) can lead to convulsions.
Transient increases in serum creatinine have been seen following concomitant administration of ciprofloxacin and cyclosporine. Therefore, monitoring of serum creatinine levels is advisable
The simultaneous administration of quinolones and glibenclamide can on occasion potentiate the effect of glibenclamide, resulting in hypo glycaemia.
Concomitant use with probenecid reduces the renal clearance of ciprofloxacin, resulting in increased quinolone plasma levels.
It is recommended that opiate premed cants or regional an aesthetic agents are not administered concomitantly with ciprofloxacin 11/hen used for surgical prophylaxis.
Use in pregnancy and lactation: Reproduction studies performed in mice, rats and rabbits using parenteral and oral administration did not reveal any evidence of teratogenicity, impairment of fertility or impairment of per post-natal development.
However, as with other quinolones, ciprofloxacin has been shown to cause arthropathy in immature animals and therefore its use during pregnancy is not recommended. Studies have indicated that ciprofloxacin is secreted in breast milk.
Administration to nursing mothers is thus not recommended.
Side-effects: Ciprofloxacin is generally well tolerated. The most frequently reported adverse reactions are: nausea, diarrhoea, vomiting, dyspepsia, abdominal pain, headache, restlessness, rash, dizziness and pruritus The following adverse reactions have been observed :
Gastro-intestinal disturbances, e.g. nausea, diarrhoea, vomiting, dyspepsia, abdominal pain, anorexia, flatulence, dysphogia. Rarely, pseudomembranous colitis.
CNS disturbances e.g. headache, restlessness, depression. diuiness, tremor convulsions, confusion, hallucinations, somnolence.
Very rarely, sleep disorders and anxiety states. There are isolated reports of intracranial hypertension associated with quinolone therapy.
Hypersensitivity skin, e.g. rash, pruritus, urticaria, photosensitivity, drug induced fever. Anaphylactic anaphylactoid reactions.
Very rarely, petechial, hemorrhagic bullae, vacuities, Stevens - Johnson syndrome and Lyell Syndrome. Treatment with ciprofloxacin should be discontinued if any of the above occurs upon first administration.
Hepatic disturbances, e. g. transient increases in liver enzymes or serum bilirubin (particularity in patients with previous liver
damage), hepatitis, jaundice and major liver disorders including hepatic necrosis.
Renal disturbances, e.g. transient increases in blood urea or serum creatinine, renal failure,crystollurio and nephritis.
Musculoskeletal disturbances. e.g. arthralgia. myalgia, rarely, tanosynovitis. -
Effects on haematological parameters,e.g. eosinophilia, leucopenia. granulocytopenia, thrombocytopenia, thrombocytosis, altered prothrombin levels and very rarely, haemolytic anaemia. Special sense disturbances, e.g. very rarely, visual disturbances, impaired taste and smell , tinnitus and transient impairment of hearing, particularly at high frequencies. Tachycardia has been reported.
Over dosage: No information on over dosage is available. Routine measures such as gastric lavage should be performed as soon as possible offer ingestion of Ciprofloxacin Tablets.
Serum levels of ciprofloxacin are reduced by dialysis
[STORAE CONDITION] Store at room temperature.
[HOW SUPPLIED] 100T

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR
MINISTRY OF HEALTH AND SPORTS
MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub—section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd.

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **CIPROXA 250**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Tablet

Presentation: Blister pack of 10 x 10 tablets in a carton box

Therapeutic Category: Anti-infective

Strength & Composition: Each film coated tablet contains Ciprofloxacin HCl 250mg.

Sales Category: Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No: 23092551

Date of issue: 24th September, 2018

Signature: [signature] 16.9.18

Name: Professor Dr. Khin Zaw

Designation: Secretary

[INDICATION AND USAGE]

For the treatment at infectins caused by susceptible strains of the designated microorganism in the conditions listed below.
Please see the DOSAGE AND ADMINISTRATION for specific recommendations.
(See the insert)

10x10 Tablets

CIPROXA 250 Tablet

Ciprofloxacin HCL 250 mg

Batch No. : 091701
Mfg. Date. : 09/ 2017
Exp. Date. : 09/ 2020

Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

CIPROXA 250 Tablet

Ciprofloxacin HCL 250 mg

[DESCRIPTION]

CIPROXA Tablet (Ciprofloxacin HCL 250 mg) is yellow and film coated oblong tablet.

[INGREDIENTS] in each tablet

Ciprofloxacin HCL USP ______________ 291 mg
(as Ciprofloxacin HCL 250 mg)

[STORAGE CONDITION]

Store at room temperature

10x10 Tablets

CIPROXA 250 Tablet

Ciprofloxacin HCL 250 mg

Manufactured by:

PACIFIC **Pacific Medical Industries Ltd.**
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm


CIPROXA 250 Tablet
Ciprofloxacin HCL 250 mg
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
CIPROXA 250 Tablet
Ciprofloxacin HCL 250 mg
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar
CIPROXA 250 Tablet
Ciprofloxacin HCL 250 mg
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar
Batch No. : 091701
Mfg. Date. : 09/ 2017
Exp. Date. : 09/ 2020



CIPROXA 250/500 mg

Ciprofloxacin HCL (USP)

[DESCRIPTION]: CIPROXA 250/500 mg , is yellow and film cooled oblong tablet. 500mg is white and film coated oblong tablet.
[INGREDIENTS] In each tablet
Ciprofloxacin HCL (USP) .... 291 mg (as Ciprofloxacin 250mg)
Ciprofloxacin HCL (USP) .... 582 mg (as Ciprofloxacin 500nng)
[INDICATION AND USAGE]
For the treatment of infections caused by susceptible strains of the designated microorganism in the conditions listed below.
Please see the DOSAGE AND ADMINISTRATION for specific recommendations.
Lower Respiratory Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae. Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae , Haemophilus porainfluenzae , or Streptococcus pneumoniae.
Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii , Morgonella morganii. Citrobacter freundii, Pseudomonas aeruginosa, staphylococcus aureus, Staphylococcus epidermidis, or Streptococcus pyogens.
Bone and Joint Infection caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginoso.
Urinary Tract Infections caused by Escherichia coli. Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterococcus faecalis.
Infectious Diarrhoea caused by Escherichia coli (Enter toxigenic strains) Campylobacter jejuni , Shigella flexneri or shigella sonnei , when antibacterial therapy is indicated.

[DOSAGE AND ADMINISTRATION]
The usual adult dosage for patients with urinary tract infections is 250mg every 12 hours. For patients with complicated infections caused by organisms not highly susceptible, 500mg may be: administered every 12 hours. Lower respiratory tract infections, skin and skin structure infections, and bone and joint infections may bo treated with 500mg every 12 hours. For more severe or complicated infections, a dosage of 750 mg may be given every 12 hours. The recommended dosage for infectious Diarrhoea is 500mg every 12 hours.

DOSAGE GUIDELINES

Location of Infoction	Type of Severity	Unit Dose	Frequency	Dolly Dose
Urinary Tract	Mild/ Moderate	250mg	q 12 h	500mg
	Severe/ Complicated	500mg	q 12 h	1000mg
Lower Respiratory Tract; Bone and Joint;	Mild/ Moderate	500mg	q 12 h	1000mg
Skin & Skin Structure	Severe/ Complicated	750mg	q 12 h	1500mg
Infectious Diarrhoea	Mild/ Moderate/ Severe	500mg	q 12 h	1000mg

The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative organism, the integrity of the patients host-defense mechanisms, and the status of renal function and hepatic function.
The duration of treatment depends upon the severity of infection. Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration 7 to 14 days; however, for severe and complicated infections more prolonged therapy may be required. Bone & Joint infections may require treatment for 4 to 6 weeks or longer. Infectious Diarrhoea may be treated for 5 - 7 days.
Concurrent Use with Antacids or Multivalent Cations: Concurrent administration of Ciprofloxacin with sucralfate or divalent and trivalent cations such as iron or antacids containing magnesium, aluminum, or calcium may substantially interfere with the absorption of Ciprofloxacin, resulting in serum and urine levels considerably lower than desired. Therefore, concurrent administration of these agents with ciprofloxacin should be avoided. However, usual dietary intake of calcium has not been shown to after the bioavailability studies trove shown that antacid may be administered either 2 hours after or 6 hours before Ciprofloxacin dosing without a significant decrease bioavailability Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of Ciprofloxacin.
Impaired Renal Function: Ciprofloxacin is eliminated primarily by renal excretion; however the drug o also metabolized and partially cleared through the biliary system of the lower and through the intestine. These alternate pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction. The following table provides dosage guidelines for use in patients with renal impairment; however, monitoring of serum drug levels provides the most reliable basis for dosage adjustment:
RECOMMENDED STARTING AND MAINTENANCE DOSES FOR PATIENTS WITH IMPAIRED RENAL FUNCTION

Creatinine Clearance (ml/min)	Dose	
>50	See Usual Dosage	
30-50	250-500 mg	q 12 h
5-29	250-500 mg	q 18 h
Patients on hemodialysis Or peritoneal dialysis	250- 500 mg (after dialysis)	q 24 h

When only the serum creatinine concentration is known, the following formula may be used to estimate creatinine clearance.

$$\text{Men: creatinine clearance (ml/min)} = \frac{\text{Weight (kg)} \times (140\text{-age})}{72 \times \text{serum creatinine (mg/dl)}}$$

Women: 0.85 x the value calculated for men
The serum creatinine should represent a steady state of renal function. In patients with severe infections and severe renal impairment a unit dose of 750mg may be administered at the intervals noted above; however, patients should be carefully monitored and the serum Ciprofloxacin concentration should be measured periodically. Peak concentrations (l -2 hours after dosing) should generally range from 2 to 4μg/ml. For patients with changing renal function or for patients with renal impairment and hepatic insufficiency, measurement of serum concentrations of Ciprofloxacin will provide additional guidance for adjusting dosage.
[CONTRA-INDICATIONS WARNINGS, etc]
Contra- indications: Ciprofloxacin is contra-indicated in patients who have shown hypersensitivity to ciprofloxacin or other quinolones. Ciprofloxacin is also contra-indicated in children and growing adolescents except where the benefits of treatment exceed the risks.

Warning and precautions: Ciprofloxacin should be used with caution in epileptics and patients with a history of CNS disorders and only if the benefits of treatment are considered to outweigh- the risk of possible CNS side-effects.
Ciprofloxacin could result in on impairment of the patient's ability to drive or operate machinery, particularly in conjunction with alcohol.
Crystal Luria related to the use of ciprofloxacin has been reported. Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.
Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity are prone to hemolytic reactions with quinolones, and so ciprofloxacin should be used with caution.
Drug interactions: Ciprofloxacin Tablets should not be administered within 4 hours of medications containing magnesium, aluminum or iron salts as interference with absorption may occur, when appropriate patients should be advised not to self-medicate with antaci.ds or iron-containing preparations during therapy with Ciprofloxacin.
Increased plasma levels of theophylline have been observed following concurrent administration with ciprofloxacin. It is recommended that the dose of theophylline should be reduced and plasma levels of theophylline monitored .When monitoring of plasma levels is not possible. the use of ciprofloxacin should be avoided in patients receiving theophylline. Particular caution is advised in those patients with convulsive disorders.
Prolongation of bleeding time has been reported during concomitant administration of ciprofloxacin and anticoagulants. Animal data have shown that high doses of quinolones in combination with some non-steroidal anti-inflammatory drugs (e .g . fenbuten , but not acetylsalicylic acid) can lead to convulsions.
Transient increases in serum creatinine have been seen following concomitant administration of ciprofloxacin and cyclosporine. Therefore, monitoring of serum creatinine levels is advisable
The simultaneous administration of quinolones and glibenclamide can on occasion potentiate the effect of glibenclamide, resulting in hypo glycaemia.
Concomitant use with probenecid reduces the renal clearance of ciprofloxacin, resulting in increased quinolone plasma levels.
It is recommended that opiate premed cants or regional an aesthetic agents are not administered concomitantly with ciprofloxacin 11/hen used for surgical prophylaxis.
Use in pregnancy and lactation: Reproduction studies performed in mice, rats and rabbits using parenteral and oral administration did not reveal any evidence of teratogenicity, impairment of fertility or impairment of per post-natal development.
However, as with other quinolones, ciprofloxacin has been shown to cause arthropathy in immature animals and therefore its use during pregnancy is not recommended. Studies have indicated that ciprofloxacin is secreted in breast milk.
Administration to nursing mothers is thus not recommended.
Side-effects: Ciprofloxacin is generally well tolerated. The most frequently reported adverse reactions are: nausea, diarrhoea, vomiting, dyspepsia, abdominal pain, headache, restlessness, rash, dizziness and pruritus The following adverse reactions have been observed :
Gastro-intestinal disturbances, e.g. nausea, diarrhoea, vomiting, dyspepsia, abdominal pain, anorexia, flatulence, dysphogia. Rarely, pseudomembranous colitis.
CNS disturbances e.g. headache, restlessness, depression. diuiness, tremor convulsions, confusion, hallucinations, somnolence.
Very rarely, sleep disorders and anxiety states. There are isolated reports of intracranial hypertension associated with quinolone therapy.
Hypersensitivity skin, e.g. rash, pruritus, urticaria, photosensitivity, drug induced fever. Anaphylactic anaphylactoid reactions.
Very rarely, petechial, hemorrhagic bullae, vaculties, Stevens - Johnson syndrome and Lyell Syndrome. Treatment with ciprofloxacin should be discontinued if any of the above occurs upon first administration.
Hepatic disturbances, e. g. transient increases in liver enzymes or serum bilirubin (particularity in patients with previous liver damage), hepatitis, jaundice and major liver disorders including hepatic necrosis.
Renal disturbances, e.g. transient increases in blood urea or serum creatinine, renal failure,crystoliurio and nephritis.
Musculoskeletal disturbances. e.g. arthralgia. myalgia, rarely, tenosynovitis. -
Effects on haematological parameters,e.g. eosinophilia, leucopenia. granulocytopenia, thrombocytopenia, thrombocytosis, altered prothrombin levels and very rarely, haemolytic anaemia. Special sense disturbances, e.g. very rarely, visual disturbances, impaired taste and smell, tinnitus and transient impairment of hearing, particularly at high frequencies. Tachycardia has been reported.
Over dosage: No information on over dosage is available. Routine measures such as gastric lavage should be performed as soon as possible offer ingestion of Ciprofloxacin Tablets.
Serum levels of ciprofloxacin are reduced by dialysis
[STORAE CONDITION] Store at room temperature.
[HOW SUPPLIED] 100T

Manufactured by:
PACIFIC Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name: Pacific Medical Industries Ltd

Address: 408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar

Name of product: **LEFLOXA 500**

Manufacturer: Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar

Dosage form: Caplet

Presentation: Blister pack of 10 x 10 caplets in a carton box

Therapeutic Category: Anti-infective

Strength & Composition: Each film coated caplet contains Levofloxacin Hemihydrate eq. to Levofloxacin 500mg.

Sales Category: Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No: 23092548

Date of issue: 24th September, 2018

Signature: [signature] 16.11.18

Name: Professor Dr. Khin Zaw

Designation: Secretary

INDICATIONS:

Levofloxacin can be used in adults, in the treatment of the following bacterial infections:

- Acute exacerbations of chronic bronchitis
- Pneumonia (community acquired)
- Sinusitis
- Urinary tract infections (complicated) and acute pyelonephritis
- Uncomplicated urinary tract infections in women
- Skin and soft tissue infections (uncomplicated)
- Skin and soft tissue infections (complicated)
- Intra-abdominal infections

Batch. No. :121701
Mfg. Date. :122017
Exp. Date. :122021

10x10 Caplets


Lefloxa 500


(LEVOFLOXACIN Caplet 500mg)


PACIFIC

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

website: www.aa.com.mm




(LEVOFLOXACIN Caplet 500 mg)
Lefloxa 500
10x10 Caplets
GMP
COMPOSITION:
Each 500 mg film coated caplet contains:
Levofloxacin Hemihydrate equivalent to 500 mg Levofloxacin.
DOSAGE AND DIRECTIONS FOR USE:
See the insert.
Lefloxa 500
(LEVOFLOXACIN Caplet 500mg)
STORAGE:
Store below 25°C in a dry place.
Protect from light.
KEEP OUT OF REACH OF CHILDREN.
PACIFIC
Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
website: www.aa.com.mm


Lefloxa 500
(LEVOFLOXACIN Caplet 500mg)
Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.

Lefloxa 500 Caplets 250mg, 500mg

GMP

COMPOSITION:
Each 250 mg film coated caplet contains: Levofloxacin Hemihydrate equivalent to 250 mg Levofloxacin.
Each 500 mg film coated caplet contains: Levofloxacin Hemihydrate equivalent to 500 mg Levofloxacin.

INDICATIONS:
Levofloxacin can be used in adults, in the treatment of the following bacterial infections:
- Acute exacerbations of chronic bronchitis: caused by H. influenzae, K. pneumoniae, S. aureus, M. catarrhalis, E. coli, H. parainfluenzae or S. pneumoniae.
- Pneumonia (community acquired): caused by H. influenzae, S. pneumoniae, S. aureus, M. catarrhalis, H. parainfluenzae, K. pneumoniae, E. coli, Mycoplasma pneumoniae, Chlamydia pneumoniae or Legionella pneumophila.
- Sinusitis: caused by H. influenzae, S. pneumoniae, S. aureus, M. catarrhalis or H. parainfluenzae.
- Urinary tract infections (complicated) and acute pyelonephritis: caused by E. coli, K. pneumoniae, S. faecalis, P. mirobilis, Enterobacter cloacae and P. aeruginosa.
- Uncomplicated urinary tract infections in women: caused by E. coli, K. pneumoniae.
- Skin and soft tissue infections (uncomplicated): caused by S. aureus, S. pyogenes, Acinetobacter calcoaceticus, E. cloacae, P. mirabilis, P. aeruginosa, E. coli, K. pneumoniae or S. faecalis.
- Skin and soft tissue infections (complicated): caused by S. aureus, S. pyogenes, P. mirobilis, E. coli, K. pneumoniae, S. faecalis, E. cloacae, K. oxytoca.
- Intra-abdominal infections: caused by E. coli and anaerobic micro-organisms.

CONTRA-INDICATIONS:
The use of levofloxacin is contra-indicated in:
- Previous hypersensitivity reactions to levofloxacin, other quinolones, or any other ingredient.
- Epilepsy.
- Patients with a history of tendon disorders associated with fluoroquinolone administration.
- Children or adolescents (under 18 years of age).
- During pregnancy and lactation.

WARNINGS:
LEVOFLOXACIN SHOULD NOT BE GIVEN TO PATIENTS UNDER 18 YEARS OF AGE.
Caution should be exercised when using levofloxacin in patients:
- Prone to seizures, such as patients with pre-existing central nervous system lesions,
- Being treated with fenbufen or nonsteroidal anti-inflammatory medicines or
- Using medicines which lower the cerebral seizure threshold, such as theophylline.
- Driving or operating machinery as the use of levofloxacin may alter the ability to drive or operate machinery
- Being tested for tuberculosis as levofloxacin inhibits the growth of Mycobacterium tuberculosis and therefore may give false-negative results in the bacteriological diagnosis of tuberculosis
- Exposed to ultraviolet light such as sunlight through window glass or longer wavelength ultraviolet (UVA) from sun beds, in order to prevent photosensitisation.

INTERACTIONS:
The absorption of levofloxacin is significantly reduced when administered with iron salts, antacids and sucralfate. It is recommended that preparations containing iron salts, sucralfate, magnesium- or aluminium-containing antacids should not be taken two hours before or after levofloxacin tablet administration. Levofloxacin is known to inhibit hepatic medicine metabolism and may interfere with the clearance of medicines, such as theophylline, fenbufen or similar non-steroidal anti-inflammatory medicines that lower the seizure threshold.

PREGNANCY AND LACTATION:
The use of levofloxacin during pregnancy and lactation is contra-indicated.

DOSAGE AND DIRECTIONS FOR USE:
Levofloxacin caplets should be swallowed whole, without crushing. Levofloxacin may be taken on an empty stomach or with meals.
Levofloxacin is to be taken once or twice daily in a usual dose of 250 or 500 mg. The dosage will depend on the type of pathogen and the severity of the infection. The use of Levofloxacin should be continued for a minimum of 48 to 72 hours after commencement of therapy. The duration of therapy varies according to the course of the disease.
The following daily doses are recommended for Levofloxacin:

Daily dosage recommended in patients with normal renal function:
Bronchitis, bacterial exacerbations: 500 mg once daily for 5-10 days.
Pneumonia, community acquired: 500 mg once or twice daily for 10-14 days. (The higher dosage should be chosen in the presence of complicating factors e.g. co-morbidity, advanced age).
Sinusitis: 500 mg once daily for 10 to 14 days.
Urinary tract infections, (complicated) and acute pyelonephritis: 250 mg once daily for 10 days.
Urinary tract infections (uncomplicated) in women: 250 mg once daily for 3 days.
Uncomplicated skin and soft tissue infections: 250 to 500 mg once daily for 7-10 days.
Complicated skin and soft tissue infections: 500 mg once daily for 10-14 days.
Intra-abdominal infections: 500 mg once daily in combination with an antibiotic with anaerobic coverage for 10-14 days.
Above infections when bacteraemia or septicaemia is present: 500 mg twice daily for 10-14 days.

Daily dosage recommended in patients with impaired renal function:
Dosage must be adjusted in patients with impaired renal function according to the degree of impairment (creatinine clearance <50 mL/min):
Patients with a creatinine clearance between 20 and 50 mL/min:
Patients meant to be taking 250 or 500 mg once daily: a normal single dose should be given initially and then reduced by half this dose once daily.
Patients meant to be taking 500 mg twice daily: the initial dose should be 500 mg and then 250 mg should be taken twelve hourly.
Patients with a creatinine clearance between 10 and 19 mL/min:
Patients to be taking 250 mg once daily: a normal single dose should be given initially and then reduced to 125 mg every 48 hours.
Patients to be taking 500 mg once daily: should be given a normal single dose initially and then this dose should be reduced to 125 mg every 24 hours.
Patients to be taking 500 mg twice daily: should be given 500 mg initially and then this dose should be reduced to 125 mg every 12 hours.
Patients with a creatinine clearance of less than 10 mL/min or in patients on haemodialysis or CAPD (Continuous Ambulatory Peritoneal Dialysis):
In patients where the prescribed dosage is 250 mg once daily: a normal single dose should be given initially and then this dose should be reduced to 125 mg every 48 hours.
Patients to be taking 500 mg once daily: should be given a normal single dose initially and then this dose should be reduced to 125 mg every 24 hours.
Patients to be taking 500 mg twice daily: should be given 500 mg initially and then this dose should be reduced to 125 mg every 24 hours.
No adjustment of dosage is required in the elderly or in patients with impaired liver function.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
The symptoms that can be expected from an acute overdosage of levofloxacin are central nervous system symptoms such as confusion, dizziness, impairment of consciousness and convulsive seizures.
The treatment of an overdosage is symptomatic and supportive.
Levofloxacin is not effectively removed by hemodialysis or peritoneal dialysis.

STORAGE:
Store below 25°C in a dry place. Protect from light.
KEEP OUT OF REACH OF CHILDREN.

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
website: www.aa.com.mm

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub—section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name	Pacific Medical Industries Ltd.
Address	408/410, Mahabandoola St. #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar
Name of product	ADVIL 400
Manufacturer	Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar
Dosage form	Tablet
Presentation	Blister pack of 10 x 10 tablets in a carton box
Therapeutic Category	Analgesic & Anti-inflammatory (Non-steroidal)
Strength & Composition	Each film coated tablet contains Ibuprofen 400mg.
Sales Category	Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No 2309D2549

Date of issue 24th September, 2018


Signature 16.11.18

Name Professor Dr. Khin Zaw

Designation Secretary


10 x10 Tablets
ADVIL 400 Tab.
Ibuprofen Tablets 400 mg
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar
website: www.aa.com.mm
ADVIL 400 Tab.
Ibuprofen Tablets 400 mg
Each film coated tablet contains:
Ibuprofen ....400 mg
Excipients...................................q.s.
Dosage and Administration: See the insert.
Indications: Relief of signs and symptoms of Rheumatoid arthritis [including Still's disease] & Osteoarthrosis. Relief of mild-to- moderate pain; Treatment of primary dysmenorrhea. Reduction of fever. Ankylosing spondylitis, seronegative arthropathies, cervical spondylosis. Dental & traumatic inflammations.
Store at a temperature not exceeding 30°C




ADVIL 400 Tab.
Ibuprofen Tablets 400 mg
10 x10 Tablets
ADVIL 400 Tab.
Ibuprofen Tablets 400 mg
Manufactured by:
PACIFIC
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar
website: www.aa.com.mm
Keep Out of the Reach of Children.
Store at a temperature not exceeding 30°C
Batch No.: 101701
Mfg. Date: 10/2017
Expiry Date: 10/2020


ADVIL 400 Tab.
Ibuprofen Tablets 400 mg
ADVIL 400 Tab.
Ibuprofen Tablets 400 mg
ADVIL 400 Tab.
Ibuprofen Tablets 400 mg
ADVIL 400 Tab.
Ibuprofen Tablets 400 mg

ADVIL 400 Tab.

Ibuprofen Tablets 400 mg

Composition: IBUPROFEN TABLETS 400 mg
Each film coated tablet contains:
Ibuprofen ....400 mg
Excipients..............................q.s.

Description : The active ingredient is ibuprofen, which is a member of the propionic acid group of nonsteroidal antiinflommatory drugs. Ibuprofen is a racemic mixture of [+]S-and [-] R enantiomers. These preparations are used for treatment of inflammatory disorders, muscle spasm and rheumatic disorders.

Method of Action:
Ibuprofen have analgesic and antipyretic activities. Exact mode of actions is not known. Major mechanism is believed to be inhibition of cycloxygenase activity and prostaglandin synthesis.
Although most ibuprofen are primarily used for anti-inflammatory effects, they are effective analgesics and useful for relief of mild to moderate pain. They do not alter the course of the underlying disease.

Pharmacokinetics: Ibuprofen is nonsteriodal anti-in-flammatory, analgesic and antipyretic activity. Its mode of action, like that of other NSAIDs, is not completely understood, but may be related to prastaglandin synthetasein hibition. After absorption of the racemic ibuprofen.

ON SET OF ACTION : Analgesic action 30 mins; antiinflammatiry action up to 7 days.

DURATION OF ACTION: 4-6 hours.

Indications: Relief of signs and symptoms of Rheumatoid arthritis [including Still's disease] & Osteoarthrosis. Relief of mild-to-moderate pain; Treatment of primary dysmenorrhea. Reduction of fever. Ankylosing spondylitis, seronegative arthropathies, cervical spondylosis. Dental & traumatic inflammations.
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

Contraindications: Active peptic ulcer. GI bleeding, hypersensitivity.

Dosage and Administration: Adult: Do not exceed 3.2 g/day. If GI upset occurs, take with meals Rheumatoid arthritis and osteoarthritis- individualize dosage. 1.2 to 3.2 g/day [300mg 4 times daily or 400, 600 or 800mg 3 or 4 times daily]. In chronic conditions, therapeutic response sometimes occurs in a few days to a week, but most often within 2 weeks. Rheumatoid arthritis patients seem to require higher doses than osteoarthritis patients.
Mild-to-moderate pain 400mg every 4 to 6 hours, as necessary.
Primary dysmenorrhea 400mg every 4 to 6 hours, as necessary.
OTC use [minor aches and pains, dysmenorrheal, fever reduction]-200mg every 4 to 6 hours while symptoms persist. If pain or fever do not respond to 200mg, 400mg may be used. Do not exceed 1.2 g in 24 hours. Do not take for pain for 10 days or for fever for 3 days, unless directed by physician.
Children: Mild Analgesic or antipyretic: 10-15 mg/kg/dose every 4-6 hours. Juvenile Rheumatoid Arthritis: Usual dose is 30 to 70 mg/kg/day in 3 or 4 divided doses; 20mg/kg/day may be adequate for milder disease.
Fever reduction: [6 months to 12 years of age] Adjust dosage on the basis to the initial temperature level.

Warnings and Precautions: Bleeding disorders, aspirin or anti-inflammatory drug induced allergy, asthma, hypertension, hepatic or renal or cardiac dysfunction.

Interactions: Cummarin-type anticoagulants. Aspirin, Methotrexate, H2 Antagonists, Furosemide, Lithium.

Adverse effects: Nausea, vomiting, epigastric discomfort, skin rash, peptic ulcer, fluid retention, oedema, impairment of hepatic function rarely.

Overdosage: Symptoms that may occur within 24 hours of overdosage include nausea, vomiting, lethargy and sweating. Abdominal pain may be the first indication of liver damage, which is not usually apparent for 24 to 48 hours and is generally at a maximum 72 to 96 hours after ingestion.

Storage: Store at temperature not exceeding 30°C

Presentation: Box of 10 blisters of 10 tablets. Box of 100 blisters of 10 tablets.
Bulk pack of 100 tablets. Bulk pack of 1000 tablets.

KEEP ALL THE MEDICINES AWAY FROM REACH OF CHILDREN.

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
website: www.aa.com.mm

THE GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR

MINISTRY OF HEALTH AND SPORTS

MYANMAR FOOD AND DRUG BOARD OF AUTHORITY

DRUG REGISTRATION CERTIFICATE

In accordance with Section (5) Sub–section (g) of the National Drug Law, it is hereby certified that the undermentioned pharmaceutical product has been granted registration with reference to the application made by,

Applicant's name	Pacific Medical Industries Ltd.
Address	408/410, Mahabandoola St., #06-00, Samsung Plaza, Kyauktada Township, Yangon, Myanmar
Name of product	CARDISAFE
Manufacturer	Pacific Medical Industries Ltd., Dagon Seikkan Township, Yangon, Myanmar
Dosage form	Tablet
Presentation	Blister pack of 10 x 10 tablets in a carton box.
Therapeutic Category	Antihypertensive
Strength & Composition	Each film-coated tablet contains Atenolol 50mg.
Sales Category	Prescription Only Medicine

This certificate shall be valid until September, 2023 unless earlier suspended or cancelled.

No change in specifications of the product shall be made without the approval of Myanmar Food and Drug Board of Authority.

Ref: DAC (N/S) (4/2018)

Registration No 2809L559

Date of issue 24th September, 2018

Signature 28.11.18

Name Professor Dr. Khin Zaw

Designation Secretary

10 x 10 Tabs

Cardisafe

(Atenolol 50 mg) 100 Tabs

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon,
website: www.es.com.mm

Cardisafe
(Atenolol 50 mg) 100 Tabs

Composition: Each tablet contains
Atenolol..50 mg
Indication: Hypertension, Angina pactoris, Myocardial infarction.
Appearance: White, round film-coated tablet.
Dosage & Administration: Carefully read the enclosed leaflet.

Cardisafe
(Atenolol 50 mg) 100 Tabs

10 x 10 Tabs

Cardisafe

(Atenolol 50 mg) 100 Tabs

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon,
website: www.es.com.mm

Precautions: See enclosed leaflet.
Storage: Store in airtight, light-resistant container.

Batch No. : 111701
Mfg.Date. : 11/2017
Exp.Date. : 11/2020




Cardisafe
Atenolol 50 mg
Manufactured by:
Pacific Medical Industries Ltd.
Cardisafe
Atenolol 50 mg
Manufactured by
Pacific Medical Industries Ltd.
Cardisafe
Atenolol 50 mg
Pacific Medical Industries Ltd.
Batch No. : 111701
Mfg.Date. : 11/2017
Exp.Date. : 11/2020

Cardisafe Tablets
(Atenolol 50 mg)

- **COMPOSITION :**
  Each tablet contains
  Atenolol..50 mg
- **APPEARANCE :**
  White, round film-coated tablet
- **INDICATIONS :** Control of hypertension, Management of angina pectoris. Control of cardiac dysrhythmias. Treatment of myocardial infarction. Early intervention and late intervention after myocardial infarction.
- **DOSAGE & ADMINISTRATION :** *Adults:* Hypertension: Most patients respond to 50-100mg daily given orally as a single dose. The effect will be fully established after 1-2 weeks. A further reduction in blood pressure may be achieved by combining CARDISAFE with other antihypertensive agents.
  Angina: Most patients with angina pectoris will respond to 100mg daily given orally as a single or divided dose. It is unlikely that additional benefit will be gained by increasing the dose.
  Myocardial Infarction: Reduction of infarct size, incidence of ventricular dysrhythmias, morbidity, pain, need for opiate analgesics and early mortality: For patients suitable for treatment with IV β-blockade and preseting within 12hrs or the onset of chest pain, CARDISAFE 5-10mg should be given immediately by slow IV injection (1mg/min) followed by CARDISAFE 50mg orally about 15min later provided no untoward effects occur from the IV dose. This should be followed by 50mg orally 12hrs after the IV dose and the 12hrs later by 100mg orally to be given once daily. If bradycardia and/or hypotension requiring treatment, or any other untoward effects occur. CARDISAFE should be discontinued.
  Late Intervention After Acute Myocardial Infarction: For patients who present some days after suffering an acute myocardial infarction an oral dose of CARDISAFE (100mg daily) is recommended for long-term prophylaxis of myocardial infarction.
  Children: There is no paediatric experience with
  and for this reason it is not recommended for use in children.
  Elderly: dosage requirements may be reduced, especially in patients with impaired renal function.
  Renal Failure: Since CARDISAFE is excreted via the kidneys dosage should be adjusted in cases of severe impairment of renal function. No significant accumulation of CARDISAFE occurs in patients who have a creatinine clearance >35mL/min/1.73m2 (normal range is 100-150 mL/min/1.73m2). For patients with a creatinine clearance of 15-35 mL/min/1.73m2 (equivalent to serum creatinine of 300-600 μmol/L) the oral dose should be 50mg daily and the IV dose should be 10mg once every 2 days. For patients with a creatinine clearance of <15mL/min/1.73 m2 (equivalent to serum creatinine of >600 μmol/L) the oral dose should be 50mg on alternate days and the IV dose should be 10mg once every 4 days. Patients on haemodialysis should be given 50mg orally after each dialysis; This should be done under hospital supervision as marked falls in blood pressure can occur.
- **OVERDOSAGE :** Excessive bradycardia can be countered with atropine 1-2mg IV. If necessary, this may be followed by a bolus dose of glucagon 10mg IV. If required, this may be repeated or followed by an IV infusion of glucagon 1-10mg/hr depending on respones. If no response to glucagon occurs or if it is unavailable, a β-adrenoceptor stimulant, eg dobutamine 2.5-10μg/kg/min by IV infusion or isoprenaline 10-25μg given as an infusion at a rate not exceeding 5μg/min. It is likely that these doses would be inadequate to reverse the cardiac effects of β-blockade if a large overdose has been taken. The dose of dobutamine or isoprenaline should therefore be increased if necessary to achieve the required response according to the clinical condition of the patient. There is a possibility of hypotension occurring following the use of β-adrenoceptor agonists but this will be reduced by the use of the more selective agents, prenalterol and dobutamine. Excessive diuresis should be countered by maintaining normal fluid and electrolyte balance.

■ **CONTRAINDICATIONS :** CARDISAFE should not be used in the presence of 2nd-or 3rd-degree heart block.
CARDISAFE should not be used in patients with cardiogenic shock.

■ **PRECAUTIONS :** Special card should be taken with patients whose cardiac reserve is poor. β-adrenoceptor blocking drugs should be avoided in overt heart failure. However, they may be used in patients whose signs of failure have been controlled.
One of the pharmacological actions of CARDISAFE is to reduce heart rate. In the rare instances when symptoms may be attributable to the slow heart rate, the dose may be reduced.
CARDISAFE modifies the tachycardia of hypoglycacmia.
CARDISAFE may be used with caution in patients with chronic obstructive airways disease. However, some increase in airways resistance may occur occasionally in asthmatic patients. This can usually be reversed by the commonly used dosage of bronchodilators, eg salbutamol or isoprenaline. In patients suffering from ischaemic heart disease, as with other β-blocking agents, treatment should not be discontinued abruptly.
CARDISAFE may aggravate peripheral arterial circulatory disorders. While taking β-blocker, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge. Such patients may be unresponsive to the usual doses of adrenaline used to treat the allergic reactions. Care should be taken in prescribing a β-adrenoceptor blocking drug with class I antidysrhythmic agents. eg disopyramide.
Combined use of β-blockers and calcium channel blockers with negative inotropic effects. eg verapamil, diltiazem can lead to an exaggeration of these effects particularly in patients with impaired ventricular function and/or SA or AV conduction abnormalities. This may result in severe hypotension, bradycardia and cardiac failure. Neither the β-blockers nor the calcium channel blockers should be administered IV within 48hrs of discontinuing the other, Beta-blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the 2 drugs are co-administered, the β-blocker should be withdrawn several days before discontinuing clonidine. If replacing clonidine by β-block therapy, the introduction of β-blockers should be delayed for several days after clonidine administration has stopped (also see prescribing information for clonidine).
Anaesthesia: Care should be taken when using anaesthetic agents with CARDISAFE . The anaesthetist should be informed and the choice of anaesthetic should be the agent with as little negative inotropic activity as possible.
Effects on the Ability to Drive of Operate Machineries: The use of CARDISAFE is unlikely to result in any impairment of the ability of patients to drive or operate machinery.
Use in pregnancy & lactation: The use of CARDISAFE in women who are, or may become pregnant, requires that the anticipated benefit be weighed against the possible risks, particularly in the 1st and 2nd trimesters. There is significant accumulation of CARDISAFE in breast milk. Caution should be exercised when CARDISAFE is administered to a nursing woman.

■ **SIDE EFFECTS :** In clinical studies, the side effects reported are usually attributable to its pharmacological actions and include coldness of the extremities, fatigue, gastrointestinal distrubance and, in isolated cases, bradycardia. Headache, mood changes and deterioration in heart failure may occasionally occur. Sleep disturbances of the type noted with other β-blockers, postural hypotension which may be associated with syncope, alopecia, thrombocytopenia, purpura, psoriasiform skin reaction, exacerbation of psoriasis and precipitation of heart block in susceptible patient have rarely been reported. There have been reports of skin rashes and/or dry eyes associated with the use of β-adrenergic blocking drugs. The reported incidence is small and in most cases the symptoms have cleared when treatment was withdrawn. Discontinuance of CARDISAFE should be considered if any such reaction is not otherwise explicable.

■ **STORAGE :** CARDISAFE should be stored at room temperature, in air tight, light-resistant container.

Manufactured by:
Pacific Medical Industries Ltd.
City of Industry, Dagon Seikkan Tsp., Yangon, Myanmar.
PACIFIC
website: www.aa.com.mm

၅။ ဝန်ထမ်းခန့်ထားမှု အခြေပြဇယား

PACIFIC MEDICAL INDUSTRIAL LTD

List of Local Personnel and Expatriate Consultant Technician

Sr	Designation	No of Person	Expatriate USD/month	Local Kyat/month	Total Amount (USD)	Total Amount (Kyats)
	Manangement					
1	Managing Director	1				
2	Consultant (General Manager Quality Duty)	1	5,000		5,000	-
3	Consultant (General Manager Operation Duty)	1	6,500		6,500	-
4	Deputy General Manger	1		4,670,000	-	4,670,000
5	Finance Manager	1	2,800	30,000	2,800	30,000
6	Quality Control Manager	2		2,495,000	-	4,990,000
7	Quality Assurance Manager	1		1,050,000	-	1,050,000
8	Admin & HR Manager	1		1,730,000	-	1,730,000
9	Consultant (M & E Duty)	1	3,500	480,000	3,500	480,000
10	Consultant (PPIC Duty)	1	3,500	312,000	3,500	312,000
11	Consultant (R & D Duty)	3	1,617	136,667	4,850	410,000
	Skill Workers Quality & Operation				-	-
1	QC Technician	17		467,176	-	7,941,992
2	QA Technician	5		552,750	-	2,763,750
3	Procurement	1		720,000	-	720,000
4	Engineer	4		385,750	-	1,543,000
5	R & D Technician	2		350,000	-	700,000
6	MFG Staff	7		147,000	-	1,029,000
7	MFG Technician	11		382,818	-	4,210,998
8	Accountant	2		438,500	-	877,000
9	HR and Admin Staff	3		229,166	-	687,498
10	Warehouse Supervisor	1		940,000	-	940,000
11	Warehouse Staff	2		259,500	-	519,000
1	General Workers				-	-
2	Gardner	1		290,000	-	290,000
3	Cleaner	4		228,000	-	912,000
4	Driver	6		350,000	-	2,100,000
5	Security	10		314,000	-	3,140,000
6	Helper	2		260,000	-	520,000
	Total	92			26,150	42,566,238

Pacific Medical Industries

ကြီးကြပ်အုပ်ချုပ်သူအမည် - ဦးဇော်မိုးနိုင်

ပညာအရည်အချင်း - MBA

(၁) စီမံခန့်ခွဲသူ ဦးရေ	ကျား	မ
Managing Director	၁	
Consultant Quality General Manager Duty	၁	
Consultant Operation General Manager Duty	၁	-
Deputy General Manager	၁	-
Finance Manager	-	၁
Quality Control Manager	-	၂
Quality Assurance Manager	-	၁
Admin and HR Manager	၁	-
Consultant (M & E Duty)	၁	-
Consultant (PPIC Duty)	၁	-
Consultant Research and Development Duty	၃	-
ဦးရေ	၁၀ ဦး	၄ ဦး

(၂) ကျွမ်းကျင်လုပ်သားဦးရေ	ကျား	မ
Quality Control Department	၂	၁၅
Quality Assurance Dept:	၁	၄
Procurement Department	-	၁
Engineering Department	၃	၁
Finance Department	-	၂
Admin and HR Department	၁	၂
Warehouse Department	၃	-
Manufacturing Department	၁၁	၇
R & D Department	၁	၁
ဦးရေ	၂၂ ဦး	၃၃ ဦး

(၃) ရိုးရိုးလုပ်သားဦးရေ	ကျား	မ
Gardner	၁	-
Helper	၂	-
Cleaner	-	၄
Security	၉	၁
Driver	၆	-
ဦးရေ	၁၈ ဦး	၅ ဦး

လူဦးရေအမျိုးအစား	ကျား	မ
(၁) စီမံခန့်ခွဲသူလုပ်သားဦးရေ	၁၀	၄
(၂) ကျွမ်းကျင်လုပ်သားဦးရေ	၂၂	၃၃
(၃) ရိုးရိုးလုပ်သားဦးရေ	၁၈	၅
စုစုပေါင်း ဦးရေ	၅၀ ဦး	၄၂ ဦး
	၉၂ ဦး	

၆။ ပုဂ္ဂလိက စက်မှုလုပ်ငန်းမှတ်ပုံတင်လက်မှတ်

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်အစိုးရ

စက်မှုဝန်ကြီးဌာန

စက်မှုကြီးကြပ်ရေးနှင့်စစ်ဆေးရေးဦးစီးဌာန

ပုဂ္ဂလိကစက်မှုလုပ်ငန်းမှတ်ပုံတင်လက်မှတ်

စက်မှုမှတ်ပုံတင်အမှတ် ရက/ကြီး/၄၈၅၇ ရက်စွဲ ၁၁.၁၂.၂၀၁၇

လုပ်ငန်းအရွယ်အစား အကြီးစား ပြည်ထောင်စုနယ်မြေ/တိုင်းဒေသကြီး/ပြည်နယ် ရန်ကုန်

အောက်ပါလုပ်ငန်းသည် ပုဂ္ဂလိကစက်မှုလုပ်ငန်း ဥပဒေ ပုဒ်မ ၇ ပုဒ်မခွဲ (က)အရ မှတ်ပုံတင်ပြီး ဖြစ်ပါသည်။

Pacific Medical Industries Ltd.ဆေးဝါးထုတ်လုပ်ခြင်းနှင့်ဆက်စပ်လျက်ရှိသော

၁။ လုပ်ငန်းအမည် ပစ္စည်းများထုတ်လုပ်ခြင်းလုပ်ငန်း

၂။ လုပ်ငန်းအမျိုးအမည် လူသုံးပစ္စည်းလုပ်ငန်း

၃။ အဓိကကုန်ချောပစ္စည်းအမျိုးအမည် Medigesic (Paracetamol Tablets 500 mg)

၄။ တည်နေရာလိပ်စာ မြေကွက်အမှတ်(၂၀၉၊ ၂၁၀၊ ၂၁၁)၊ စက်မှုဇုန်(၁)၊ ဒဂုံမြို့သစ်(ဆိပ်ကမ်း)မြို့နယ်၊ အရှေ့ပိုင်းခရိုင်

၅။ ပိုင်ဆိုင်မှုအမျိုးအစား ကုမ္ပဏီပိုင်

၆။ လုပ်ငန်းရှင်အမည် ဦးဇော်မိုးခိုင်(M.D)

၇။ ကိုင်ဆောင်သည့်မှတ်ပုံတင်အမှတ် ၁၂/ကတတ(နိုင်)၀၂၈၇၄၄

၈။ ရင်းနှီးမြှုပ်နှံမှုတန်ဖိုး(ကျပ်) ၂၂၆.၉၈၂၅သန်း+USD ၃၇၇၇၉၄၆ တည်ထောင်သည့်ခုနှစ် ၂၀၁၇

၉။ အသုံးပြုသည့်အားအမျိုးအစား ထရန်စဖော်မာ/လျှပ်ထုတ်စက် မြင်းကောင်ရေ ၂၄၈၄ HP/ ၈၀၀ KVA

၁၀။ အလုပ်သမားဦးရေ ၅၇ ဦး

၁၁။ မှတ်ပုံတင်သက်တမ်းကုန်ဆုံးသည့်နေ့ရက် ၃၁.၁၂.၂၀၁၈



နေပြည်တော်

အေးအေးဝင်း

ညွှန်ကြားရေးမှူးချုပ်

လုပ်ငန်းရှင်များလိုက်နာရန်စည်းကမ်းချက်များ

၁။ ဤမှတ်ပုံတင်လက်မှတ်ကို အများမြင်သာသည့်နေရာတွင် ချိတ်ဆွဲထားရမည်။
၂။ ဤမှတ်ပုံတင်လက်မှတ်ကို မသက်ဆိုင်သူအား လွှဲအပ်ခြင်း သို့မဟုတ် လွှဲပြောင်းပေးခြင်းမပြုရ။
၃။ ဤမှတ်ပုံတင်လက်မှတ်ပါ အချက်အလက်များကို ပြင်ဆင်ခြင်း သို့မဟုတ် ဖြည့်စွက်ခြင်းမပြုရ။
၄။ ဤမှတ်ပုံတင်လက်မှတ် ပျောက်ဆုံးလျှင် မှတ်ပုံတင်လက်မှတ်မိတ္တူကို ထုတ်ပေးရန် ပြည်ထောင်စုနယ်မြေ သို့မဟုတ် တိုင်းဒေသကြီး သို့မဟုတ် ပြည်နယ်ဦးစီးဌာနမှူးထံ ခိုင်လုံသော အထောက်အထားနှင့်အတူ လျှောက်ထားရမည်။
၅။ မှတ်ပုံတင်လက်မှတ်ပျက်စီးလျှင် သို့မဟုတ် မထင်မရှားဖြစ်လျှင် သို့မဟုတ် မှတ်ပုံတင်လက်မှတ် ပါ အချက်အလက်များ ပြောင်းလဲရန်လိုအပ်လျှင် ပြည်ထောင်စုနယ်မြေ သို့မဟုတ် တိုင်းဒေသကြီး သို့မဟုတ် ပြည်နယ်ဦးစီးဌာနမှူးထံ မှတ်ပုံတင်လက်မှတ်နှင့် ပူးတွဲတင်ပြလျှောက်ထားရမည်။
၆။ ဤမှတ်ပုံတင်လက်မှတ်ကို စက်မှုလုပ်ငန်းနှင့်စပ်လျဉ်းသည့်ကိစ္စမှအပ မည်သည့်ကိစ္စတွင်မျှ အသုံးမပြုရ။
၇။ မှတ်ပုံတင်သက်တမ်းမကုန်ဆုံးမီ သက်တမ်းတိုးမြှင့်ပေးရန် လျှောက်ထားရာတွင် ဤမှတ်ပုံတင် လက်မှတ်ကို ပူးတွဲတင်ပြရမည်။
၈။ သက်တမ်းကုန်ဆုံးပြီး ရက်ပေါင်း (၆၀)အတွင်း သက်တမ်းတိုးမြှင့်လျှောက်ထားပါက သတ်မှတ်သည့် ဒဏ်ကြေးကို ပေးဆောင်ရမည်။
၉။ သက်တမ်းတိုးမြှင့်ရန် လျှောက်ထားခြင်းမရှိပါက မှတ်ပုံတင်ပျက်ပြယ်ပြီးဖြစ်သည်။

မှတ်ပုံတင်သက်တမ်းတိုးမြှင့်ခြင်း

စဉ်	ချလန်အမှတ်/ရက်စွဲ	မှတ်ပုံတင်သက်တမ်းကုန်ဆုံးမည့်နေ့ရက်	ခွင့်ပြုသူလက်မှတ်
၁။	၁၆၆/၄၉/၂၀.၁၂.၁၈	၃၁.၁၂.၂၀၁၉	

၇။ ဘဏ္ဍိုင်လာ အသုံးပြုခွင့်လက်မှတ်

၇

ဘွိုင်လာယာယီအသုံးပြုခွင့်လက်မှတ်

{ လုပ်ထုံးလုပ်နည်း အပိုဒ် ၆ အပိုဒ်ခွဲ (ဆ) }

ရက
စာအမှတ် ၂၀၁၇-၁၈ / ၄၁၃၀ / ယာ-၃၃

ဦးကျော်စွာခေါင် ၊ Pacific Medical Indy; Ltd ၊ အေးဝါ၊ ထုတ်လုပ်ခြင်း လုပ်ငန်း ၊ အမှတ် ၄၂၀၉/၁ ၂၁၁၁ ၊ ဆိပ်ကမ်းသာလမ်း နှင့် ကျွန်းဂုဏ် မင်းသားကြီးလမ်း ထောင့် ၊ စက်မှုဇုန် ၁ ၊ ဒဂုံဆိပ်ကမ်းမြို့နယ် ၊ ရန်ကုန်တိုင်းဒေသကြီး ......
..............................အား..............................

..............................ကုမ္ပဏီ၊..............................နိုင်ငံမှ

ထုတ်လုပ်သည့်ဘွိုင်လာအမှတ်..............................ပါသော

သို့မဟုတ်ဘွိုင်လာမှတ်ပုံတင်အမှတ် မ.စ .....၅၅၃၃.....ဖြစ်သော...အာသျှား ကျွတ်..ဘွိုင်လာကို

ခွင့်ပြုဖိအား.......၂၀၀.....psi........ဖြင့်လက်မှတ်ထုတ်ပေးသည့်နေ့မှ (၆)လအသုံးပြုခွင့်ရှိသည်။

ယင်းကာလအပိုင်းအခြားကျော်လွန်သည့်အခါ ထုတ်ပေးထားသည့် ဤယာယီအသုံးပြုခွင့်လက်မှတ်

ပျက်ပြယ်စေရမည်။

(မြင့်ဝင်း)	ဖြိုး ချမ်း ဇော်
ဒုတိယညွှန်ကြားရေးမှူး	ဘွိုင်လာစစ်ဆေးရေးမှူး
(ဘွိုင်လာစစ်ဆေးရေး)	ဌာနခွဲမှူး
ရန်ကုန်တိုင်းဒေသကြီး	(ဘွိုင်လာစစ်ဆေးရေး)
	ရန်ကုန်တိုင်းဒေသကြီး

ရက်စွဲ။ ၂၆.၈.၂၀၁၈...............

မှတ်ချက် ။ ။ ဘွိုင်လာဥပဒေပုဒ်မ ၁၅ ပါပြဋ္ဌာန်းထားသည့် သက်ဆိုင်ရာအစိုးရဌာန အဖွဲ့အစည်းက လိုအပ်၍တောင်းဆိုသည့်အခါ ဤလက်မှတ်ကို တင်ပြရမည်။

ဘိွုင်လာယာယီအသုံးပြုခွင့်လက်မှတ်

{ လုပ်ထုံးလုပ်နည်း အပိုဒ် ၆ အပိုဒ်ခွဲ (ဆ) }

စာအမှတ် ၁၀၁ / ၂၀၁၈-၁၉ / [illegible] ၁၀ / [illegible]

...ဦးကျော်ဇောအောင်...

...Pacific Medical Indy. Ltd. ၊ [illegible]...

...[illegible]...

...[illegible]...

....ကုမ္ပဏီ၊...နိုင်ငံမှ

ထုတ်လုပ်သည့်ဘိွုင်လာအမှတ်...ပါသော

သို့မဟုတ်ဘိွုင်လာမှတ်ပုံတင်အမှတ် မ.စ ..[illegible]..........ဖြစ်သော.[illegible].ဘိွုင်လာကို

ခွင့်ပြုဖိုအား......[illegible]..........ဖြင့်လက်မှတ်ထုတ်ပေးသည့်နေ့မှ (၆)လအသုံးပြုခွင့်ရှိသည်။

ယင်းကာလအပိုင်းအခြားကျော်လွန်သည့်အခါ ထုတ်ပေးထားသည့် ဤယာယီအသုံးပြုခွင့်လက်မှတ်

ပျက်ပြယ်စေရမည်။

(ဦးနိုင်ဂျင်)
ဒုတိယညွှန်ကြားရေးမှူး
(ဘွိုင်လာစစ်ဆေးရေး)
ရန်ကုန်တိုင်းဒေသကြီး

([illegible])
ဘိွုင်လာစစ်ဆေးရေးမှူး
ဌာနခွဲမှူး
(ဘိွုင်လာစစ်ဆေးရေး)
ရန်ကုန်တိုင်းဒေသကြီး

ရက်စွဲ။ ၂၉-၈-၂၀၁၈...........

မှတ်ချက် ။ ။ ဘိွုင်လာဥပဒေပုဒ်မ ၁၅ ပါပြဋ္ဌာန်းထားသည့် သက်ဆိုင်ရာအစိုးရဌာန အဖွဲ့အစည်းက လိုအပ်၍တောင်းဆိုသည့်အခါ ဤလက်မှတ်ကို တင်ပြရမည်။

၈။ YCDC _ Certificate

ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ
ရန်ကုန်မြို့တော်

ကျန်းမာရေးဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ်

၂၀၁၈ ခုနှစ်၊ ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးဥပဒေပုဒ်မ-၁၇၃၊ ၁၇၆၊ ၁၈၁ တို့အရ အများပြည်သူတို့အား ကျန်းမာရေးဘေးအန္တရာယ်ဖြစ်စေတတ်သော လုပ်ငန်းကို စစ်ဆေးရာတွင် ဥပဒေပါစည်းကမ်းချက်များနှင့် ကိုက်ညီကြောင်း စစ်ဆေးတွေ့ရှိရသဖြင့် အောက်ဖော်ပြပါလုပ်ငန်းအား အများပြည်သူအတွက် ကျန်းမာရေး ဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ်ကို ထုတ်ပေးလိုက်သည် -

လုပ်ငန်းအမျိုးအစား	၊	စားဂါးထုတ် ၁
လုပ်ငန်းပိုင်ရှင်အမည်	၊	ဦးဇော်မိုးနိုင်
လုပ်ငန်းလိပ်စာ	၊	၂၀၉/၂၁၀/၂၁၁၊ ကမ်းနားလမ်း၊ ဆိပ်ကမ်းမြို့နယ်
ထောက်ခံချက်အမှတ်	၊	၄၅၀ / ဒဂဆက (စား) ၂၀၁၈-၂၀၁၉
ထောက်ခံချက်လက်မှတ်	၊	
ထုတ်ပေးသည့်ရက်စွဲ	၊	၂၀၁၈ ခုနှစ်၊ ဒီဇင်ဘာ လ ၁၁ ရက်
ထောက်ခံချက်လက်မှတ်သက်တမ်း	၊	ဘဏ္ဍာရေးနှစ် (၁) နှစ်အတွက်သာ

(. .) မှ (. .) အထိ
(၁-၁၀-၂၀၁၈) မှ (၃၀-၉-၂၀၁၉) အထိ

ဝန်ဆောင်ခနှုန်းထား

(က) အဆင့်	၁၅၀၀၀ကျပ်	(ဃ) အဆင့်	၆၀၀၀ကျပ်
(ခ) အဆင့်	၁၂၀၀၀ကျပ်	(င) အဆင့်	၃၀၀၀ကျပ်
(ဂ) အဆင့်	၉၀၀၀ကျပ်		

No. 01457764

ဌာနမှူး (ကခ)
ကျန်းမာရေးဌာန
ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ

လုပ်ငန်းရှင်များလိုက်နာရန် စည်းကမ်းချက်များ

၁။ အစားအသောက်ထုတ်လုပ်၊ သိုလှောင်၊ ဖြန့်ဖြူးရောင်းချသည့် လုပ်ငန်းဖြစ်ပါက အစားအသောက်ကုန်ပစ္စည်းများထည့်သည့်ဘူး၊ ပုလင်း၊ ကတ်ပြား၊ ဘူးခွံ (သို့မဟုတ်) အစားအသောက်ထုပ်ပိုးသော ပစ္စည်းတစ်ခုခုပေါ်တွင် ထည့်သွင်းဖော်ပြရန်သတ်မှတ်ထားသည့် အချက်အလက်များနှင့်အတူ အစားအသောက်ထုတ်လုပ်သည့် ရက်စွဲနှင့်သက်တမ်းကုန်ဆုံးသည့် ရက်စွဲတို့ကို ဖော်ပြရမည်။

၂။ လုပ်ငန်းသုံးပစ္စည်း၊ ကုန်ကြမ်းပစ္စည်းနှင့် ထုတ်လုပ်သော၊ သိုလှောင်သော ဖြန့်ဖြူးသော၊ ရောင်းချသောပစ္စည်းများသည် သက်ဆိုင်ရာဝန်ကြီးဌာန၊ အဖွဲ့အစည်းများက သတ်မှတ်ထားသည့် စံချိန်စံညွှန်းနှင့် ကိုက်ညီသော ပစ္စည်းများဖြစ်ရမည့်အပြင် ကိုင်တွယ်သူ အသုံးပြုသူများအတွက် ကျန်းမာရေး ဘေးအန္တရာယ်မရှိစေရန် အစီအမံများ စီစဉ်ဆောင်ရွက်ရမည်။

၃။ ဤကျန်းမာရေးဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ်ကို အများမြင်သာသည့်နေရာတွင် ချိတ်ဆွဲထားရမည်။

၄။ ဤကျန်းမာရေးဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ်ပါ အချက်အလက်များကို ပြင်ဆင်ခြင်း (သို့မဟုတ်) ဖြည့်စွက်ခြင်းပြုလုပ်ရန်ရှိပါက လျှောက်ထားတင်ပြရမည်။

၅။ ဤကျန်းမာရေးဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ်ပျောက်ဆုံးလျှင် ကျန်းမာရေးဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ်မိတ္တူကို ထုတ်ပေးရန် ခိုင်လုံသော အထောက်အထားနှင့်အတူ လျှောက်ထားရမည်။

၆။ ဤကျန်းမာရေးဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ်ကို ဘေးအန္တရာယ်ဖြစ်စေတတ်သော လုပ်ငန်းနှင့်စပ်လျဉ်းသည့် ကိစ္စမှအပ မည်သည့်ကိစ္စတွင်မှ အသုံးမပြုရ။ သက်ဆိုင်ခြင်းမရှိသူထံ လွှဲအပ်ခြင်း/လွှဲပြောင်းခြင်း မပြုရ။

၇။ ဤကျန်းမာရေး ဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ် သက်တမ်းမကုန်ဆုံးမီ သက်တမ်းတိုးမြှင့်ပေးရန် (၃)လကြိုတင်လျှောက်ထားရာတွင် ဤကျန်းမာရေး ဘေးအန္တရာယ်ကင်းရှင်းကြောင်း ထောက်ခံချက်လက်မှတ်ကို ပူးတွဲတင်ပြရမည်။

ပြည်ထောင်စုသမ္မတမြန်မာနိုင်ငံတော်
ရန်ကုန်တိုင်းဒေသကြီးအစိုးရ
ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ
စီမံရေးရာဌာန

0041716



၀၇၂၂၂၀၁၆၀

(၂၀၁၈) နှစ် လုပ်ငန်းလိုင်စင်

(စက်ရုံ၊ အလုပ်ရုံ၊ သိုလှောင်ရုံသုံးစွဲရန် အထောက်အကူပစ္စည်းထုတ်လုပ်ခြင်း၊ ရောင်းချခြင်း၊ တည်ခင်းခြင်း၊ ဖြန့်ဖြူးခြင်း၊ ဝန်ဆောင်မှုလုပ်ငန်း၊ အခြားလုပ်ငန်း)

ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ၊ စီမံခန့်ခွဲရေးဆိုင်ရာနည်းဥပဒေအခန်း (၂)၊ နည်းဥပဒေ ၃ (ဈ)အရ အောက်အမည်ပါသူတို့အား လိုင်စင်နှုန်း ၁၅၀၀၀၀/- တဖြင့် (ကျပ်တစ်သိန်းငါးသောင်းတိတိ) ပေးသွင်းစေပြီး ဒဂုံဆိပ်ကမ်း မြို့နယ်၊ ရပ်ကွက်၊ လမ်း၊ အမှတ် စက်မှုဇုန်-၁(*) အခန်းအမှတ် ကမ်းနား ၂၀၉+၂၁၀+၂၁၁ တွင် အမည်ပါ Pacific Medical Industries Ltd ဆိုင်/လုပ်ငန်းအား လုပ်ကိုင်ခွင့်ပြု၍ ဤလုပ်ငန်းလိုင်စင်ကို ထုတ်ပေးလိုက်သည်။ ရေအေး/ပါးထုတ်လုပ်

လိုင်စင်ခွင့်ပြုချက်ရရှိသူ

စဉ်	အမည်	နိုင်ငံသားစိစစ်ရေးကတ်ပြားအမှတ်	လိပ်စာ
၁။	ဦးဇော်မိုးနိုင်	၁၂/ကတတ(နိုင်)၀၂၈၇၇၄	အမှတ်(၄၀၈/၄၁၁)၊မဟာဗန္ဓုလလမ်း၊ ကျောက်တံတားမြို့နယ်။
၂။			
၃။			
၄။			
၅။			

ဤလုပ်ငန်းလိုင်စင်သည် ၂၀၁၈ ခုနှစ်၊ စက်တင်ဘာ ၃၀ ရက်နေ့တွင် သက်တမ်းကုန်ဆုံးသည်။
ဤလုပ်ငန်းလိုင်စင်အား မြင်သာသော နေရာတွင် မှန်ဘောင်ဖြင့် ချိတ်ဆွဲထားရမည်။
လိုင်စင်အမှတ်
မြို့နယ် ၀၇၂၂၂၀၁၆၀

ကျောသက်ပါ သွန်ကြား ဒဂုံဆိပ်ကမ်း ကိုက်နာဆောင်ရွက်ရမည်။

ဘုတ်ချုပ်ရေးမှူး
စည်ပင်သာယာ ဘုတ်ချုပ်ရေးမှူး ဌာနမှူး
(အရှေ့ပိုင်းခရိုင်) မြို့နယ်

လုပ်ငန်းလုပ်ကိုင်ခွင့်ရရှိသူလိုက်နာရန် စည်းကမ်းချက် ညွှန်ကြားချက်များ

၁။ လုပ်ငန်းလုပ်ကိုင်ခွင့်ရရှိသူသည် လုပ်ငန်းတည်နေရာ ပတ်ဝန်းကျင်ရှိ အများပြည်သူအား လုပ်ငန်းနှင့်ပတ်သက်၍ အနှောင့်အယှက် တစ်စုံတစ်ရာ မဖြစ်ပေါ်စေရ။ လုပ်ငန်းကို ခွင့်ပြုသည့် ဥပစာအတွင်း၌သာ ဆောင်ရွက်ရမည်။

၂။ လုပ်ငန်းလိုင်စင်သည် ပိုင်ဆိုင်မှု အရှုပ်အရှင်း ပုဂ္ဂိုလ်ရေးအရ ကန့်ကွက်မှုများနှင့် မသက်ဆိုင်စေရ။

၃။ လုပ်ငန်းလုပ်ကိုင်ခွင့်ရရှိသူသည် ပြဋ္ဌာန်းထားသော တည်ဆဲဥပဒေ၊ နည်းဥပဒေ၊ အမိန့်ညွှန်ကြားချက်များ အုပ်ချုပ်ရေးအဖွဲ့ အစည်းများ၏ အခါအားလျော်စွာထုတ်ပြန်သည့် အမိန့်ညွှန်ကြားချက်များနှင့် ဝန်ကြီးဌာန အသီးသီးက ထုတ်ပြန်သည့် အမိန့်ညွှန်ကြားချက်များ၊ စည်းမျဉ်းစည်းကမ်း လုပ်ထုံးလုပ်နည်းများကို တိကျစွာ လိုက်နာရမည်။

၄။ ဝန်ကြီးဌာနနှင့် အုပ်ချုပ်ရေးအဖွဲ့ အစည်းအသီးသီး၏ ဥပဒေပြဋ္ဌာန်းချက်များနှင့် အကျုံးဝင်သည့် လုပ်ငန်းများ လုပ်ကိုင်ခြင်း အတွက် ယင်းဌာနနှင့် အဖွဲ့ အစည်းများ၏ မှတ်ပုံတင်/ခွင့်ပြုချက်ကို လက်ဝယ်ရယူထားရမည်။

၅။ လုပ်ငန်းလုပ်ကိုင်ခွင့်ရရှိသူသည် ကော်မတီက ညွှန်ကြားသည့် သောက်/သုံးရေထားရှိမှု အစီအမံများ၊ သန့်ရှင်းရေးဆောင်ရွက်ရန် အတွက် အစီအမံများ၊ အညစ်အကြေးစွန့်ပစ်မှုနှင့် ပတ်ဝန်းကျင်ထိခိုက်မှုမဖြစ်စေရေး အစီအမံများ၊ မြို့တော်သာယာလှပရေးနှင့် လုံခြုံရေးအတွက် အစီအမံများ၊ အလုပ်သမားများ/လာရောက်ရောင်းဝယ်သူများအတွက် ကျန်းမာမှုနှင့်ဘေးအန္တရာယ်ကင်းရှင်းရေး အစီအမံများ၊ ယာဉ်/လူသွားလမ်းပိတ်ဆို့မှုမရှိစေရေးအစီအမံများ၊ မီးဘေးကြိုတင်ကာကွယ်ရေး အစီအမံများကို ထားရှိ၍ တိကျ စွာ လိုက်နာရမည်။

၆။ ကုန်ကြမ်းအဖြစ်အသုံးပြုသော ထုတ်လုပ်သော၊ သိုလှောင်သော၊ တည်းခင်းဖြန့်ဖြူးသော၊ ပစ္စည်းသည် သက်ဆိုင်ရာ ဝန်ကြီးဌာန/ အဖွဲ့ အစည်းများက သတ်မှတ်ထားသည့် စံချိန်စံညွှန်းနှင့် ကိုက်ညီသည့် ပစ္စည်းများဖြစ်ရမည့်အပြင် ကိုင်တွယ်အသုံးပြုစားသုံးသူ များအတွက် ကျန်းမာရေးနှင့် ညီညွတ်ရမည့် သို့မဟုတ် ဘေးအန္တရာယ်ကင်းရှင်းရေး အစီအမံများဖြင့် စီစဉ်ဆောင်ရွက်ပြီးဖြစ်ရ မည်။

၇။ လိုင်စင်ခွင့်ပြုထားသော လုပ်ငန်းကို လိုအပ်သည့်အခါ အချိန်နှင့်တစ်ပြေးညီဝင်ရောက် စစ်ဆေးခြင်းကို လက်ခံရမည်။ ယင်းအပြင် လုပ်ငန်းတာဝန်ခံကိုယ်တိုင်က လုပ်ငန်းဆောင်ရွက်ထားရှိမှုကို ရှင်းပြရမည်။

၈။ လိုင်စင်ခွင့်ပြုထားသော လုပ်ငန်းအားလိုအပ်ချက်အရ ပြောင်းရွှေ့ဖယ်ရှားပေးရန် ညွှန်ကြားပါက သတ်မှတ်ညွှန်ကြားချက်အတိုင်း တိကျစွာ လိုက်နာရမည်။

၉။ အထက်ပါ သတ်မှတ်ချက် တစ်စုံတစ်ရာကို ဖောက်ဖျက်ကျူးလွန်ပါက သို့မဟုတ် လိုက်နာရန် ပျက်ကွက်ပါက လုပ်ငန်းလိုင်စင်အား ယာယီပိတ်သိမ်းခြင်း၊ ပယ်ဖျက်ခြင်းစသည့် စီမံခန့်ခွဲမှုပြစ်ဒဏ်ကို ခံရမည်။ လိုအပ်ပါက ဥပဒေအရ အရေးယူခြင်းခံရမည်။ လုပ်ငန်းပိတ်သိမ်းသည့် ဖြစ်ရပ်ကာလအတွင်း အလုပ်သမားများအတွက် ကိစ္စအဝဝသည် လုပ်ငန်းလုပ်ကိုင်ခွင့်ရရှိသူနှင့်သာ သက်ဆိုင် စေရမည်။

ခွင့်ရက်နှင့် အလုပ်ပိတ်ရက် အခကြေးဥပဒေ၊ ပြဋ္ဌာန်းချက်များ ကို တိကျစွာလိုက်နာရမည်။

စီမံရေးရာဌာန

ရန်ကုန်မြို့တော်စည်ပင်သာယာရေးကော်မတီ

လုပ်ငန်းလိုင်စင်သက်တမ်းတိုးမှတ်တမ်း

စဉ်	ဘဏ္ဍာရေးနှစ်	လိုင်စင်နှုန်း	ပြေစာအမှတ်/ရက်စွဲ	ခွင့်ပြုသူလက်မှတ်	မှတ်ချက်
၁။	၂၀၁၈-[illegible] [illegible]	၁၅၀၀၀၀/ [illegible]	[illegible]/၂၉.၆.၁၈	[illegible] အုပ်ချုပ်ရေးမှူး မြို့နယ်စည်ပင်သာယာ-အုပ်ချုပ်ရေးမှူး ဒဂုံမြို့သစ်(ဆိပ်ကမ်း)မြို့နယ်	
၂။	၂၀၁၈-၂၀၁၉ [illegible]	၁၅၀၀၀၀/ [illegible]	[illegible]/၂၁.၁.၁၉	[illegible] အုပ်ချုပ်ရေးမှူး မြို့နယ်စည်ပင်သာယာအုပ်ချုပ်ရေးမှူး ဒဂုံမြို့သစ်(ဆိပ်ကမ်း)မြို့နယ်	